

APPROVED DRUG PRODUCTS


With Therapeutic Equivalence Evaluations



The "Orange Book"

FDA data supplied by [DrugPatentWatch.com](https://www.drugpatentwatch.com)

**CUMULATIVE
SUPPLEMENT 10
OCTOBER 2015**



**APPROVED
DRUG PRODUCTS**

**WITH
THERAPEUTIC EQUIVALENCE EVALUATIONS**

35th EDITION

Department of Health and Human Services

**Food and Drug Administration
Office of Medical Products and Tobacco
Center for Drug Evaluation and Research
Office of Generic Drugs**

2015

Prepared By
Office of Generic Drugs
Office of Medical Products and Tobacco
Center for Drug Evaluation and Research
Food and Drug Administration

**APPROVED DRUG PRODUCTS
with
THERAPEUTIC EQUIVALENCE EVALUATIONS**

35th EDITION Cumulative

Supplement 10

October 2015

CONTENTS

	<i>PAGE</i>
1.0 INTRODUCTION	iii
1.1 How to use the Cumulative Supplement	iii
1.2 Cumulative Supplement Content	iv
1.3 Applicant Name Changes	v
1.4 Levothyroxine Sodium	v
1.5 Availability of the Edition	vi
1.6 Report of Counts for the Prescription Drug Product List	vii
1.7 Cumulative Supplement Legend	viii
 DRUG PRODUCT LISTS	
Prescription Drug Product List	1-1
OTC Drug Product List	2-1
Drug Products with Approval under Section 505 of the Act	
Administered by the Center for Biologics Evaluation and Research List	3-1
Orphan Product Designations and Approvals List	4-1
Drug Products Which Must Demonstrate in vivo Bioavailability	
Only if Product Fails to Achieve Adequate Dissolution	5-1
 PATENT AND EXCLUSIVITY INFORMATION ADDENDUM	
A. Patent and Exclusivity Lists	A-1
B. Patent and Exclusivity Terms	B-1

**APPROVED DRUG PRODUCTS
with
THERAPEUTIC EQUIVALENCE EVALUATIONS**

35th EDITION CUMULATIVE

**SUPPLEMENT 10
October 2015**

1.0 INTRODUCTION

1.1 HOW TO USE THE CUMULATIVE SUPPLEMENT

This Cumulative Supplement is one of a series of monthly updates to the Approved Drug Products with Therapeutic Equivalence Evaluations, 35th Edition (the List). The List is composed of four parts: approved prescription drug products with therapeutic equivalence evaluations; over-the-counter (OTC) drug products that require approved applications as a condition of marketing; drug products with approval under Section 505 of the Act administered by the Center for Biologics Evaluation and Research; and products that have never been marketed, are for exportation, are for military use, have been discontinued from marketing or that have had their approvals withdrawn for other than safety or efficacy reasons.

The Cumulative Supplement provides, among other things, information on newly approved drugs and, if necessary, revised therapeutic equivalence evaluations and updated patent and exclusivity data. The Addendum contains appropriate drug patent and exclusivity information required of the Agency by the "Drug Price Competition and Patent Term Restoration Act of 1984" for the Prescription, OTC, and Drug Products with Approval under Section 505 of the Act Administered by the Center for Biologics Evaluation and Research Lists.

Because all parts of the publication are subject to changes, additions, or deletions, the List must be used in conjunction with the most current Cumulative Supplement. Users may wish to mark to the left of the ingredient(s) in the List to indicate that changes to that entry appear in the Cumulative Supplement. Drug product information is provided in each Cumulative Supplement for completeness to assist in locating the proper place in the List for the revision.

The presence of any therapeutic equivalence code indicates that the drug product is multisource; the deletion of a therapeutic equivalence code indicates that the drug product has become single source. (An infrequent exception exists when a therapeutic equivalence code is revised. In that case, the deletion of the therapeutic equivalence code is followed immediately by the addition of the revised one.)

Products that have never been marketed, are for exportation, are for military use, or have been discontinued from marketing or that have had their approvals withdrawn for other than safety or efficacy reasons, will be flagged in this Cumulative Supplement with the "@" symbol to designate their non-marketed status. All products having a "@" symbol in the 12th Cumulative Supplement of this Edition List will then be added to the "Discontinued Drug Product List" appearing in the next Edition. The current Annual Edition Section 2.1, How To Use The Drug Product Lists, describes the layout and usage of the List.

New additions to the Prescription Drug Product List and OTC Drug Product List are indicated by the symbol >A>. The Patent and Exclusivity List new additions are indicated by the symbol >A> to the left of Patent Number or Exclusivity Code. The >A> symbol is then dropped in subsequent Cumulative Supplements for that item.

New deletions to the Prescription Drug Product List and OTC Drug Product List are indicated by the symbol >D> (DELETE) to the left of the line. The information line with the >D> symbol is dropped in subsequent Cumulative Supplements for that item.

The Patent and Exclusivity List is arranged in alphabetical order by active ingredient name(s) and trade name. The trade name will follow the active ingredient name separated by a dash symbol. Also shown is the application number and product number (FDA's internal file number) for reference purposes. All patents with their expiration dates are displayed for each application number. Drug substance and drug product patents are indicated as such with DS or DP in the Patent codes column. Use patents are indicated with the symbol "U" followed by a number representing a specific use. Exclusivity information for a specific drug is indicated by an abbreviation followed by the date upon which the exclusivity expires. Refer to the Exclusivity Terms, Section B, in the Patent and Exclusivity Information Addendum for an explanation of all codes and abbreviations. Refer to Section 1.3 for internet access to the most current list of Patent and Exclusivity terms.

1.2 CUMULATIVE SUPPLEMENT CONTENT

Since February 2005, we have been providing daily Electronic Orange Book (EOB) product information for new generic drug approvals. Daily generic updates provide the consumer with the current list of approved generic products which is important for substitution purposes. Previously, a first-time-generic product approved early in the month would not be published in the Cumulative Supplement (CS) for several weeks.

The CS monthly update publish goal is by the end of the following month's second work week (e.g., November's supplement will be updated by the end of the second full work week in December).

Currently, the monthly PDF CS includes:

- Generic product ANDA (Abbreviated New Drug Approval) approvals as of the date of publication.
- All product changes received and processed as of the date of publication.
 - o Refer to CS Section 1.8 Cumulative Supplement Legend for types of changes
 - o Discontinued products will be processed as of the date of publication. There will be circumstances where a product is discontinued in one month, however, it will be reported in a different month's CS. For example, the Orange Book Staff received a letter November 7 that the product has been discontinued from manufacturing and marketing. The Orange Book subsequently publishes the October CS on November 14. The product will show in the October CS that it is discontinued even though the date of discontinuance is the day that the Orange Book Staff receives notification (November 7).
- New Drug Application (NDA) approvals appear in the CS month they were approved.

- Patent information, also updated daily in the EOB, is current to the date of publication.
- Exclusivity information is updated monthly and current to the date of publication.

Every effort is made to ensure the Cumulative Supplement is current and accurate. Applicant holders are requested to inform the FDA Orange Book Staff (OBS) of any changes or corrections. The OBS can be contacted by email at orangebook@fda.hhs.gov. Send changes by FAX: 301-595-1446.

mail to: FDA/CDER Orange Book Staff
Office of Generic Drugs
7620 Standish Place
Rockville, MD 20855-2773

1.3 APPLICANT NAME CHANGES

It is not practical to identify in the Cumulative Supplement each and every product involved when an applicant transfers its entire line of approved drug products to another applicant, or when an applicant changes its name. Therefore, the cumulation of these transfers and name changes will be identified in this section only. Where only partial lines of approved products are transferred between applicants, each approved product involved will appear as an applicant name change entry in the Cumulative Supplement.

It is also not practical to identify each and every product involved when an applicant name is changed to meet internal publication standards (e.g., MSD or Zenith [Former Abbreviated Names] are changed, respectively to Merck Sharp Dohme or Zenith Labs [New Abbreviated Names]). When this occurs, each product involved (either currently in the Cumulative Supplement or in the following year's edition) will reflect the new abbreviated name. Consequently, it will not appear as an applicant name change entry in the Cumulative Supplement nor will the cumulation of these name changes appear in this section. The Electronic Orange Book Query, updated monthly, will contain the most current applicant holder name.

<u>FORMER APPLICANT NAME</u> <u>(FORMER ABBREVIATED NAME)</u>	<u>NEW APPLICANT NAME</u> <u>(NEW ABBREVIATED NAME)</u>
AGILA SPECIALTIES PRIVATE LTD (AGILA SPECLTS)	MYLAN LABORATORIES LTD (MYLAN LABS LTD)
EXCELLIUM PHARMACEUTICAL INC (EXCELLIUM)	LEADING PHARMA LLC (LEADING PHARMA LLC)
MYLAN PHARMACEUTICALS INC (MYLAN PHARMS INC)	MYLAN LABORATORIES LTD (MYLAN LABS LTD)
ONCO THERAPIES LTD (ONCO THERAPIES LTD)	MYLAN LABORATORIES LTD (MYLAN LABS LTD)
REDKITT BENCKISER PHARMACEUTICALS INC (RECKITT BENCKISER)	INDIVIOR INC (INDIVIOR INC)

1.4 LEVOTHYROXINE SODIUM

Because there are multiple reference listed drugs of levothyroxine sodium tablets and some reference listed drugs' sponsors have conducted studies

to establish their drugs' therapeutic equivalence to other reference listed drugs, FDA has determined that its usual practice of assigning two or three character TE codes may be potentially confusing and inadequate for these drug products. Accordingly, FDA provides the following explanation and chart of therapeutic equivalence evaluations for levothyroxine sodium drug products.

Levothyroxine Sodium (Mylan ANDA 76187) and Levo-T (Alara NDA 21342) tablets have been determined to be therapeutically equivalent to corresponding strengths of Unithroid (Jerome Stevens NDA 021210) tablets. Levo-T (Alara NDA 021342), Levothyroxine Sodium (Mylan ANDA 76187), Unithroid (Jerome Stevens NDA 021210), and Levothyroxine Sodium (Merck KGAA ANDA 76752) tablets have been determined to be therapeutically equivalent to corresponding strengths of Synthroid (Abbott NDA 021402) tablets.

Levo-T (Alara NDA 021342), Unithroid (Jerome Stevens NDA 021210), Levothyroxine Sodium (Mylan ANDA 076187), and Levothyroxine Sodium (Merck KGAA ANDA 76752) tablets have been determined to be therapeutically equivalent to corresponding strengths of Levoxyl (King Pharms NDA 021301) tablets.

Levothyroxine Sodium (Mylan ANDA 76187) tablets have been determined to be therapeutically equivalent to corresponding strengths of Levotheroid (Lloyd NDA 021116) tablets.

The chart outlines TE codes for all 0.025mg products. Other product strengths may be similar. Therapeutic equivalence has been established between products that have the same AB+number TE code. More than one TE code may apply to some products. One common TE code indicates therapeutic equivalence between products.

Trade Name	Applicant	Potency	TE Code	Appl No	Product No
UNITHROID	STEVENS J	0.025MG	AB1	21210	001
LEVOTHYROXINE SODIUM	MYLAN	0.025MG	AB1	76187	001
LEVOXYL	KING PHARMS	0.025MG	AB1	21301	001
SYNTHROID	ABBOTT	0.025MG	AB1	21402	001
LEVO-T	ALARA PHARM	0.025MG	AB1	21342	001
SYNTHROID	ABBOTT	0.025MG	AB2	21402	001
LEVOTHYROXINE SODIUM	MYLAN	0.025MG	AB2	76187	001
LEVO-T	ALARA PHARM	0.025MG	AB2	21342	001
UNITHROID	STEVENS J	0.025MG	AB2	21210	001
LEVOXYL	KUNG PHARMS	0.025MG	AB3	21301	001
LEVO-T	ALARA PHARM	0.025MG	AB3	21342	001
UNITHROID	STEVENS J	0.025MG	AB3	21210	001
LEVOTHYROXINE SODIUM	MYLAN	0.025MG	AB3	76187	001
LEVOTHROID	LLOYD	0.025MG	AB4	21116	001
LEVOTHYROXINE SODIUM	MYLAN	0.025MG	AB4	76187	001

1.5 AVAILABILITY OF THE EDITION

Since 1997, the Electronic Orange Book Query (EOBQ) <http://www.accessdata.fda.gov/scripts/cder/ob/default.cfm>, has been available on the internet and has become the updated-every-month Orange Book. The Query provides searching of the approved drug list by active ingredient, proprietary name, applicant holder, applicant number or patent

number. Product search categories are: prescription, over-the-counter, discontinued drugs. There are links to patent and exclusivity information that may be applicable to each product.

Commencing with the 25th edition, the Annual Edition and monthly Cumulative Supplements have been provided in downloadable Portable Document Format (PDF) at the EOB home page by clicking on Publications. The PDF annual and cumulative supplements duplicate previous paper versions. Over time, there will be an archive for the annuals and each year's December Cumulative Supplement.

The downloaded Annual Edition and Cumulative Supplements are also available in a paper version (Approved Drug Products with Therapeutic Equivalence Evaluations, ADP) from the U.S. Government Printing Office: <http://bookstore.gpo.gov>; toll free 866-512-1800.

There are historical lists of Orange Book cumulative supplement product monthly changes at <http://www.fda.gov/Drugs/InformationOnDrugs/ucm086229.htm>. There are ASCII text files of the Orange Book drug product, patent, and exclusivity data at <http://www.fda.gov/Drugs/InformationOnDrugs/ucm129689.htm>. The drug product text files are provided in eobzip.zip format. The files are updated concurrently with the monthly cumulative supplements. The annual Orange Book Edition Appendices A, B, and C in PDF format are updated quarterly.

Effective August 18, 2003, patent submissions for publication in the Orange Book and Docket *95S-0117 need to be submitted on form FDA-3542 which may be downloaded from the FDA Forms List, <http://www.fda.gov/opacom/morechoices/fdaforms/default.html>.

The current listing of the Orphan Product Designations and Approvals is available at <http://www.fda.gov/orphan/designat/list.htm>.

1.6 REPORT OF COUNTS FOR THE PRESCRIPTION DRUG PRODUCT LIST

DESCRIPTION OF REPORT

This report provides summary counts derived from the product information in the Prescription Drug Product List and the current Cumulative Supplement. Products included in the counts are domestically marketed drug products approved for both safety and effectiveness under section 505 of the Federal Food, Drug, and Cosmetic Act. Excluded are approved drug products marketed by distributors; those marketed solely abroad; and those now regarded as medical devices, biologics or foods.

The baseline column (December of the previous Annual Edition) refers to the products in the Prescription Drug Product List. For each three-month period, a column of quarterly data is added which incorporates counts of product activity from the previous quarter(s) with those in the baseline count.

DEFINITIONS

Drug Product

For this report, a drug product is the representation in the Prescription Drug Product List of an active moiety (molecular entity and its salts, esters and derivatives) either as a single ingredient or as a combination product provided in a specific dosage form and strength for a given route of administration with approval for marketing by a firm under a particular generic or trade name.

New Molecular Entity

A new molecular entity is considered an active moiety that has not previously been approved (either as the parent compound or as a salt, ester or derivative of the parent compound) in the United States for use in a drug product either as a single ingredient or as part of a combination.

REPORT OF COUNTS FOR THE PRESCRIPTION DRUG PRODUCT LIST COUNTS CUMULATIVE BY QUARTER

<u>CATEGORIES COUNTED</u>	<u>DEC 2014</u>	<u>MAR 2015</u>	<u>JUN 2015</u>	<u>SEPT 2015</u>	<u>DEC 2015</u>
DRUG PRODUCTS LISTED	16150	16352	16543	16824	
SINGLE SOURCE	2572 (15.9%)	2608 (15.9%)	2586 (15.6%)	2613 (15.5%)	
MULTISOURCE	13578 (84.1%)	13744 (84.1%)	13957 (84.4%)	14211 (84.5%)	
THERAPEUTICALLY EQUIVALENT	13443 (83.2%)	13610 (83.2%)	13832 (83.6%)	14089 (83.7%)	
NOT THERAPEUTICALLY EQUIVALENT	135 (0.8%)	134 (0.8%)	125 (0.8%)	122 (0.7%)	
EXCEPTIONS ¹	77 (0.5%)	75 (0.5%)	75 (0.5%)	75 (0.4%)	
NEW MOLECULAR ENTITIES APPROVED	13	22	12	37	
NUMBER OF APPLICANTS	927	935	957	975	

¹Amino acid-containing products of varying composition (see Introduction, page xx of the List).

1.7 CUMULATIVE SUPPLEMENT LEGEND

The List is sorted by Ingredient(s) and, within each grouping, by the Dosage Form; Route and then by trade name.

The individual product record contains the Therapeutic Equivalence Code, Reference Listed Drug symbol, applicant holder, strength(s), New Drug Application number, product number, and approval date. The application number preceded by "N" is a New Drug Application (NDA or innovator). The application number preceded by an "A" is an Abbreviated New Drug Application (ANDA or generic). The last two columns describe the action. The Action Month is the CS month the action occurred. The OB Action is the type of change that has occurred.

New ingredient(s), new dosage form; route(s), new trade names, and new product additions are preceded by >A> during the action month. The change month is the current CS month; the change code for new approvals is NEWA. Following months will display the same information without the >A>.

Changes to currently listed products will list two records. The deleted product record will be preceded by >D>. The product record change addition being made will be preceded by >A>. Following months will display only the >A> record without the >A>. All changes that occur to the product through the Annual year will be listed. The change month and change code will document the change.

The change code and description:

NEWA	New drug product approval usually in the supplement month.
CAHN	Applicant holder firm name has changed.

CAIN	Change. There has been a change in the Ingredient(s) name. All products will be deleted under the old name and all products will be added under the changed ingredient(s) name.
CDFR	Change. Dosage Form; Route of Administration.
CFTG	Change. A first time generic for the innovator product. A TE Code is added.
CMFD	Change. The product is moved from the Discontinued Section due to a change in marketing status.
CMS1	Change. Miscellaneous addition to list.
CMS2	Change. Miscellaneous deletion from list.
CPOT	Change. Potency amount/unit.
CRLD	Change. Reference Listed Drug.
CTEC	Change. Therapeutic Equivalence Code.
CTNA	Change. Trade Name.
DISC	Discontinued. The Rx or OTC listed product is not being marketed and will be moved to the discontinued section in the next edition.

ACETAMINOPHEN

SOLUTION; IV (INFUSION)
ACETAMINOPHEN

>A>	FRESENIUS KABI USA	1GM/100ML (10MG/ML)	N204767	001	Oct 28, 2015	Oct NEWA
-----	--------------------	---------------------	---------	-----	--------------	----------

ACETAMINOPHEN; BUTALBITAL

TABLET; ORAL

BUTALBITAL AND ACETAMINOPHEN

>A> AA	TEDOR PHARMA INC	325MG; 50MG	A205120	001	Oct 30, 2015	Oct NEWA
--------	------------------	-------------	---------	-----	--------------	----------

BUTAPAP

>D>	+ MIKART	325MG; 50MG	A089987	001	Oct 26, 1992	Oct CTEC
-----	----------	-------------	---------	-----	--------------	----------

>A> AA	+	325MG; 50MG	A089987	001	Oct 26, 1992	Oct CTEC
--------	---	-------------	---------	-----	--------------	----------

ACETAMINOPHEN; BUTALBITAL; CAFFEINE

TABLET; ORAL

FIORICET

@ ACTAVIS LABS UT INC 325MG; 50MG; 40MG

A088616	001	Nov 09, 1984	Feb CAHN
---------	-----	--------------	----------

ACETAMINOPHEN; BUTALBITAL; CAFFEINE; CODEINE PHOSPHATE

CAPSULE; ORAL

FIORICET W/ CODEINE

AB	+ ACTAVIS LABS UT INC	325MG; 50MG; 40MG; 30MG	N020232	001	Jul 30, 1992	Jan CAHN
----	-----------------------	-------------------------	---------	-----	--------------	----------

ACETAMINOPHEN; CODEINE PHOSPHATE

TABLET; ORAL

ACETAMINOPHEN AND CODEINE PHOSPHATE

AA	SUN PHARM INDS LTD	300MG; 30MG	A085868	001		Apr CAHN
----	--------------------	-------------	---------	-----	--	----------

AA		300MG; 60MG	A087083	001		Apr CAHN
----	--	-------------	---------	-----	--	----------

ACETAMINOPHEN; HYDROCODONE BITARTRATE

TABLET; ORAL

HYDROCODONE BITARTRATE AND ACETAMINOPHEN

AA	+ MIKART	325MG; 2.5MG	A040846	001	Jun 09, 2010	Feb CTEC
----	----------	--------------	---------	-----	--------------	----------

@	SUN PHARM INDS LTD	325MG; 10MG	A040826	001	Aug 16, 2007	Apr CAHN
---	--------------------	-------------	---------	-----	--------------	----------

NORCO

AA	ACTAVIS LABS FL INC	325MG; 2.5MG	A040148	004	Jul 07, 2014	Feb NEWA
----	---------------------	--------------	---------	-----	--------------	----------

AA		325MG; 5MG	A040148	005	Jul 07, 2014	Feb NEWA
----	--	------------	---------	-----	--------------	----------

ACETAZOLAMIDE

CAPSULE, EXTENDED RELEASE; ORAL

DIAMOX

AB	+ TEVA BRANDED PHARM	500MG	N012945	001		Jun CAHN
----	----------------------	-------	---------	-----	--	----------

ACETOHEXAMIDE

TABLET; ORAL

ACETOHEXAMIDE

@	ANI PHARMS INC	250MG	A070869	001	Feb 09, 1987	Jul CAHN
---	----------------	-------	---------	-----	--------------	----------

@		500MG	A070870	001	Feb 09, 1987	Jul CAHN
---	--	-------	---------	-----	--------------	----------

ACETYLCYSTEINE

INJECTABLE; INTRAVENOUS

ACETYLCYSTEINE

AP	AKORN INC	6GM/30ML (200MG/ML)	A203173	001	Mar 24, 2015	Mar NEWA
----	-----------	---------------------	---------	-----	--------------	----------

AP	MYLAN INSTITUTIONAL	6GM/30ML (200MG/ML)	A203624	001	Jun 19, 2015	Jun NEWA
----	---------------------	---------------------	---------	-----	--------------	----------

SOLUTION; INHALATION, ORAL

ACETYLCYSTEINE

AN	ALVOGEN INC	10%	A204674	001	Feb 11, 2014	Sep CAHN
----	-------------	-----	---------	-----	--------------	----------

AN		20%	A203853	001	Jun 21, 2012	Sep CAHN
----	--	-----	---------	-----	--------------	----------

ACITRETIN

CAPSULE; ORAL

ACITRETIN

AB	MYLAN PHARMS INC	10MG	A202148	001	Sep 10, 2015	Aug NEWA
----	------------------	------	---------	-----	--------------	----------

AB		17.5MG	A203707	001	Sep 10, 2015	Aug NEWA
----	--	--------	---------	-----	--------------	----------

AB		22.5MG	A203707	002	Sep 10, 2015	Aug NEWA
----	--	--------	---------	-----	--------------	----------

AB		25MG	A202148	002	Sep 10, 2015	Aug NEWA
----	--	------	---------	-----	--------------	----------

AB	SIGMAPHARM LABS LLC	10MG	A204633	001	May 22, 2015	May NEWA
----	---------------------	------	---------	-----	--------------	----------

AB		17.5MG	A204633	002	May 22, 2015	May NEWA
----	--	--------	---------	-----	--------------	----------

AB		22.5MG	A204633	003	May 22, 2015	May NEWA
----	--	--------	---------	-----	--------------	----------

CAPSULE;ORAL							
ACITRETIN							
AB	25MG	A204633	004	May 22, 2015	May	NEWA	
<u>ACLIDINIUM BROMIDE</u>							
POWDER, METERED;INHALATION							
TUDORZA PRESSAIR							
+	ASTRAZENECA PHARMS	0.375MG/INH	N202450	001	Jul 23, 2012	Apr	CAHN
+		0.4MG/INH	N202450	001	Jul 23, 2012	Aug	CPOT
<u>ACYCLOVIR</u>							
TABLET;ORAL							
ACYCLOVIR							
AB	SUN PHARM INDS LTD	400MG	A074980	001	Sep 30, 1998	Apr	CAHN
AB		800MG	A074980	002	Sep 30, 1998	Apr	CAHN
<u>ADAPALENE; BENZOYL PEROXIDE</u>							
GEL;TOPICAL							
ADAPALENE AND BENZOYL PEROXIDE							
AB	ACTAVIS MID ATLANTIC	0.1%;2.5%	A203790	001	Sep 30, 2015	Sep	NEWA
EPIDUO							
AB	+ GALDERMA LABS LP	0.1%;2.5%	N022320	001	Dec 08, 2008	Sep	CFTG
EPIDUO FORTE							
+	GALDERMA LABS	0.3%;2.5%	N207917	001	Jul 15, 2015	Aug	CAHN
+	GALDERMA R AND D	0.3%;2.5%	N207917	001	Jul 15, 2015	Jul	NEWA
<u>ADENOSINE</u>							
INJECTABLE;INJECTION							
ADENOSINE							
AP	EUROHLTH INTL SARL	3MG/ML	A076500	001	Jun 16, 2004	Jun	CAHN
	@	3MG/ML	A076501	001	Jun 16, 2004	Sep	CAHN
	@ WOCKHARDT	3MG/ML	A090220	001	Jul 20, 2009	May	DISC
<u>ALBENDAZOLE</u>							
TABLET, CHEWABLE;ORAL							
ALBENZA							
+	AMEDRA PHARMS LLC	200MG	N207844	001	Jun 11, 2015	Jun	NEWA
<u>ALBUTEROL SULFATE</u>							
POWDER, METERED;INHALATION							
PROAIR RESPICLICK							
+	TEVA BRANDED PHARM	EQ 0.090MG BASE/INH	N205636	001	Mar 31, 2015	Mar	NEWA
SYRUP;ORAL							
ALBUTEROL SULFATE							
AA	G AND W LABS INC	EQ 2MG BASE/5ML	A074454	001	Sep 25, 1995	Apr	CAHN
<u>ALBUTEROL SULFATE; IPRATROPIUM BROMIDE</u>							
AEROSOL, METERED;INHALATION							
COMBIVENT							
	@ BOEHRINGER INGELHEIM	EQ 0.09MG BASE/INH;0.018MG/INH	N020291	001	Oct 24, 1996	May	DISC
<u>ALFUZOSIN HYDROCHLORIDE</u>							
TABLET, EXTENDED RELEASE;ORAL							
ALFUZOSIN HYDROCHLORIDE							
	@ WOCKHARDT LTD	10MG	A090221	001	Aug 10, 2012	Feb	DISC
UROXATRAL							
AB	+ CONCORDIA PHARMS INC	10MG	N021287	001	Jun 12, 2003	Jun	CAHN
<u>ALISKIREN HEMIFUMARATE; AMLODIPINE BESYLATE</u>							
TABLET;ORAL							
TEKAMLO							
	@ NOVARTIS	EQ 150MG BASE;EQ 5MG BASE	N022545	001	Aug 26, 2010	May	DISC
	@	EQ 150MG BASE;EQ 10MG BASE	N022545	002	Aug 26, 2010	May	DISC
	@	EQ 300MG BASE;EQ 5MG BASE	N022545	003	Aug 26, 2010	May	DISC
	@	EQ 300MG BASE;EQ 10MG BASE	N022545	004	Aug 26, 2010	May	DISC

ALISKIREN HEMIFUMARATE; AMLODIPINE BESYLATE; HYDROCHLOROTHIAZIDE

TABLET; ORAL

AMTURNIDE

@	NOVARTIS	EQ 150MG BASE;EQ 5MG BASE;12.5MG	N200045	001	Dec 21, 2010	May DISC
@		EQ 300MG BASE;EQ 5MG BASE;12.5MG	N200045	002	Dec 21, 2010	May DISC
@		EQ 300MG BASE;EQ 5MG BASE;25MG	N200045	003	Dec 21, 2010	May DISC
@		EQ 300MG BASE;EQ 10MG BASE;12.5MG	N200045	004	Dec 21, 2010	May DISC
@		EQ 300MG BASE;EQ 10MG BASE;25MG	N200045	005	Dec 21, 2010	May DISC

ALMOTRIPTAN MALATE

TABLET; ORAL

ALMOTRIPTAN MALATE

>A>	AB	MYLAN PHARMS INC	EQ 6.25MG BASE	A205171	001	Nov 09, 2015	Oct NEWA
>A>	AB		EQ 12.5MG BASE	A205171	002	Nov 09, 2015	Oct NEWA
	AB	TEVA PHARMS USA	EQ 6.25MG BASE	A078027	001	Jul 07, 2015	Jun NEWA
	AB		EQ 12.5MG BASE	A078027	002	Jul 07, 2015	Jun NEWA
		AXERT					
	AB	JANSSEN PHARMS	EQ 6.25MG BASE	N021001	001	May 07, 2001	Jun CFTG
	AB	+	EQ 12.5MG BASE	N021001	002	May 07, 2001	Jun CFTG

ALOSETRON HYDROCHLORIDE

TABLET; ORAL

ALOSETRON HYDROCHLORIDE

	AB	ROXANE	EQ 0.5MG BASE	A200652	001	May 04, 2015	Apr NEWA
	AB		EQ 1MG BASE	A200652	002	May 04, 2015	Apr NEWA
		LOTRONEX					
	AB	PROMETHEUS LABS	EQ 0.5MG BASE	N021107	002	Dec 23, 2003	Apr CFTG
	AB	+	EQ 1MG BASE	N021107	001	Feb 09, 2000	Apr CFTG

ALPRAZOLAM

TABLET; ORAL

ALPRAZOLAM

	@	ANI PHARMS INC	0.25MG	A074085	001	Feb 16, 1994	Jul CAHN
	@		0.5MG	A074085	002	Feb 16, 1994	Jul CAHN
	@		1MG	A074085	003	Feb 16, 1994	Jul CAHN
	@		2MG	A074085	004	Feb 26, 1996	Jul CAHN
	AB	AUROBINDO PHARMA LTD	0.25MG	A203346	001	Jul 31, 2015	Jul NEWA
	AB		0.5MG	A203346	002	Jul 31, 2015	Jul NEWA
	AB		1MG	A203346	003	Jul 31, 2015	Jul NEWA
	AB		2MG	A203346	004	Jul 31, 2015	Jul NEWA
	AB	NATCO PHARMA LTD	0.25MG	A200739	001	Apr 15, 2015	Mar NEWA
	AB		0.5MG	A200739	002	Apr 15, 2015	Mar NEWA
	AB		1MG	A200739	003	Apr 15, 2015	Mar NEWA
	AB		2MG	A200739	004	Apr 15, 2015	Mar NEWA

TABLET, EXTENDED RELEASE; ORAL

ALPRAZOLAM

	AB	HERITAGE PHARMS INC	0.5MG	A078489	001	Oct 17, 2008	Sep CAHN
	AB		1MG	A078489	002	Oct 17, 2008	Sep CAHN
	AB		2MG	A078489	003	Oct 17, 2008	Sep CAHN
	AB		3MG	A078489	004	Oct 17, 2008	Sep CAHN

AMANTADINE HYDROCHLORIDE

CAPSULE; ORAL

AMANTADINE HYDROCHLORIDE

	AB	BANNER LIFE SCIENCES	100MG	A078720	001	May 29, 2008	Jan CAHN
--	----	----------------------	-------	---------	-----	--------------	----------

SYRUP; ORAL

AMANTADINE HYDROCHLORIDE

	@	G AND W LABS INC	50MG/5ML	A072655	001	Oct 30, 1990	May CAHN	
>D>	AA	+	SILARX	50MG/5ML	A076352	001	Sep 10, 2004	Oct DISC
>A>		@		50MG/5ML	A076352	001	Sep 10, 2004	Oct DISC
>D>	AA	+	VINTAGE	50MG/5ML	A077992	001	Dec 12, 2006	Oct DISC
>A>		@		50MG/5ML	A077992	001	Dec 12, 2006	Oct DISC

AMIKACIN SULFATE

INJECTABLE; INJECTION

AMIKACIN SULFATE

@	IGI LABS INC	EQ 50MG BASE/ML	A063167	001	Dec 14, 1995	Mar CAHN
@		EQ 250MG BASE/ML	A063169	001	Dec 14, 1995	Mar CAHN

AMILORIDE HYDROCHLORIDE

TABLET;ORAL

AMILORIDE HYDROCHLORIDE

AB	ZYDUS PHARMS USA INC	5MG	A204180	001	Aug 07, 2015	Jul	NEWA
----	----------------------	-----	---------	-----	--------------	-----	------

AMINO ACIDS

INJECTABLE;INJECTION

BRANCHAMIN 4% IN PLASTIC CONTAINER

@ BAXTER HLTHCARE	4% (4GM/100ML)	N018684	001	Sep 28, 1984	Feb	DISC
-------------------	----------------	---------	-----	--------------	-----	------

AMINO ACIDS; MAGNESIUM CHLORIDE; POTASSIUM PHOSPHATE, DIBASIC; SODIUM ACETATE; SODIUM CHLORIDE

INJECTABLE;INJECTION

TRAVASOL 3.5% SULFITE FREE W/ ELECTROLYTES IN PLASTIC CONTAINER

@ BAXTER HLTHCARE	3.5%;51MG/100ML;131MG/100ML;218MG/100ML;35MG/100ML	N020177	001	Oct 23, 1995	Feb	DISC
-------------------	--	---------	-----	--------------	-----	------

AMINOCAPROIC ACID

SYRUP;ORAL

AMINOCAPROIC ACID

AA	VERSAPHARM INC	1.25GM/5ML	A074759	001	Sep 02, 1998	May	CAHN
----	----------------	------------	---------	-----	--------------	-----	------

TABLET;ORAL

AMINOCAPROIC

AB	VERSAPHARM INC	500MG	A075602	001	May 24, 2001	May	CAHN
----	----------------	-------	---------	-----	--------------	-----	------

AMITRIPTYLINE HYDROCHLORIDE

TABLET;ORAL

AMITRIPTYLINE HYDROCHLORIDE

@ ANI PHARMS INC	10MG	A084910	003		Aug	CAHN
@	25MG	A085031	001		Aug	CAHN
@	50MG	A085032	001		Aug	CAHN
@	75MG	A085030	001		Aug	CAHN

AMITRIPTYLINE HYDROCHLORIDE; CHLORDIAZEPOXIDE

TABLET;ORAL

LIMBITROL

@ HERITAGE PHARMS INC	EQ 12.5MG BASE;5MG	N016949	001		Jul	CAHN
-----------------------	--------------------	---------	-----	--	-----	------

LIMBITROL DS

@ HERITAGE PHARMS INC	EQ 25MG BASE;10MG	N016949	002		Jul	CAHN
-----------------------	-------------------	---------	-----	--	-----	------

AMLODIPINE BESYLATE

TABLET;ORAL

AMLODIPINE BESYLATE

AB	CHINA RESOURCES	EQ 5MG BASE	A090752	001	Apr 15, 2011	Mar	CAHN
AB		EQ 10MG BASE	A090752	002	Apr 15, 2011	Mar	CAHN
AB	MYLAN PHARMS INC	EQ 2.5MG BASE	A078224	001	Feb 27, 2008	Sep	CAHN
AB		EQ 5MG BASE	A078224	002	Feb 27, 2008	Sep	CAHN
AB		EQ 10MG BASE	A078224	003	Feb 27, 2008	Sep	CAHN
AB	SOVEREIGN PHARMS	EQ 2.5MG BASE	A204900	001	Jul 23, 2015	Jul	NEWA
AB		EQ 5MG BASE	A204900	002	Jul 23, 2015	Jul	NEWA
AB		EQ 10MG BASE	A204900	003	Jul 23, 2015	Jul	NEWA
AB	SUN PHARM INDS LTD	EQ 2.5MG BASE	A077974	001	Jul 09, 2007	Apr	CAHN
AB		EQ 5MG BASE	A077974	002	Jul 09, 2007	Apr	CAHN
AB		EQ 10MG BASE	A077974	003	Jul 09, 2007	Apr	CAHN

AMLODIPINE BESYLATE; HYDROCHLOROTHIAZIDE; VALSARTAN

TABLET;ORAL

AMLODIPINE BESYLATE, VALSARTAN AND HYDROCHLOROTHIAZIDE

AB	LUPIN LTD	5MG;12.5MG;160MG	A200797	001	Jun 03, 2015	May	NEWA
AB		5MG;25MG;160MG	A200797	002	Jun 03, 2015	May	NEWA
AB		10MG;12.5MG;160MG	A200797	003	Jun 03, 2015	May	NEWA
AB		10MG;25MG;160MG	A200797	004	Jun 03, 2015	May	NEWA
AB		10MG;25MG;320MG	A200797	005	Jun 03, 2015	May	NEWA
AB	PAR PHARM	5MG;12.5MG;160MG	A201087	001	Jun 01, 2015	May	NEWA
AB		5MG;25MG;160MG	A201087	002	Jun 01, 2015	May	NEWA
AB		10MG;12.5MG;160MG	A201087	003	Jun 01, 2015	May	NEWA
AB		10MG;25MG;160MG	A201087	004	Jun 01, 2015	May	NEWA
AB		10MG;25MG;320MG	A201087	005	Jun 01, 2015	May	NEWA
AB	TEVA PHARMS	5MG;12.5MG;160MG	A200435	001	Sep 25, 2012	May	CAIN
AB		5MG;25MG;160MG	A200435	002	Sep 25, 2012	May	CAIN
AB		10MG;12.5MG;160MG	A200435	005	Sep 25, 2012	May	CAIN
AB		10MG;25MG;160MG	A200435	003	Sep 25, 2012	May	CAIN

TABLET;ORAL

AMLODIPINE BESYLATE, VALSARTAN AND HYDROCHLOROTHIAZIDE

AB		10MG;25MG;320MG	A200435	004	Sep 25, 2012	May CAIN
AB	TORRENT PHARMS LTD	5MG;12.5MG;160MG	A201593	001	Jun 03, 2015	Sep CMS1
AB		5MG;12.5MG;160MG	A201593	001	Jun 04, 2015	May NEWA
AB		5MG;25MG;160MG	A201593	002	Jun 03, 2015	Sep CMS1
AB		5MG;25MG;160MG	A201593	002	Jun 04, 2015	May NEWA
AB		10MG;12.5MG;160MG	A201593	003	Jun 03, 2015	Sep CMS1
AB		10MG;12.5MG;160MG	A201593	003	Jun 04, 2015	May NEWA
AB		10MG;25MG;160MG	A201593	004	Jun 03, 2015	Sep CMS1
AB		10MG;25MG;160MG	A201593	004	Jun 04, 2015	May NEWA
AB		10MG;25MG;320MG	A201593	005	Jun 03, 2015	Sep CMS1
AB		10MG;25MG;320MG	A201593	005	Jun 04, 2015	May NEWA

AMLODIPINE BESYLATE; PERINDOPRIL ARGININE

TABLET;ORAL

PRESTALIA

	SYMPLMED PHARMS LLC	EQ 2.5MG BASE;3.5MG	N205003	001	Jan 21, 2015	Jan NEWA
		EQ 5MG BASE;7MG	N205003	002	Jan 21, 2015	Jan NEWA
+		EQ 10MG BASE;14MG	N205003	003	Jan 21, 2015	Jan NEWA

AMLODIPINE BESYLATE; VALSARTAN

TABLET;ORAL

AMLODIPINE BESYLATE AND VALSARTAN

AB	ALEMBIC PHARMS LTD	EQ 5MG BASE;160MG	A202713	001	Apr 03, 2015	Mar NEWA
AB		EQ 5MG BASE;320MG	A202713	003	Apr 03, 2015	Mar NEWA
AB		EQ 10MG BASE;160MG	A202713	002	Apr 03, 2015	Mar NEWA
AB		EQ 10MG BASE;320MG	A202713	004	Apr 03, 2015	Mar NEWA
AB	LUPIN	EQ 5MG BASE;160MG	A090245	001	Mar 30, 2015	Mar NEWA
AB		EQ 5MG BASE;320MG	A090245	003	Mar 30, 2015	Mar NEWA
AB		EQ 10MG BASE;160MG	A090245	002	Mar 30, 2015	Mar NEWA
AB		EQ 10MG BASE;320MG	A090245	004	Mar 30, 2015	Mar NEWA
AB	MATRIX LABS LTD	EQ 5MG BASE;160MG	A090483	001	Mar 30, 2015	Mar NEWA
AB		EQ 5MG BASE;320MG	A090483	003	Mar 30, 2015	Mar NEWA
AB		EQ 10MG BASE;160MG	A090483	002	Mar 30, 2015	Mar NEWA
AB		EQ 10MG BASE;320MG	A090483	004	Mar 30, 2015	Mar NEWA
AB	MYLAN PHARMS INC	EQ 5MG BASE;160MG	A090483	001	Mar 30, 2015	Apr CAHN
AB		EQ 5MG BASE;320MG	A090483	003	Mar 30, 2015	Apr CAHN
AB		EQ 10MG BASE;160MG	A090483	002	Mar 30, 2015	Apr CAHN
AB		EQ 10MG BASE;320MG	A090483	004	Mar 30, 2015	Apr CAHN
AB	NOVEL LABS INC	EQ 5MG BASE;160MG	A202829	001	Mar 30, 2015	Mar NEWA
AB		EQ 5MG BASE;320MG	A202829	003	Mar 30, 2015	Mar NEWA
AB		EQ 10MG BASE;160MG	A202829	002	Mar 30, 2015	Mar NEWA
AB		EQ 10MG BASE;320MG	A202829	004	Mar 30, 2015	Mar NEWA
AB	TEVA PHARMS USA	EQ 5MG BASE;160MG	A091235	001	Mar 30, 2015	Mar NEWA
AB		EQ 5MG BASE;320MG	A091235	003	Mar 30, 2015	Mar NEWA
AB		EQ 10MG BASE;160MG	A091235	002	Mar 30, 2015	Mar NEWA
AB		EQ 10MG BASE;320MG	A091235	004	Mar 30, 2015	Mar NEWA
AB	TORRENT PHARMS LTD	EQ 5MG BASE;160MG	A202377	001	Mar 30, 2015	Mar NEWA
AB		EQ 5MG BASE;320MG	A202377	002	Mar 30, 2015	Mar NEWA
AB		EQ 10MG BASE;160MG	A202377	003	Mar 30, 2015	Mar NEWA
AB		EQ 10MG BASE;320MG	A202377	004	Mar 30, 2015	Mar NEWA

AMMONIA N-13

INJECTABLE;INTRAVENOUS

AMMONIA N 13

>A>	AP	3D IMAGING DRUG	30mCi-300mCi/8ML (3.75-37.5mCi/ML)	A203779	001	Oct 19, 2015	Oct NEWA
	AP	BIOMEDCL RES FDN	48.75mCi-487.5mCi/13ML (3.75-37.5mCi/ML)	A204352	001	May 01, 2015	Apr NEWA
		CENTRAL RADIOPHARM	3.75-260mCi/ML	A204539	001	Jun 23, 2015	Jun NEWA
	AP	IBA MOLECULAR N AM	18.8mCi-188mCi/5ML (3.75-37.5mCi/ML)	A204667	001	Apr 22, 2015	Apr NEWA
		NCM USA BRONX LLC	3.75-260mCi/mL	A204515	001	Feb 04, 2015	Jan NEWA
>A>	AP	PETNET	30mCi-300mCi (3.75-37.5mCi/ML)	A204510	001	Nov 02, 2015	Oct NEWA
		PRECISION NUCLEAR	3.75-260mCi/ML	A204547	001	Aug 14, 2015	Aug NEWA
	AP	SPECTRON MRC LLC	30mCi-300mCi/8ML (3.75-37.5mCi/ML)	A204455	001	Apr 23, 2015	Apr NEWA

AMOXICILLIN

CAPSULE;ORAL

AMOXICILLIN

AB	SUN PHARM INDS LTD	250MG	A065016	001	Apr 08, 1999	Apr CAHN
AB		500MG	A065016	002	Apr 08, 1999	Apr CAHN

FOR SUSPENSION;ORAL

AMOXICILLIN

@ SUN PHARM INDS LTD

200MG/5ML

A 065113 001 Nov 29, 2002 Apr CAHN

@

400MG/5ML

A 065113 002 Nov 29, 2002 Apr CAHN

TABLET;ORAL

AMOXICILLIN

AB SUN PHARM INDS LTD

500MG

A 065059 001 Nov 24, 2000 Apr CAHN

AB

875MG

A 065059 002 Nov 24, 2000 Apr CAHN

TABLET, CHEWABLE;ORAL

AMOXICILLIN

AB SUN PHARM INDS LTD

125MG

A 065021 001 Dec 23, 1999 Apr CAHN

@

200MG

A 065060 001 Nov 29, 2000 Apr CAHN

AB

250MG

A 065021 002 Dec 23, 1999 Apr CAHN

@

400MG

A 065060 002 Nov 29, 2000 Apr CAHN

AMOXICILLIN; CLAVULANATE POTASSIUM

FOR SUSPENSION;ORAL

AMOXICILLIN AND CLAVULANATE POTASSIUM

AB SUN PHARM INDS LTD 200MG/5ML;EQ 28.5MG BASE/5ML

A 065132 001 Mar 19, 2003 Apr CAHN

AB 400MG/5ML;EQ 57MG BASE/5ML

A 065132 002 Mar 19, 2003 Apr CAHN

AB 600MG/5ML;EQ 42.9MG BASE/5ML

A 065207 002 Jan 30, 2007 Apr CAHN

TABLET;ORAL

AMOXICILLIN AND CLAVULANATE POTASSIUM

AB @ SUN PHARM INDS LTD 500MG;EQ 125MG BASE

A 065109 001 Nov 04, 2002 Apr CAHN

AB 875MG;EQ 125MG BASE

A 065102 001 Sep 17, 2002 Apr CAHN

TABLET, CHEWABLE;ORAL

AMOXICILLIN AND CLAVULANATE POTASSIUM

AB SUN PHARM INDS LTD 200MG;EQ 28.5MG BASE

A 065161 001 Dec 03, 2003 Apr CAHN

AB 400MG;EQ 57MG BASE

A 065161 002 Dec 03, 2003 Apr CAHN

AMPHETAMINE

>A> SUSPENSION, EXTENDED RELEASE;ORAL

>A> DYANAVAL XR

>A> + TRIS PHARMA INC EQ 2.5MG BASE/ML

N 208147 001 Oct 19, 2015 Oct NEWA

AMPHETAMINE ASPARTATE; AMPHETAMINE SULFATE; DEXTROAMPHETAMINE SACCHARATE; DEXTROAMPHETAMINE SULFATE

TABLET;ORAL

DEXTROAMP SACCHARATE, AMP ASPARTATE, DEXTROAMP SULFATE AND AMP SULFATE

AB COREPHARMA 1.875MG;1.875MG;1.875MG;1.875MG

A 040444 005 Nov 03, 2014 May NEWA

AB 3.125MG;3.125MG;3.125MG;3.125MG

A 040444 006 Nov 03, 2014 May NEWA

AB 3.75MG;3.75MG;3.75MG;3.75MG

A 040444 007 Nov 03, 2014 May NEWA

>A> AB MYLAN PHARMS INC 1.25MG;1.25MG;1.25MG;1.25MG

A 206721 001 Nov 10, 2015 Oct NEWA

>A> AB 1.875MG;1.875MG;1.875MG;1.875MG

A 206721 002 Nov 10, 2015 Oct NEWA

>A> AB 2.5MG;2.5MG;2.5MG;2.5MG

A 206721 003 Nov 10, 2015 Oct NEWA

>A> AB 3.125MG;3.125MG;3.125MG;3.125MG

A 206721 004 Nov 10, 2015 Oct NEWA

>A> AB 3.75MG;3.75MG;3.75MG;3.75MG

A 206721 005 Nov 10, 2015 Oct NEWA

>A> AB 5MG;5MG;5MG;5MG

A 206721 006 Nov 10, 2015 Oct NEWA

>A> AB 7.5MG;7.5MG;7.5MG;7.5MG

A 206721 007 Nov 10, 2015 Oct NEWA

AMPHETAMINE SULFATE

TABLET;ORAL

EVEKEO

ARBOR PHARMS LLC

5MG

A 200166 001 Aug 09, 2012 Mar CTNA

+

10MG

A 200166 002 Aug 09, 2012 Mar CTNA

AMPICILLIN SODIUM

INJECTABLE;INJECTION

AMPICILLIN SODIUM

AP HOSPIRA INC EQ 250MG BASE/VIAL

A 202864 001 Sep 04, 2015 Aug NEWA

AP EQ 500MG BASE/VIAL

A 202864 002 Sep 04, 2015 Aug NEWA

AP EQ 1GM BASE/VIAL

A 202864 003 Sep 04, 2015 Aug NEWA

AP EQ 2GM BASE/VIAL

A 202864 004 Sep 04, 2015 Aug NEWA

AP EQ 10GM BASE/VIAL

A 202865 001 Sep 04, 2015 Aug NEWA

>A> AP SAGENT PHARMS EQ 10GM BASE/VIAL

A 090581 001 Oct 20, 2015 Oct NEWA

AMPICILLIN/AMPICILLIN TRIHYDRATE; PROBENECID

FOR SUSPENSION;ORAL

PROBAMPACIN

@ G AND W LABS INC

EQ 3.5GM BASE/BOT;1GM/BOT

A 061741 001

Apr CAHN

ANASTROZOLETABLET; ORAL
ANASTROZOLE

@ KREMERS URBAN PHARMS 1MG A091331 001 Jan 05, 2011 Mar CAHN

ARGATROBANINJECTABLE; INJECTION
ARGATROBANAP FRESSENIUS KABI USA 250MG/2.5ML (100MG/ML) N201811 001 Mar 23, 2015 Apr CDFR
AP + PFIZER 250MG/2.5ML (100MG/ML) N020883 001 Jun 30, 2000 Aug CTNAINJECTABLE; IV (INFUSION)
ARGATROBAN

AP FRESSENIUS KABI USA 250MG/2.5ML (100MG/ML) N201811 001 Mar 23, 2015 Mar NEWA

ARIPIPIRAZOLESOLUTION; ORAL
ARIPIPIRAZOLEAA AMNEAL PHARMS 1MG/ML A203906 001 Aug 14, 2015 Aug NEWA
AA APOTEX INC 1MG/ML A204094 001 Sep 30, 2015 Sep NEWA
AA SILARX PHARMS INC 1MG/ML A204171 001 Aug 14, 2015 Aug NEWA

TABLET; ORAL

ABILIFY

AB OTSUKA 2MG N021436 006 Nov 15, 2002 Apr CFTG
AB + 5MG N021436 005 Nov 15, 2002 Apr CFTG
AB + 10MG N021436 001 Nov 15, 2002 Apr CFTG
AB 15MG N021436 002 Nov 15, 2002 Apr CFTG
AB 20MG N021436 003 Nov 15, 2002 Apr CFTG
AB 30MG N021436 004 Nov 15, 2002 Apr CFTG

ARIPIPIRAZOLE

AB ALEMBIC PHARMS LTD 2MG A202101 001 Apr 28, 2015 Apr NEWA
AB 5MG A202101 002 Apr 28, 2015 Apr NEWA
AB 10MG A202101 003 Apr 28, 2015 Apr NEWA
AB 15MG A202101 004 Apr 28, 2015 Apr NEWA
AB 20MG A202101 005 Apr 28, 2015 Apr NEWA
AB 30MG A202101 006 Apr 28, 2015 Apr NEWA
AB APOTEX INC 2MG A078583 001 Jul 24, 2015 Jul NEWA
AB 5MG A078583 002 Jul 24, 2015 Jul NEWA
AB 10MG A078583 003 Jul 24, 2015 Jul NEWA
AB 15MG A078583 004 Jul 24, 2015 Jul NEWA
AB 20MG A078583 005 Jul 24, 2015 Jul NEWA
AB 30MG A078583 006 Jul 24, 2015 Jul NEWA
AB AUROBINDO PHARMA LTD 2MG A203908 001 Oct 08, 2015 Sep NEWA
AB 5MG A203908 002 Oct 08, 2015 Sep NEWA
AB 10MG A203908 003 Oct 08, 2015 Sep NEWA
AB 15MG A203908 004 Oct 08, 2015 Sep NEWA
AB 20MG A203908 005 Oct 08, 2015 Sep NEWA
AB 30MG A203908 006 Oct 08, 2015 Sep NEWA
AB HETERO LABS LTD V 2MG A205064 001 Apr 28, 2015 Apr NEWA
AB 5MG A205064 002 Apr 28, 2015 Apr NEWA
AB 10MG A205064 003 Apr 28, 2015 Apr NEWA
AB 15MG A205064 004 Apr 28, 2015 Apr NEWA
AB 20MG A205064 005 Apr 28, 2015 Apr NEWA
AB 30MG A205064 006 Apr 28, 2015 Apr NEWA
AB TEVA PHARMS USA 2MG A078607 001 Apr 28, 2015 Apr NEWA
AB 5MG A078607 002 Apr 28, 2015 Apr NEWA
AB 10MG A078608 001 Apr 28, 2015 Apr NEWA
AB 15MG A078708 001 Apr 28, 2015 Apr NEWA
AB 20MG A078708 002 Apr 28, 2015 Apr NEWA
AB 30MG A078708 003 Apr 28, 2015 Apr NEWA
AB TORRENT PHARMS LTD 2MG A201519 001 Apr 28, 2015 Apr NEWA
AB 10MG A201519 003 Apr 28, 2015 Apr NEWA
AB 5MG A201519 002 Apr 28, 2015 Apr NEWA
AB 15MG A201519 004 Apr 28, 2015 Apr NEWA
AB 20MG A201519 005 Apr 28, 2015 Apr NEWA
AB 30MG A201519 006 Apr 28, 2015 Apr NEWA

TABLET, ORALLY DISINTEGRATING; ORAL

ABILIFY

AB + OTSUKA 10MG N021729 002 Jun 07, 2006 Apr CFTG
AB 15MG N021729 003 Jun 07, 2006 Apr CFTG

ARIPIPIRAZOLE

AB ALEMBIC PHARMS LTD 10MG A202102 001 Apr 28, 2015 Apr NEWA
AB 15MG A202102 002 Apr 28, 2015 Apr NEWA

>A>	<u>ARIPIPRAZOLE LAUROXIL</u>							
>A>	SUSPENSION, EXTENDED RELEASE;INTRAMUSCULAR							
>A>	ARISTADA							
>A>	ALKERMES INC	441MG/1.6ML (275.63MG/ML)	N207533	001	Oct 05, 2015	Oct	NEWA	
>A>		662MG/2.4ML (275.83MG/ML)	N207533	002	Oct 05, 2015	Oct	NEWA	
>A>	+	882MG/3.2ML (275.63MG/ML)	N207533	003	Oct 05, 2015	Oct	NEWA	
<u>ASCORBIC ACID; BIOTIN; CYANOCOBALAMIN; DEXPANTHENOL; ERGOCALCIFEROL; FOLIC ACID; NIACINAMIDE; PYRIDOXINE; RIBOFLAVIN 5'-PHOSPHATE SODIUM; THIAMINE; VITAMIN A; VITAMIN E</u>								
INJECTABLE;INJECTION								
M.V.I.-12 LYOPHILIZED								
	@ IGI LABS INC	100MG/VIAL;0.06MG/VIAL;0.005MG/VIAL;15MG/VIAL;5MCG/VIAL;0.4MG/VIAL;40MG/VIAL;4MG/VIAL;3.6MG/VIAL;3MG/VIAL;1MG/VIAL;10MG/VIAL	N018933	002	Aug 08, 1985	Jun	CAHN	
<u>ASCORBIC ACID; POLYETHYLENE GLYCOL 3350; POTASSIUM CHLORIDE; SODIUM ASCORBATE; SODIUM CHLORIDE; SODIUM SULFATE</u>								
FOR SOLUTION;ORAL								
	PEG-3350, SODIUM SULFATE, SODIUM CHLORIDE, POTASSIUM CHLORIDE, SODIUM ASCORBATE AND ASCORBIC ACID							
	@ NOVEL LABS INC	4.7GM;100GM;1.015GM;5.9GM;2.691GM;7.5GM	A090145	001	Jan 25, 2012	Aug	CTNA	
<u>ASENAPINE MALEATE</u>								
TABLET;SUBLINGUAL								
SAPHRIS								
	FOREST LABS LLC	EQ 5MG BASE	N022117	001	Aug 13, 2009	Jun	CAHN	
	+	EQ 10MG BASE	N022117	002	Aug 13, 2009	Jun	CAHN	
<u>ASPIRIN</u>								
CAPSULE, EXTENDED RELEASE;ORAL								
DURLAZA								
	+	NEW HAVEN PHARMS	162.5MG	N200671	001	Sep 04, 2015	Sep	NEWA
<u>ASPIRIN; BUTALBITAL; CAFFEINE</u>								
CAPSULE;ORAL								
FIORINAL								
AA	+	ACTAVIS LABS UT INC	325MG;50MG;40MG	N017534	005	Apr 16, 1986	Jan	CAHN
TABLET;ORAL								
FIORINAL								
	@ ACTAVIS LABS UT INC	325MG;50MG;40MG	N017534	003	Apr 16, 1986	Jan	CAHN	
<u>ASPIRIN; BUTALBITAL; CAFFEINE; CODEINE PHOSPHATE</u>								
CAPSULE;ORAL								
BUTALBITAL, ASPIRIN, CAFFEINE AND CODEINE PHOSPHATE								
>A> AB		COASTAL PHARMS	325MG;50MG;40MG;30MG	A203335	001	Oct 30, 2015	Oct	NEWA
FIORINAL W/CODEINE								
AB	+	ACTAVIS LABS UT INC	325MG;50MG;40MG;30MG	N019429	003	Oct 26, 1990	Jan	CAHN
<u>ASPIRIN; CAFFEINE; DIHYDROCODEINE BITARTRATE</u>								
CAPSULE;ORAL								
SYNALGOS-DC								
	+	SUN PHARM INDS	356.4MG;30MG;16MG	N011483	004	Sep 06, 1983	Aug	CAHN
<u>ASPIRIN; CAFFEINE; ORPHENADRINE CITRATE</u>								
TABLET;ORAL								
ORPHENADRINE CITRATE, ASPIRIN, AND CAFFEINE								
	SANDOZ	385MG;30MG;25MG	A074654	001	Dec 31, 1996	Mar	CTEC	
	+	770MG;60MG;50MG	A074654	002	Dec 31, 1996	Mar	CTEC	
<u>ASPIRIN; OXYCODONE HYDROCHLORIDE</u>								
TABLET;ORAL								
OXYCODONE AND ASPIRIN								
AA	ACTAVIS LABS FL INC	325MG;4.8355MG	A090084	001	Mar 22, 2011	Mar	CAHN	

ATAZANAVIR SULFATE; COBICISTAT

TABLET;ORAL

EVOTAZ

+	BRISTOL MYERS SQUIBB	EQ 300MG BASE;150MG	N206353	001	Jan 29, 2015	Jan NEWA
---	----------------------	---------------------	---------	-----	--------------	----------

ATENOLOL

TABLET;ORAL

ATENOLOL

AB	ALVOGEN IPCO SARL	25MG	A073646	001	Jul 31, 1992	Jul CAHN
AB		50MG	A072303	001	Jul 15, 1988	Jul CAHN
AB		100MG	A072304	001	Jul 15, 1988	Jul CAHN
	@ DAVA PHARMS INC	25MG	A074099	001	Apr 28, 1992	Jun DISC
	TENORMIN					
AB	ALVOGEN IPCO SARL	25MG	N018240	004	Apr 09, 1990	Feb CAHN
AB		50MG	N018240	001		Feb CAHN
AB	+	100MG	N018240	002		Feb CAHN

ATENOLOL; CHLORTHALIDONE

TABLET;ORAL

ATENOLOL AND CHLORTHALIDONE

AB	ALVOGEN IPCO SARL	50MG;25MG	A072301	001	May 31, 1990	Jul CAHN	
AB		100MG;25MG	A072302	001	May 31, 1990	Jul CAHN	
	TENORETIC 100						
AB	+	ALVOGEN IPCO SARL	100MG;25MG	N018760	001	Jun 08, 1984	Feb CAHN
	TENORETIC 50						
AB	ALVOGEN IPCO SARL	50MG;25MG	N018760	002	Jun 08, 1984	Feb CAHN	

ATORVASTATIN CALCIUM

TABLET;ORAL

ATORVASTATIN CALCIUM

AB	KREMERS URBAN PHARMS	EQ 10MG BASE	A091624	001	Apr 05, 2013	Mar CAHN
AB		EQ 20MG BASE	A091624	002	Apr 05, 2013	Mar CAHN
AB		EQ 40MG BASE	A091624	003	Apr 05, 2013	Mar CAHN
AB		EQ 80MG BASE	A091624	004	Apr 05, 2013	Mar CAHN
AB	SUN PHARM INDS LTD	EQ 10MG BASE	A076477	001	Nov 30, 2011	Apr CAHN
AB		EQ 20MG BASE	A076477	002	Nov 30, 2011	Apr CAHN
AB		EQ 40MG BASE	A076477	003	Nov 30, 2011	Apr CAHN
AB		EQ 80MG BASE	A076477	004	Nov 30, 2011	Apr CAHN

ATORVASTATIN CALCIUM; EZETIMIBE

TABLET;ORAL

LIPTRUZET

@ MERCK SHARP DOHME

EQ 10MG BASE;10MG

EQ 20MG BASE;10MG

@ EQ 40MG BASE;10MG

@ EQ 80MG BASE;10MG

N200153	001	May 03, 2013	May DISC
N200153	002	May 03, 2013	May DISC
N200153	003	May 03, 2013	May DISC
N200153	004	May 03, 2013	May DISC

ATOVAQUONE; PROGUANIL HYDROCHLORIDE

TABLET;ORAL

ATOVAQUONE AND PROGUANIL HYDROCHLORIDE

AB	GLENMARK GENERICS	62.5MG;25MG	A091211	002	Apr 06, 2015	Mar NEWA
----	-------------------	-------------	---------	-----	--------------	----------

ATRACURIUM BESYLATE

INJECTABLE;INJECTION

ATRACURIUM BESYLATE

AP	AUROBINDO PHARMA LTD	10MG/ML	A206011	001	Apr 08, 2015	Mar NEWA
	ATRACURIUM BESYLATE PRESERVATIVE FREE					
AP	AUROBINDO PHARMA LTD	10MG/ML	A206010	001	Apr 08, 2015	Mar NEWA

ATROPINE SULFATE

SOLUTION/DROPS;OPHTHALMIC

ATROPINE SULFATE

+	AKORN	1%	N206289	001	Jul 18, 2014	May CRLD
---	-------	----	---------	-----	--------------	----------

ATROPINE SULFATE; DIFENOXIN HYDROCHLORIDE

TABLET;ORAL

MOTOFEN

+	SEBELA IRELAND LTD	0.025MG;1MG	N017744	002		Feb CAHN
	MOTOFEN HALF-STRENGTH					
@	SEBELA IRELAND LTD	0.025MG;0.5MG	N017744	001		Feb CAHN

ATROPINE SULFATE; DIPHENOXYLATE HYDROCHLORIDE

TABLET;ORAL

DIPHENOXYLATE HYDROCHLORIDE AND ATROPINE SULFATE

@ ANI PHARMS INC

0.025MG;2.5MG

A086727 001

Jul CAHN

AVIBACTAM SODIUM; CEFTAZIDIME

POWDER;IV (INFUSION)

AVYCAZ

+ CEREXA INC

EQ 0.5GM BASE;2GM/VIAL

N206494 001 Feb 25, 2015

Feb NEWA

AZELAIC ACID

AEROSOL, FOAM;TOPICAL

FINACEA

+ BAYER HLTHCARE

15%

N207071 001 Jul 29, 2015

Jul NEWA

AZELASTINE HYDROCHLORIDE

SPRAY, METERED;NASAL

AZELASTINE HYDROCHLORIDE

AB BRECKENRIDGE PHARMS

EQ 0.125MG BASE/SPRAY

A090176 001 Jul 28, 2015

Jul NEWA

AZITHROMYCIN

FOR SUSPENSION;ORAL

AZITHROMYCIN

AB LUPIN LTD

EQ 100MG BASE/5ML

A065488 001 May 15, 2015

May NEWA

AB LUPIN LTD

EQ 200MG BASE/5ML

A065488 002 May 15, 2015

May NEWA

INJECTABLE;INJECTION

AZITHROMYCIN

AP AUROBINDO PHARMA LTD

EQ 500MG BASE/VIAL

A203294 001 Jun 19, 2015

Jun NEWA

TABLET;ORAL

AZITHROMYCIN

AB LUPIN LTD

EQ 250MG BASE

A065398 001 May 15, 2015

May NEWA

AB LUPIN LTD

EQ 500MG BASE

A065399 001 May 15, 2015

May NEWA

AB LUPIN LTD

EQ 600MG BASE

A065400 001 May 15, 2015

May NEWA

BALSALAZIDE DISODIUM

CAPSULE;ORAL

COLAZAL

AB + VALEANT PHARMS INTL

750MG

N020610 001 Jul 18, 2000

Jul CAHN

TABLET;ORAL

BALSALAZIDE DISODIUM

AB PAR PHARM INC

1.1GM

A206336 001 Sep 08, 2015

Aug NEWA

GIAZO

AB + VALEANT PHARMS INTL

1.1GM

N022205 001 Feb 03, 2012

Aug CFTG

+

1.1GM

N022205 001 Feb 03, 2012

Jul CAHN

BENAZEPRIL HYDROCHLORIDE

TABLET;ORAL

BENAZEPRIL HYDROCHLORIDE

AB AMNEAL PHARMS LLC

5MG

A076820 001 Feb 03, 2006

Jan CAHN

AB AMNEAL PHARMS LLC

10MG

A076820 002 Feb 03, 2006

Jan CAHN

AB AMNEAL PHARMS LLC

20MG

A076820 003 Feb 03, 2006

Jan CAHN

AB AMNEAL PHARMS LLC

40MG

A076820 004 Feb 03, 2006

Jan CAHN

AB SUN PHARM INDS LTD

5MG

A076344 001 Feb 11, 2004

Apr CAHN

AB SUN PHARM INDS LTD

10MG

A076344 002 Feb 11, 2004

Apr CAHN

AB SUN PHARM INDS LTD

20MG

A076344 003 Feb 11, 2004

Apr CAHN

AB SUN PHARM INDS LTD

40MG

A076344 004 Feb 11, 2004

Apr CAHN

BENAZEPRIL HYDROCHLORIDE; HYDROCHLOROTHIAZIDE

TABLET;ORAL

BENAZEPRIL HYDROCHLORIDE AND HYDROCHLOROTHIAZIDE

AB SUN PHARM INDS LTD

5MG;6.25MG

A077483 001 Sep 08, 2005

Apr CAHN

AB SUN PHARM INDS LTD

10MG;12.5MG

A077483 002 Sep 08, 2005

Apr CAHN

AB SUN PHARM INDS LTD

20MG;12.5MG

A077483 003 Sep 08, 2005

Apr CAHN

AB SUN PHARM INDS LTD

20MG;25MG

A077483 004 Sep 08, 2005

Apr CAHN

BENZONATATECAPSULE;ORAL
BENZONATATE

AA	APOTEX INC	100MG	A091310	001	Jan 16, 2015	Jan NEWA
AA		200MG	A091310	002	Jan 16, 2015	Jan NEWA
AA	BANNER LIFE SCIENCES	100MG	A081297	001	Jan 29, 1993	Jan CAHN
AA		200MG	A081297	002	Oct 30, 2007	Jan CAHN
AA	CSPC NBP PHARM CO	200MG	A202765	001	Jul 31, 2015	Jul NEWA
AA	STRIDES ARCOLAB LTD	100MG	A091133	001	Jul 30, 2015	Jul NEWA
AA		200MG	A091133	002	Jul 30, 2015	Jul NEWA
AA	STRIDES PHARMA	100MG	A091133	001	Jul 30, 2015	Aug CAHN
AA		200MG	A091133	002	Jul 30, 2015	Aug CAHN

BENZOYL PEROXIDE; CLINDAMYCIN PHOSPHATEGEL;TOPICAL
ACANYA

AB	+ DOW PHARM	2.5%;EQ 1.2% BASE	N050819	001	Oct 23, 2008	Jun CFTG
	CLINDAMYCIN PHOSPHATE AND BENZOYL PEROXIDE					
AB	ACTAVIS LABS UT INC	2.5%;EQ 1.2% BASE	A205128	001	Jun 19, 2015	Jun NEWA
AB	PERRIGO ISRAEL	5%;EQ 1% BASE	A202440	001	Sep 21, 2015	Sep NEWA
	ONEXTON					
	+ DOW PHARM	3.75%;EQ 1.2% BASE	N050819	002	Nov 24, 2014	Jan CRLD

BENZOYL PEROXIDE; ERYTHROMYCINGEL;TOPICAL
ERYTHROMYCIN AND BENZOYL PEROXIDE

AB	LYNE	5%;3%	A065385	001	Sep 18, 2015	Sep NEWA
----	------	-------	---------	-----	--------------	----------

BENZPHETAMINE HYDROCHLORIDETABLET;ORAL
BENZPHETAMINE HYDROCHLORIDE

AA	+ KVK TECH	50MG	A090968	001	Jul 20, 2010	Jun CRLD
	DIDREX					
	@ PHARMACIA AND UPJOHN	50MG	N012427	002		Jun DISC

BENZTROPINE MESYLATETABLET;ORAL
BENZTROPINE MESYLATE

AA	NUVO PHARM INC	0.5MG	A204713	001	Apr 14, 2015	Mar NEWA
AA		1MG	A204713	002	Apr 14, 2015	Mar NEWA
AA		2MG	A204713	003	Apr 14, 2015	Mar NEWA

BETAMETHASONE DIPROPIONATELOTION;TOPICAL
BETAMETHASONE DIPROPIONATE

AB	G AND W LABS INC	EQ 0.05% BASE	A071467	001	Aug 10, 1987	Apr CAHN
	@	EQ 0.05% BASE	A071882	001	Jun 06, 1988	Apr CAHN

BETAMETHASONE DIPROPIONATE; CALCIPOTRIENE

>A>	AEROSOL, FOAM;TOPICAL					
>A>	ENSTILAR					
>A>	+ LEO PHARMA AS	0.064%;0.005%	N207589	001	Oct 16, 2015	Oct NEWA

BETAMETHASONE DIPROPIONATE; CLOTRIMAZOLECREAM;TOPICAL
CLOTRIMAZOLE AND BETAMETHASONE DIPROPIONATE

>A> AB	GLENMARK PHARMS LTD	EQ 0.05% BASE;1%	A202894	001	Oct 30, 2015	Oct NEWA
--------	---------------------	------------------	---------	-----	--------------	----------

BETAMETHASONE VALERATECREAM;TOPICAL
BETA-VAL

AB	G AND W LABS INC	EQ 0.1% BASE	N018642	001	Mar 24, 1983	Aug CAHN
----	------------------	--------------	---------	-----	--------------	----------

LOTION;TOPICAL
BETA-VAL

AB	G AND W LABS INC	EQ 0.1% BASE	A070072	001	Jun 27, 1985	Apr CAHN
----	------------------	--------------	---------	-----	--------------	----------

OINTMENT;TOPICAL
BETA-VAL

>A> AB	G AND W LABS INC	EQ 0.1% BASE	A070069	001	Dec 19, 1985	Oct CAHN
>D>	@ TEVA	EQ 0.1% BASE	A070069	001	Dec 19, 1985	Oct CAHN

BETHANECHOL CHLORIDE

TABLET;ORAL

BETHANECHOL CHLORIDE

AA	HERITAGE PHARMA	5MG	A091256	001	May 04, 2010	Mar CAHN
AA		10MG	A091256	002	May 04, 2010	Mar CAHN
AA		25MG	A091256	003	May 04, 2010	Mar CAHN
AA		50MG	A091256	004	May 04, 2010	Mar CAHN
AA	LANNETT HOLDINGS INC	5MG	A040703	001	Mar 27, 2008	Feb CMFD
AA		50MG	A040677	001	Mar 27, 2008	Feb CMFD
	DUVOID					
AA	WELLSPRING PHARM	10MG	A086262	001		Jan CMFD
AA		25MG	A086263	001		May CMFD
AA		50MG	A085882	003		May CMFD

BEXAROTENE

CAPSULE;ORAL

BEXAROTENE

AB	BANNER LIFE SCIENCES	75MG	A203174	001	Aug 12, 2014	Jun CMFD
	@	75MG	A203174	001	Aug 12, 2014	Jan CAHN
	TARGRETIN					
AB	+ VALEANT LUXEMBOURG	75MG	N021055	001	Dec 29, 1999	Jun CTEC

BICALUTAMIDE

TABLET;ORAL

BICALUTAMIDE

AB	APOTEX INC	50MG	A200274	001	May 21, 2015	May NEWA
AB	STASON PHARMS	50MG	A091011	001	Jun 10, 2015	May NEWA

BIMATOPROST

SOLUTION/DROPS;OPHTHALMIC

BIMATOPROST

AT	ALCON RES LTD	0.03%	A202565	001	May 05, 2015	Apr NEWA
AT	APOTEX INC	0.03%	A090449	001	Jul 20, 2015	Jul NEWA
AT	+ LUPIN LTD	0.03%	A203991	001	Feb 20, 2015	Apr CTEC
	+	0.03%	A203991	001	Feb 20, 2015	Mar CTEC
AT	+	0.03%	A203991	001	Feb 20, 2015	Feb NEWA

BIPERIDEN HYDROCHLORIDE

TABLET;ORAL

AKINETON

@ ABBVIE

2MG

N012003 001 Aug DISC

BISMUTH SUBCITRATE POTASSIUM; METRONIDAZOLE; TETRACYCLINE

CAPSULE;ORAL

PYLERA

+	FOREST LABS LLC	140MG;125MG;125MG	N050786	001	Sep 28, 2006	Jul CAHN
---	-----------------	-------------------	---------	-----	--------------	----------

BIVALIRUDIN

INJECTABLE;INTRAVENOUS

BIVALIRUDIN

AP	HOSPIRA INC	250MG/VIAL	A090811	001	Jul 14, 2015	Jun NEWA
AP		250MG/VIAL	A090816	001	Jul 14, 2015	Jun NEWA

BOSUTINIB MONOHYDRATE

TABLET;ORAL

BOSULIF

+	WYETH PHARMS INC	EQ 100MG BASE	N203341	001	Sep 04, 2012	Jun CRLD
		EQ 500MG BASE	N203341	002	Sep 04, 2012	Jun CRLD

BREXPIRAZOLE

TABLET;ORAL

REXULTI

	OTSUKA PHARM CO LTD	0.25MG	N205422	001	Jul 10, 2015	Jul NEWA
		0.5MG	N205422	002	Jul 10, 2015	Jul NEWA
		1MG	N205422	003	Jul 10, 2015	Jul NEWA
		2MG	N205422	004	Jul 10, 2015	Jul NEWA
		3MG	N205422	005	Jul 10, 2015	Jul NEWA
+		4MG	N205422	006	Jul 10, 2015	Jul NEWA

BROMFENAC SODIUM

		SOLUTION/DROPS;OPHTHALMIC					
		BROMDAY					
AT2	+	@ BAUSCH AND LOMB INC	EQ 0.09% ACID	N021664	002	Oct 16, 2010	Sep DISC
			EQ 0.09% ACID	N021664	002	Oct 16, 2010	May CTEC
		BROMFENAC SODIUM					
AT2		APOTEX INC	EQ 0.09% ACID	A202620	001	Jun 23, 2014	May CTEC
AT1	+	COASTAL PHARMS	EQ 0.09% ACID	A201211	001	May 11, 2011	May CRLD
AT2		HI-TECH PHARMACAL	EQ 0.09% ACID	A203395	001	Jan 22, 2014	May CTEC
AT1		PADDOCK LLC	EQ 0.09% ACID	A201941	001	Feb 10, 2015	Jan NEWA

BUDESONIDE

AEROSOL, FOAM;RECTAL							
UCERIS							
+	VALEANT PHARMS INTL	2MG/ACTUATION	N205613	001	Oct 07, 2014	Apr	CAHN
SPRAY, METERED;NASAL							
BUDESONIDE							
	APOTEX INC	0.032MG/INH	A078949	001	May 12, 2014	Mar	CTEC
TABLET, EXTENDED RELEASE;ORAL							
UCERIS							
+	VALEANT PHARMS INTL	9MG	N203634	001	Jan 14, 2013	Aug	CAHN

BUMETANIDE

INJECTABLE;INJECTION							
BUMETANIDE							
AP		EUROHLTH INTL SARL	0.25MG/ML	A079196	001	Apr 30, 2008	Jun CAHN
TABLET;ORAL							
BUMEX							
>D>		@ VALIDUS PHARMS INC	0.5MG	N018225	002	Feb 28, 1983	Oct CMFD
>A>	AB		0.5MG	N018225	002	Feb 28, 1983	Oct CMFD
>D>		@	1MG	N018225	001	Feb 28, 1983	Oct CMFD
>A>	AB		1MG	N018225	001	Feb 28, 1983	Oct CMFD
>D>		@	2MG	N018225	003	Jun 14, 1985	Oct CMFD
>A>	AB		2MG	N018225	003	Jun 14, 1985	Oct CMFD
>A>	<u>BUPRENORPHINE HYDROCHLORIDE</u>						
>A>	FILM;BUCCAL						
>A>	BELBUCA						
>A>		ENDO PHARMS INC	75MCG	N207932	001	Oct 23, 2015	Oct NEWA
>A>			150MCG	N207932	002	Oct 23, 2015	Oct NEWA
>A>			300MCG	N207932	003	Oct 23, 2015	Oct NEWA
>A>			450MCG	N207932	004	Oct 23, 2015	Oct NEWA
>A>			600MCG	N207932	005	Oct 23, 2015	Oct NEWA
>A>			750MCG	N207932	006	Oct 23, 2015	Oct NEWA
>A>			900MCG	N207932	007	Oct 23, 2015	Oct NEWA

INJECTABLE;INJECTION							
BUPRENORPHINE HYDROCHLORIDE							
AP		PAR STERILE PRODUCTS	EQ 0.3MG BASE/ML	A206586	001	Jul 28, 2015	Jul NEWA
TABLET;SUBLINGUAL							
BUPRENORPHINE HYDROCHLORIDE							
AB		ACTAVIS ELIZABETH	EQ 2MG BASE	A090819	001	Feb 19, 2015	Feb NEWA
AB			EQ 8MG BASE	A090819	002	Feb 19, 2015	Feb NEWA
AB		MYLAN PHARMS INC	EQ 2MG BASE	A201066	001	Mar 06, 2015	Feb NEWA
AB			EQ 8MG BASE	A201066	002	Mar 06, 2015	Feb NEWA
AB		SANDOZ INC	EQ 2MG BASE	A090279	001	Jun 10, 2015	May NEWA
AB			EQ 8MG BASE	A090279	002	Jun 10, 2015	May NEWA

BUPRENORPHINE HYDROCHLORIDE; NALOXONE HYDROCHLORIDE

FILM;BUCCAL, SUBLINGUAL								
SUBOXONE								
INDIVIOR INC		EQ 2MG BASE;EQ 0.5MG BASE	N022410	001	Aug 30, 2010	Sep	CDFR	
		EQ 4MG BASE;EQ 1MG BASE	N022410	003	Aug 10, 2012	Sep	CDFR	
		EQ 8MG BASE;EQ 2MG BASE	N022410	002	Aug 30, 2010	Sep	CDFR	
+		EQ 12MG BASE;EQ 3MG BASE	N022410	004	Aug 10, 2012	Sep	CDFR	
TABLET;SUBLINGUAL								
BUPRENORPHINE HYDROCHLORIDE AND NALOXONE HYDROCHLORIDE								
>A>	AB	ETHYPHARM USA CORP	EQ 2MG BASE;EQ 0.5MG BASE	A204431	001	Oct 16, 2015	Oct	NEWA
>A>	AB		EQ 8MG BASE;EQ 2MG BASE	A204431	002	Oct 16, 2015	Oct	NEWA
ZUBSOLV								
	OREXO AB	EQ 2.9MG BASE;EQ 0.71MG BASE	N204242	005	Jun 04, 2015	Jun	NEWA	

BUPROPION HYDROBROMIDE

TABLET, EXTENDED RELEASE;ORAL
APLENZIN

VALEANT PHARMS NORTH 174MG
348MG
+ 522MG

N022108 001 Apr 23, 2008 Feb CAHN
N022108 002 Apr 23, 2008 Feb CAHN
N022108 003 Apr 23, 2008 Feb CAHN

BUPROPION HYDROCHLORIDE

TABLET, EXTENDED RELEASE;ORAL
BUPROPION HYDROCHLORIDE

AB1 PRINSTON INC 100MG
AB1 150MG
AB1 200MG
AB2 SANDOZ INC 150MG
@ WOCKHARDT LTD 100MG
@ 150MG
@ 200MG

A202304 001 May 26, 2015 May NEWA
A202304 002 May 26, 2015 May NEWA
A202304 003 May 26, 2015 May NEWA
A077475 001 Mar 12, 2008 Mar CAHN
A201331 001 Aug 30, 2012 May DISC
A201331 002 Aug 30, 2012 May DISC
A201331 003 Aug 30, 2012 May DISC

BUSPIRONE HYDROCHLORIDE

TABLET;ORAL
BUSPIRONE HYDROCHLORIDE

AB EMCURE PHARMS USA 5MG
AB 10MG
AB 15MG
AB 30MG

A204582 001 Sep 18, 2015 Sep NEWA
A204582 002 Sep 18, 2015 Sep NEWA
A204582 003 Sep 18, 2015 Sep NEWA
A204582 004 Sep 18, 2015 Sep NEWA

BUTABARBITAL SODIUM

ELIXIR;ORAL
BUTISOL SODIUM

@ MEDA PHARMS 30MG/5ML

A085380 001 Jul DISC

TABLET;ORAL
BUTISOL SODIUM

@ MEDA PHARMS 50MG

N000793 003 May DISC

BUTOCONAZOLE NITRATE

CREAM;VAGINAL
BUTOCONAZOLE NITRATE

@ ELAN PHARMA INTL LTD 2%
GYNAZOLE-1

N019881 001 Feb 07, 1997 May CTNA

+ PERRIGO ISRAEL 2%

A200923 001 May 18, 2012 Jun CTNA

CAFFEINE CITRATE

SOLUTION;INTRAVENOUS
CAFFEINE CITRATE

AP AUROBINDO PHARMA LTD EQ 30MG BASE/3ML (EQ 10MG BASE/ML)

A205013 001 Sep 22, 2015 Sep NEWA

CALCIPOTRIENE

CREAM;TOPICAL
CALCIPOTRIENE

AB GLENMARK PHARMS LTD 0.005%

A205772 001 Jun 09, 2015 May NEWA

CALCITONIN SALMON

INJECTABLE;INJECTION
CALCITONIN-SALMON

@ IGI LABS INC 200 IU/ML
MIACALCIN

A073690 001 Apr 14, 1995 Mar CAHN

@ MYLAN IRELAND LTD 100 IU/ML
+ 200 IU/ML

N017808 001 Jul 03, 1986 Aug CAHN
N017808 002 Mar 29, 1991 Aug CAHN

SPRAY, METERED;NASAL
MIACALCIN

AB + MYLAN IRELAND LTD 200 IU/SPRAY

N020313 002 Aug 17, 1995 Aug CAHN

CALCITRIOL

CAPSULE;ORAL
CALCITRIOL

AB BANNER LIFE SCIENCES 0.25MCG
AB 0.5MCG
AB STRIDES PHARMA 0.25MCG
AB 0.5MCG

A091174 001 May 24, 2013 Jan CAHN
A091174 002 May 24, 2013 Jan CAHN
A091356 001 Dec 12, 2014 Jan CAHN
A091356 002 Dec 12, 2014 Jan CAHN

INJECTABLE; INJECTION

CALCIJEX

@ ABBVIE	0.001MG/ML	N018874	001	Sep 25, 1986	Jun DISC
@	0.002MG/ML	N018874	002	Sep 25, 1986	Jun DISC

CALCITRIOL

@ AKORN	0.002MG/ML	A078066	002	Jan 29, 2008	Jun DISC
@ FRESENIUS KABI USA	0.001MG/ML	A075836	001	Dec 31, 2002	Jun DISC
@	0.002MG/ML	A075836	002	Dec 31, 2002	Jun DISC
@ FRESENIUS MEDCL	0.001MG/ML	A075766	001	Feb 20, 2003	Jun DISC
@	0.002MG/ML	A075766	002	Feb 20, 2003	Jun DISC
@ LUITPOLD	0.001MG/ML	A075746	001	Sep 26, 2003	Jun DISC
@	0.002MG/ML	A075746	002	Sep 26, 2003	Jun DISC
@ SAGENT PHARMS	0.001MG/ML	A077102	001	Feb 08, 2006	Jun DISC

CALCIUM ACETATE

CAPSULE; ORAL

CALCIUM ACETATE

AB	HERITAGE PHARMS INC	EQ 169MG CALCIUM	A202315	001	Jun 29, 2015	Sep CAHN	
AB	LUPIN LTD	EQ 169MG CALCIUM	A202127	001	Jul 09, 2015	Jun NEWA	
>A>	AB	NOSTRUM LABS INC	EQ 169MG CALCIUM	A203179	001	Oct 26, 2015	Oct NEWA
AB	ZYDUS PHARMS USA INC	EQ 169MG CALCIUM	A202315	001	Jun 29, 2015	Jun NEWA	

TABLET; ORAL

CALCIUM ACETATE

AB	HERITAGE PHARMS INC	EQ 169MG CALCIUM	A202885	001	Jan 22, 2015	Sep CAHN
AB	ZYDUS PHARMS USA INC	EQ 169MG CALCIUM	A202885	001	Jan 22, 2015	Jan NEWA

CALCIUM CHLORIDE; DEXTROSE; LACTIC ACID; MAGNESIUM CHLORIDE; POTASSIUM CHLORIDE; SODIUM BICARBONATE; SODIUM CHLORIDE

INJECTABLE; INJECTION

PRISMASOL B22GK 2/0 IN PLASTIC CONTAINER

>A>	+	BAXTER HLTHCARE	N/A/1000ML; 20GM/1000ML; 5.4GM/1000ML; 3.05GM/1000ML; 0.157GM/1000ML; 2.21GM/1000ML; 7.07GM/1000ML (5000ML)	N021703	010	Oct 10, 2008	Oct CAHN
-----	---	-----------------	---	---------	-----	--------------	----------

>D>	+	GAMBRO RENAL PRODS	N/A/1000ML; 20GM/1000ML; 5.4GM/1000ML; 3.05GM/1000ML; 0.157GM/1000ML; 2.21GM/1000ML; 7.07GM/1000ML (5000ML)	N021703	010	Oct 10, 2008	Oct CAHN
-----	---	--------------------	---	---------	-----	--------------	----------

+		N/A/1000ML; 20GM/1000ML; 5.4GM/1000ML; 3.05GM/1000ML; 0.157GM/1000ML; 2.21GM/1000ML; 7.07GM/1000ML (5000ML)	N021703	010	Oct 10, 2008	Jan CPOT
---	--	---	---------	-----	--------------	----------

PRISMASOL B22GK 2/2.5 IN PLASTIC CONTAINER

>A>	@	BAXTER HLTHCARE	3.68GM/1000ML; 20GM/1000ML; 5.4GM/1000ML; 3.05GM/1000ML; 0.157GM/1000ML; 2.21GM/1000ML; 7.07GM/1000ML (5000ML)	N021703	012	Oct 10, 2008	Oct CAHN
-----	---	-----------------	--	---------	-----	--------------	----------

>D>	@	GAMBRO RENAL PRODS	3.68GM/1000ML; 20GM/1000ML; 5.4GM/1000ML; 3.05GM/1000ML; 0.157GM/1000ML; 2.21GM/1000ML; 7.07GM/1000ML (5000ML)	N021703	012	Oct 10, 2008	Oct CAHN
-----	---	--------------------	--	---------	-----	--------------	----------

@		3.68GM/1000ML; 20GM/1000ML; 5.4GM/1000ML; 3.05GM/1000ML; 0.157GM/1000ML; 2.21GM/1000ML; 7.07GM/1000ML (5000ML)	N021703	012	Oct 10, 2008	Jan CPOT
---	--	--	---------	-----	--------------	----------

PRISMASOL B22GK 4/0 IN PLASTIC CONTAINER

>A>	+	BAXTER HLTHCARE	N/A/1000ML; 20GM/1000ML; 5.4GM/1000ML; 3.05GM/1000ML; 0.314GM/1000ML; 2.21GM/1000ML; 7.07GM/1000ML (5000ML)	N021703	011	Oct 10, 2008	Oct CAHN
-----	---	-----------------	---	---------	-----	--------------	----------

>D>	+	GAMBRO RENAL PRODS	N/A/1000ML; 20GM/1000ML; 5.4GM/1000ML; 3.05GM/1000ML; 0.314GM/1000ML; 2.21GM/1000ML; 7.07GM/1000ML (5000ML)	N021703	011	Oct 10, 2008	Oct CAHN
-----	---	--------------------	---	---------	-----	--------------	----------

+		N/A/1000ML; 20GM/1000ML; 5.4GM/1000ML; 3.05GM/1000ML; 0.314GM/1000ML; 2.21GM/1000ML; 7.07GM/1000ML (5000ML)	N021703	011	Oct 10, 2008	Jan CPOT
---	--	---	---------	-----	--------------	----------

PRISMASOL B22GK 4/2.5 IN PLASTIC CONTAINER

>A>	+	BAXTER HLTHCARE	3.68GM/1000ML; 20GM/1000ML; 5.4GM/1000ML; 3.05GM/1000ML; 0.314GM/1000ML; 2.21GM/1000ML; 7.07GM/1000ML (5000ML)	N021703	013	Oct 10, 2008	Oct CAHN
-----	---	-----------------	--	---------	-----	--------------	----------

>D>	+	GAMBRO RENAL PRODS	3.68GM/1000ML; 20GM/1000ML; 5.4GM/1000ML; 3.05GM/1000ML; 0.314GM/1000ML; 2.21GM/1000ML; 7.07GM/1000ML (5000ML)	N021703	013	Oct 10, 2008	Oct CAHN
-----	---	--------------------	--	---------	-----	--------------	----------

INJECTABLE; INJECTION

PRISMASOL B22GK 4/2.5 IN PLASTIC CONTAINER

+		3.68GM/1000ML; 20GM/1000ML; 5.4GM/1000ML; 3.05GM/1000ML; 0.314GM/1000ML; 2.21GM/1000ML; 7.07GM/1000ML (5000ML)	N021703	013	Oct 10, 2008	Jan CPOT
---	--	--	---------	-----	--------------	----------

PRISMASOL BGK 0/2.5 IN PLASTIC CONTAINER

>A>	+	BAXTER HLTHCARE	3.68GM/1000ML; 20GM/1000ML; 5.4GM/1000ML; 3.05GM/1000ML; N/A/1000ML; 3.09GM/1000ML; 6.46GM/1000ML (5000ML)	N021703	006	Oct 25, 2006	Oct CAHN
-----	---	-----------------	--	---------	-----	--------------	----------

>D>	+	GAMBRO RENAL PRODS	3.68GM/1000ML; 20GM/1000ML; 5.4GM/1000ML; 3.05GM/1000ML; N/A/1000ML; 3.09GM/1000ML; 6.46GM/1000ML (5000ML)	N021703	006	Oct 25, 2006	Oct CAHN
-----	---	--------------------	--	---------	-----	--------------	----------

+		3.68GM/1000ML; 20GM/1000ML; 5.4GM/1000ML; 3.05GM/1000ML; N/A/1000ML; 3.09GM/1000ML; 6.46GM/1000ML (5000ML)	N021703	006	Oct 25, 2006	Jan CPOT
---	--	--	---------	-----	--------------	----------

PRISMASOL BGK 2/0 IN PLASTIC CONTAINER

>A>	+	BAXTER HLTHCARE	N/A/1000ML; 20GM/1000ML; 5.4GM/1000ML; 2.03GM/1000ML; 0.157GM/1000ML; 3.09GM/1000ML; 6.46GM/1000ML (5000ML)	N021703	002	Oct 25, 2006	Oct CAHN
-----	---	-----------------	---	---------	-----	--------------	----------

>D>	+	GAMBRO RENAL PRODS	N/A/1000ML; 20GM/1000ML; 5.4GM/1000ML; 2.03GM/1000ML; 0.157GM/1000ML; 3.09GM/1000ML; 6.46GM/1000ML (5000ML)	N021703	002	Oct 25, 2006	Oct CAHN
-----	---	--------------------	---	---------	-----	--------------	----------

+		N/A/1000ML; 20GM/1000ML; 5.4GM/1000ML; 2.03GM/1000ML; 0.157GM/1000ML; 3.09GM/1000ML; 6.46GM/1000ML (5000ML)	N021703	002	Oct 25, 2006	Jan CPOT
---	--	---	---------	-----	--------------	----------

PRISMASOL BGK 2/3.5 IN PLASTIC CONTAINER

>A>	+	BAXTER HLTHCARE	5.15GM/1000ML; 20GM/1000ML; 5.4GM/1000ML; 2.03GM/1000ML; 0.157GM/1000ML; 3.09GM/1000ML; 6.46GM/1000ML (5000ML)	N021703	003	Oct 25, 2006	Oct CAHN
-----	---	-----------------	--	---------	-----	--------------	----------

>D>	+	GAMBRO RENAL PRODS	5.15GM/1000ML; 20GM/1000ML; 5.4GM/1000ML; 2.03GM/1000ML; 0.157GM/1000ML; 3.09GM/1000ML; 6.46GM/1000ML (5000ML)	N021703	003	Oct 25, 2006	Oct CAHN
-----	---	--------------------	--	---------	-----	--------------	----------

+		5.15GM/1000ML; 20GM/1000ML; 5.4GM/1000ML; 2.03GM/1000ML; 0.157GM/1000ML; 3.09GM/1000ML; 6.46GM/1000ML (5000ML)	N021703	003	Oct 25, 2006	Jan CPOT
---	--	--	---------	-----	--------------	----------

PRISMASOL BGK 4/0 IN PLASTIC CONTAINER

>A>	@	BAXTER HLTHCARE	N/A/1000ML; 20GM/1000ML; 5.4GM/1000ML; 3.05GM/1000ML; 0.314GM/1000ML; 3.09GM/1000ML; 6.46GM/1000ML (5000ML)	N021703	005	Oct 25, 2006	Oct CAHN
-----	---	-----------------	---	---------	-----	--------------	----------

>D>	@	GAMBRO RENAL PRODS	N/A/1000ML; 20GM/1000ML; 5.4GM/1000ML; 3.05GM/1000ML; 0.314GM/1000ML; 3.09GM/1000ML; 6.46GM/1000ML (5000ML)	N021703	005	Oct 25, 2006	Oct CAHN
-----	---	--------------------	---	---------	-----	--------------	----------

@		N/A/1000ML; 20GM/1000ML; 5.4GM/1000ML; 3.05GM/1000ML; 0.314GM/1000ML; 3.09GM/1000ML; 6.46GM/1000ML (5000ML)	N021703	005	Oct 25, 2006	Jan CPOT
---	--	---	---------	-----	--------------	----------

PRISMASOL BGK 4/0/1.2 IN PLASTIC CONTAINER

>A>	+	BAXTER HLTHCARE	N/A/1000ML; 20GM/1000ML; 5.4GM/1000ML; 2.44GM/1000ML; 0.314GM/1000ML; 3.09GM/1000ML; 6.46GM/1000ML (5000ML)	N021703	015	Oct 10, 2008	Oct CAHN
-----	---	-----------------	---	---------	-----	--------------	----------

>D>	+	GAMBRO RENAL PRODS	N/A/1000ML; 20GM/1000ML; 5.4GM/1000ML; 2.44GM/1000ML; 0.314GM/1000ML; 3.09GM/1000ML; 6.46GM/1000ML (5000ML)	N021703	015	Oct 10, 2008	Oct CAHN
-----	---	--------------------	---	---------	-----	--------------	----------

+		N/A/1000ML; 20GM/1000ML; 5.4GM/1000ML; 2.44GM/1000ML; 0.314GM/1000ML; 3.09GM/1000ML; 6.46GM/1000ML (5000ML)	N021703	015	Oct 10, 2008	Jan CPOT
---	--	---	---------	-----	--------------	----------

PRISMASOL BGK 4/2.5 IN PLASTIC CONTAINER

>A>	+	BAXTER HLTHCARE	3.68GM/1000ML; 20GM/1000ML; 5.4GM/1000ML; 3.05GM/1000ML; 0.314GM/1000ML; 3.09GM/1000ML; 6.46GM/1000ML (5000ML)	N021703	004	Oct 25, 2006	Oct CAHN
-----	---	-----------------	--	---------	-----	--------------	----------

>D>	+	GAMBRO RENAL PRODS	3.68GM/1000ML; 20GM/1000ML; 5.4GM/1000ML; 3.05GM/1000ML; 0.314GM/1000ML; 3.09GM/1000ML; 6.46GM/1000ML (5000ML)	N021703	004	Oct 25, 2006	Oct CAHN
-----	---	--------------------	--	---------	-----	--------------	----------

INJECTABLE; INJECTION

PRISMASOL BGK 4/2.5 IN PLASTIC CONTAINER

+		3.68GM/1000ML; 20GM/1000ML; 5.4GM/1000ML; 3.05GM/1000ML; 0.314GM/1000ML; 3.09GM/1000ML; 6.46GM/1000ML (5000ML)	N021703	004	Oct 25, 2006	Jan CPOT
---	--	--	---------	-----	--------------	----------

PRISMASOL BGK 4/3.5 IN PLASTIC CONTAINER

>A>	@ BAXTER HLTHCARE	5.15GM/1000ML; 20GM/1000ML; 5.4GM/1000ML; 2.03GM/1000ML; 0.314GM/1000ML; 3.09GM/1000ML; 6.46GM/1000ML (5000ML)	N021703	008	Oct 25, 2006	Oct CAHN
-----	-------------------	--	---------	-----	--------------	----------

>D>	@ GAMBRO RENAL PRODS	5.15GM/1000ML; 20GM/1000ML; 5.4GM/1000ML; 2.03GM/1000ML; 0.314GM/1000ML; 3.09GM/1000ML; 6.46GM/1000ML (5000ML)	N021703	008	Oct 25, 2006	Oct CAHN
-----	----------------------	--	---------	-----	--------------	----------

	@	5.15GM/1000ML; 20GM/1000ML; 5.4GM/1000ML; 2.03GM/1000ML; 0.314GM/1000ML; 3.09GM/1000ML; 6.46GM/1000ML (5000ML)	N021703	008	Oct 25, 2006	Jan CPOT
--	---	--	---------	-----	--------------	----------

PRISMASOL BK 0/0 IN PLASTIC CONTAINER

>A>	@ BAXTER HLTHCARE	N/A/1000ML; N/A/1000ML; 5.4GM/1000ML; 3.05GM/1000ML; N/A/1000ML; 3.09GM/1000ML; 6.46GM/1000ML (5000ML)	N021703	007	Oct 25, 2006	Oct CAHN
-----	-------------------	--	---------	-----	--------------	----------

>D>	@ GAMBRO RENAL PRODS	N/A/1000ML; N/A/1000ML; 5.4GM/1000ML; 3.05GM/1000ML; N/A/1000ML; 3.09GM/1000ML; 6.46GM/1000ML (5000ML)	N021703	007	Oct 25, 2006	Oct CAHN
-----	----------------------	--	---------	-----	--------------	----------

	@	N/A/1000ML; N/A/1000ML; 5.4GM/1000ML; 3.05GM/1000ML; N/A/1000ML; 3.09GM/1000ML; 6.46GM/1000ML (5000ML)	N021703	007	Oct 25, 2006	Jan CPOT
--	---	--	---------	-----	--------------	----------

PRISMASOL BK 0/0/1.2 IN PLASTIC CONTAINER

>A>	+ BAXTER HLTHCARE	N/A/1000ML; N/A/1000ML; 5.4GM/1000ML; 2.44GM/1000ML; N/A/1000ML; 3.09GM/1000ML; 6.46GM/1000ML (5000ML)	N021703	014	Oct 10, 2008	Oct CAHN
-----	-------------------	--	---------	-----	--------------	----------

>D>	+ GAMBRO RENAL PRODS	N/A/1000ML; N/A/1000ML; 5.4GM/1000ML; 2.44GM/1000ML; N/A/1000ML; 3.09GM/1000ML; 6.46GM/1000ML (5000ML)	N021703	014	Oct 10, 2008	Oct CAHN
-----	----------------------	--	---------	-----	--------------	----------

+		N/A/1000ML; N/A/1000ML; 5.4GM/1000ML; 2.44GM/1000ML; N/A/1000ML; 3.09GM/1000ML; 6.46GM/1000ML (5000ML)	N021703	014	Oct 10, 2008	Jan CPOT
---	--	--	---------	-----	--------------	----------

PRISMASOL BK 0/3.5 IN PLASTIC CONTAINER

>A>	+ BAXTER HLTHCARE	5.15GM/1000ML; N/A/1000ML; 5.4GM/1000ML; 2.03GM/1000ML; N/A/1000ML; 3.09GM/1000ML; 6.46GM/1000ML (5000ML)	N021703	001	Oct 25, 2006	Oct CAHN
-----	-------------------	---	---------	-----	--------------	----------

>D>	+ GAMBRO RENAL PRODS	5.15GM/1000ML; N/A/1000ML; 5.4GM/1000ML; 2.03GM/1000ML; N/A/1000ML; 3.09GM/1000ML; 6.46GM/1000ML (5000ML)	N021703	001	Oct 25, 2006	Oct CAHN
-----	----------------------	---	---------	-----	--------------	----------

+		5.15GM/1000ML; N/A/1000ML; 5.4GM/1000ML; 2.03GM/1000ML; N/A/1000ML; 3.09GM/1000ML; 6.46GM/1000ML (5000ML)	N021703	001	Oct 25, 2006	Jan CPOT
---	--	---	---------	-----	--------------	----------

PRISMASOL BK 4/2.5 IN PLASTIC CONTAINER

>A>	@ BAXTER HLTHCARE	3.68GM/1000ML; N/A/1000ML; 5.4GM/1000ML; 3.05GM/1000ML; 0.314GM/1000ML; 3.09GM/1000ML; 6.46GM/1000ML (5000ML)	N021703	009	Oct 25, 2006	Oct CAHN
-----	-------------------	---	---------	-----	--------------	----------

>D>	@ GAMBRO RENAL PRODS	3.68GM/1000ML; N/A/1000ML; 5.4GM/1000ML; 3.05GM/1000ML; 0.314GM/1000ML; 3.09GM/1000ML; 6.46GM/1000ML (5000ML)	N021703	009	Oct 25, 2006	Oct CAHN
-----	----------------------	---	---------	-----	--------------	----------

	@	3.68GM/1000ML; N/A/1000ML; 5.4GM/1000ML; 3.05GM/1000ML; 0.314GM/1000ML; 3.09GM/1000ML; 6.46GM/1000ML (5000ML)	N021703	009	Oct 25, 2006	Jan CPOT
--	---	---	---------	-----	--------------	----------

CALCIUM CHLORIDE; DEXTROSE; LACTIC ACID; MAGNESIUM CHLORIDE; POTASSIUM CHLORIDE; SODIUM BICARBONATE; SODIUM CHLORIDE; SODIUM PHOSPHATE

INJECTABLE; INJECTION

PHOXILLUM B22K 4/0 IN PLASTIC CONTAINER

+	GAMBRO LUNDIA	N/A/1000ML; N/A/1000ML; N/A/1000ML; 3.05GM/1000ML; 0.314GM/1000ML; 2.21GM/1000ML; 6.95GM/1000ML; 0.187GM/1000ML (5000ML)	N207026	002	Jan 13, 2015	Jan NEWA
---	---------------	--	---------	-----	--------------	----------

INJECTABLE;INJECTION

PHOXILLUM BK 4/2.5 IN PLASTIC CONTAINER

+	GAMBRO LUNDIA	3.68GM/1000ML;N/A/1000ML;N/A/1000ML;3.05GM/1000ML;0.314GM/1000ML;3.09GM/1000ML;6.34GM/1000ML;0.187GM/1000ML (5000ML)	N207026	001	Jan 13, 2015	Jan NEWA
---	---------------	--	---------	-----	--------------	----------

CALCIUM CHLORIDE; DEXTROSE; MAGNESIUM CHLORIDE; OXIGLUTATIONE; POTASSIUM CHLORIDE; SODIUM BICARBONATE; SODIUM CHLORIDE; SODIUM PHOSPHATE

SOLUTION;IRRIGATION

NAVSTEL

@	ALCON PHARMS LTD	0.154MG/ML;0.92MG/ML;0.2MG/ML;0.184MG/ML;0.38MG/ML;2.1MG/ML;7.14MG/ML;0.42MG/ML	N022193	001	Jul 24, 2008	Jun DISC
---	------------------	---	---------	-----	--------------	----------

CALCIUM CHLORIDE; DEXTROSE; MAGNESIUM CHLORIDE; POTASSIUM CHLORIDE; SODIUM ACETATE; SODIUM CHLORIDE; SODIUM LACTATE

INJECTABLE;INJECTION

PLASMA-LYTE M AND DEXTROSE 5% IN PLASTIC CONTAINER

@	BAXTER HLTHCARE	37MG/100ML;5GM/100ML;30MG/100ML;119MG/100ML;161MG/100ML;94MG/100ML;138MG/100ML	N017390	001		Mar DISC
---	-----------------	--	---------	-----	--	----------

CALCIUM CHLORIDE; MAGNESIUM CHLORIDE; POTASSIUM CHLORIDE; SODIUM ACETATE; SODIUM CHLORIDE; SODIUM LACTATE

INJECTABLE;INJECTION

PLASMA-LYTE R IN PLASTIC CONTAINER

@	BAXTER HLTHCARE	36.8MG/100ML;30.5MG/100ML;74.6MG/100ML;640MG/100ML;496MG/100ML;89.6MG/100ML	N017438	001		Mar DISC
---	-----------------	---	---------	-----	--	----------

CALCIUM CHLORIDE; MAGNESIUM CHLORIDE; POTASSIUM CHLORIDE; SODIUM BICARBONATE; SODIUM CHLORIDE; SODIUM PHOSPHATE

INJECTABLE;INJECTION

PHOXILLUM B22K 4/0 IN PLASTIC CONTAINER

>A>	+	BAXTER HLTHCARE	N/A/1000ML;3.05GM/1000ML;0.314GM/1000ML;2.21GM/1000ML;6.95GM/1000ML;0.187GM/1000ML (5000ML)	N207026	002	Jan 13, 2015	Oct CAHN
>D>	+	GAMBRO LUNDIA	N/A/1000ML;3.05GM/1000ML;0.314GM/1000ML;2.21GM/1000ML;6.95GM/1000ML;0.187GM/1000ML (5000ML)	N207026	002	Jan 13, 2015	Oct CAHN
	+		N/A/1000ML;3.05GM/1000ML;0.314GM/1000ML;2.21GM/1000ML;6.95GM/1000ML;0.187GM/1000ML (5000ML)	N207026	002	Jan 13, 2015	Feb CAIN
>A>	+	BAXTER HLTHCARE	3.68GM/1000ML;3.05GM/1000ML;0.314GM/1000ML;3.09GM/1000ML;6.34GM/1000ML;0.187GM/1000ML	N207026	001	Jan 13, 2015	Oct CAHN
>D>	+	GAMBRO LUNDIA	3.68GM/1000ML;3.05GM/1000ML;0.314GM/1000ML;3.09GM/1000ML;6.34GM/1000ML;0.187GM/1000ML	N207026	001	Jan 13, 2015	Oct CAHN
	+		3.68GM/1000ML;3.05GM/1000ML;0.314GM/1000ML;3.09GM/1000ML;6.34GM/1000ML;0.187GM/1000ML	N207026	001	Jan 13, 2015	Feb CAIN

CALCIUM CHLORIDE; POTASSIUM CHLORIDE; SODIUM CHLORIDE; SODIUM LACTATE

SOLUTION;IRRIGATION

LACTATED RINGER'S IN PLASTIC CONTAINER

@	BAXTER HLTHCARE	20MG/100ML;30MG/100ML;600MG/100ML;310MG/100ML	N019933	001	Aug 29, 1989	Sep DISC
---	-----------------	---	---------	-----	--------------	----------

CANDESARTAN CILEXETIL; HYDROCHLOROTHIAZIDE

TABLET;ORAL

CANDESARTAN CILEXETIL AND HYDROCHLOROTHIAZIDE

AB	MACLEODS PHARMS LTD	16MG;12.5MG	A204100	001	Feb 27, 2015	Feb NEWA
AB		32MG;12.5MG	A204100	002	Feb 27, 2015	Feb NEWA
AB		32MG;25MG	A204100	003	Feb 27, 2015	Feb NEWA

CAPECITABINE

TABLET;ORAL

CAPECITABINE

AB	ACCORD HLTHCARE	150MG	A202593	001	Apr 23, 2015	Apr NEWA
AB		500MG	A202593	002	Apr 23, 2015	Apr NEWA

CAPTOPRIL

TABLET;ORAL

CAPTOPRIL

	@ G AND W LABS INC	12.5MG	A074433	001	Feb 13, 1996	Jul CAHN
	@	12.5MG	A074462	001	Feb 13, 1996	Apr CAHN
	@	12.5MG	A074483	001	Feb 13, 1996	Jul CAHN
	@	12.5MG	A074590	004	Aug 30, 1996	Apr CAHN
	@	25MG	A074433	002	Feb 13, 1996	Jul CAHN
	@	25MG	A074462	002	Feb 13, 1996	Apr CAHN
	@	25MG	A074483	002	Feb 13, 1996	Jul CAHN
	@	25MG	A074590	002	Aug 30, 1996	Apr CAHN
	@	50MG	A074433	003	Feb 13, 1996	Jul CAHN
	@	50MG	A074462	003	Feb 13, 1996	Apr CAHN
	@	50MG	A074483	003	Feb 13, 1996	Jul CAHN
	@	50MG	A074590	001	Aug 30, 1996	Apr CAHN
	@	100MG	A074433	004	Feb 13, 1996	Jul CAHN
	@	100MG	A074462	004	Feb 13, 1996	Apr CAHN
	@	100MG	A074483	004	Feb 13, 1996	Jul CAHN
	@	100MG	A074590	003	Aug 30, 1996	Apr CAHN
AB	+ MYLAN	100MG	A074434	004	Feb 13, 1996	May CRLD

CAPTOPRIL; HYDROCHLOROTHIAZIDE

TABLET;ORAL

CAPTOPRIL AND HYDROCHLOROTHIAZIDE

AB	G AND W LABS INC	25MG;15MG	A074827	001	Dec 29, 1997	Apr CAHN
AB		25MG;25MG	A074827	002	Dec 29, 1997	Apr CAHN
AB		50MG;15MG	A074827	004	Dec 29, 1997	Apr CAHN
AB		50MG;25MG	A074827	003	Dec 29, 1997	Apr CAHN

CARBAMAZEPINE

CAPSULE, EXTENDED RELEASE;ORAL

CARBAMAZEPINE

AB	MYLAN PHARMS INC	100MG	A076697	001	May 20, 2011	May CAHN
AB		200MG	A076697	002	May 20, 2011	May CAHN
AB		300MG	A076697	003	May 20, 2011	May CAHN

CARBIDOPA; LEVODOPA

CAPSULE, EXTENDED RELEASE;ORAL

RYTARY

IMPAX LABS INC

		23.75MG;95MG	N203312	001	Jan 07, 2015	Jan NEWA
		36.25MG;145MG	N203312	002	Jan 07, 2015	Jan NEWA
		48.75MG;195MG	N203312	003	Jan 07, 2015	Jan NEWA
	+	61.25MG;245MG	N203312	004	Jan 07, 2015	Jan NEWA

SUSPENSION;ENTERAL

DUOPA

+ ABBVIE INC

		4.63MG/ML;20MG/ML	N203952	001	Jan 09, 2015	Jan NEWA
--	--	-------------------	---------	-----	--------------	----------

CARIPRAZINE HYDROCHLORIDE

CAPSULE;ORAL

VRAYLAR

FOREST RES INST INC

		EQ 1.5MG BASE	N204370	001	Sep 17, 2015	Sep NEWA
		EQ 3MG BASE	N204370	002	Sep 17, 2015	Sep NEWA
		EQ 4.5MG BASE	N204370	003	Sep 17, 2015	Sep NEWA
	+	EQ 6MG BASE	N204370	004	Sep 17, 2015	Sep NEWA

CARISOPRODOL

TABLET;ORAL

CARISOPRODOL

AB	INDICUS PHARMA	250MG	A205126	001	Jul 08, 2015	Jun NEWA
AA		350MG	A205126	002	Jul 08, 2015	Jun NEWA
>A> AB	SHASUN PHARMS LTD	250MG	A205513	001	Nov 12, 2015	Oct NEWA
>A> AA		350MG	A205513	002	Nov 12, 2015	Oct NEWA
	SOMA					
AB	+ MEDA PHARMS	250MG	N011792	004	Sep 13, 2007	Jun CTEC

CARVEDILOL

TABLET;ORAL

CARVEDILOL

@ HIKMA

		3.125MG	A077887	001	Sep 07, 2007	Jun DISC
	@	6.25MG	A077887	002	Sep 07, 2007	Jun DISC
	@	12.5MG	A077887	003	Sep 07, 2007	Jun DISC

TABLET;ORAL
CARVEDILOL

	@	25MG	A077887	004	Sep 07, 2007	Jun DISC
AB	SUN PHARM INDS LTD	3.125MG	A076989	001	Sep 05, 2007	Apr CAHN
AB		6.25MG	A076989	002	Sep 05, 2007	Apr CAHN
AB		12.5MG	A076989	003	Sep 05, 2007	Apr CAHN
AB		25MG	A076989	004	Sep 05, 2007	Apr CAHN

CEFADROXIL/CEFADROXIL HEMIHYDRATE

FOR SUSPENSION;ORAL
CEFADROXIL

	SUN PHARM INDS LTD	EQ 125MG BASE/5ML	A065115	001	Mar 26, 2003	Apr CAHN
AB		EQ 250MG BASE/5ML	A065115	002	Mar 26, 2003	Apr CAHN
AB		EQ 500MG BASE/5ML	A065115	003	Mar 26, 2003	Apr CAHN

CEFAZOLIN SODIUM

INJECTABLE;INJECTION
CEFAZOLIN SODIUM

AP	FACTA FARMA	EQ 500MG BASE/VIAL	A063214	001	Dec 27, 1991	Jan CAHN
AP		EQ 1GM BASE/VIAL	A063207	001	Dec 27, 1991	Jan CAHN
AP		EQ 10GM BASE/VIAL	A063209	001	Dec 27, 1991	Jan CAHN
AP	+	EQ 20GM BASE/VIAL	A063209	002	Apr 30, 1999	Jan CAHN

SOLUTION;INTRAVENOUS

CEFAZOLIN IN PLASTIC CONTAINER

	BAXTER HLTHCARE	EQ 2GM BASE/100ML (EQ 20MG BASE/ML)	N207131	001	Aug 07, 2015	Sep CAHN
	CELERITY PHARMS	EQ 2GM BASE/100ML (EQ 20MG BASE/ML)	N207131	001	Aug 07, 2015	Aug NEWA

CEFIXIME

FOR SUSPENSION;ORAL
CEFIXIME

AB	AUROBINDO PHARMA LTD	100MG/5ML	A204835	001	Apr 14, 2015	Apr NEWA
AB		200MG/5ML	A204835	002	Apr 14, 2015	Apr NEWA
	SUPRAX					
AB	LUPIN PHARMS	100MG/5ML	A065129	001	Feb 23, 2004	Apr CFTG
AB		200MG/5ML	A065355	001	Apr 10, 2007	Apr CFTG

CEFOTETAN DISODIUM

INJECTABLE;INJECTION
CEFOTAN

@	IGI LABS INC	EQ 1GM BASE/VIAL	A063293	001	Apr 29, 1993	May CAHN
@		EQ 1GM BASE/VIAL	N050588	001	Dec 27, 1985	Mar CAHN
@		EQ 2GM BASE/VIAL	A063293	002	Apr 29, 1993	May CAHN
@		EQ 2GM BASE/VIAL	N050588	002	Dec 27, 1985	Mar CAHN
@		EQ 10GM BASE/VIAL	N050588	003	Apr 25, 1988	Mar CAHN

CEFOTAN IN PLASTIC CONTAINER

@	IGI LABS INC	EQ 20MG BASE/ML	N050694	002	Jul 30, 1993	Mar CAHN
@		EQ 40MG BASE/ML	N050694	001	Jul 30, 1993	Mar CAHN

CEFPODOXIME PROXETIL

FOR SUSPENSION;ORAL
CEFPODOXIME PROXETIL

AB	SUN PHARM INDS LTD	EQ 50MG BASE/5ML	A065082	001	May 31, 2002	Apr CAHN
AB		EQ 100MG BASE/5ML	A065082	002	May 31, 2002	Apr CAHN

TABLET;ORAL

CEFPODOXIME PROXETIL

AB	SUN PHARM INDS LTD	EQ 100MG BASE	A065083	001	Aug 20, 2003	Apr CAHN
AB		EQ 200MG BASE	A065083	002	Aug 20, 2003	Apr CAHN

CEFTAZIDIME

INJECTABLE;INJECTION
FORTAZ

>D>	AP	+	CONCORDIA PHARMS INC	500MG/VIAL	N050578	001	Jul 19, 1985	Oct CAHN
	AP	+		500MG/VIAL	N050578	001	Jul 19, 1985	Jun CAHN
>D>	AP	+		1GM/VIAL	N050578	002	Jul 19, 1985	Oct CAHN
	AP	+		1GM/VIAL	N050578	002	Jul 19, 1985	Jun CAHN
>D>	AP	+		2GM/VIAL	N050578	003	Jul 19, 1985	Oct CAHN
	AP	+		2GM/VIAL	N050578	003	Jul 19, 1985	Jun CAHN
>D>	AP	+		6GM/VIAL	N050578	004	Jul 19, 1985	Oct CAHN
	AP	+		6GM/VIAL	N050578	004	Jul 19, 1985	Jun CAHN
>A>	AP	+	IGI LABS INC	500MG/VIAL	N050578	001	Jul 19, 1985	Oct CAHN

INJECTABLE;INJECTION
FORTAZ

>A>	AP	+	1GM/VIAL	N050578	002	Jul 19, 1985	Oct CAHN
>A>	AP	+	2GM/VIAL	N050578	003	Jul 19, 1985	Oct CAHN
>A>	AP	+	6GM/VIAL	N050578	004	Jul 19, 1985	Oct CAHN

CEFTAZIDIME SODIUM

INJECTABLE;INJECTION
FORTAZ IN PLASTIC CONTAINER

>D>		@ CONCORDIA PHARMS INC	EQ 10MG BASE/ML	N050634	001	Apr 28, 1989	Oct CAHN
		@	EQ 10MG BASE/ML	N050634	001	Apr 28, 1989	Jun CAHN
>D>		+	EQ 20MG BASE/ML	N050634	002	Apr 28, 1989	Oct CAHN
		+	EQ 20MG BASE/ML	N050634	002	Apr 28, 1989	Jun CAHN
>D>		+	EQ 40MG BASE/ML	N050634	003	Apr 28, 1989	Oct CAHN
		+	EQ 40MG BASE/ML	N050634	003	Apr 28, 1989	Jun CAHN
>A>		@ IGI LABS INC	EQ 10MG BASE/ML	N050634	001	Apr 28, 1989	Oct CAHN
>A>		+	EQ 20MG BASE/ML	N050634	002	Apr 28, 1989	Oct CAHN
>A>		+	EQ 40MG BASE/ML	N050634	003	Apr 28, 1989	Oct CAHN

CEFTOLOZANE SULFATE; TAZOBACTAM SODIUM

POWDER;IV (INFUSION)
ZERBAXA

+	CUBIST PHARMS LLC	EQ 1GM BASE/VIAL;EQ 0.5GM BASE/VIAL	N206829	001	Dec 19, 2014	Aug CAHN
---	-------------------	-------------------------------------	---------	-----	--------------	----------

CEFTRIAXONE SODIUM

INJECTABLE;INJECTION
CEFTRIAXONE

AP		FACTA FARMA	EQ 10GM BASE/VIAL	A065269	001	Feb 28, 2007	Jan CAHN
		INJECTABLE;INTRAMUSCULAR, INTRAVENOUS					
		CEFTRIAXONE					
		@ FACTA FARMA	EQ 1GM BASE/VIAL	A065268	001	Feb 28, 2007	Jan CAHN
		@	EQ 2GM BASE/VIAL	A065268	002	Feb 28, 2007	Jan CAHN
		@ FRESENIUS KABI USA	EQ 250MG BASE/VIAL	A065245	001	Feb 15, 2006	Jul DISC

CEFUROXIME AXETIL

FOR SUSPENSION;ORAL
CEFUROXIME AXETIL

AB		SUN PHARM INDS LTD	EQ 125MG BASE/5ML	A065323	001	Feb 05, 2008	Apr CAHN
AB			EQ 250MG BASE/5ML	A065323	002	Feb 05, 2008	Apr CAHN

TABLET;ORAL

CEFUROXIME AXETIL

AB		ANI PHARMS INC	EQ 250MG BASE	A065190	001	Oct 18, 2004	Jul CAHN
AB			EQ 500MG BASE	A065190	002	Oct 18, 2004	Jul CAHN
AB		SUN PHARM INDS LTD	EQ 125MG BASE	A065118	001	Apr 25, 2003	Apr CAHN
AB			EQ 250MG BASE	A065118	002	Apr 25, 2003	Apr CAHN
AB			EQ 500MG BASE	A065118	003	Apr 25, 2003	Apr CAHN

CEFUROXIME SODIUM

INJECTABLE;INJECTION
CEFUROXIME SODIUM

AP		FACTA FARMA	EQ 1.5GM BASE/VIAL	A064125	002	May 30, 1997	Jan CAHN
AP			EQ 7.5GM BASE/VIAL	A064124	001	May 30, 1997	Jan CAHN
		ZINACEF					
AP	+	CONCORDIA PHARMS INC	EQ 1.5GM BASE/VIAL	N050558	003	Oct 19, 1983	Jun CAHN
AP	+		EQ 7.5GM BASE/VIAL	N050558	004	Oct 23, 1986	Jun CAHN
		ZINACEF IN PLASTIC CONTAINER					
		@ CONCORDIA PHARMS INC	EQ 15MG BASE/ML	N050643	001	Apr 28, 1989	Jun CAHN
		+	EQ 30MG BASE/ML	N050643	002	Apr 28, 1989	Jun CAHN
		INJECTABLE;INTRAMUSCULAR, INTRAVENOUS					
		CEFUROXIME SODIUM					
AB		FACTA FARMA	EQ 750MG BASE/VIAL	A064125	001	May 30, 1997	Jan CAHN
		ZINACEF					
AB	+	CONCORDIA PHARMS INC	EQ 750MG BASE/VIAL	N050558	002	Oct 19, 1983	Jun CAHN

CELECOXIB

CAPSULE;ORAL
CELECOXIB

AB		ALEMBIC PHARMS LTD	50MG	A204519	001	Aug 21, 2015	Aug NEWA
AB			100MG	A204519	002	Aug 21, 2015	Aug NEWA
AB			200MG	A204519	003	Aug 21, 2015	Aug NEWA
AB			400MG	A204519	004	Aug 21, 2015	Aug NEWA

CAPSULE; ORAL							
CELECOXIB							
AB	APOTEX INC	50MG	A204197	001	Jun 02, 2015	May	NEWA
AB		100MG	A204197	002	Jun 02, 2015	May	NEWA
AB		200MG	A204197	003	Jun 02, 2015	May	NEWA
AB	CIPLA LTD	50MG	A207446	001	Sep 23, 2015	Sep	NEWA
AB		100MG	A207446	002	Sep 23, 2015	Sep	NEWA
AB		200MG	A207446	003	Sep 23, 2015	Sep	NEWA
AB		400MG	A207446	004	Sep 23, 2015	Sep	NEWA
AB	LUPIN LTD	100MG	A202240	002	Jun 09, 2015	May	NEWA
AB		200MG	A202240	003	Jun 09, 2015	May	NEWA
AB		400MG	A202240	004	Jun 09, 2015	May	NEWA
AB	MYLAN PHARMS INC	100MG	A078857	002	Feb 11, 2015	Jan	NEWA
AB		200MG	A078857	003	Feb 11, 2015	Jan	NEWA
AB		400MG	A078857	004	Feb 11, 2015	Jan	NEWA
AB	WATSON LABS INC	50MG	A200562	001	Feb 11, 2015	Jan	NEWA
AB		100MG	A200562	002	Feb 11, 2015	Jan	NEWA
AB		200MG	A200562	003	Feb 11, 2015	Jan	NEWA
AB		400MG	A200562	004	Feb 11, 2015	Jan	NEWA
<u>CEPHALEXIN</u>							
CAPSULE; ORAL							
CEPHALEXIN							
AB	SUN PHARM INDS LTD	EQ 250MG BASE	A065007	001	Sep 16, 1999	Apr	CAHN
AB		EQ 500MG BASE	A065007	002	Sep 16, 1999	Apr	CAHN
FOR SUSPENSION; ORAL							
CEPHALEXIN							
	@ SUN PHARM INDS LTD	EQ 125MG BASE/5ML	A065081	001	Jul 27, 2001	Apr	CAHN
	@	EQ 250MG BASE/5ML	A065081	002	Jul 27, 2001	Apr	CAHN
<u>CETIRIZINE HYDROCHLORIDE</u>							
SYRUP; ORAL							
ZYRTEC							
AA	+ J AND J CONSUMER INC	5MG/5ML	N020346	001	Sep 27, 1996	Aug	CAHN
<u>CHLOROTHIAZIDE SODIUM</u>							
INJECTABLE; INJECTION							
CHLOROTHIAZIDE SODIUM							
AP	SAGENT PHARMS	EQ 500MG BASE/VIAL	A202462	001	May 29, 2015	May	NEWA
<u>CHLORPHENIRAMINE MALEATE; CODEINE PHOSPHATE</u>							
TABLET, EXTENDED RELEASE; ORAL							
CODEINE PHOSPHATE AND CHLORPHENIRAMINE MALEATE							
	SPRIASO LLC	8MG; 54.3MG	N206323	001	Jun 22, 2015	Jun	NEWA
<u>CHLORPHENIRAMINE MALEATE; HYDROCODONE BITARTRATE</u>							
SOLUTION; ORAL							
HYDROCODONE BITARTRATE AND CHLORPHENIRAMINE MALEATE							
AA	TRIS PHARMA INC	4MG/5ML; 5MG/5ML	A206438	001	Jan 27, 2015	Jan	NEWA
	VITUZ						
AA	+ CYPRESS PHARM	4MG/5ML; 5MG/5ML	N204307	001	Feb 20, 2013	Jan	CFTG
<u>CHLORPHENIRAMINE MALEATE; HYDROCODONE BITARTRATE; PSEUDOEPHEDRINE HYDROCHLORIDE</u>							
SOLUTION; ORAL							
HYDROCODONE BITARTRATE, CHLORPHENIRAMINE MALEATE AND PSEUDOEPHEDRINE HYDROCHLORIDE							
AA	COASTAL PHARMS	4MG/5ML; 5MG/5ML; 60MG/5ML	A205657	001	Aug 03, 2015	Jul	NEWA
<u>CHLORPHENIRAMINE POLISTIREX; CODEINE POLISTIREX</u>							
SUSPENSION, EXTENDED RELEASE; ORAL							
TUZISTRA XR							
	+ TRIS PHARMA INC	EQ 2.8MG BASE/5ML; EQ 14.7MG BASE/5ML	N207768	001	Apr 30, 2015	Apr	NEWA
	+ VERNALIS R AND D LTD	EQ 2.8MG BASE/5ML; EQ 14.7MG BASE/5ML	N207768	001	Apr 30, 2015	Jun	CAHN
<u>CHLORPROMAZINE HYDROCHLORIDE</u>							
CONCENTRATE; ORAL							
CHLORPROMAZINE HYDROCHLORIDE INTENSOL							
	@ CYCLE PHARMS LTD	30MG/ML	A088157	001	Apr 27, 1983	Jun	CAHN
	@	100MG/ML	A088158	001	Apr 27, 1983	Jun	CAHN

INJECTABLE; INJECTION

CHLORPROMAZINE HYDROCHLORIDE

+ EUROHLTH INTL SARL 25MG/ML

A083329 001

Feb CAHN

TABLET; ORAL

CHLORPROMAZINE HYDROCHLORIDE

@ CYCLE PHARMS LTD 10MG

A085331 001

Jun CAHN

@ 25MG

A085331 002

Jun CAHN

@ 50MG

A085331 003

Jun CAHN

@ 100MG

A085331 004

Jun CAHN

@ 200MG

A085331 005

Jun CAHN

@ SANDOZ 10MG

A080439 001

May DISC

@ 25MG

A080439 002

May DISC

@ 50MG

A080439 003

May DISC

@ 100MG

A080439 004

May DISC

@ 200MG

A080439 005

May DISC

CHLORTHALIDONE

TABLET; ORAL

CHLORTHALIDONE

@ G AND W LABS INC 50MG

A088651 001

May 30, 1985

Apr CAHN

AB MUTUAL PHARM 50MG

A089286 001

Jul 21, 1986

Mar CMFD

AB + MYLAN 50MG

A086831 001

Jun CTEC

THALITONE

@ CITRON PHARMA LLC 15MG

N019574 001

Dec 20, 1988

Jun DISC

CHOLESTYRAMINE

POWDER; ORAL

CHOLESTYRAMINE

@ ANI PHARMS INC EQ 4GM RESIN/PACKET

A074554 001

Oct 02, 1996

Aug CAHN

@ EQ 4GM RESIN/SCOOPFUL

A074554 002

Oct 02, 1996

Aug CAHN

CHOLIC ACID

CAPSULE; ORAL

CHOLBAM

ASKLEPION PHARMS LLC 50MG

N205750 001

Mar 17, 2015

Mar NEWA

+ 250MG

N205750 002

Mar 17, 2015

Mar NEWA

RTRX 50MG

N205750 001

Mar 17, 2015

Apr CAHN

+ 250MG

N205750 002

Mar 17, 2015

Apr CAHN

CHOLINE C-11

INJECTABLE; INTRAVENOUS

CHOLINE C-11

>D> + MCPRF 4-33.1mCi/ML

N203155 001

Sep 12, 2012

Oct CFTG

>A> AP + 4-33.1mCi/ML

N203155 001

Sep 12, 2012

Oct CFTG

>A> AP UNIV TX MD ANDERSON 4-33.1mCi/ML

A205690 001

Oct 29, 2015

Oct NEWA

CHOLINE FENOFIBRATE

CAPSULE, DELAYED RELEASE; ORAL

FENOFIBRIC ACID

AB ACTAVIS ELIZABETH EQ 45MG FENOFIBRIC ACID

A200920 001

Oct 07, 2015

Sep NEWA

AB EQ 135MG FENOFIBRIC ACID

A200920 002

Oct 07, 2015

Sep NEWA

CICLOPIROX

SOLUTION; TOPICAL

CICLOPIROX

AT APOTEX INC 8%

A078172 001

Sep 18, 2007

Sep CMFD

CIDOFOVIR

INJECTABLE; INJECTION

CIDOFOVIR

AP + MYLAN INSTITUTIONAL EQ 75MG BASE/ML

A201276 001

Jun 27, 2012

May CRLD

CIMETIDINE HYDROCHLORIDE

SOLUTION; ORAL

CIMETIDINE HYDROCHLORIDE

@ G AND W LABS INC EQ 300MG BASE/5ML

A074176 001

Jun 01, 1994

Apr CAHN

CIPROFLOXACIN

INJECTABLE;INJECTION
CIPROFLOXACIN

AP	CLARIS PHARMASERVICE	200MG/20ML (10MG/ML)	A078062	001	Apr 29, 2008	Apr CAHN
AP		400MG/40ML (10MG/ML)	A078062	002	Apr 29, 2008	Apr CAHN
	CIPROFLOXACIN IN DEXTROSE 5% IN PLASTIC CONTAINER					
AP	CLARIS PHARMASERVICE	200MG/100ML	A078024	001	Mar 18, 2008	Apr CAHN
AP		400MG/200ML	A078024	002	Mar 18, 2008	Apr CAHN

CIPROFLOXACIN HYDROCHLORIDE

SOLUTION/DROPS;OPHTHALMIC
CIPROFLOXACIN HYDROCHLORIDE

>D>	AT	NEXUS PHARMS	EQ 0.3% BASE	A077689	001	Dec 13, 2006	Oct CAHN
>A>	AT	RISING PHARMS INC	EQ 0.3% BASE	A077689	001	Dec 13, 2006	Oct CAHN

TABLET;ORAL

		CIPROFLOXACIN HYDROCHLORIDE					
AB	SUN PHARM INDS LTD	EQ 250MG BASE	A075747	001	Jun 09, 2004	Apr CAHN	
AB		EQ 500MG BASE	A075747	002	Jun 09, 2004	Apr CAHN	
AB		EQ 750MG BASE	A075747	003	Jun 09, 2004	Apr CAHN	

CISATRACURIUM BESYLATE

INJECTABLE;INJECTION
CISATRACURIUM BESYLATE

AP	FRESENIUS KABI USA	EQ 2MG BASE/ML	A203183	001	Feb 26, 2015	Feb NEWA
	CISATRACURIUM BESYLATE PRESERVATIVE FREE					
AP	FRESENIUS KABI USA	EQ 2MG BASE/ML	A203182	001	Feb 26, 2015	Feb NEWA
AP		EQ 10MG BASE/ML	A203182	002	Feb 26, 2015	Feb NEWA

CISPLATIN

INJECTABLE;INJECTION
CISPLATIN

AP	ACCORD HLTHCARE	1MG/ML	A206774	001	Aug 18, 2015	Aug NEWA
----	-----------------	--------	---------	-----	--------------	----------

CITALOPRAM HYDROBROMIDE

TABLET;ORAL
CITALOPRAM HYDROBROMIDE

AB	G AND W LABS INC	EQ 10MG BASE	A077048	001	Nov 16, 2004	Apr CAHN
AB		EQ 20MG BASE	A077048	002	Nov 16, 2004	Apr CAHN
AB		EQ 40MG BASE	A077048	003	Nov 16, 2004	Apr CAHN

CLARITHROMYCIN

FOR SUSPENSION;ORAL
CLARITHROMYCIN

AB	SUN PHARM INDS LTD	125MG/5ML	A065382	001	Aug 30, 2007	Apr CAHN
AB		250MG/5ML	A065382	002	Aug 30, 2007	Apr CAHN

TABLET;ORAL

	CLARITHROMYCIN					
AB	HEC PHARM USA INC	250MG	A203584	001	Sep 28, 2015	Sep NEWA
AB		500MG	A203584	002	Sep 28, 2015	Sep NEWA
AB	SUN PHARM INDS LTD	250MG	A065174	001	Sep 24, 2004	Apr CAHN
AB		500MG	A065174	002	Sep 24, 2004	Apr CAHN

TABLET, EXTENDED RELEASE;ORAL
CLARITHROMYCIN

AB	LUPIN LTD	500MG	A202532	001	Sep 15, 2015	Aug NEWA
AB	+ TEVA	500MG	A065154	001	May 18, 2005	Jan CRLD

CLAVULANATE POTASSIUM; TICARCILLIN DISODIUM

INJECTABLE;INJECTION
TIMENTIN

@	GLAXOSMITHKLINE	EQ 100MG BASE/VIAL;EQ 3GM BASE/VIAL	A062691	001	Dec 19, 1986	May DISC
@		EQ 100MG BASE/VIAL;EQ 3GM BASE/VIAL	N050590	001	Apr 01, 1985	May DISC
@		EQ 200MG BASE/VIAL;EQ 3GM BASE/VIAL	N050590	002	Apr 01, 1985	May DISC
@		EQ 1GM BASE/VIAL;EQ 30GM BASE/VIAL	N050590	003	Aug 18, 1987	May DISC
	TIMENTIN IN PLASTIC CONTAINER					
@	GLAXOSMITHKLINE	EQ 100MG BASE/100ML;EQ 3GM BASE/100ML	N050658	001	Dec 15, 1989	May DISC

CLEMASTINE FUMARATE

TABLET;ORAL

CLEMASTINE FUMARATE

@ ANI PHARMS INC

1.34MG

A073282 001 Jan 31, 1992 Jul CAHN

CLINDAMYCIN HYDROCHLORIDE

CAPSULE;ORAL

CLINDAMYCIN HYDROCHLORIDE

AB G AND W LABS INC

EQ 150MG BASE

A063029 001 Sep 20, 1989 Apr CAHN

AB EQ 300MG BASE

EQ 300MG BASE

A063029 002 Aug 05, 2005 Apr CAHN

AB SUN PHARM INDS LTD

EQ 150MG BASE

A065061 001 Feb 02, 2001 Apr CAHN

AB EQ 300MG BASE

EQ 300MG BASE

A065061 002 Feb 02, 2001 Apr CAHN

CLINDAMYCIN PHOSPHATE

INJECTABLE;INJECTION

CLINDAMYCIN PHOSPHATE

AP ALVOGEN INC

EQ 150MG BASE/ML

A062800 001 Jul 24, 1987 Sep CAHN

AP EQ 150MG BASE/ML

EQ 150MG BASE/ML

A062801 001 Jul 24, 1987 Sep CAHN

AP EQ 150MG BASE/ML

EQ 150MG BASE/ML

A062943 001 Sep 29, 1988 Sep CAHN

@ IGI LABS INC

EQ 150MG BASE/ML

A062928 001 Feb 13, 1989 Mar CAHN

SOLUTION;TOPICAL

CLINDAMYCIN PHOSPHATE

@ BOCA PHARMA LLC

EQ 1% BASE

A062944 001 Jan 11, 1989 Jan CAHN

AT VINTAGE PHARMS

EQ 1% BASE

A203343 001 May 29, 2015 May NEWA

CLINDAMYCIN PHOSPHATE; TRETINOIN

GEL;TOPICAL

CLINDAMYCIN PHOSPHATE AND TRETINOIN

AB ACTAVIS MID ATLANTIC

1.2%;0.025%

A202564 001 Jun 12, 2015 Jun NEWA

ZIANA

AB + MEDICIS

1.2%;0.025%

N050802 001 Nov 07, 2006 Jun CTEC

CLOBETASOL PROPIONATE

CREAM;TOPICAL

CLOBETASOL PROPIONATE (EMOLLIENT)

AB2 + FOUGERA PHARMS

0.05%

A075430 001 May 26, 1999 May CRLD

CORMAX

AB1 + HI TECH PHARMA

0.05%

A074220 001 May 16, 1997 Jun CRLD

GEL;TOPICAL

CLOBETASOL PROPIONATE

AB + FOUGERA PHARMS

0.05%

A075368 001 Feb 15, 2000 May CRLD

OINTMENT;TOPICAL

CLOBETASOL PROPIONATE

AB G AND W LABS INC

0.05%

A074089 001 Feb 16, 1994 Feb CAHN

SOLUTION;TOPICAL

CLOBETASOL PROPIONATE

AT G AND W LABS INC

0.05%

A074331 001 Dec 15, 1995 Mar CMFD

CLOMIPHENE CITRATE

TABLET;ORAL

SEROPHENE

@ EMD SERONO

50MG

N018361 001 Mar 22, 1982 Jun DISC

CLONIDINE

FILM, EXTENDED RELEASE;TRANSDERMAL

CLONIDINE

AB ACTAVIS LABS UT INC

0.1MG/24HR

A090873 001 May 06, 2014 Mar CAHN

AB 0.2MG/24HR

0.2MG/24HR

A090873 002 May 06, 2014 Mar CAHN

AB 0.3MG/24HR

0.3MG/24HR

A090873 003 May 06, 2014 Mar CAHN

CLONIDINE HYDROCHLORIDE

TABLET;ORAL

CLONIDINE HYDROCHLORIDE

@ DAVA PHARMS INC

0.1MG

A071783 001 Apr 05, 1988 May DISC

@

0.2MG

A071784 001 Apr 05, 1988 May DISC

@

0.3MG

A071785 001 Apr 05, 1988 May DISC

TABLET, EXTENDED RELEASE;ORAL

CLONIDINE HYDROCHLORIDE

AB2 ACTAVIS ELIZABETH

0.1MG

A202792 001 May 15, 2015 May NEWA

AB1 0.1MG

0.1MG

A203320 001 May 15, 2015 May NEWA

TABLET, EXTENDED RELEASE;ORAL									
CLONIDINE HYDROCHLORIDE									
	@	0.2MG		A202792	002	May 15, 2015	Aug	DISC	
AB2		0.2MG		A202792	002	May 15, 2015	May	NEWA	
	@	0.2MG		A203320	002	May 15, 2015	Aug	DISC	
AB1		0.2MG		A203320	002	May 15, 2015	May	NEWA	
	@ ANCHEN PHARMS	0.1MG		A202983	001	Apr 02, 2014	Aug	DISC	
AB2		0.1MG		A202983	001	Apr 02, 2014	May	CTEC	
	@	0.2MG		A202983	002	Apr 02, 2014	Aug	DISC	
AB2		0.2MG		A202983	002	Apr 02, 2014	May	CTEC	
CLONIDINE HYDROCHLORIDE									
AB1	ANCHEN PHARMS	0.1MG		A202984	001	Sep 30, 2013	May	CTEC	
	@	0.2MG		A202984	002	Sep 30, 2013	Aug	DISC	
AB1		0.2MG		A202984	002	Sep 30, 2013	May	CTEC	
KAPVAY									
AB1	+ CONCORDIA PHARMS INC	0.1MG		N022331	003	Sep 28, 2010	Aug	CRLD	
AB1		0.1MG		N022331	003	Sep 28, 2010	Jun	CRLD	
AB1	+	0.1MG		N022331	003	Sep 28, 2010	May	CTEC	
	@	0.2MG		N022331	004	Sep 28, 2010	Aug	DISC	
AB1	+	0.2MG		N022331	004	Sep 28, 2010	Jun	CRLD	
AB1		0.2MG		N022331	004	Sep 28, 2010	May	CTEC	
<u>CLORAZEPATE DIPOTASSIUM</u>									
TABLET;ORAL									
CLORAZEPATE DIPOTASSIUM									
AB	SUN PHARM INDS LTD	3.75MG		A076911	001	Sep 29, 2004	Apr	CAHN	
AB		7.5MG		A076911	002	Sep 29, 2004	Apr	CAHN	
AB		15MG		A076911	003	Sep 29, 2004	Apr	CAHN	
<u>CLOZAPINE</u>									
TABLET;ORAL									
CLOZAPINE									
AB	ACTAVIS LABS FL INC	25MG		A203807	001	Sep 17, 2015	Sep	NEWA	
AB		100MG		A203807	002	Sep 17, 2015	Sep	NEWA	
CLOZARIL									
AB	HERITAGE LIFE	25MG		N019758	001	Sep 26, 1989	Aug	CAHN	
AB	+	100MG		N019758	002	Sep 26, 1989	Aug	CAHN	
TABLET, ORALLY DISINTEGRATING;ORAL									
CLOZAPINE									
AB	MYLAN PHARMS INC	25MG		A201824	002	Sep 15, 2015	Aug	NEWA	
AB		100MG		A201824	003	Sep 15, 2015	Aug	NEWA	
FAZACLO ODT									
AB	JAZZ PHARMS III	25MG		N021590	001	Feb 10, 2004	Aug	CFTG	
AB	+	100MG		N021590	002	Feb 10, 2004	Aug	CFTG	
<u>COBICISTAT; DARUNAVIR ETHANOLATE</u>									
TABLET;ORAL									
PREZCOBIX									
+	JANSSEN PRODS	150MG;EQ 800MG BASE		N205395	001	Jan 29, 2015	Jan	NEWA	
<u>CODEINE PHOSPHATE; PHENYLEPHRINE HYDROCHLORIDE; PROMETHAZINE HYDROCHLORIDE</u>									
SYRUP;ORAL									
PROMETHAZINE HYDROCHLORIDE,PHENYLEPHRINE HYDROCHLORIDE W/CODEINE PHOSPHATE									
AA	AMNEAL PHARMS	10MG/5ML;5MG/5ML;6.25MG/5ML		A200963	001	Aug 26, 2015	Aug	NEWA	
<u>CODEINE SULFATE</u>									
SOLUTION;ORAL									
CODEINE SULFATE									
	@ ROXANE	30MG/5ML		N202245	001	Jun 30, 2011	Jan	DISC	
<u>COLCHICINE</u>									
CAPSULE;ORAL									
MITIGARE									
	HIKMA INTL PHARMS	0.6MG		N204820	001	Sep 26, 2014	Jan	CAHN	
<u>COLCHICINE; PROBENECID</u>									
TABLET;ORAL									
PROBENECID AND COLCHICINE									
	@ ANI PHARMS INC	0.5MG;500MG		A083734	001		Aug	CAHN	

COLISTIMETHATE SODIUM

INJECTABLE; INJECTION					
COLISTIMETHATE SODIUM					
AP	XELLIA PHARMS APS	EQ 150MG BASE/VIAL	A205356	001	May 29, 2015 May NEWA

CORTICOTROPIN

INJECTABLE; INJECTION					
H.P. ACTHAR GEL					
	@ MALLINCKRODT ARD	40 UNITS/ML	N008372	006	Aug CAHN
+		80 UNITS/ML	N008372	008	Aug CAHN

CYANOCOBALAMIN

INJECTABLE; INJECTION					
CYANOCOBALAMIN					
	@ EUROHLTH INTL SARL	1MG/ML	A080515	002	Feb CAHN

CYCLOBENZAPRINE HYDROCHLORIDE

TABLET; ORAL					
CYCLOBENZAPRINE HYDROCHLORIDE					
AB	ORIT LABS LLC	5MG	A078218	002	Jun 19, 2015 Jun NEWA
AB	SUN PHARM INDS LTD	5MG	A078722	001	May 12, 2008 Apr CAHN
AB		7.5MG	A078722	002	May 12, 2008 Apr CAHN
AB		10MG	A078722	003	May 12, 2008 Apr CAHN

CYPROHEPTADINE HYDROCHLORIDE

TABLET; ORAL					
CYPROHEPTADINE HYDROCHLORIDE					
AA	MIRROR PHARMS LLC	4MG	A205087	001	Sep 23, 2015 Sep NEWA

DABRAFENIB MESYLATE

CAPSULE; ORAL					
TAFINLAR					
	NOVARTIS PHARMS CORP	EQ 50MG BASE	N202806	001	May 29, 2013 Mar CAHN
+		EQ 75MG BASE	N202806	002	May 29, 2013 Mar CAHN

DACLATASVIR DIHYDROCHLORIDE

TABLET; ORAL					
DAKLINZA					
	BRISTOL-MYERS SQUIBB	EQ 30MG BASE	N206843	001	Jul 24, 2015 Jul NEWA
+		EQ 60MG BASE	N206843	002	Jul 24, 2015 Jul NEWA

DALTEPARIN SODIUM

INJECTABLE; INJECTION					
FRAGMIN					
	@ PFIZER INC	7,500 IU/0.75ML	N020287	008	Apr 04, 2002 Jun CAHN
	@ PHARMACIA AND UPJOHN	7,500 IU/0.75ML	N020287	008	Apr 04, 2002 Apr CAHN
INJECTABLE; SUBCUTANEOUS					
FRAGMIN					
	PFIZER INC	2,500IU/0.2ML (12,500IU/ML)	N020287	001	Dec 22, 1994 Jun CAHN
		5,000IU/0.2ML (25,000IU/ML)	N020287	003	Mar 18, 1996 Jun CAHN
		7,500IU/0.3ML (25,000IU/ML)	N020287	005	Apr 04, 2002 Jun CAHN
	@	10,000IU/0.4ML (25,000IU/ML)	N020287	002	May 01, 2007 Jun CAHN
		10,000IU/ML (10,000IU/ML)	N020287	004	Jan 30, 1998 Jun CAHN
		12,500IU/0.5ML (25,000IU/ML)	N020287	009	May 01, 2007 Jun CAHN
		15,000IU/0.6ML (25,000IU/ML)	N020287	010	May 01, 2007 Jun CAHN
		18,000IU/0.72ML (25,000IU/ML)	N020287	011	May 01, 2007 Jun CAHN
+		95,000IU/3.8ML (25,000IU/ML)	N020287	006	Apr 04, 2002 Jun CAHN
	@	95,000IU/9.5ML (10,000IU/ML)	N020287	007	Apr 04, 2002 Jun CAHN
	PHARMACIA AND UPJOHN	2,500IU/0.2ML (12,500IU/ML)	N020287	001	Dec 22, 1994 Apr CAHN
		5,000IU/0.2ML (25,000IU/ML)	N020287	003	Mar 18, 1996 Apr CAHN
		7,500IU/0.3ML (25,000IU/ML)	N020287	005	Apr 04, 2002 Apr CAHN
	@	10,000IU/0.4ML (25,000IU/ML)	N020287	002	May 01, 2007 Apr CAHN
		10,000IU/ML (10,000IU/ML)	N020287	004	Jan 30, 1998 Apr CAHN
		12,500IU/0.5ML (25,000IU/ML)	N020287	009	May 01, 2007 Apr CAHN
		15,000IU/0.6ML (25,000IU/ML)	N020287	010	May 01, 2007 Apr CAHN
		18,000IU/0.72ML (25,000IU/ML)	N020287	011	May 01, 2007 Apr CAHN
+		95,000IU/3.8ML (25,000IU/ML)	N020287	006	Apr 04, 2002 Apr CAHN
	@	95,000IU/9.5ML (10,000IU/ML)	N020287	007	Apr 04, 2002 Apr CAHN

DANTROLENE SODIUM

CAPSULE;ORAL

DANTROLENE SODIUM

AB	ELITE LABS INC	25MG	A076686	001	Oct 24, 2005	May CAHN
AB		50MG	A076686	002	Oct 24, 2005	May CAHN
AB		100MG	A076686	003	Oct 24, 2005	May CAHN

DARIFENACIN HYDROBROMIDE

TABLET, EXTENDED RELEASE;ORAL

DARIFENACIN HYDROBROMIDE

AB	ANCHEN PHARMS	EQ 7.5MG BASE	A091190	001	Mar 13, 2015	Mar NEWA
AB		EQ 15MG BASE	A091190	002	Mar 13, 2015	Mar NEWA
	ENABLEX					
AB	WARNER CHILCOTT LLC	EQ 7.5MG BASE	N021513	001	Dec 22, 2004	Mar CFTG
AB	+	EQ 15MG BASE	N021513	002	Dec 22, 2004	Mar CFTG

DASATINIB

TABLET;ORAL

SPRYCEL

+	BRISTOL MYERS SQUIBB	100MG	N021986	004	May 30, 2008	Sep CRLD
		140MG	N021986	006	Oct 28, 2010	Sep CRLD

DECITABINE

INJECTABLE;INTRAVENOUS

DACOGEN

AP	+	OTSUKA PHARM CO LTD	50MG/VIAL	N021790	001	May 02, 2006	Jan CAHN
----	---	---------------------	-----------	---------	-----	--------------	----------

DEFERASIROX

TABLET;ORAL

JADENU

	NOVARTIS PHARMS CORP	90MG	N206910	001	Mar 30, 2015	Mar NEWA
		180MG	N206910	002	Mar 30, 2015	Mar NEWA
+		360MG	N206910	003	Mar 30, 2015	Mar NEWA

DEFERIPRONE

SOLUTION;ORAL

FERRIPROX

+	AOPHARMA INC	100MG/ML	N208030	001	Sep 09, 2015	Sep NEWA
---	--------------	----------	---------	-----	--------------	----------

DEMECLOCYCLINE HYDROCHLORIDE

TABLET;ORAL

DEMECLOCYCLINE HYDROCHLORIDE

AB	EPIC PHARMA LLC	150MG	A065447	001	Aug 18, 2015	Aug NEWA
AB		300MG	A065447	002	Aug 18, 2015	Aug NEWA

DEOXYCHOLIC ACID

SOLUTION;SUBCUTANEOUS

KYBELLA

+	KYATHERA BIOPHARMS	20MG/2ML (10MG/ML)	N206333	001	Apr 29, 2015	Apr NEWA
---	--------------------	--------------------	---------	-----	--------------	----------

DESIPRAMINE HYDROCHLORIDE

TABLET;ORAL

DESIPRAMINE HYDROCHLORIDE

	ANI PHARMS INC	25MG	A071803	002	Dec 08, 1987	Sep CMS1
		50MG	A071803	003	Dec 08, 1987	Sep CMS1
		75MG	A071803	004	Dec 08, 1987	Sep CMS1
		150MG	A071803	005	May 29, 1997	Sep CMS1

DESIRUDIN RECOMBINANT

INJECTABLE;SUBCUTANEOUS

IPRIVASK

+	VALEANT PHARMS NORTH	15MG/VIAL	N021271	001	Apr 04, 2003	May CAHN
---	----------------------	-----------	---------	-----	--------------	----------

DESLORATADINE

SOLUTION;ORAL

CLARINEX

AA	+	MERCK SHARP DOHME	0.5MG/ML	N021300	001	Sep 01, 2004	Jun CFTG
		DESLORATADINE					
AA		TARO PHARM INDS	0.5MG/ML	A202592	001	Jun 30, 2015	Jun NEWA

DESMOPRESSIN ACETATE

TABLET; ORAL

DDAVP

AB	FERRING PHARMS INC	0.1MG	N019955	001	Sep 06, 1995	Jan CAHN
AB	+	0.2MG	N019955	002	Sep 06, 1995	Jan CAHN
DESMOPRESSIN ACETATE						
AB	GLENMARK PHARMS LTD	0.1MG	A201831	001	May 28, 2015	May NEWA
AB		0.2MG	A201831	002	May 28, 2015	May NEWA

DESOGESTREL; ETHINYL ESTRADIOL

TABLET; ORAL-28

BEKYREE

AB	LUPIN LTD	0.15MG, N/A; 0.02MG, 0.01MG	A202226	001	Aug 12, 2015	Jul NEWA
CYCLESSA						
AB	+	0.1MG, 0.125MG, 0.15MG; 0.025MG, 0.025MG, 0.025MG	N021090	001	Dec 20, 2000	Aug CAHN
ISIBLOOM						
AB	SANDOZ INC	0.15MG; 0.03MG	A202789	001	Aug 12, 2015	Jul NEWA
KARIVA						
AB	+	0.15MG, N/A; 0.02MG, 0.01MG	A075863	001	Apr 05, 2002	Apr CTEC
KIMIDESS						
AB	VINTAGE PHARMS	0.15MG, N/A; 0.02MG, 0.01MG	A076681	001	Apr 30, 2015	Apr NEWA

DESONIDE

CREAM; TOPICAL

DESONIDE

AB	TEVA PHARMS	0.05%	A074027	001	Sep 28, 1992	May CMFD
----	-------------	-------	---------	-----	--------------	----------

DESOXIMETASONE

CREAM; TOPICAL

DESOXIMETASONE

AB	ACTAVIS MID ATLANTIC	0.25%	A205082	001	Sep 04, 2015	Aug NEWA
AB	VERSAPHARM INC	0.25%	A203234	001	Jun 12, 2015	Jun NEWA

OINTMENT; TOPICAL

DESOXIMETASONE

AB	PERRIGO NEW YORK	0.25%	A077770	001	Apr 20, 2015	Apr NEWA
----	------------------	-------	---------	-----	--------------	----------

DESVENLAFAXINE SUCCINATE

TABLET, EXTENDED RELEASE; ORAL

DESVENLAFAXINE SUCCINATE

AB	ALEMBIC PHARMS LTD	EQ 50MG BASE	A204003	001	Jun 29, 2015	Jun NEWA
AB		EQ 100MG BASE	A204003	002	Jun 29, 2015	Jun NEWA
AB	LUPIN LTD	EQ 50MG BASE	A204172	001	Jun 29, 2015	Jun NEWA
AB		EQ 100MG BASE	A204172	002	Jun 29, 2015	Jun NEWA
AB	MYLAN PHARMS INC	EQ 50MG BASE	A204095	001	Jun 29, 2015	Jun NEWA
AB		EQ 100MG BASE	A204095	002	Jun 29, 2015	Jun NEWA
AB	SANDOZ INC	EQ 50MG BASE	A204028	001	Jun 29, 2015	Jun NEWA
AB		EQ 100MG BASE	A204028	002	Jun 29, 2015	Jun NEWA
PRISTIQ						
AB	+	EQ 50MG BASE	N021992	001	Feb 29, 2008	Jun CFTG
AB	+	EQ 100MG BASE	N021992	002	Feb 29, 2008	Jun CFTG

DEXAMETHASONE SODIUM PHOSPHATE

INJECTABLE; INJECTION

DEXAMETHASONE SODIUM PHOSPHATE

AP	BD RX	EQ 4MG PHOSPHATE/ML	A203129	001	Sep 30, 2015	Sep NEWA
	@ EUROHLTH INTL SARL	EQ 4MG PHOSPHATE/ML	A084282	001		Mar CAHN
AP	+	EQ 10MG PHOSPHATE/ML	A087702	001	Sep 07, 1982	Feb CAHN

DEXAMETHASONE; NEOMYCIN SULFATE; POLYMYXIN B SULFATE

OINTMENT; OPHTHALMIC

MAXITROL

AT	+	ALCON LABS INC	0.1%; EQ 3.5MG BASE/GM; 10,000 UNITS/GM	N050065	002	Mar CAHN
----	---	----------------	---	---------	-----	----------

SUSPENSION/DROPS; OPHTHALMIC

MAXITROL

AT	+	ALCON LABS INC	0.1%; EQ 3.5MG BASE/ML; 10,000 UNITS/ML	N050023	002	Mar CAHN
----	---	----------------	---	---------	-----	----------

DEXMEDETOMIDINE HYDROCHLORIDE

INJECTABLE; INJECTION

DEXMEDETOMIDINE HYDROCHLORIDE

AP	FRESENIUS KABI USA	EQ 200MCG BASE/2ML (EQ 100MCG BASE/ML)	A201072	001	Sep 18, 2015	Sep NEWA
AP	SUN PHARM INDS INC	EQ 200MCG BASE/2ML (EQ 100MCG BASE/ML)	A202126	001	Aug 20, 2015	Aug NEWA

PRECEDEX

HOSPIRA

EQ 80MCG BASE/20ML (EQ 4MCG BASE/ML)

N021038 004 Nov 14, 2014 Jan NEWA

>A> SOLUTION; IV (INFUSION)

DEXMEDETOMIDINE HYDROCHLORIDE

>A>	+ HQ SPCLT PHARMA	EQ 1MG BASE/10ML (EQ 100MCG BASE/ML)	N206628	002	Oct 21, 2015	Oct NEWA
>A>		EQ 400MCG BASE/4ML (EQ 100MCG BASE/ML)	N206628	001	Oct 21, 2015	Oct NEWA

DEXMETHYLPHENIDATE HYDROCHLORIDE

CAPSULE, EXTENDED RELEASE; ORAL

DEXMETHYLPHENIDATE HYDROCHLORIDE

AB	MYLAN PHARMS INC	5MG	A204266	001	Aug 25, 2015	Aug NEWA
AB		10MG	A204266	002	Aug 25, 2015	Aug NEWA
AB		15MG	A204266	003	Aug 25, 2015	Aug NEWA
AB		40MG	A204266	007	Aug 25, 2015	Aug NEWA
AB	WATSON LABS INC	5MG	A079108	001	Aug 05, 2015	Jul NEWA
AB		10MG	A079108	002	Aug 05, 2015	Jul NEWA

TABLET; ORAL

DEXMETHYLPHENIDATE HYDROCHLORIDE

AB	SUN PHARM INDS LTD	2.5MG	A201231	001	Sep 24, 2015	Sep NEWA
AB		5MG	A201231	002	Sep 24, 2015	Sep NEWA
AB		10MG	A201231	003	Sep 24, 2015	Sep NEWA

DEXTROSE; MAGNESIUM CHLORIDE; POTASSIUM CHLORIDE; SODIUM ACETATE; SODIUM CHLORIDE; SODIUM GLUCONATE

INJECTABLE; INJECTION

PLASMA-LYTE 148 AND DEXTROSE 5% IN PLASTIC CONTAINER

@ BAXTER HLTHCARE	5GM/100ML; 30MG/100ML; 37MG/100ML; 36 8MG/100ML; 526MG/100ML; 502MG/100ML	N017451	001			Mar DISC
-------------------	---	---------	-----	--	--	----------

DIATRIZOATE MEGLUMINE; DIATRIZOATE SODIUM

INJECTABLE; INJECTION

MD-76R

AP	+ LIEBEL-FLARSHEIM	66%; 10%	N019292	001	Sep 29, 1989	Feb CAHN
	SOLUTION; ORAL, RECTAL					
	MD-GASTROVIEW					
AA	LIEBEL-FLARSHEIM	66%; 10%	A087388	001		Jan CAHN

DICHLORPHENAMIDE

TABLET; ORAL

KEVEYIS

TARO

50MG

N011366 002 Aug 07, 2015 Aug NEWA

DICLOFENAC SODIUM

GEL; TOPICAL

VOLTAREN

+ GLAXOSMITHKLINE CONS	1%	N022122	001	Oct 17, 2007	Aug CAHN
------------------------	----	---------	-----	--------------	----------

SOLUTION; TOPICAL

DICLOFENAC SODIUM

AT	IGI LABS INC	1.5%	A202769	001	Jul 08, 2015	Jun NEWA
AT	LUPIN LTD	1.5%	A204132	001	Aug 20, 2015	Aug NEWA

TABLET, EXTENDED RELEASE; ORAL

DICLOFENAC SODIUM

>D>	AB	VALEANT INTL	100MG	A075492	001	Feb 11, 2000	Oct CAHN
>A>	AB	VPNA	100MG	A075492	001	Feb 11, 2000	Oct CAHN

DIETHYLPROPION HYDROCHLORIDE

TABLET; ORAL

TENUATE

AA	+ ACTAVIS LABS UT INC	25MG	N011722	002		Mar CAHN
----	-----------------------	------	---------	-----	--	----------

TABLET, EXTENDED RELEASE;ORAL
TENUATE DOSPAN

AB + ACTAVIS LABS UT INC 75MG N012546 001 Mar CAHN

DIFLORASONE DIACETATE

OINTMENT;TOPICAL
DIFLORASONE DIACETATE

AB VERSAPHARM INC 0.05% A206572 001 Jul 24, 2015 Jul NEWA

DIFLUNISAL

TABLET;ORAL
DIFLUNISAL

AB HERITAGE PHARMA 500MG A202845 001 Mar 08, 2012 Mar CAHN

DIGOXIN

INJECTABLE;INJECTION
DIGOXIN

AP EUROHLTH INTL SARL 0.25MG/ML A083391 001 Feb CAHN

TABLET;ORAL

DIGOXIN

AB MYLAN PHARMS INC 0.125MG A040282 001 Dec 23, 1999 Jan CTEC

AB 0.25MG A040282 002 Dec 23, 1999 Jan CTEC

AB SUN PHARM INDS INC 0.125MG A076363 001 Jan 31, 2003 Feb CMFD

AB 0.25MG A076363 002 Jan 31, 2003 Feb CMFD

LANOXIN

AB CONCORDIA PHARMS INC 0.0625MG N020405 001 Sep 30, 1997 Apr CAHN

AB 0.125MG N020405 002 Sep 30, 1997 Apr CAHN

AB 0.1875MG N020405 003 Sep 30, 1997 Apr CAHN

AB + 0.25MG N020405 004 Sep 30, 1997 Apr CAHN

@ 0.375MG N020405 005 Sep 30, 1997 Apr CAHN

@ 0.5MG N020405 006 Sep 30, 1997 Apr CAHN

DILTIAZEM HYDROCHLORIDE

CAPSULE, EXTENDED RELEASE;ORAL

>D> DILT-CD

>D> AB3 APOTEX 120MG A076151 001 May 20, 2004 Oct DISC

>A> @ 120MG A076151 001 May 20, 2004 Oct DISC

>D> AB3 180MG A076151 002 May 20, 2004 Oct DISC

>A> @ 180MG A076151 002 May 20, 2004 Oct DISC

>D> AB3 240MG A076151 003 May 20, 2004 Oct DISC

>A> @ 240MG A076151 003 May 20, 2004 Oct DISC

>D> AB3 300MG A076151 004 May 20, 2004 Oct DISC

>A> @ 300MG A076151 004 May 20, 2004 Oct DISC

DILTIAZEM HYDROCHLORIDE

AB2 + MYLAN 240MG A075124 001 Mar 18, 1998 Feb CRLD

TIAZAC

AB4 VALEANT PHARMS NORTH 120MG N020401 001 Sep 11, 1995 Feb CAHN

AB4 180MG N020401 002 Sep 11, 1995 Feb CAHN

AB4 240MG N020401 003 Sep 11, 1995 Feb CAHN

AB4 300MG N020401 004 Sep 11, 1995 Feb CAHN

AB4 360MG N020401 005 Sep 11, 1995 Feb CAHN

AB4 + 420MG N020401 006 Oct 16, 1998 Feb CAHN

INJECTABLE;INJECTION

DILTIAZEM HYDROCHLORIDE

AP EUROHLTH INTL SARL 5MG/ML A078538 001 Dec 17, 2008 Jun CAHN

DIPHENHYDRAMINE HYDROCHLORIDE

INJECTABLE;INJECTION

DIPHENHYDRAMINE HYDROCHLORIDE

AP + EUROHLTH INTL SARL 50MG/ML A080817 002 Jun CAHN

DIPYRIDAMOLE

INJECTABLE;INJECTION

DIPYRIDAMOLE

AP EUROHLTH INTL SARL 5MG/ML A074521 001 Oct 18, 1996 Jun CAHN

DISULFIRAMTABLET; ORAL
DISULFIRAM

AB	MYLAN PHARMS INC	250MG	A203916	001	Mar 04, 2015	Feb NEWA
AB		500MG	A203916	002	Mar 04, 2015	Feb NEWA

DIVALPROEX SODIUMTABLET, EXTENDED RELEASE; ORAL
DIVALPROEX SODIUM

AB	AMNEAL PHARMS	EQ 250MG VALPROIC ACID	A203730	001	May 29, 2015	May NEWA
AB		EQ 500MG VALPROIC ACID	A203730	002	May 29, 2015	May NEWA
	@ G AND W LABS INC	EQ 500MG VALPROIC ACID	A078700	001	Aug 03, 2009	Jul CAHN

DOBUTAMINE HYDROCHLORIDEINJECTABLE; INJECTION
DOBUTAMINE HYDROCHLORIDE

	@ IGI LABS INC	EQ 12.5MG BASE/ML	A074098	001	Feb 21, 1995	Mar CAHN
--	----------------	-------------------	---------	-----	--------------	----------

DOCETAXELINJECTABLE; INJECTION
DOCETAXEL

AP	TEVA PHARMS USA	20MG/ML (20MG/ML)	A203877	001	Sep 16, 2015	Aug NEWA
AP		80MG/4ML (20MG/ML)	A203877	002	Sep 16, 2015	Aug NEWA

DONEPEZIL HYDROCHLORIDETABLET; ORAL
DONEPEZIL HYDROCHLORIDE

AB	HETERO LABS LTD V	5MG	A203034	001	Jan 30, 2015	Jan NEWA
AB		10MG	A203034	002	Jan 30, 2015	Jan NEWA
>A> AB	LUPIN LTD	23MG	A202782	001	Oct 30, 2015	Oct NEWA
>A> AB	MYLAN PHARMS INC	23MG	A202656	001	Oct 22, 2015	Oct NEWA
AB	SUN PHARM INDS LTD	5MG	A076786	001	Nov 26, 2010	Apr CAHN
AB		10MG	A076786	002	Nov 26, 2010	Apr CAHN
AB		23MG	A204293	001	Jun 05, 2015	May NEWA

DONEPEZIL HYDROCHLORIDE; MEMANTINE HYDROCHLORIDECAPSULE, EXTENDED RELEASE; ORAL
NAMZARIC

	FOREST LABS LLC	10MG; 14MG	N206439	001	Dec 23, 2014	Mar CAHN
+		10MG; 28MG	N206439	002	Dec 23, 2014	Mar CAHN

DOPAMINE HYDROCHLORIDEINJECTABLE; INJECTION
DOPAMINE HYDROCHLORIDE

	@ IGI LABS INC	40MG/ML	A070087	001	Oct 23, 1985	Mar CAHN
	@	40MG/ML	N018656	001	Jun 28, 1983	Mar CAHN
	@	80MG/ML	A070089	001	Oct 23, 1985	Mar CAHN
	@	80MG/ML	A070090	001	Oct 23, 1985	Mar CAHN
	@	80MG/ML	A070091	001	Oct 23, 1985	Mar CAHN
	@	160MG/ML	A070092	001	Oct 23, 1985	Mar CAHN
	@	160MG/ML	A070093	001	Oct 23, 1985	Mar CAHN
	@	160MG/ML	A070094	001	Oct 23, 1985	Mar CAHN

DOXAPRAM HYDROCHLORIDEINJECTABLE; INJECTION
DOPRAM

AP	+	EUROHLTH INTL SARL	20MG/ML	N014879	001	Jun CAHN
----	---	--------------------	---------	---------	-----	----------

DOXEPIIN HYDROCHLORIDECAPSULE; ORAL
DOXEPIIN HYDROCHLORIDE

AB	+	MYLAN PHARMS INC	EQ 100MG BASE	A070791	005	May 13, 1986	Jan CRLD
	+	PAR PHARM	EQ 150MG BASE	A071669	001	Nov 09, 1987	Jan CRLD
		CREAM; TOPICAL					
		ZONALON					
	+	DELCOR ASSET CORP	5%	N020126	001	Apr 01, 1994	Mar CAHN

DOXERCALCIFEROLINJECTABLE; INJECTION
DOXERCALCIFEROL

AP	AKORN INC	4MCG/2ML (2MCG/ML)	A203929	001	May 07, 2015	Apr	NEWA
----	-----------	--------------------	---------	-----	--------------	-----	------

DOXORUBICIN HYDROCHLORIDEINJECTABLE; INJECTION
ADRIAMYCIN PFS

>D>	@ PHARMACIA AND UPJOHN	2MG/ML	N050629	001	Dec 23, 1987	Oct	CTNA
>D>	@	200MG/100ML	N050629	002	May 03, 1988	Oct	CTNA
>D>	ADRIAMYCIN RDF						
>D>	@ PHARMACIA AND UPJOHN	10MG/VIAL	N050467	001		Oct	CTNA
>D>	@	20MG/VIAL	N050467	003	May 20, 1985	Oct	CTNA
>D>	@	50MG/VIAL	N050467	002		Oct	CTNA
>D>	@	150MG/VIAL	N050467	004	Jul 22, 1987	Oct	CTNA

DOXORUBICIN HYDROCHLORIDE

>A>	AP	+	PHARMACIA AND UPJOHN	2MG/ML	N050629	001	Dec 23, 1987	Oct	CMFD
>A>			@	2MG/ML	N050629	001	Dec 23, 1987	Oct	CTNA
>A>			@	10MG/VIAL	N050467	001		Oct	CTNA
>A>			@	20MG/VIAL	N050467	003	May 20, 1985	Oct	CTNA
>A>			@	50MG/VIAL	N050467	002		Oct	CTNA
>A>			@	150MG/VIAL	N050467	004	Jul 22, 1987	Oct	CTNA
>A>				150MG/75ML	N050629	003	Mar 28, 2011	Oct	NEWA
>A>	AP	+		200MG/100ML	N050629	002	May 03, 1988	Oct	CMFD
>A>			@	200MG/100ML	N050629	002	May 03, 1988	Oct	CTNA

DOXYCYCLINECAPSULE; ORAL
DOXYCYCLINE

AB	NOVEL LABS INC	EQ 50MG BASE	A204446	001	May 28, 2015	May	NEWA
AB		EQ 75MG BASE	A204446	002	May 28, 2015	May	NEWA
AB		EQ 100MG BASE	A204446	003	May 28, 2015	May	NEWA
AB	SUN PHARM INDS LTD	EQ 50MG BASE	A065053	001	Nov 22, 2000	Apr	CAHN
AB		EQ 75MG BASE	A065053	003	Sep 10, 2003	Apr	CAHN
AB		EQ 100MG BASE	A065053	002	Nov 22, 2000	Apr	CAHN

TABLET; ORAL

DOXYCYCLINE

AB	SUN PHARM INDS LTD	EQ 50MG BASE	A065356	001	May 31, 2006	Apr	CAHN
AB		EQ 75MG BASE	A065356	002	May 31, 2006	Apr	CAHN
AB		EQ 100MG BASE	A065356	003	May 31, 2006	Apr	CAHN

DOXYCYCLINE HYCLATEINJECTABLE; INJECTION
DOXYCYCLINE

@	EUROHLTH INTL SARL	EQ 100MG BASE/VIAL	A062450	001	Oct 27, 1983	Jun	CAHN
@		EQ 200MG BASE/VIAL	A062450	002	Oct 27, 1983	Jun	CAHN

DROPERIDOLINJECTABLE; INJECTION
DROPERIDOL

@	IGI LABS INC	2.5MG/ML	A072019	001	Oct 19, 1988	Mar	CAHN
@		2.5MG/ML	A072020	001	Oct 19, 1988	Mar	CAHN
@		2.5MG/ML	A072021	001	Oct 19, 1988	Mar	CAHN

DROSPIRENONE; ETHINYL ESTRADIOL

TABLET; ORAL

DROSPIRENONE AND ETHINYL ESTRADIOL

AB	GLENMARK PHARMS LTD	3MG;0.02MG	A204296	001	Aug 17, 2015	Aug	NEWA
>A>	AB	JAI PHARMA LTD	A202594	001	Oct 22, 2015	Oct	NEWA

DULOXETINE HYDROCHLORIDECAPSULE, DELAYED REL PELLETS; ORAL
DULOXETINE HYDROCHLORIDE

AB	ALKEM LABS LTD	EQ 20MG BASE	A203197	001	Aug 26, 2015	Aug	NEWA
AB		EQ 30MG BASE	A203197	002	Aug 26, 2015	Aug	NEWA
AB		EQ 60MG BASE	A203197	003	Aug 26, 2015	Aug	NEWA
>A>	AB	ANCHEN PHARMS	A090780	001	Oct 28, 2015	Oct	NEWA
>A>	AB		A090780	002	Oct 28, 2015	Oct	NEWA
>A>	AB		A090780	003	Oct 28, 2015	Oct	NEWA
>A>	AB	INVENTIA HLTHCARE	A202336	001	Oct 28, 2015	Oct	NEWA
>A>	AB		A202336	002	Oct 28, 2015	Oct	NEWA

CAPSULE, DELAYED REL PELLETS;ORAL
DULOXETINE HYDROCHLORIDE

>A> AB	EQ 60MG BASE	A202336	003	Oct 28, 2015	Oct NEWA
--------	--------------	---------	-----	--------------	----------

ECONAZOLE NITRATE

CREAM;TOPICAL

ECONAZOLE NITRATE

AB	FOUGERA PHARMS	1%	A076075	001	Nov 26, 2002	Mar CRLD
AB	+ PERRIGO NEW YORK	1%	A076479	001	Jun 23, 2004	Mar CRLD

EDOXABAN TOSYLATE

TABLET;ORAL

SAVAYSA

	DAIICHI SANKYO	EQ 15MG BASE
		EQ 30MG BASE
+		EQ 60MG BASE

N206316	001	Jan 08, 2015	Jan NEWA
N206316	002	Jan 08, 2015	Jan NEWA
N206316	003	Jan 08, 2015	Jan NEWA

EDROPHONIUM CHLORIDE

INJECTABLE;INJECTION

ENLON

+	MYLAN INSTITUTIONAL	10MG/ML
---	---------------------	---------

A088873	001	Aug 06, 1985	Mar CRLD
---------	-----	--------------	----------

ELTROMBOPAG OLAMINE

FOR SUSPENSION;ORAL

PROMACTA

+	NOVARTIS PHARMS CORP	EQ 25MG ACID/PACKET
---	----------------------	---------------------

N207027	001	Aug 24, 2015	Aug NEWA
---------	-----	--------------	----------

TABLET;ORAL

PROMACTA

	NOVARTIS PHARMS CORP	EQ 12.5MG ACID
		EQ 25MG ACID
		EQ 50MG ACID
+		EQ 50MG ACID
+		EQ 75MG ACID
		EQ 75MG ACID
+		EQ 100MG ACID
		EQ 100MG ACID

N022291	004	Oct 20, 2011	Mar CAHN
N022291	001	Nov 20, 2008	Mar CAHN
N022291	002	Nov 20, 2008	May CRLD
N022291	002	Nov 20, 2008	Mar CAHN
N022291	003	Sep 08, 2009	May CRLD
N022291	003	Sep 08, 2009	Mar CAHN
N022291	005	Nov 16, 2012	May CRLD
N022291	005	Nov 16, 2012	Mar CAHN

ELUXADOLINE

TABLET;ORAL

VIBERZI

	FOREST TOSARA LTD	75MG
+		100MG
	FURIEX PHARMS	75MG
+		100MG

N206940	001	May 27, 2015	Jul CAHN
N206940	002	May 27, 2015	Jul CAHN
N206940	001	May 27, 2015	May NEWA
N206940	002	May 27, 2015	May NEWA

EMPAGLIFLOZIN; LINAGLIPTIN

TABLET;ORAL

GLYXAMBI

	BOEHRINGER INGELHEIM	10MG;5MG
+		25MG;5MG

N206073	001	Jan 30, 2015	Jan NEWA
N206073	002	Jan 30, 2015	Jan NEWA

EMPAGLIFLOZIN; METFORMIN HYDROCHLORIDE

TABLET;ORAL

SYNJARDY

	BOEHRINGER INGELHEIM	5MG;500MG
		5MG;1GM
		12.5MG;500MG
+		12.5MG;1GM

N206111	001	Aug 26, 2015	Aug NEWA
N206111	002	Aug 26, 2015	Aug NEWA
N206111	003	Aug 26, 2015	Aug NEWA
N206111	004	Aug 26, 2015	Aug NEWA

ENALAPRIL MALEATE

TABLET;ORAL

ENALAPRIL MALEATE

AB	SANDOZ INC	2.5MG	A075496	001	Aug 22, 2000	Mar CMFD
AB		5MG	A075496	002	Aug 22, 2000	Mar CMFD
AB		10MG	A075459	001	Aug 22, 2000	Mar CMFD
AB		20MG	A075459	002	Aug 22, 2000	Mar CMFD
	@ SUN PHARM INDS LTD	2.5MG	A075556	001	Aug 22, 2000	Apr CAHN
	@	5MG	A075556	002	Aug 22, 2000	Apr CAHN
	@	10MG	A075556	003	Aug 22, 2000	Apr CAHN
	@	20MG	A075556	004	Aug 22, 2000	Apr CAHN
	VASOTEC					
AB	VALEANT PHARMS NORTH	2.5MG	N018998	005	Jul 26, 1988	Apr CAHN

TABLET;ORAL
VASOTEC

AB		5MG	N018998	001	Dec 24, 1985	Apr CAHN
AB		10MG	N018998	002	Dec 24, 1985	Apr CAHN
AB	+	20MG	N018998	003	Dec 24, 1985	Apr CAHN

ENALAPRIL MALEATE; HYDROCHLOROTHIAZIDE

TABLET;ORAL
ENALAPRIL MALEATE AND HYDROCHLOROTHIAZIDE

AB	G AND W LABS INC	5MG;12.5MG	A075727	001	Sep 18, 2001	Apr CAHN
AB		10MG;25MG	A075727	002	Sep 18, 2001	Apr CAHN

ENTACAPONE

TABLET;ORAL
ENTACAPONE

AB	AUROBINDO PHARMA LTD	200MG	A203437	001	Jun 19, 2015	Jun NEWA
----	----------------------	-------	---------	-----	--------------	----------

ENTECAVIR

TABLET;ORAL
ENTECAVIR

>A>	AB	AMNEAL PHARMS	0.5MG	A206652	001	Nov 12, 2015	Oct NEWA
>A>	AB		1MG	A206652	002	Nov 12, 2015	Oct NEWA
	AB	AUROBINDO PHARMA LTD	0.5MG	A206217	001	Aug 26, 2015	Aug NEWA
	AB		1MG	A206217	002	Aug 26, 2015	Aug NEWA
	AB	HETERO LABS LTD V	0.5MG	A205740	001	Aug 21, 2015	Aug NEWA
	AB		1MG	A205740	002	Aug 21, 2015	Aug NEWA

EPINEPHRINE

INJECTABLE;INTRAMUSCULAR, INTRAOCULAR, SUBCUTANEOUS
ADRENALIN

+	PAR STERILE PRODUCTS	EQ 1MG BASE/ML (EQ 1MG BASE/ML)	N204200	001	Dec 07, 2012	Jul CAIN
---	----------------------	---------------------------------	---------	-----	--------------	----------

INJECTABLE;INTRAMUSCULAR, SUBCUTANEOUS
ADRENALIN

+	PAR STERILE PRODUCTS	EQ 30MG BASE/30ML (EQ 1MG BASE/ML)	N204640	001	Dec 18, 2013	Jul CAIN
---	----------------------	------------------------------------	---------	-----	--------------	----------

EPINEPHRINE HYDROCHLORIDE

>D>	SOLUTION;IV (INFUSION)						
>D>	EPINEPHRINE						
>D>		BELCHER PHARMS LLC	EQ 1MG BASE/ML	N205029	001	Jul 29, 2014	Oct CDFR
>A>	SOLUTION;IV (INFUSION), INTRAOCULAR						
>A>	EPINEPHRINE						
>A>		BELCHER PHARMS LLC	EQ 1MG BASE/ML (EQ 1MG BASE/ML)	N205029	001	Jul 29, 2014	Oct CDFR

EPINEPHRINE; LIDOCAINE HYDROCHLORIDE

INJECTABLE;INJECTION
LIDOCAINE HYDROCHLORIDE AND EPINEPHRINE
@ EUROHLTH INTL SARL 0.01MG/ML;1%
@ 0.01MG/ML;2%

A080406	001		Sep CAHN
A080406	002		Sep CAHN

EPROSARTAN MESYLATE; HYDROCHLOROTHIAZIDE

TABLET;ORAL
TEVETEN HCT

@	ABBVIE	600MG;12.5MG	N021268	001	Nov 01, 2001	Jun DISC
@		600MG;25MG	N021268	002	Nov 01, 2001	Jun DISC

EPTIFIBATIDE

INJECTABLE;INJECTION
EPTIFIBATIDE

AP	TEVA PHARMS USA	2MG/ML	A090854	001	Jun 12, 2015	Jun NEWA	
AP		75MG/100ML	A091555	001	Jun 05, 2015	May NEWA	
	INTEGRILIN						
AP	+	SCHERING	2MG/ML	N020718	001	May 18, 1998	Jun CTEC
AP	+		75MG/100ML	N020718	002	May 18, 1998	May CFTG

ERGOCALCIFEROL

CAPSULE;ORAL
VITAMIN D

AA	BANNER LIFE SCIENCES	50,000 IU	A080704	001		Jan CAHN
----	----------------------	-----------	---------	-----	--	----------

ERGOTAMINE TARTRATETABLET;SUBLINGUAL
ERGOSTAT

@ WATSON LABS INC

2MG

A088337 001 Jun 08, 1984 Aug CAHN

ERLOTINIB HYDROCHLORIDE

TABLET;ORAL

ERLOTINIB HYDROCHLORIDE

@ MYLAN PHARMS INC

EQ 25MG BASE

A091002 001 Jun 11, 2014 Sep DISC

@

EQ 100MG BASE

A091002 002 Jun 11, 2014 Sep DISC

@

EQ 150MG BASE

A091002 003 Jun 11, 2014 Sep DISC

>D> AB

TEVA PHARMS USA

EQ 100MG BASE

A091059 002 Aug 28, 2015 Oct DISC

>A>

@

EQ 100MG BASE

A091059 002 Aug 28, 2015 Oct DISC

AB

EQ 100MG BASE

A091059 002 Aug 28, 2015 Aug NEWA

>D> AB

EQ 150MG BASE

A091059 003 Aug 28, 2015 Oct DISC

>A>

@

EQ 150MG BASE

A091059 003 Aug 28, 2015 Oct DISC

AB

EQ 150MG BASE

A091059 003 Aug 28, 2015 Aug NEWA

TARCEVA

OSI PHARMS

EQ 25MG BASE

N021743 001 Nov 18, 2004 Sep CTEC

>D> AB

EQ 100MG BASE

N021743 002 Nov 18, 2004 Oct CTEC

>A>

EQ 100MG BASE

N021743 002 Nov 18, 2004 Oct CTEC

>D> AB

+

EQ 150MG BASE

N021743 003 Nov 18, 2004 Oct CTEC

>A>

+

EQ 150MG BASE

N021743 003 Nov 18, 2004 Oct CTEC

ERYTHROMYCIN ESTOLATE

SUSPENSION;ORAL

ERYTHROMYCIN ESTOLATE

@ G AND W LABS INC

EQ 125MG BASE/5ML

A062169 001 Oct 17, 1990 Apr CAHN

@

EQ 250MG BASE/5ML

A062169 002 Oct 17, 1990 Apr CAHN

ERYTHROMYCIN ETHYLSUCCINATE

GRANULE;ORAL

ERYTHROMYCIN ETHYLSUCCINATE

@ ANI PHARMS INC

EQ 200MG BASE/5ML

A062055 001 Jul CAHN

ESCITALOPRAM OXALATE

SOLUTION;ORAL

ESCITALOPRAM OXALATE

AA

ANTRIM PHARMS LLC

EQ 5MG BASE/5ML

A203967 001 May 26, 2015 May NEWA

TABLET;ORAL

ESCITALOPRAM OXALATE

AB

MYLAN PHARMS INC

EQ 5MG BASE

A077550 001 May 14, 2015 Apr NEWA

AB

EQ 10MG BASE

A077550 002 May 14, 2015 Apr NEWA

AB

EQ 20MG BASE

A077550 003 May 14, 2015 Apr NEWA

AB

PRINSTON INC

EQ 5MG BASE

A078032 001 Aug 28, 2015 Aug NEWA

AB

EQ 10MG BASE

A078032 002 Aug 28, 2015 Aug NEWA

AB

EQ 20MG BASE

A078032 003 Aug 28, 2015 Aug NEWA

ESMOLOL HYDROCHLORIDE

INJECTABLE;INJECTION

ESMOLOL HYDROCHLORIDE

AP

AUROBINDO PHARMA LTD

10MG/ML

A205520 001 Jul 23, 2015 Jul NEWA

AP

LUITPOLD

10MG/ML

A201126 001 Feb 20, 2015 Feb NEWA

ESOMEPRAZOLE MAGNESIUM

CAPSULE, DELAYED REL PELLETS;ORAL

ESOMEPRAZOLE MAGNESIUM

AB

DR REDDYS LABS LTD

EQ 20MG BASE

A078279 001 Sep 25, 2015 Sep NEWA

AB

EQ 40MG BASE

A078279 002 Sep 25, 2015 Sep NEWA

AB

HETERO LABS LTD III

EQ 20MG BASE

A202784 001 Sep 21, 2015 Sep NEWA

AB

EQ 40MG BASE

A202784 002 Sep 21, 2015 Sep NEWA

AB

IVAX SUB TEVA PHARMS

EQ 20MG BASE

A078003 001 Jan 26, 2015 Jan NEWA

AB

EQ 40MG BASE

A078003 002 Jan 26, 2015 Jan NEWA

AB

MYLAN LABS LTD

EQ 20MG BASE

A078936 001 Aug 02, 2015 Jul NEWA

AB

EQ 40MG BASE

A078936 002 Aug 03, 2015 Jul NEWA

AB

MYLAN PHARMS INC

EQ 20MG BASE

A078936 001 Aug 02, 2015 Sep CAHN

AB

EQ 40MG BASE

A078936 002 Aug 03, 2015 Sep CAHN

>A> AB

TORRENT PHARMS LTD

EQ 20MG BASE

A203636 001 Oct 19, 2015 Oct NEWA

>A> AB

EQ 40MG BASE

A203636 002 Oct 19, 2015 Oct NEWA

NEXIUM

AB

ASTRAZENECA PHARMS

EQ 20MG BASE

N021153 001 Feb 20, 2001 Jan CFTG

CAPSULE, DELAYED REL PELLETS;ORAL
NEXIUM

AB	+	EQ 40MG BASE	N021153	002	Feb 20, 2001	Jan CFTG
----	---	--------------	---------	-----	--------------	----------

ESOMEPRAZOLE SODIUMINJECTABLE;INTRAVENOUS
ESOMEPRAZOLE SODIUM

AP		ACCORD HLTHCARE EQ 40MG BASE/VIAL	A205379	001	Sep 25, 2015	Sep NEWA
----	--	-----------------------------------	---------	-----	--------------	----------

ESOMEPRAZOLE STRONTIUMCAPSULE, DELAYED RELEASE;ORAL
ESOMEPRAZOLE STRONTIUM

		HANMI PHARM CO LTD	24.65MG			
+			49.3MG			

N202342	001	Aug 06, 2013	Aug CPOT
N202342	002	Aug 06, 2013	Aug CPOT

ESTRADIOLFILM, EXTENDED RELEASE;TRANSDERMAL
ALORA

BX		ACTAVIS LABS UT INC	0.025MG/24HR	N020655	004	Apr 05, 2002	Mar CAHN
BX			0.05MG/24HR	N020655	001	Dec 20, 1996	Mar CAHN
BX			0.075MG/24HR	N020655	002	Dec 20, 1996	Mar CAHN
BX			0.1MG/24HR	N020655	003	Dec 20, 1996	Mar CAHN

MINIVELLE

		NOVEN	0.025MG/24HR			
--	--	-------	--------------	--	--	--

N203752	005	Sep 23, 2014	Jan NEWA
---------	-----	--------------	----------

TABLET;ORAL
ESTRADIOL

>A>	@	EPIC PHARMA INC	0.5MG	A040275	001	Dec 29, 1998	Oct CAHN
>A>	@		1MG	A040275	002	Dec 29, 1998	Oct CAHN
>A>	@		2MG	A040275	003	Dec 29, 1998	Oct CAHN
>D>	@	HERITAGE PHARMS INC	0.5MG	A040275	001	Dec 29, 1998	Oct CAHN
>D>	@		1MG	A040275	002	Dec 29, 1998	Oct CAHN
>D>	@		2MG	A040275	003	Dec 29, 1998	Oct CAHN

TABLET;VAGINAL
ESTRADIOL

	@	AMNEAL PHARMS	10MCG			
--	---	---------------	-------	--	--	--

A205256	001	May 29, 2015	May DISC
---------	-----	--------------	----------

ESZOPICLONETABLET;ORAL
ESZOPICLONE

AB		MACLEODS PHARMS LTD	1MG	A202929	001	Jan 30, 2015	Jan NEWA
AB			2MG	A202929	002	Jan 30, 2015	Jan NEWA
AB			3MG	A202929	003	Jan 30, 2015	Jan NEWA

ETHACRYNATE SODIUMINJECTABLE;INJECTION
EDECRIN

AP	+	ATON EQ 50MG BASE/VIAL	N016093	001		Jul CFTG
----	---	------------------------	---------	-----	--	----------

ETHACRYNATE SODIUM

AP		PAR STERILE PRODUCTS EQ 50MG BASE/VIAL	A205473	001	Jul 29, 2015	Jul NEWA
----	--	--	---------	-----	--------------	----------

ETHAMBUTOL HYDROCHLORIDE

TABLET;ORAL

ETHAMBUTOL HYDROCHLORIDE

AB		VERSAPHARM INC	100MG	A075095	001	Nov 30, 1999	Jan CMFD
AB			400MG	A075095	002	Nov 30, 1999	Jan CMFD

ETHINYL ESTRADIOL; LEVONORGESTREL

TABLET;ORAL

ASHLYNA

AB		GLENMARK GENERICS	0.03MG;0.01MG;0.15MG,N/A	A203163	001	Feb 23, 2015	Feb NEWA
----	--	-------------------	--------------------------	---------	-----	--------------	----------

LEVONORGESTREL AND ETHINYL ESTRADIOL

AB		GLENMARK GENERICS	0.02MG;0.09MG	A202791	001	Apr 09, 2015	Mar NEWA
AB		GLENMARK PHARMS LTD	0.03MG;0.15MG	A203164	001	Jun 12, 2015	Jun NEWA
AB	+	WATSON LABS	0.02MG;0.09MG	A079218	001	Jun 06, 2011	Mar CTEC

TABLET;ORAL-28

LEVORA 0.15/30-28

AB	+	WATSON LABS	0.03MG;0.15MG	A073594	001	Dec 13, 1993	Aug CRLD
----	---	-------------	---------------	---------	-----	--------------	----------

NORDETTE-28

	@	TEVA BRANDED PHARM	0.03MG;0.15MG			
--	---	--------------------	---------------	--	--	--

N018782	001	Jul 21, 1982	Aug DISC
---------	-----	--------------	----------

VIENVA

AB1		SANDOZ INC	0.02MG;0.1MG	A201088	001	May 21, 2015	May NEWA
-----	--	------------	--------------	---------	-----	--------------	----------

ETHINYL ESTRADIOL; NORELGESTROMINFILM, EXTENDED RELEASE;TRANSDERMAL
XULANE

AB	+	MYLAN TECHNOLOGIES	0.035MG/24HR;0.15MG/24HR	A200910	001	Apr 16, 2014	Feb CRLD
----	---	--------------------	--------------------------	---------	-----	--------------	----------

ETHINYL ESTRADIOL; NORETHINDRONETABLET;ORAL-21
BREVICON 21-DAY

		@ ACTAVIS LABS UT INC	0.035MG;0.5MG	N017566	001		Mar CAHN
		NORINYL 1+35 21-DAY					

AB		ACTAVIS LABS UT INC	0.035MG;1MG	N017565	001		Feb CAHN
		TRI-NORINYL 21-DAY					

		@ ACTAVIS LABS UT INC	0.035MG,0.035MG,0.035MG;0.5MG,1MG,0.5MG	N018977	001	Apr 13, 1984	Feb CAHN
--	--	-----------------------	---	---------	-----	--------------	----------

TABLET;ORAL-28

BREVICON 28-DAY

AB		ACTAVIS LABS UT INC	0.035MG;0.5MG	N017743	001		Mar CAHN
		NORETHINDRONE AND ETHINYL ESTRADIOL					

AB		FAMY CARE LTD	0.035MG;0.4MG	A200897	001	May 11, 2015	Apr NEWA
----	--	---------------	---------------	---------	-----	--------------	----------

AB	+	JAI PHARMA LTD	0.035MG;0.4MG	A200897	001	May 11, 2015	Jul CRLD
----	---	----------------	---------------	---------	-----	--------------	----------

>A>	AB		0.035MG;0.5MG	A200488	001	Oct 21, 2015	Oct NEWA
-----	----	--	---------------	---------	-----	--------------	----------

>A>	AB		0.035MG;1MG	A200489	001	Oct 21, 2015	Oct NEWA
-----	----	--	-------------	---------	-----	--------------	----------

	+		0.05MG;1MG	A203006	001	Aug 05, 2013	Jul CTEC
--	---	--	------------	---------	-----	--------------	----------

		NORINYL 1+35 28-DAY					
AB		ACTAVIS LABS UT INC	0.035MG;1MG	N017565	002		Feb CAHN
		OVCON-35					

		@ WARNER CHILCOTT LLC	0.035MG;0.4MG	N017716	001		Jul DISC
		TRI-NORINYL 28-DAY					

AB	+	ACTAVIS LABS UT INC	0.035MG,0.035MG,0.035MG;0.5MG,1MG,0.5MG	N018977	002	Apr 13, 1984	Feb CAHN
----	---	---------------------	---	---------	-----	--------------	----------

ETHINYL ESTRADIOL; NORETHINDRONE ACETATE

TABLET;ORAL

>A>		BLISOVI 24 FE					
-----	--	---------------	--	--	--	--	--

>A>	AB	LUPIN LTD	0.02MG;1MG	A091398	001	Oct 28, 2015	Oct NEWA
		FEMHRT					

AB		WARNER CHILCOTT LLC	0.0025MG;0.5MG	N021065	001	Jan 14, 2005	Mar CTEC
----	--	---------------------	----------------	---------	-----	--------------	----------

		LARIN 24 FE					
AB		NOVAST LABS LTD	0.02MG;1MG	A202994	001	Feb 18, 2015	Feb NEWA
		NORETHINDRONE ACETATE AND ETHINYL ESTRADIOL					

AB	+	BARR LABS INC	0.005MG;1MG	A076221	001	Nov 06, 2009	Mar CTEC
----	---	---------------	-------------	---------	-----	--------------	----------

AB		GLENMARK GENERICS	0.0025MG;0.5MG	A203038	001	Apr 02, 2015	Mar NEWA
----	--	-------------------	----------------	---------	-----	--------------	----------

AB			0.005MG;1MG	A203038	002	Apr 02, 2015	Mar NEWA
----	--	--	-------------	---------	-----	--------------	----------

NORETHINDRONE ACETATE AND ETHINYL ESTRADIOL AND FERROUS FUMARATE

AB	+	AMNEAL PHARMS	0.02MG;1MG	A078267	001	Sep 01, 2009	Jan CRLD
----	---	---------------	------------	---------	-----	--------------	----------

ETHINYL ESTRADIOL; NORGESTIMATE

TABLET;ORAL-28

NORGESTIMATE AND ETHINYL ESTRADIOL

>A>	AB	HAUPT PHARMA	0.035MG,0.035MG,0.035MG;0.18MG,0.215MG,0.25MG	A203870	001	Nov 12, 2015	Oct NEWA
-----	----	--------------	---	---------	-----	--------------	----------

>A>	AB		0.035MG;0.25MG	A203865	001	Oct 27, 2015	Oct NEWA
-----	----	--	----------------	---------	-----	--------------	----------

AB		JAI PHARMA LTD	0.025MG,0.025MG,0.025MG;0.18MG,0.215MG,0.25MG	A202132	001	Sep 09, 2015	Aug NEWA
----	--	----------------	---	---------	-----	--------------	----------

AB		OC PHARMA	0.035MG;0.035MG;0.035MG;0.18MG;0.215MG;0.25MG	A200383	001	Apr 07, 2015	Mar NEWA
----	--	-----------	---	---------	-----	--------------	----------

AB			0.035MG;0.25MG	A200384	001	Apr 07, 2015	Mar NEWA
----	--	--	----------------	---------	-----	--------------	----------

TRI-LO-ESTARYLLA

AB		SANDOZ INC	0.025MG,0.025MG,0.025MG;0.18MG,0.215MG,0.25MG	A091232	001	Jun 29, 2015	Jun NEWA
----	--	------------	---	---------	-----	--------------	----------

ETHINYL ESTRADIOL; NORGESTREL

TABLET;ORAL-28

LOW-OGESTREL-28

AB		WATSON LABS	0.03MG;0.3MG	A075288	002	Jul 28, 1999	Feb CMFD
----	--	-------------	--------------	---------	-----	--------------	----------

ETHOSUXIMIDECAPSULE;ORAL
ETHOSUXIMIDE

AB	BANNER LIFE SCIENCES	250MG	A040430	001	Oct 28, 2002	Jan CAHN
AB	HERITAGE PHARMS INC	250MG	A200892	001	Sep 25, 2012	Sep CAHN

ETODOLACTABLET;ORAL
ETODOLAC

@ LEHIGH VALLEY	400MG	A074927	001	Oct 30, 1997	Sep CAHN
-----------------	-------	---------	-----	--------------	----------

ETONOGESTRELIMPLANT;IMPLANTATION
IMPLANON

@ ORGANON USA INC	68MG/IMPLANT	N021529	001	Jul 17, 2006	Jun DISC
-------------------	--------------	---------	-----	--------------	----------

EZETIMIBETABLET;ORAL
EZETIMIBE

@ GLENMARK PHARMS LTD	10MG	A078560	001	Jun 26, 2015	Jun DISC
AB	10MG	A078560	001	Jun 26, 2015	Jun NEWA
ZETIA					
+ MSD INTL GMBH	10MG	N021445	001	Oct 25, 2002	Jun CTEC
AB +	10MG	N021445	001	Oct 25, 2002	Jun CFTG

FAMOTIDINEINJECTABLE;INJECTION
FAMOTIDINE

AP + EUROHLTH INTL SARL	10MG/ML	A075488	001	Apr 16, 2001	Jun CAHN
@	10MG/ML	A075799	001	Apr 30, 2002	Sep CAHN
FAMOTIDINE PRESERVATIVE FREE					
AP + EUROHLTH INTL SARL	10MG/ML	A075486	001	Apr 16, 2001	Jun CAHN
TABLET;ORAL					
PEPCID					
AB VALEANT PHARMS NORTH	20MG	N019462	001	Oct 15, 1986	Feb CAHN
AB +	40MG	N019462	002	Oct 15, 1986	Feb CAHN

FELBAMATETABLET;ORAL
FELBAMATE

>A> AB	COREPHARMA	400MG	A202284	001	Nov 04, 2015	Oct NEWA
>A> AB		600MG	A202284	002	Nov 04, 2015	Oct NEWA

FELODIPINETABLET, EXTENDED RELEASE;ORAL
FELODIPINE

AB ORCHID HLTHCARE	2.5MG	A203032	001	May 21, 2015	May NEWA
AB	5MG	A203032	002	May 21, 2015	May NEWA
AB	10MG	A203032	003	May 21, 2015	May NEWA
AB SUN PHARM INDS LTD	2.5MG	A091200	001	Dec 13, 2013	Apr CAHN
AB	5MG	A091200	002	Dec 13, 2013	Apr CAHN
AB	10MG	A091200	003	Dec 13, 2013	Apr CAHN

FENOFIBRATECAPSULE;ORAL
FENOFIBRATE

AB SUN PHARM INDS LTD	43MG	A201748	001	Oct 31, 2014	Apr CAHN
AB	130MG	A201748	002	Oct 31, 2014	Apr CAHN

TABLET;ORAL
FENOFIBRATE

AB LUPIN LTD	54MG	A204019	001	Aug 17, 2015	Aug NEWA
AB	160MG	A204019	002	Aug 17, 2015	Aug NEWA
AB SUN PHARM INDS LTD	54MG	A076635	001	Oct 31, 2005	Apr CAHN
	107MG	A076635	002	Oct 31, 2005	Apr CAHN
AB	160MG	A076635	003	Oct 31, 2005	Apr CAHN
AB VALEANT PHARMS NORTH	48MG	A090715	001	Apr 05, 2012	Aug CAHN
AB	145MG	A090715	002	Apr 05, 2012	Aug CAHN

FENOFIBRIC ACIDTABLET;ORAL
FIBRICOR

	TRIBUTE PHARMS INTL	35MG	N022418	001	Aug 14, 2009	Jun CAHN
+		105MG	N022418	002	Aug 14, 2009	Jun CAHN

FENTANYLFILM, EXTENDED RELEASE;TRANSDERMAL
FENTANYL-100

AB	ACTAVIS LABS UT INC	100MCG/HR	A076709	004	Aug 20, 2007	Mar CAHN
	FENTANYL-12					
AB	MALLINCKRODT INC	12.5MCG/HR	A077154	005	Jun 11, 2015	Jun NEWA
	FENTANYL-25					
AB	ACTAVIS LABS UT INC	25MCG/HR	A076709	001	Aug 20, 2007	Mar CAHN
	FENTANYL-50					
AB	ACTAVIS LABS UT INC	50MCG/HR	A076709	002	Aug 20, 2007	Mar CAHN
	FENTANYL-75					
AB	ACTAVIS LABS UT INC	75MCG/HR	A076709	003	Aug 20, 2007	Mar CAHN

FENTANYL CITRATEFILM;BUCCAL
ONSOLIS

@	BIODELIVERY SCI INTL	EQ 0.2MG BASE	N022266	001	Jul 16, 2009	Mar CAHN
@		EQ 0.4MG BASE	N022266	002	Jul 16, 2009	Mar CAHN
@		EQ 0.6MG BASE	N022266	003	Jul 16, 2009	Mar CAHN
@		EQ 0.8MG BASE	N022266	004	Jul 16, 2009	Mar CAHN
@		EQ 1.2MG BASE	N022266	005	Jul 16, 2009	Mar CAHN

INJECTABLE;INJECTION

FENTANYL CITRATE PRESERVATIVE FREE

AP	+	EUROHLTH INTL SARL	EQ 0.05MG BASE/ML	N019101	001	Jul 11, 1984	Feb CAHN
----	---	--------------------	-------------------	---------	-----	--------------	----------

FENTANYL HYDROCHLORIDESYSTEM;IONTOPHORESIS, TRANSDERMAL
IONSYS

@	THE MEDICINES CO	10.8MCG	N021338	001	May 22, 2006	Apr CAHN
+		EQ 40MCG BASE/ACTIVATION	N021338	001	May 22, 2006	Jun CMFD

FERRIC CITRATETABLET;ORAL
AURYXIA

+	KERYX BIOPHARMS	EQ 210MG IRON	N205874	001	Sep 05, 2014	Jan CTNA
---	-----------------	---------------	---------	-----	--------------	----------

FERRIC PYROPHOSPHATE CITRATESOLUTION;IV (INFUSION)
TRIFERIC

>A>	+	ROCKWELL MEDICAL INC	27.2MG IRON/5ML (5.44MG IRON/ML)	N206317	001	Jan 23, 2015	Jan NEWA
			272MG IRON/50ML (5.44MG IRON/ML)	N206317	002	Sep 04, 2015	Oct NEWA

FIDAXOMICINTABLET;ORAL
DIFICID

+	CUBIST PHARMS LLC	200MG	N201699	001	May 27, 2011	Aug CAHN
---	-------------------	-------	---------	-----	--------------	----------

FLECAINIDE ACETATE

TABLET;ORAL

FLECAINIDE ACETATE

AB	ANI PHARMS INC	50MG	A075882	001	Oct 28, 2002	Apr CAHN
AB		100MG	A075882	002	Oct 28, 2002	Apr CAHN
AB		150MG	A075882	003	Oct 28, 2002	Apr CAHN
AB	AUROBINDO PHARMA LTD	50MG	A202821	001	Jul 08, 2015	Jun NEWA
AB		100MG	A202821	002	Jul 08, 2015	Jun NEWA
AB		150MG	A202821	003	Jul 08, 2015	Jun NEWA
AB	SUN PHARM INDS LTD	50MG	A076421	001	Mar 28, 2003	Apr CAHN
AB		100MG	A076421	002	Mar 28, 2003	Apr CAHN
AB		150MG	A076421	003	Mar 28, 2003	Apr CAHN

FLIBANSERINTABLET; ORAL
ADDYI

+ SPROUT PHARMS 100MG N022526 001 Aug 18, 2015 Aug NEWA

FLUCONAZOLEFOR SUSPENSION; ORAL
FLUCONAZOLEAB SUN PHARM INDS LTD 50MG/5ML A076332 001 Jul 29, 2004 Apr CAHN
AB 200MG/5ML A076332 002 Jul 29, 2004 Apr CAHN

INJECTABLE; INJECTION

FLUCONAZOLE IN DEXTROSE 5% IN PLASTIC CONTAINER

AP CLARIS PHARMASERVICE 200MG/100ML (2MG/ML) A077988 001 May 26, 2010 Apr CAHN
AP 400MG/200ML (2MG/ML) A077988 002 May 26, 2010 Apr CAHN

FLUCONAZOLE IN SODIUM CHLORIDE 0.9%

AP CLARIS PHARMASERVICE 200MG/100ML (2MG/ML) A077947 001 May 26, 2010 Apr CAHN
AP 400MG/200ML (2MG/ML) A077947 002 May 26, 2010 Apr CAHN

FLUCONAZOLE IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER

CLARIS PHARMASERVICE 100MG/50ML (2MG/ML) A077909 003 Apr 20, 2015 Apr NEWA
100MG/50ML (2MG/ML) A077909 003 Apr 20, 2015 Apr CAHN
AP 200MG/100ML (2MG/ML) A077909 001 May 26, 2010 Apr CAHN
AP 400MG/200ML (2MG/ML) A077909 002 May 26, 2010 Apr CAHN

TABLET; ORAL

FLUCONAZOLE

AB HARRIS PHARM 50MG A078423 001 Mar 07, 2011 May CMFD
AB 100MG A078423 002 Mar 07, 2011 May CMFD
AB 150MG A078423 003 Mar 07, 2011 May CMFD
AB 200MG A078423 004 Mar 07, 2011 May CMFDFLUDEOXYGLUCOSE F-18

INJECTABLE; INTRAVENOUS

FLUDEOXYGLUCOSE F18

>A> AP 3D IMAGING DRUG 20-300mCi/ML A203778 001 Oct 30, 2015 Oct NEWA
AP IBA MOLECULAR N AM 20-300mCi/ML A203591 001 Aug 31, 2015 Aug NEWA
>A> AP KETTERING MEDCTR 4-40mCi/ML A204759 001 Oct 27, 2015 Oct NEWA
AP METHODIST HOSP RES 20-300mCi/ML A203904 001 Apr 23, 2015 Apr NEWA
AP MIPS CRF 20-300mCi/ML A204472 001 Sep 11, 2015 Aug NEWA
PRECISION NUCLEAR 20-500mCi/ML A204546 001 Apr 07, 2015 Mar NEWA
QUEEN HAMAMATSU PET 10-100mCi/ML A203771 001 Aug 31, 2015 Aug NEWA
SPECTRON MRC LLC 4-500mCi/ML A203911 001 Apr 22, 2015 Apr NEWA
>D> + UCLA BIOMEDICAL 4-40mCi/ML A203811 001 Jun 27, 2013 Oct CTEC
>A> AP + 4-40mCi/ML A203811 001 Jun 27, 2013 Oct CTEC
AP UNIV MICHIGAN 20-300mCi/ML A204531 001 Jul 17, 2015 Jul NEWAFLUMAZENIL

INJECTABLE; INJECTION

FLUMAZENIL

@ CLARIS PHARMASERVICE 0.5MG/5ML (0.1MG/ML) A076755 002 Oct 12, 2004 Apr CAHN
@ 1MG/10ML (0.1MG/ML) A076755 001 Oct 12, 2004 Apr CAHN
AP EUROHLTH INTL SARL 0.5MG/5ML (0.1MG/ML) A076787 002 Oct 12, 2004 Jun CAHN
AP 1MG/10ML (0.1MG/ML) A076787 001 Oct 12, 2004 Jun CAHNFLUOCINOLONE ACETONIDE

OIL; TOPICAL

FLUOCINOLONE ACETONIDE

AT VERSAPHARM INC 0.01% A091514 001 Jun 25, 2015 Jun NEWA

SOLUTION; TOPICAL

FLUOCINOLONE ACETONIDE

AT GAVIS PHARMS LLC 0.01% A206422 001 Sep 02, 2015 Aug NEWA

FLUOCINONIDE

GEL; TOPICAL

FLUOCINONIDE

AB G AND W LABS INC 0.05% A072537 001 Feb 07, 1989 Apr CAHN

FLUOROURACIL

CREAM; TOPICAL

CARAC

AB + VALEANT PHARMS NORTH 0.5% N020985 001 Oct 27, 2000 Apr CFTG
+ 0.5% N020985 001 Oct 27, 2000 Feb CAHN

CREAM; TOPICAL						
FLUOROURACIL						
AB	SPEAR PHARMS INC	0.5%	A203122	001	Apr 20, 2015	Apr NEWA
TOLAK						
+	HILL DERMACEUTICALS	4%	N022259	001	Sep 18, 2015	Sep NEWA

FLUOXETINE HYDROCHLORIDE

CAPSULE; ORAL						
FLUOXETINE HYDROCHLORIDE						
	@ ANI PHARMS INC	EQ 10MG BASE	A076287	001	May 20, 2008	Mar DISC
	@	EQ 20MG BASE	A076287	002	May 20, 2008	Mar DISC
+	MYLAN	EQ 20MG BASE	A078045	002	Nov 17, 2008	Mar CRLD
		EQ 20MG BASE	A078045	002	Nov 17, 2008	Mar CTEC
	@ SANDOZ	EQ 10MG BASE	A077469	001	Nov 17, 2008	Mar DISC
	@	EQ 20MG BASE	A077469	002	Nov 17, 2008	Mar DISC
AB1	SCIEGEN PHARMS INC	EQ 10MG BASE	A204597	001	Mar 16, 2015	Mar NEWA
AB1		EQ 20MG BASE	A204597	002	Mar 16, 2015	Mar NEWA
AB		EQ 40MG BASE	A204597	003	Mar 16, 2015	Mar NEWA
AB	SUN PHARM INDS LTD	EQ 40MG BASE	A076990	001	Dec 13, 2004	Apr CAHN

FLURANDRENOLIDE

OINTMENT; TOPICAL						
CORDRAN						
+	AQUA PHARMS	0.05%	N012806	001		Jun CRLD
		0.05%	N012806	001		May CMFD
TAPE; TOPICAL						
CORDRAN						
+	ACTAVIS LABS UT INC	0.004MG/SQ CM	N016455	001		Mar CAHN

FLURBIPROFEN

TABLET; ORAL							
ANSAID							
>D>							
>D>	AB	PHARMACIA AND UPJOHN	50MG	N018766	002	Oct 31, 1988	Oct DISC
>A>		@	50MG	N018766	002	Oct 31, 1988	Oct DISC
>D>	AB	+	100MG	N018766	003	Oct 31, 1988	Oct DISC
>A>		@	100MG	N018766	003	Oct 31, 1988	Oct DISC
FLURBIPROFEN							
>D>	AB	MYLAN	100MG	A074358	002	Jun 20, 1994	Oct CRLD
>A>	AB	+	100MG	A074358	002	Jun 20, 1994	Oct CRLD

FLUTICASONE FUROATE; VILANTEROL TRIFENATATE

POWDER; INHALATION						
BREO ELLIPTA						
	GLAXO GRP LTD	0.2MG/INH; EQ 0.025MG BASE/INH	N204275	002	Apr 30, 2015	Apr NEWA

FLUTICASONE PROPIONATE

CREAM; TOPICAL							
FLUTICASONE PROPIONATE							
>D>	AB	PERRIGO NEW YORK	0.05%	A076793	001	May 14, 2004	Oct CRLD
>A>	AB	+	0.05%	A076793	001	May 14, 2004	Oct CRLD

FLUVASTATIN SODIUM

TABLET, EXTENDED RELEASE; ORAL							
FLUVASTATIN SODIUM							
AB	MYLAN PHARMS INC	80MG	A202458	001	Sep 11, 2015	Aug NEWA	
	LESCOL XL						
AB	+	NOVARTIS	80MG	N021192	001	Oct 06, 2000	Aug CFTG

FLUVOXAMINE MALEATE

TABLET; ORAL						
FLUVOXAMINE MALEATE						
AB	ANI PHARMS INC	25MG	A075897	001	Jan 25, 2001	Jul CAHN
	@	25MG	A075898	001	Mar 12, 2001	Jul CAHN
AB		50MG	A075897	002	Jan 25, 2001	Jul CAHN
	@	50MG	A075898	002	Mar 12, 2001	Jul CAHN
AB		100MG	A075897	003	Jan 25, 2001	Jul CAHN
	@	100MG	A075898	003	Mar 12, 2001	Jul CAHN

FOLIC ACIDTABLET; ORAL
FOLIC ACID

AA	AIPING PHARM INC	1MG	A091145	001	Jul 12, 2013	Aug CAHN
AA	NUVO PHARM INC	1MG	A204418	001	Jul 28, 2015	Jul NEWA

FOSINOPRIL SODIUM; HYDROCHLOROTHIAZIDETABLET; ORAL
FOSINOPRIL SODIUM AND HYDROCHLOROTHIAZIDE

AB	SUN PHARM INDS LTD	10MG;12.5MG	A076739	001	Dec 17, 2004	Apr CAHN
AB		20MG;12.5MG	A076739	002	Dec 17, 2004	Apr CAHN

FUROSEMIDEINJECTABLE; INJECTION
FUROSEMIDE

@	IGI LABS INC	10MG/ML	A070095	001	Sep 09, 1985	Mar CAHN
@		10MG/ML	A070096	001	Sep 09, 1985	Mar CAHN

GABAPENTINCAPSULE; ORAL
GABAPENTIN

AB	SUN PHARM INDS LTD	100MG	A076606	001	Oct 07, 2005	Apr CAHN
AB		300MG	A076606	002	Oct 07, 2005	Apr CAHN
AB		400MG	A076606	003	Oct 07, 2005	Apr CAHN

TABLET; ORAL
GABAPENTIN

@	HIKMA PHARMS	600MG	A078782	001	Jul 21, 2011	Jun DISC
@		800MG	A078782	002	Jul 21, 2011	Jun DISC

GADOVERSETAMIDEINJECTABLE; INJECTION
OPTIMARK

+	LIEBEL-FLARSHEIM	1654.5MG/5ML (330.9MG/ML)	N020937	001	Dec 08, 1999	Feb CAHN
+		3309MG/10ML (330.9MG/ML)	N020937	002	Dec 08, 1999	Feb CAHN
+		4963.5MG/15ML (330.9MG/ML)	N020937	003	Dec 08, 1999	Feb CAHN
+		6618MG/20ML (330.9MG/ML)	N020937	004	Dec 08, 1999	Feb CAHN
+		16.545GM/50ML (330.9MG/ML)	N020975	001	Dec 08, 1999	Feb CAHN

OPTIMARK IN PLASTIC CONTAINER

+	LIEBEL-FLARSHEIM	3309MG/10ML (330.9MG/ML)	N020976	002	Dec 08, 1999	Feb CAHN
+		4963.5MG/15ML (330.9MG/ML)	N020976	003	Dec 08, 1999	Feb CAHN
+		6618MG/20ML (330.9MG/ML)	N020976	004	Dec 08, 1999	Feb CAHN
+		9927MG/30ML (330.9MG/ML)	N020976	001	Dec 08, 1999	Feb CAHN

GEFITINIBTABLET; ORAL
IRESSA

+	ASTRAZENECA PHARMS	250MG	N206995	001	Jul 13, 2015	Jul NEWA
---	--------------------	-------	---------	-----	--------------	----------

GEMFIBROZILTABLET; ORAL
GEMFIBROZIL

AB	AUROBINDO PHARMA LTD	600MG	A202726	001	Sep 16, 2015	Aug NEWA
----	----------------------	-------	---------	-----	--------------	----------

GEMIFLOXACIN MESYLATETABLET; ORAL
FACTIVE

AB	+ LG LIFE SCIENCES	EQ 320MG BASE	N021158	001	Apr 04, 2003	Jun CFTG
AB	GEMIFLOXACIN MESYLATE					
AB	ORCHID HLTHCARE	EQ 320MG BASE	A090466	001	Jun 15, 2015	Jun NEWA

GLATIRAMER ACETATEINJECTABLE; SUBCUTANEOUS
COPAXONE

AP	+ TEVA PHARMS USA	20MG/ML	N020622	002	Feb 12, 2002	Mar CFTG
AP	GLATOPIA					
AP	SANDOZ INC	20MG/ML	A090218	001	Apr 16, 2015	Mar NEWA

GLIMEPIRIDE

TABLET; ORAL

GLIMEPIRIDE

@	HIKMA PHARMS	1MG	A078952	001	Aug 01, 2013	Apr	DISC
@		2MG	A078952	002	Aug 01, 2013	Apr	DISC
@		4MG	A078952	003	Aug 01, 2013	Apr	DISC

GLIPIZIDE

TABLET; ORAL

GLIPIZIDE

	@	ANI PHARMS INC	5MG	A074387	001	Mar 04, 1996	Aug	CAHN
>A>	AB		5MG	A074497	001	Aug 31, 1995	Oct	CAHN
	@		10MG	A074387	002	Mar 04, 1996	Aug	CAHN
>A>	AB		10MG	A074497	002	Aug 31, 1995	Oct	CAHN
>D>	AB	IVAX SUB TEVA PHARMS	5MG	A074497	001	Aug 31, 1995	Oct	CAHN
>D>	AB		10MG	A074497	002	Aug 31, 1995	Oct	CAHN

TABLET, EXTENDED RELEASE; ORAL

GLIPIZIDE

AB		MYLAN PHARMS INC	2.5MG	A202298	001	May 19, 2015	May	NEWA
AB			5MG	A202298	002	May 19, 2015	May	NEWA
AB			10MG	A202298	003	May 19, 2015	May	NEWA

GLUCAGON HYDROCHLORIDE

POWDER; INTRAMUSCULAR, INTRAVENOUS

GLUCAGON

+	FRESENIUS KABI USA	EQ 1MG BASE/VIAL	N201849	001	May 08, 2015	May	NEWA
---	--------------------	------------------	---------	-----	--------------	-----	------

GLYBURIDE

TABLET; ORAL

DIABETA

AB2		SANOFI AVENTIS US	1.25MG	N017532	001	May 01, 1984	Sep	CFTG
AB2			2.5MG	N017532	002	May 01, 1984	Sep	CFTG
AB2	+		5MG	N017532	003	May 01, 1984	Sep	CFTG

GLYBURIDE

AB1		AUROBINDO PHARMA	1.25MG	A077537	001	Oct 18, 2007	Sep	CTEC
AB1			2.5MG	A077537	002	Oct 18, 2007	Sep	CTEC
AB1			5MG	A077537	003	Oct 18, 2007	Sep	CTEC
AB1		COREPHARMA	1.25MG	A076257	001	Jun 27, 2002	Sep	CTEC
AB2			1.25MG	A206079	001	Sep 30, 2015	Sep	NEWA
AB1			2.5MG	A076257	002	Jun 27, 2002	Sep	CTEC
AB2			2.5MG	A206079	002	Sep 30, 2015	Sep	NEWA
AB1			5MG	A076257	003	Jun 27, 2002	Sep	CTEC
AB2			5MG	A206079	003	Sep 30, 2015	Sep	NEWA
AB1		HERITAGE PHARMS INC	1.25MG	A090937	001	Feb 28, 2011	Sep	CTEC
AB1			2.5MG	A090937	002	Feb 28, 2011	Sep	CTEC
AB1			5MG	A090937	003	Feb 28, 2011	Sep	CTEC
AB1		TEVA	1.25MG	A074388	001	Aug 29, 1995	Sep	CTEC
AB1			2.5MG	A074388	002	Aug 29, 1995	Sep	CTEC
AB1	+		5MG	A074388	003	Aug 29, 1995	Sep	CTEC

GLYBURIDE; METFORMIN HYDROCHLORIDE

TABLET; ORAL

GLUCOVANCE

>D>	AB	BRISTOL MYERS SQUIBB	1.25MG; 250MG	N021178	001	Jul 31, 2000	Oct	DISC
>A>		@	1.25MG; 250MG	N021178	001	Jul 31, 2000	Oct	DISC

GLYCEROL PHENYLBUTYRATE

LIQUID; ORAL

RAVICTI

+	HORIZON THERAPS INC	1.1GM/ML	N203284	001	Feb 01, 2013	May	CAHN
---	---------------------	----------	---------	-----	--------------	-----	------

GLYCOPYRROLATE

INJECTABLE; INJECTION

ROBINUL

AP	+	EUROHLTH INTL SARL	0.2MG/ML	N017558	001		Jun	CAHN
>A>		POWDER; INHALATION						
>A>		SEEBRI						
>A>	+	NOVARTIS PHARMS CORP	15.6MCG/INH	N207923	001	Oct 29, 2015	Oct	NEWA
		TABLET; ORAL						
		GLYCOPYRROLATE						
AA		SUN PHARM INDS LTD	1MG	A040844	001	Aug 18, 2009	Apr	CAHN

TABLET;ORAL
GLYCOPYRROLATE

AA 2MG A040844 002 Aug 18, 2009 Apr CAHN

>A> GLYCOPYRROLATE ; INDACATEROL MALEATE

>A> POWDER; INHALATION

>A> UTIBRON

>A> + NOVARTIS PHARMS CORP 15.6MCG/INH;27.5MCG/INH N207930 001 Oct 29, 2015 Oct NEWA

GRANISETRON HYDROCHLORIDE

INJECTABLE; INJECTION

GRANISETRON HYDROCHLORIDE

AP BANNER LIFE SCIENCES EQ 0.1MG BASE/ML (EQ 0.1MG BASE/ML) A078863 001 Jun 30, 2008 Jan CAHN

AP EQ 4MG BASE/4ML (EQ 1MG BASE/ML) A078880 001 Jun 30, 2008 Jan CAHN

@ CLARIS PHARMASERVICE EQ 1MG BASE/ML (EQ 1MG BASE/ML) A078198 001 Jun 30, 2008 Apr CAHN

@ EQ 4MG BASE/4ML (EQ 1MG BASE/ML) A078198 002 Jun 30, 2008 Apr CAHN

AP EUROHLTH INTL SARL EQ 4MG BASE/4ML (EQ 1MG BASE/ML) A077177 001 Dec 31, 2007 Jun CAHN

GRANISETRON HYDROCHLORIDE PRESERVATIVE FREE

AP BANNER LIFE SCIENCES EQ 1MG BASE/ML (EQ 1MG BASE/ML) A078863 002 Jun 30, 2008 Jan CAHN

GUAIFENESIN; HYDROCODONE BITARTRATE

SOLUTION; ORAL

FLOWTUSS

MIKART INC 200MG/5ML; 2.5MG/5ML N022424 001 May 14, 2015 May NEWA

MISSION PHARMACAL CO 200MG/5ML; 2.5MG/5ML N022424 001 May 14, 2015 Sep CAHN

GUAIFENESIN; HYDROCODONE BITARTRATE; PSEUDOEPHEDRINE HYDROCHLORIDE

SOLUTION; ORAL

HYCOFENIX

+ MIKART INC 200MG/5ML; 2.5MG/5ML; 30MG/5ML N022279 001 May 14, 2015 May NEWA

GUANFACINE HYDROCHLORIDE

TABLET, EXTENDED RELEASE; ORAL

GUANFACINE HYDROCHLORIDE

>A> AB IMPAX LABS INC EQ 1MG BASE A202238 001 Oct 20, 2015 Oct NEWA

>A> AB EQ 2MG BASE A202238 002 Oct 20, 2015 Oct NEWA

>A> AB EQ 3MG BASE A202238 003 Oct 20, 2015 Oct NEWA

>A> AB EQ 4MG BASE A202238 004 Oct 20, 2015 Oct NEWA

AB MYLAN PHARMS INC EQ 1MG BASE A202578 001 Jun 02, 2015 May NEWA

AB EQ 2MG BASE A202578 002 Jun 02, 2015 May NEWA

AB EQ 3MG BASE A202578 003 Jun 02, 2015 May NEWA

AB EQ 4MG BASE A202578 004 Jun 02, 2015 May NEWA

AB SANDOZ INC EQ 1MG BASE A202568 001 Jun 03, 2015 May NEWA

AB EQ 2MG BASE A202568 002 Jun 03, 2015 May NEWA

AB EQ 3MG BASE A202568 003 Jun 03, 2015 May NEWA

AB EQ 4MG BASE A202568 004 Jun 03, 2015 May NEWA

AB TEVA PHARMS USA EQ 1MG BASE A201382 001 Jun 02, 2015 May NEWA

AB EQ 2MG BASE A201382 002 Jun 02, 2015 May NEWA

AB EQ 3MG BASE A201382 003 Jun 02, 2015 May NEWA

AB EQ 4MG BASE A201382 004 Jun 02, 2015 May NEWA

AB TWI PHARMS INC EQ 1MG BASE A201408 001 Jun 02, 2015 May NEWA

AB EQ 2MG BASE A201408 002 Jun 02, 2015 May NEWA

AB EQ 3MG BASE A201408 003 Jun 02, 2015 May NEWA

AB EQ 4MG BASE A201408 004 Jun 02, 2015 May NEWA

HALOPERIDOL

TABLET; ORAL

HALOPERIDOL

@ CYCLE PHARMS LTD 0.5MG A071128 001 Feb 17, 1987 May CAHN

@ 1MG A071129 001 Feb 17, 1987 Jun CAHN

@ 5MG A071131 001 Feb 17, 1987 Jun CAHN

@ 10MG A071132 001 May 12, 1987 Jun CAHN

@ 20MG A071133 001 May 12, 1987 May CAHN

@ ROXANE 2MG A071130 001 Feb 17, 1987 Jun CAHN

HALOPERIDOL LACTATE

CONCENTRATE; ORAL

HALOPERIDOL INTENSOL

@ CYCLE PHARMS LTD EQ 2MG BASE/ML A072045 001 Apr 12, 1988 May CAHN

INJECTABLE; INJECTION

HALOPERIDOL

@ CLARIS PHARMASERVICE EQ 5MG BASE/ML
 @ EQ 5MG BASE/ML

A076791 001 Aug 25, 2004 Apr CAHN
 A076828 001 Aug 25, 2004 May CAHN

HEPARIN SODIUM

INJECTABLE; INJECTION

HEPARIN SODIUM

AP + @ EUROHLTH INTL SARL 1,000 UNITS/ML
 1,000 UNITS/ML
 @ 2,500 UNITS/ML
 @ 5,000 UNITS/ML
 @ 5,000 UNITS/0.5ML
 AP + 5,000 UNITS/ML
 @ 5,000 UNITS/0.5ML
 @ 7,500 UNITS/ML
 @ 10,000 UNITS/ML
 AP + 10,000 UNITS/ML
 @ 15,000 UNITS/ML
 @ 20,000 UNITS/ML

N017007 001 Aug CAHN
 N017037 001 Jun CAHN
 N017007 007 Aug CAHN
 N017007 002 Aug CAHN
 N017007 010 Aug CAHN
 N017037 002 Jun CAHN
 N017037 013 Apr 07, 1986 Jun CAHN
 N017007 003 Aug CAHN
 N017007 004 Aug CAHN
 N017037 003 Jun CAHN
 N017007 005 Aug CAHN
 N017007 006 Aug CAHN

HYDRALAZINE HYDROCHLORIDE

INJECTABLE; INJECTION

HYDRALAZINE HYDROCHLORIDE

AP + AKORN 20MG/ML
 AP LUITPOLD 20MG/ML
 AP X-GEN PHARMS INC 20MG/ML

A040730 001 Apr 21, 2009 Feb CRLD
 A040136 001 Jun 30, 1997 Feb CRLD
 A203110 001 Jun 29, 2015 Jun NEWA

TABLET; ORAL

HYDRALAZINE HYDROCHLORIDE

@ HERITAGE PHARMS INC 10MG
 @ 25MG
 @ 50MG
 @ 100MG

A040858 001 Feb 26, 2010 Sep CAHN
 A040858 002 Feb 26, 2010 Sep CAHN
 A040858 003 Feb 26, 2010 Sep CAHN
 A040858 004 Feb 26, 2010 Sep CAHN

HYDROCHLOROTHIAZIDE

CAPSULE; ORAL

HYDROCHLOROTHIAZIDE

@ SUN PHARM INDS INC 12.5MG
 MICROZIDE

AB + ACTAVIS LABS UT INC 12.5MG

A090651 001 Apr 07, 2014 Aug DISC
 N020504 001 Dec 27, 1996 Feb CAHN

HYDROCHLOROTHIAZIDE; LISINAPRIL

TABLET; ORAL

LISINAPRIL AND HYDROCHLOROTHIAZIDE

AB SUN PHARM INDS LTD 12.5MG; 10MG
 AB 12.5MG; 20MG
 AB 25MG; 20MG

A076007 001 Jul 01, 2002 Apr CAHN
 A076007 002 Jul 01, 2002 Apr CAHN
 A076007 003 Jul 01, 2002 Apr CAHN

ZESTORETIC

AB ALVOGEN IPCO SARL 12.5MG; 10MG
 AB + 12.5MG; 20MG
 AB + 25MG; 20MG

N019888 003 Nov 18, 1993 Feb CAHN
 N019888 001 Sep 20, 1990 Feb CAHN
 N019888 002 Jul 20, 1989 Feb CAHN

HYDROCHLOROTHIAZIDE; METOPROLOL SUCCINATE

TABLET, EXTENDED RELEASE; ORAL

DUTOPROL

CONCORDIA PHARMS INC 12.5MG; EQ 25MG TARTRATE
 12.5MG; EQ 50MG TARTRATE
 + 12.5MG; EQ 100MG TARTRATE

N021956 001 Aug 28, 2006 Jun CAHN
 N021956 002 Aug 28, 2006 Jun CAHN
 N021956 003 Aug 28, 2006 Jun CAHN

HYDROCHLOROTHIAZIDE; PROPRANOLOL HYDROCHLORIDE

TABLET; ORAL

INDERIDE-40/25

>D> INDERIDE-40/25
 >D> AB + WYETH PHARMS INC 25MG; 40MG
 >A> @ 25MG; 40MG
 PROPRANOLOL HYDROCHLORIDE AND HYDROCHLOROTHIAZIDE
 @ ANI PHARMS INC 25MG; 40MG
 AB 25MG; 40MG
 @ 25MG; 80MG
 AB 25MG; 80MG
 >D> AB MYLAN 25MG; 40MG
 >A> AB + 25MG; 40MG

N018031 001 Oct DISC
 N018031 001 Oct DISC
 A070704 001 Oct 01, 1986 Jul CAHN
 A072042 001 Mar 14, 1988 Aug CAHN
 A070705 001 Oct 01, 1986 Jul CAHN
 A072043 001 Mar 14, 1988 Aug CAHN
 A070947 002 Mar 04, 1987 Oct CRLD
 A070947 002 Mar 04, 1987 Oct CRLD

HYDROCHLOROTHIAZIDE; QUINAPRIL HYDROCHLORIDE

TABLET; ORAL

QUINAPRIL HYDROCHLORIDE AND HYDROCHLOROTHIAZIDE

AB	SUN PHARM INDS LTD	12.5MG;EQ 10MG BASE	A078211	001	Mar 04, 2009	Apr CAHN
AB		12.5MG;EQ 20MG BASE	A078211	002	Mar 04, 2009	Apr CAHN
AB		25MG;EQ 20MG BASE	A078211	003	Mar 04, 2009	Apr CAHN

HYDROCHLOROTHIAZIDE; TELMISARTAN

TABLET; ORAL

TELMISARTAN AND HYDROCHLOROTHIAZIDE

>A> AB	MACLEODS PHARMS LTD	12.5MG;40MG	A204169	001	Nov 02, 2015	Oct NEWA
>A> AB		12.5MG;80MG	A204169	002	Nov 02, 2015	Oct NEWA
>A> AB		25MG;80MG	A204169	003	Nov 02, 2015	Oct NEWA

HYDROCHLOROTHIAZIDE; TRIAMTERENE

CAPSULE; ORAL

TRIAMTERENE AND HYDROCHLOROTHIAZIDE

@ ANI PHARMS INC 25MG;37.5MG

A074970 001 Jan 06, 1998 Aug CAHN

TABLET; ORAL

TRIAMTERENE AND HYDROCHLOROTHIAZIDE

AB	ANI PHARMS INC	50MG;75MG	A073467	001	Jan 31, 1996	Aug CAHN
----	----------------	-----------	---------	-----	--------------	----------

HYDROCODONE BITARTRATE

CAPSULE, EXTENDED RELEASE; ORAL

ZOHYDRO ER

+	FERRIMILL LTD	10MG	N202880	001	Oct 25, 2013	Apr CAHN
		15MG	N202880	002	Oct 25, 2013	Apr CAHN
		20MG	N202880	003	Oct 25, 2013	Apr CAHN
		30MG	N202880	004	Oct 25, 2013	Apr CAHN
		40MG	N202880	005	Oct 25, 2013	Apr CAHN
		50MG	N202880	006	Oct 25, 2013	Apr CAHN
+	PERNIX IRELAND PAIN	10MG	N202880	001	Oct 25, 2013	Jun CAHN
		15MG	N202880	002	Oct 25, 2013	Jun CAHN
		20MG	N202880	003	Oct 25, 2013	Jun CAHN
		30MG	N202880	004	Oct 25, 2013	Jun CAHN
		40MG	N202880	005	Oct 25, 2013	Jun CAHN
		50MG	N202880	006	Oct 25, 2013	Jun CAHN

TABLET, EXTENDED RELEASE; ORAL

HYSINGLA

+	PURDUE PHARMA LP	20MG	N206627	001	Nov 20, 2014	Mar CRLD
---	------------------	------	---------	-----	--------------	----------

HYDROCORTISONE

CREAM; TOPICAL

HYDROCORTISONE

AT	RISING PHARMS INC	2.5%	A040879	001	Aug 20, 2010	Mar CAHN
----	-------------------	------	---------	-----	--------------	----------

POWDER; FOR RX COMPOUNDING

HYDRO-RX

@ X GEN PHARMS 100%

A085982 001 Apr DISC

TABLET; ORAL

HYDROCORTISONE

AB	HIKMA INTL PHARMS	5MG	A083365	002	Feb 23, 2015	Feb NEWA
AB		10MG	A083365	003	Feb 23, 2015	Feb NEWA
AB		20MG	A083365	001		Feb CMFD

HYDROCORTISONE ACETATE

POWDER; FOR RX COMPOUNDING

HYDROCORTISONE ACETATE

@ X GEN PHARMS 100%

A085981 001 Apr DISC

HYDROCORTISONE VALERATE

CREAM; TOPICAL

HYDROCORTISONE VALERATE

@ G AND W LABS INC 0.2%

A074489 001 Aug 12, 1998 Apr CAHN

HYDROCORTISONE; NEOMYCIN SULFATE; POLYMYXIN B SULFATE

SUSPENSION/DROPS; OTIC

CORTISPORIN

AT	+	CITRON PHARMA LLC	1%;EQ 3.5MG BASE/ML;10,000 UNITS/ML	N060613	001	Jun CMS2
----	---	-------------------	-------------------------------------	---------	-----	----------

HYDROMORPHONE HYDROCHLORIDEINJECTABLE; INJECTION
DILAUDID-HP

>D>	+	PURDUE PHARM PRODS	250MG/VIAL	N019034	002	Aug 04, 1994	Oct DISC
>A>	@		250MG/VIAL	N019034	002	Aug 04, 1994	Oct DISC

TABLET, EXTENDED RELEASE; ORAL
HYDROMORPHONE HYDROCHLORIDE

AB		PADDOCK LLC	8MG	A204278	001	Apr 06, 2015	Mar NEWA
AB			12MG	A204278	002	Apr 06, 2015	Mar NEWA
AB			16MG	A204278	003	Apr 06, 2015	Mar NEWA

HYDROXOCOBALAMININJECTABLE; INJECTION
CYANOKIT

	@	SERB SAS	2.5GM/VIAL (5GM/KIT)	N022041	002	Dec 15, 2006	Apr CAHN
+			5GM/VIAL (5GM/KIT)	N022041	001	Apr 08, 2011	Apr CAHN

HYDROXYCHLOROQUINE SULFATETABLET; ORAL
PLAQUENIL

AB	+	CONCORDIA PHARMS INC	200MG	N009768	001		Jun CAHN
----	---	----------------------	-------	---------	-----	--	----------

HYDROXYPROGESTERONE CAPROATEINJECTABLE; INJECTION
HYDROXYPROGESTERONE CAPROATE

	@	ACTAVIS LABS UT INC	125MG/ML	N017439	001		Mar CAHN
	@		250MG/ML	N017439	002		Mar CAHN
+		MCGUFF	250MG/ML	A200271	001	Aug 24, 2015	Aug NEWA

HYDROXYZINE HYDROCHLORIDETABLET; ORAL
HYDROXYZINE HYDROCHLORIDE

AB		ELITE LABS INC	10MG	A040600	001	Dec 28, 2004	Jun CAHN
AB			25MG	A040602	001	Dec 28, 2004	Jun CAHN
AB			50MG	A040604	001	Dec 28, 2004	Jun CAHN
AB		HERITAGE PHARMA	10MG	A204279	001	Aug 20, 2014	Mar CAHN
AB			25MG	A204279	002	Aug 20, 2014	Mar CAHN
AB			50MG	A204279	003	Aug 20, 2014	Mar CAHN
AB		MIKAH PHARMA	10MG	A040600	001	Dec 28, 2004	Mar CMFD
AB			25MG	A040602	001	Dec 28, 2004	Mar CMFD
AB			50MG	A040604	001	Dec 28, 2004	Mar CMFD
	@	MUTUAL PHARM	10MG	A089381	001	May 19, 1986	Jul DISC
	@		25MG	A089382	001	May 19, 1986	Jul DISC
	@		50MG	A089383	001	May 19, 1986	Jul DISC
	@	WATSON LABS	10MG	A088348	001	Sep 15, 1983	Jul DISC
	@		25MG	A088349	001	Sep 15, 1983	Jul DISC
	@		50MG	A088350	001	Sep 15, 1983	Jul DISC

HYDROXYZINE PAMOATECAPSULE; ORAL
HYDROXYZINE PAMOATE

AB		HERITAGE PHARMA	EQ 25MG HYDROCHLORIDE	A201507	001	Jun 03, 2013	Mar CAHN
AB			EQ 50MG HYDROCHLORIDE	A201507	002	Jun 03, 2013	Mar CAHN

IBANDRONATE SODIUMINJECTABLE; INTRAVENOUS
IBANDRONATE SODIUM

>A>	AP	APOTEX INC	EQ 3MG BASE/3ML	A204222	001	Oct 16, 2015	Oct NEWA
	AP	AUROBINDO PHARMA LTD	EQ 3MG BASE/3ML	A205332	001	Aug 19, 2015	Aug NEWA

IBUPROFENTABLET; ORAL
IBUPROFEN

AB		GRANULES INDIA LTD	400MG	A091625	001	Sep 15, 2015	Aug NEWA
AB			600MG	A091625	002	Sep 15, 2015	Aug NEWA
AB			800MG	A091625	003	Sep 15, 2015	Aug NEWA
	@	VINTAGE PHARMS	300MG	A071230	001	Oct 22, 1986	Jul DISC
	@		400MG	A071231	001	Oct 22, 1986	Jul DISC
	@		600MG	A071232	001	Oct 22, 1986	Jul DISC
	@		800MG	A072004	001	Nov 18, 1987	Jul DISC

ILOPERIDONE

TABLET;ORAL

FANAPT

+	VANDA PHARMS INC	1MG	N022192	001	May 06, 2009	Jan CAHN
		2MG	N022192	002	May 06, 2009	Jan CAHN
		4MG	N022192	003	May 06, 2009	Jan CAHN
		6MG	N022192	004	May 06, 2009	Jan CAHN
		8MG	N022192	005	May 06, 2009	Jan CAHN
		10MG	N022192	006	May 06, 2009	Jan CAHN
		12MG	N022192	007	May 06, 2009	Jan CAHN

IMIQUIMOD

CREAM;TOPICAL

IMIQUIMOD

AB	G AND W LABS INC	5%	A200481	001	Apr 18, 2011	Apr CAHN
----	------------------	----	---------	-----	--------------	----------

INDAPAMIDE

TABLET;ORAL

INDAPAMIDE

AB	ANI PHARMS INC	1.25MG	A074299	002	Apr 29, 1996	Jul CAHN
	@	1.25MG	A074498	002	Feb 12, 1998	Jul CAHN
AB		2.5MG	A074299	001	Jul 27, 1995	Jul CAHN
	@	2.5MG	A074498	001	Oct 31, 1996	Jul CAHN

INDOMETHACIN

CAPSULE, EXTENDED RELEASE;ORAL

INDOMETHACIN

AB	JUBILANT GENERICS	75MG	A202706	001	Oct 05, 2015	Sep NEWA
----	-------------------	------	---------	-----	--------------	----------

INGENOL MEBUTATE

GEL;TOPICAL

PICATO

+	LEO PHARMA AS	0.015%	N202833	001	Jan 23, 2012	May CRLD
---	---------------	--------	---------	-----	--------------	----------

INSULIN DEGLUDEC

SOLUTION;SUBCUTANEOUS

TRESIBA

	NOVO NORDISK INC	300 UNITS/3ML (100 UNITS/ML)	N203314	001	Sep 25, 2015	Sep NEWA
+		600 UNITS/3ML (200 UNITS/ML)	N203314	002	Sep 25, 2015	Sep NEWA

INSULIN GLARGINE RECOMBINANT

SOLUTION;SUBCUTANEOUS

TOUJEO SOLOSTAR

+	SANOFI US SERVICES	300 UNITS/ML (300 UNITS/ML)	N206538	001	Feb 25, 2015	Feb NEWA
---	--------------------	-----------------------------	---------	-----	--------------	----------

INSULIN LISPRO RECOMBINANT

SOLUTION;SUBCUTANEOUS

HUMALOG KWIKPEN

+	ELI LILLY AND CO	200 UNITS/ML	N205747	001	May 26, 2015	May NEWA
---	------------------	--------------	---------	-----	--------------	----------

INSULIN RECOMBINANT HUMAN

POWDER;INHALATION

AFREZZA

	SANOFI AVENTIS	12 UNITS/INH	N022472	003	Apr 17, 2015	Apr NEWA
--	----------------	--------------	---------	-----	--------------	----------

IOHEXOL

FOR SOLUTION;ORAL

ORALTAG

	INTERPHARMA PRAHA AS	9.7GM/BOT	N205383	001	Mar 26, 2015	Mar NEWA
--	----------------------	-----------	---------	-----	--------------	----------

IOPAMIDOL

INJECTABLE;INJECTION

IOPAMIDOL-250

	@ FRESENIUS KABI USA	51%	A074679	001	Apr 02, 1997	Jan DISC
--	----------------------	-----	---------	-----	--------------	----------

IOPAMIDOL-300

	@ FRESENIUS KABI USA	61%	A074679	002	Apr 02, 1997	Jan DISC
--	----------------------	-----	---------	-----	--------------	----------

IOPAMIDOL-370

	@ FRESENIUS KABI USA	76%	A074679	003	Apr 02, 1997	Jan DISC
--	----------------------	-----	---------	-----	--------------	----------

ISOVUE-200

+	BRACCO	41%	N018735	006	Jul 07, 1987	Feb CTEC
---	--------	-----	---------	-----	--------------	----------

	INJECTABLE; INJECTION						
	ISOVUE-250						
	+ BRACCO	51%		N018735	007	Jul 06, 1992	Feb CTEC
	+ ISOVUE-300	51%		N020327	002	Oct 12, 1994	Feb CTEC
	+ BRACCO	61%		N020327	003	Oct 12, 1994	Feb CTEC
	ISOVUE-370						
	+ BRACCO	76%		N020327	004	Oct 12, 1994	Feb CTEC
	SCANLUX-300						
AP	MYLAN INSTITUTIONAL	61%		A090394	001	Jun 18, 2010	Aug CAHN
	SCANLUX-370						
AP	MYLAN INSTITUTIONAL	76%		A090394	002	Jun 18, 2010	Aug CAHN

IOTHALAMATE MEGLUMINE

	INJECTABLE; INJECTION						
	CONRAY						
	+ LIEBEL-FLARSHEIM	60%		N013295	001		Feb CAHN
	CONRAY 30						
	+ LIEBEL-FLARSHEIM	30%		N016983	001		Feb CAHN
	CONRAY 43						
	+ LIEBEL-FLARSHEIM	43%		N013295	002		Feb CAHN
	SOLUTION; INTRAVESICAL						
	CYSTO-CONRAY II						
	LIEBEL-FLARSHEIM	17.2%		N017057	002		Feb CAHN

IOVERSOL

	INJECTABLE; INJECTION						
	OPTIRAY 160						
	@ LIEBEL-FLARSHEIM	34%		N019710	003	Dec 30, 1988	Feb CAHN
	OPTIRAY 240						
	+ LIEBEL-FLARSHEIM	51%		N019710	002	Dec 30, 1988	Feb CAHN
	@	51%		N020923	001	May 28, 1998	Feb CAHN
	OPTIRAY 300						
	+ LIEBEL-FLARSHEIM	64%		N019710	004	Jan 22, 1992	Feb CAHN
	+	64%		N020923	004	May 13, 1999	Feb CAHN
	OPTIRAY 320						
	+ LIEBEL-FLARSHEIM	68%		N019710	001	Dec 30, 1988	Feb CAHN
>D>	@	68%		N020923	002	May 29, 1998	Oct CMFD
>A>	+	68%		N020923	002	May 29, 1998	Oct CMFD
	@	68%		N020923	002	May 29, 1998	Feb CAHN
	OPTIRAY 350						
	+ LIEBEL-FLARSHEIM	74%		N019710	005	Jan 22, 1992	Feb CAHN
	+	74%		N020923	003	May 28, 1998	Feb CAHN

IOXAGLATE MEGLUMINE; IOXAGLATE SODIUM

	INJECTABLE; INJECTION						
	HEXABRIX						
	@ GUERBET	39.3%; 19.6%		N018905	002	Jul 26, 1985	May DISC

IRBESARTAN

	TABLET; ORAL						
	IRBESARTAN						
AB	JUBILANT GENERICS	75MG		A203534	001	Feb 23, 2015	Feb NEWA
AB		150MG		A203534	002	Feb 23, 2015	Feb NEWA
AB		300MG		A203534	003	Feb 23, 2015	Feb NEWA

IRINOTECAN HYDROCHLORIDE

	INJECTABLE, LIPOSOMAL; IV (INFUSION)						
>A>	ONIVYDE						
>A>	+ MERRIMACK PHARMS	EQ 43MG BASE/10ML (EQ 4.3MG BASE/ML)		N207793	001	Oct 22, 2015	Oct NEWA

IRON DEXTRAN

	INJECTABLE; INJECTION						
	INFED						
BP	+ ACTAVIS LABS UT INC	EQ 50MG IRON/ML		N017441	001		Mar CAHN

ISAVUCONAZONIUM SULFATE

CAPSULE; ORAL

CRESEMBA

+	ASTELLAS	186MG	N207500	001	Mar 06, 2015	Mar NEWA
---	----------	-------	---------	-----	--------------	----------

POWDER; IV (INFUSION)

CRESEMBA

+	ASTELLAS	372MG	N207501	001	Mar 06, 2015	Mar NEWA
---	----------	-------	---------	-----	--------------	----------

ISOSORBIDE DINITRATE

TABLET; ORAL

ISORDIL

AB	VALEANT PHARMS NORTH	5MG	N012093	007	Jul 29, 1988	Feb CAHN
----	----------------------	-----	---------	-----	--------------	----------

+		40MG	N012093	001	Jul 29, 1988	Feb CAHN
---	--	------	---------	-----	--------------	----------

ISOTRETINOIN

CAPSULE; ORAL

ABSORICA

RANBAXY

25MG

N021951	005	Aug 15, 2014	Feb NEWA
---------	-----	--------------	----------

35MG

N021951	006	Aug 15, 2014	Feb NEWA
---------	-----	--------------	----------

MYORISAN

AB	DOUGLAS PHARMS	30MG	A076485	004	Aug 25, 2015	Aug NEWA
----	----------------	------	---------	-----	--------------	----------

SOTRET

AB	SUN PHARM INDS LTD	10MG	A076041	001	Dec 24, 2002	Apr CAHN
----	--------------------	------	---------	-----	--------------	----------

AB		20MG	A076041	002	Dec 24, 2002	Apr CAHN
----	--	------	---------	-----	--------------	----------

AB		30MG	A076503	001	Jun 20, 2003	Apr CAHN
----	--	------	---------	-----	--------------	----------

AB		40MG	A076041	003	Dec 24, 2002	Apr CAHN
----	--	------	---------	-----	--------------	----------

ZENATANE

AB	DR REDDYS LABS LTD	30MG	A202099	004	Feb 23, 2015	Feb NEWA
----	--------------------	------	---------	-----	--------------	----------

ISRADIPINE

CAPSULE; ORAL

ISRADIPINE

AB	ELITE LABS INC	2.5MG	A077169	001	Apr 24, 2006	Mar CAHN
----	----------------	-------	---------	-----	--------------	----------

AB		5MG	A077169	002	Apr 24, 2006	Mar CAHN
----	--	-----	---------	-----	--------------	----------

ITRACONAZOLE

SOLUTION; ORAL

ITRACONAZOLE

>A>	AMNEAL PHARMS	10MG/ML	A205573	001	Oct 30, 2015	Oct NEWA
-----	---------------	---------	---------	-----	--------------	----------

>A> AA	SPORANOX					
--------	----------	--	--	--	--	--

>D>	+	JANSSEN PHARMS	10MG/ML	001	Feb 21, 1997	Oct CFTG
-----	---	----------------	---------	-----	--------------	----------

>A> AA	+	10MG/ML	N020657	001	Feb 21, 1997	Oct CFTG
--------	---	---------	---------	-----	--------------	----------

IVABRADINE HYDROCHLORIDE

TABLET; ORAL

CORLANOR

AMGEN INC

EQ 5MG BASE

N206143	001	Apr 15, 2015	Apr NEWA
---------	-----	--------------	----------

+		EQ 7.5MG BASE	N206143	002	Apr 15, 2015	Apr NEWA
---	--	---------------	---------	-----	--------------	----------

IVACAFTOR

GRANULE; ORAL

KALYDECO

VERTEX PHARMS INC

50MG/PACKET

N207925	001	Mar 17, 2015	Mar NEWA
---------	-----	--------------	----------

+		75MG/PACKET	N207925	002	Mar 17, 2015	Mar NEWA
---	--	-------------	---------	-----	--------------	----------

IVACAFTOR; LUMACAFTOR

TABLET; ORAL

ORKAMBI

+	VERTEX PHARMS INC	125MG;200MG	N206038	001	Jul 02, 2015	Jul NEWA
---	-------------------	-------------	---------	-----	--------------	----------

IXABEPILONE

INJECTABLE; IV (INFUSION)

IXEMPRA KIT

+	R-PHARM US LLC	15MG/VIAL	N022065	001	Oct 16, 2007	Jun CAHN
---	----------------	-----------	---------	-----	--------------	----------

+		45MG/VIAL	N022065	002	Oct 16, 2007	Jun CAHN
---	--	-----------	---------	-----	--------------	----------

KANAMYCIN SULFATEINJECTABLE; INJECTION
KANAMYCIN

@ EUROHLTH INTL SARL	EQ 75MG BASE/2ML	A062324	001		Jun CAHN
@	EQ 500MG BASE/2ML	A062324	002		Jun CAHN
@	EQ 1GM BASE/3ML	A062324	003		Jun CAHN

KETOROLAC TROMETHAMINEINJECTABLE; INJECTION
KETOROLAC TROMETHAMINE

AP	BD RX	15MG/ML	A203242	001	Oct 07, 2015	Sep NEWA
AP		30MG/ML	A203242	002	Oct 07, 2015	Sep NEWA
	@ CLARIS PHARMASERVICE	15MG/ML	A075631	002	Jun 29, 2001	Apr CAHN
	@	30MG/ML	A075631	001	Jun 29, 2001	Apr CAHN
	@ EUROHLTH INTL SARL	15MG/ML	A075772	001	Jul 21, 2004	Jun CAHN
	@	30MG/ML	A075772	002	Jul 21, 2004	Jun CAHN

SPRAY, METERED; NASAL
SPRIX

+	EGALET US INC	15.75MG/SPRAY	N022382	001	May 14, 2010	Jan CAHN
---	---------------	---------------	---------	-----	--------------	----------

KETOROLAC TROMETHAMINE; PHENYLEPHRINE HYDROCHLORIDESOLUTION; IRRIGATION
OMIDRIA

+	OMEROS	EQ 4.24MG BASE/ML; EQ 12.4MG BASE/ML	N205388	001	May 30, 2014	Feb CPOT
---	--------	--------------------------------------	---------	-----	--------------	----------

LABETALOL HYDROCHLORIDEINJECTABLE; INJECTION
LABETALOL HYDROCHLORIDE

@ CLARIS PHARMASERVICE	5MG/ML	A076051	001	Jul 05, 2002	Apr CAHN
------------------------	--------	---------	-----	--------------	----------

TABLET; ORAL

LABETALOL HYDROCHLORIDE

AB	MUTUAL PHARM	100MG	A075215	001	Jul 29, 1999	Jan CMFD
AB		200MG	A075215	002	Jul 29, 1999	Jan CMFD
AB		300MG	A075215	003	Jul 29, 1999	Jan CMFD

LACTULOSESOLUTION; ORAL, RECTAL
LACTULOSE

AA	BIO-PHARM INC	10GM/15ML	A203762	001	Mar 27, 2015	Mar NEWA
----	---------------	-----------	---------	-----	--------------	----------

LAMIVUDINE; RALTEGRAVIR POTASSIUMTABLET; ORAL
DUTREBIS

@ MERCK SHARP DOHME	150MG; EQ 300MG BASE	N206510	001	Feb 06, 2015	Aug DISC
+	150MG; EQ 300MG BASE	N206510	001	Feb 06, 2015	Feb NEWA

LAMIVUDINE; ZIDOVUDINE

TABLET; ORAL

LAMIVUDINE AND ZIDOVUDINE

AB	HETERO LABS LTD III	150MG; 300MG	A079124	001	Sep 17, 2015	Aug NEWA
AB	STRIDES ARCOLAB LTD	150MG; 300MG	A079128	001	May 13, 2015	Apr NEWA
AB	STRIDES PHARMA	150MG; 300MG	A079128	001	May 13, 2015	Aug CAHN

LAMOTRIGINE

TABLET; ORAL

LAMOTRIGINE

@ HIKMA PHARMS	25MG	A078134	001	Apr 19, 2011	May DISC
@	100MG	A078134	002	Apr 19, 2011	May DISC
@	150MG	A078134	003	Apr 19, 2011	May DISC
@	200MG	A078134	004	Apr 19, 2011	May DISC

TABLET, ORALLY DISINTEGRATING; ORAL

LAMOTRIGINE

>A>	AB	PAR PHARM	25MG	A204158	001	Oct 27, 2015	Oct NEWA
>A>	AB		50MG	A204158	002	Oct 27, 2015	Oct NEWA
>A>	AB		100MG	A204158	003	Oct 27, 2015	Oct NEWA
>A>	AB		200MG	A204158	004	Oct 27, 2015	Oct NEWA

LAPATINIB DITOSYLATE

TABLET;ORAL

TYKERB

+	NOVARTIS PHARMS CORP	EQ 250MG BASE	N022059	001	Mar 13, 2007	Mar CAHN
---	----------------------	---------------	---------	-----	--------------	----------

LENVATINIB MESYLATE

CAPSULE;ORAL

LENVIMA

	EISAI INC	EQ 4MG BASE	N206947	001	Feb 13, 2015	Feb NEWA
+		EQ 10MG BASE	N206947	002	Feb 13, 2015	Feb NEWA

LEVETIRACETAM

INJECTABLE;IV (INFUSION)

LEVETIRACETAM

AP	FRESENIUS KABI USA	500MG/5ML (100MG/ML)	A090876	001	Aug 13, 2015	Jul NEWA
----	--------------------	----------------------	---------	-----	--------------	----------

SOLUTION;ORAL

LEVETIRACETAM

AA	PHARM ASSOC	100MG/ML	A201157	001	Jun 04, 2015	May NEWA
----	-------------	----------	---------	-----	--------------	----------

TABLET;ORAL

SPRITAM

	APRECIA PHARMS CO	250MG	N207958	001	Jul 31, 2015	Jul NEWA
		500MG	N207958	002	Jul 31, 2015	Jul NEWA
		750MG	N207958	003	Jul 31, 2015	Jul NEWA
		1GM	N207958	004	Jul 31, 2015	Jul NEWA

TABLET, EXTENDED RELEASE;ORAL

LEVETIRACETAM

	APOTEX INC	1GM	A202958	001	Feb 25, 2015	Feb NEWA
AB	DEXCEL PHARMA	500MG	A202167	001	Sep 04, 2015	Aug NEWA
AB		750MG	A202167	002	Sep 04, 2015	Aug NEWA
AB	PHARMADAX INC	500MG	A201464	001	May 25, 2012	Aug CAHN
AB		750MG	A201464	002	May 25, 2012	Aug CAHN
AB	PRINSTON INC	500MG	A203468	001	May 21, 2015	May NEWA
AB		750MG	A203468	002	May 21, 2015	May NEWA

LEVOCARNITINE

INJECTABLE;INJECTION

LEVOCARNITINE

@	TEVA PHARMS USA	200MG/ML	A075881	001	Mar 29, 2001	Apr DISC
---	-----------------	----------	---------	-----	--------------	----------

LEVOCETIRIZINE DIHYDROCHLORIDE

TABLET;ORAL

LEVOCETIRIZINE DIHYDROCHLORIDE

AB	APOTEX INC	5MG	A203027	001	Feb 13, 2015	Feb NEWA
AB	SUN PHARM INDS LTD	5MG	A201653	001	Jun 26, 2015	Jun NEWA

LEVOFLOXACIN

INJECTABLE;INJECTION

LEVOFLOXACIN

AP	CLARIS PHARMASERVICE	EQ 500MG/20ML (EQ 25MG/ML)	A091436	001	Jun 05, 2013	Apr CAHN
AP	HOSPIRA INC	EQ 500MG/20ML (EQ 25MG/ML)	A078577	001	Aug 12, 2015	Jul NEWA
AP		EQ 750MG/30ML (EQ 25MG/ML)	A078577	002	Aug 12, 2015	Jul NEWA

LEVOFLOXACIN IN DEXTROSE 5% IN PLASTIC CONTAINER

AP	CLARIS PHARMASERVICE	EQ 250MG/50ML (EQ 5MG/ML)	A091397	001	Aug 08, 2013	Apr CAHN
AP		EQ 500MG/100ML (EQ 5MG/ML)	A091397	002	Aug 08, 2013	Apr CAHN
AP		EQ 750MG/150ML (EQ 5MG/ML)	A091397	003	Aug 08, 2013	Apr CAHN
AP	HOSPIRA INC	EQ 250MG/50ML (EQ 5MG/ML)	A078579	001	Sep 03, 2015	Aug NEWA
AP		EQ 500MG/100ML (EQ 5MG/ML)	A078579	002	Sep 03, 2015	Aug NEWA
AP		EQ 750MG/150ML (EQ 5MG/ML)	A078579	003	Sep 03, 2015	Aug NEWA

SOLUTION/DROPS;OPHTHALMIC

LEVOFLOXACIN

AT	+ NEXUS PHARMS	0.5%	A077700	001	Dec 20, 2010	Jul CRLD
	QUIXIN					
	@ SANTEN	0.5%	N021199	001	Aug 18, 2000	Jul DISC

TABLET;ORAL

LEVOFLOXACIN

AB	JUBILANT GENERICS	250MG	A203613	001	Jun 19, 2015	Jun NEWA
AB		500MG	A203613	002	Jun 19, 2015	Jun NEWA

LEVOLEUCOVORIN CALCIUM

SOLUTION;IV (INFUSION)

LEVOLEUCOVORIN CALCIUM

>A>	AP	MYLAN TEORANTA	EQ 175MG BASE/17.5ML (EQ 10MG BASE/ML)	A203576	001	Oct 20, 2015	Oct NEWA
>A>	AP		EQ 250MG BASE/25ML (EQ 10MG BASE/ML)	A203576	002	Oct 20, 2015	Oct NEWA
		SANDOZ	EQ 250MG BASE/25ML (EQ 10MG BASE/ML)	A203563	002	Mar 09, 2015	Feb NEWA
>D>		SANDOZ INC	EQ 175MG BASE/17.5ML (EQ 10MG BASE/ML)	A203563	001	Mar 09, 2015	Oct CTEC
>A>	AP		EQ 175MG BASE/17.5ML (EQ 10MG BASE/ML)	A203563	001	Mar 09, 2015	Oct CTEC
			EQ 175MG BASE/17.5ML (EQ 10MG BASE/ML)	A203563	001	Mar 09, 2015	Feb NEWA
>D>	+		EQ 250MG BASE/25ML (EQ 10MG BASE/ML)	A203563	002	Mar 09, 2015	Oct CTEC
>A>	AP	+	EQ 250MG BASE/25ML (EQ 10MG BASE/ML)	A203563	002	Mar 09, 2015	Oct CTEC
		+	EQ 250MG BASE/25ML (EQ 10MG BASE/ML)	A203563	002	Mar 09, 2015	Mar CRLD

LEVONORGESTREL

INTRAUTERINE DEVICE;INTRAUTERINE

LILETTA

MEDICINES360

52MG

N206229 001 Feb 26, 2015 Feb NEWA

LEVORPHANOL TARTRATE

TABLET;ORAL

LEVORPHANOL TARTRATE

+ SENTYNL THERAPS INC 2MG

A074278 001 Mar 31, 2000 Apr CAHN

LIDOCAINE

OINTMENT;TOPICAL

LIDOCAINE

AT AMNEAL PHARMS 5%
@ BELMORA LLC 5%A206297 001 Aug 07, 2015 Jul NEWA
A080210 001 Sep CAHN

PATCH;TOPICAL

LIDOCAINE

AB ACTAVIS LABS UT INC 5%
AB MYLAN TECHNOLOGIES 5%A200675 001 Aug 23, 2012 Mar CAHN
A202346 001 Aug 07, 2015 Jul NEWALIDOCAINE HYDROCHLORIDE

INJECTABLE;INJECTION

LIDOCAINE HYDROCHLORIDE

AP @ EUROHLTH INTL SARL 1%
@ 2%
LUITPOLD 1%A080407 001 Mar CAHN
A080407 002 Mar CAHN
A091564 001 Aug 14, 2015 Aug NEWA

LIDOCAINE HYDROCHLORIDE PRESERVATIVE FREE

@ EUROHLTH INTL SARL 1%
@ 2%A084625 001 Feb CAHN
A084625 002 Feb CAHN

JELLY;TOPICAL

ANESTACON

@ BANNER LIFE SCIENCES 2%
LIDOCAINE HYDROCHLORIDE
@ G AND W LABS INC 2%A080429 001 Jan CAHN
A081318 001 Apr 29, 1993 Apr CAHNLIDOCAINE; PRILOCAINE

CREAM;TOPICAL

EMLA

AB + ACTAVIS LABS UT INC 2.5%;2.5%

N019941 001 Dec 30, 1992 Feb CAHN

LINACLOTIDE

CAPSULE;ORAL

LINZESS

+ FOREST LABS LLC 145MCG
290MCGN202811 001 Aug 30, 2012 Mar CAHN
N202811 002 Aug 30, 2012 Mar CAHN

LINCOMYCIN HYDROCHLORIDEINJECTABLE;INJECTION
LINCOCIN

AP	+	PHARMACIA AND UPJOHN	EQ 300MG BASE/ML	N050317	001		May CFTG
AP		LINCOMYCIN					
AP		X-GEN PHARMS INC	EQ 300MG BASE/ML	A201746	001	Jun 04, 2015	May NEWA

LINEZOLIDFOR SUSPENSION;ORAL
LINEZOLID

AB		ROXANE	100MG/5ML	A200068	001	Jun 03, 2015	May NEWA
AB	+	PHARMACIA AND UPJOHN	100MG/5ML	N021132	001	Apr 18, 2000	May CFTG
		SOLUTION;IV (INFUSION)					
		LINEZOLID					
AP		HOSPIRA INC	600MG/300ML (2MG/ML)	A205442	001	Jul 07, 2015	Jun NEWA
AP		SANDOZ INC	200MG/100ML (2MG/ML)	A200904	001	Jul 16, 2015	Jul NEWA
AP			600MG/300ML (2MG/ML)	A200904	002	Jul 16, 2015	Jul NEWA
AP		TEVA PHARMS	600MG/300ML (2MG/ML)	A200222	001	Jun 27, 2012	May CDFR
		LINEZOLID IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER					
	+	HOSPIRA INC	600MG/300ML (2MG/ML)	N206473	001	Jun 18, 2015	Jun NEWA
		ZYVOX					
AP		PHARMACIA AND UPJOHN	200MG/100ML (2MG/ML)	N021131	001	Apr 18, 2000	Jul CTEC
			200MG/100ML (2MG/ML)	N021131	001	Apr 18, 2000	May CDFR
			400MG/200ML (2MG/ML)	N021131	002	Apr 18, 2000	May NEWA
AP	+		600MG/300ML (2MG/ML)	N021131	003	Apr 18, 2000	May NEWA
		TABLET;ORAL					
		LINEZOLID					
AB		TEVA PHARMS USA	600MG	A078061	001	May 18, 2015	May NEWA
		ZYVOX					
AB	+	PHARMACIA AND UPJOHN	600MG	N021130	002	Apr 18, 2000	May CFTG

LISINOPRILTABLET;ORAL
LISINOPRIL

AB		SUN PHARM INDS LTD	2.5MG	A075944	001	Jul 01, 2002	Apr CAHN
AB			5MG	A075944	002	Jul 01, 2002	Apr CAHN
AB			10MG	A075944	003	Jul 01, 2002	Apr CAHN
AB			20MG	A075944	004	Jul 01, 2002	Apr CAHN
AB			30MG	A075944	006	Feb 11, 2003	Apr CAHN
AB			40MG	A075944	005	Jul 01, 2002	Apr CAHN
		ZESTRIL					
AB		ALVOGEN IPCO SARL	2.5MG	N019777	005	Apr 29, 1993	Feb CAHN
AB			5MG	N019777	001	May 19, 1988	Feb CAHN
AB			10MG	N019777	002	May 19, 1988	Feb CAHN
AB			20MG	N019777	003	May 19, 1988	Feb CAHN
AB			30MG	N019777	006	Jan 20, 1999	Feb CAHN
AB	+		40MG	N019777	004	May 19, 1988	Feb CAHN

LITHIUM CARBONATETABLET, EXTENDED RELEASE;ORAL
LITHIUM CARBONATE

AB		ALEMBIC PHARMS LTD	300MG	A204445	001	Jun 10, 2015	May NEWA
		@ HIKMA INTL PHARMS	450MG	A076490	001	Jun 17, 2003	Feb DISC
AB		UNIQUE PHARM LABS	300MG	A204779	001	Jul 27, 2015	Jul NEWA

LOMITAPIDE MESYLATECAPSULE;ORAL
JUXTAPID

AEGERION

EQ 30MG BASE
EQ 40MG BASE
EQ 60MG BASEN203858 004 Apr 23, 2015 Apr NEWA
N203858 005 Apr 23, 2015 Apr NEWA
N203858 006 Apr 23, 2015 Apr NEWALOMUSTINECAPSULE;ORAL
GLEOSTINE

CORDEN PHARMA

5MG

N017588 004 Dec 19, 2014 Jan NEWA

LOPERAMIDE HYDROCHLORIDE

CAPSULE; ORAL					
IMODIUM					
	@ J AND J CONSUMER INC	2MG	N017690	001	Jul CAHN
AB	+	2MG	N017694	001	Jul CAHN

LOPINAVIR; RITONAVIR

CAPSULE; ORAL					
KALETRA					
	@ ABBVIE	133.3MG; 33.3MG	N021226	001	Sep 15, 2000 Jun DISC

LORAZEPAM

INJECTABLE; INJECTION					
ATIVAN					
AP	+	EUROHLTH INTL SARL	2MG/ML	N018140	001 Jun CAHN
AP	+		4MG/ML	N018140	002 Jun CAHN
TABLET; ORAL					
LORAZEPAM					
>A>	AB	ANI PHARMS INC	0.5MG	A077396	001 Dec 13, 2006 Oct CAHN
>A>	AB		1MG	A077396	002 Dec 13, 2006 Oct CAHN
>A>	AB		2MG	A077396	003 Dec 13, 2006 Oct CAHN
>D>	AB	IVAX SUB TEVA PHARMS	0.5MG	A077396	001 Dec 13, 2006 Oct CAHN
>D>	AB		1MG	A077396	002 Dec 13, 2006 Oct CAHN
>D>	AB		2MG	A077396	003 Dec 13, 2006 Oct CAHN
	AB	SUN PHARM INDS LTD	0.5MG	A076045	001 Aug 29, 2001 Apr CAHN
	AB		1MG	A076045	002 Aug 29, 2001 Apr CAHN
	AB		2MG	A076045	003 Aug 29, 2001 Apr CAHN

LOSARTAN POTASSIUM

TABLET; ORAL					
LOSARTAN POTASSIUM					
AB		HETERO LABS LTD V	25MG	A203835	001 Aug 12, 2015 Jul NEWA
AB			50MG	A203835	002 Aug 12, 2015 Jul NEWA
AB			100MG	A203835	003 Aug 12, 2015 Jul NEWA
>A>	AB	UNICHEM LABS LTD	25MG	A203030	001 Oct 14, 2015 Oct NEWA
>A>	AB		50MG	A203030	002 Oct 14, 2015 Oct NEWA
>A>	AB		100MG	A203030	003 Oct 14, 2015 Oct NEWA
	AB	WATSON LABS	25MG	A091129	001 Oct 06, 2010 Feb CMFD
	AB		50MG	A091129	002 Oct 06, 2010 Feb CMFD
	AB		100MG	A091129	003 Oct 06, 2010 Feb CMFD

LOVASTATIN

TABLET, EXTENDED RELEASE; ORAL					
ALTOPREV					
	@ COVIS PHARMA SARL	10MG	N021316	001	Jun 26, 2002 May CAHN
		20MG	N021316	002	Jun 26, 2002 May CAHN
		40MG	N021316	003	Jun 26, 2002 May CAHN
	+	60MG	N021316	004	Jun 26, 2002 May CAHN

LOXAPINE HYDROCHLORIDE

CONCENTRATE; ORAL					
LOXITANE C					
	@ ACTAVIS LABS UT INC	EQ 25MG BASE/ML	N017658	001	Mar CAHN
INJECTABLE; INJECTION					
LOXITANE IM					
	@ ACTAVIS LABS UT INC	EQ 50MG BASE/ML	N018039	001	Mar CAHN

LOXAPINE SUCCINATE

CAPSULE; ORAL					
LOXAPINE SUCCINATE					
AB		ELITE LABS INC	EQ 5MG BASE	A076868	001 Aug 04, 2005 May CAHN
AB			EQ 10MG BASE	A076868	002 Aug 04, 2005 May CAHN
AB			EQ 25MG BASE	A076868	003 Aug 04, 2005 May CAHN
AB			EQ 50MG BASE	A076868	004 Aug 04, 2005 May CAHN
LOXITANE					
	@ ACTAVIS LABS UT INC	EQ 5MG BASE	N017525	001	Mar CAHN
	@	EQ 10MG BASE	N017525	002	Mar CAHN
	@	EQ 25MG BASE	N017525	003	Mar CAHN
	@	EQ 50MG BASE	N017525	004	Mar CAHN

TABLET; ORAL

LOXITANE

@	ACTAVIS LABS UT INC	EQ 10MG BASE	N017525	006		Mar	CAHN
@		EQ 25MG BASE	N017525	007		Mar	CAHN
@		EQ 50MG BASE	N017525	008		Mar	CAHN

LUCINACTANT

SUSPENSION; INTRATRACHEAL

SURFAXIN

@	DISCOVERY LABS	8.5ML	N021746	001	Mar 06, 2012	May	DISC
---	----------------	-------	---------	-----	--------------	-----	------

MAGNESIUM ACETATE TETRAHYDRATE; POTASSIUM ACETATE; SODIUM CHLORIDE

INJECTABLE; INJECTION

PLASMA-LYTE 56 IN PLASTIC CONTAINER

@	BAXTER HLTHCARE	32MG/100ML; 128MG/100ML; 234MG/100ML	N019047	001	Jun 15, 1984	Mar	DISC
---	-----------------	--------------------------------------	---------	-----	--------------	-----	------

MAGNESIUM SULFATE

SOLUTION; INTRAMUSCULAR, INTRAVENOUS

MAGNESIUM SULFATE

AP	EXELA PHARMA SCS LLC	5GM/10ML (500MG/ML)	A206039	001	Dec 18, 2014	Apr	CDFR
AP	+ FRESenius KABI USA	5GM/10ML (500MG/ML)	N019316	001	Sep 08, 1986	Apr	CPOT
AP	+ HOSPIRA	5GM/10ML (500MG/ML)	A075151	001	Apr 25, 2000	Apr	CDFR
	HOSPIRA INC	10GM/20ML (500MG/ML)	A202411	001	May 14, 2015	Apr	NEWA

MAGNESIUM SULFATE

SOLUTION; INTRAMUSCULAR, INTRAVENOUS

MAGNESIUM SULFATE

+	FRESenius KABI USA	1GM/2ML (500MG/ML)	N019316	002	Sep 08, 1986	Apr	NEWA
---	--------------------	--------------------	---------	-----	--------------	-----	------

MAGNESIUM SULFATE; POLYETHYLENE GLYCOL 3350; POTASSIUM CHLORIDE; POTASSIUM SULFATE; SODIUM BICARBONATE; SODIUM CHLORIDE; SODIUM SULFATE

SOLUTION; ORAL

SUCLEAR

@	BRAINTREE LABS	1.6GM/BOT, 3.13GM/BOT, 17.5GM/BOT, N/A, N/A, N/A, N/A, N/A, N/A, N/A, 210GM, 0.74GM, 2.86GM, 5.6GM	N203595	001	Jan 18, 2013	Aug	DISC
---	----------------	--	---------	-----	--------------	-----	------

MANNITOL

INJECTABLE; INJECTION

MANNITOL 25%

@	IGI LABS INC	12.5GM/50ML	A089239	001	May 06, 1987	Mar	CAHN
@		12.5GM/50ML	A089240	001	May 06, 1987	Mar	CAHN

MECLIZINE HYDROCHLORIDE

TABLET; ORAL

MECLIZINE HYDROCHLORIDE

@	ANI PHARMS INC	12.5MG	A084975	001		Aug	CAHN
@		25MG	A084657	001		Aug	CAHN
@	VINTAGE PHARMS	12.5MG	A040179	001	Jan 30, 1997	Jun	DISC
@		25MG	A040179	002	Jan 30, 1997	Jun	DISC

MELOXICAM

>A> CAPSULE; ORAL

>A> VIVLODEX

>A>	IROKO PHARMS LLC	5MG	N207233	001	Oct 22, 2015	Oct	NEWA
>A>	+	10MG	N207233	002	Oct 22, 2015	Oct	NEWA

MEMANTINE HYDROCHLORIDE

CAPSULE, EXTENDED RELEASE; ORAL

NAMENDA XR

	FOREST LABS LLC	7MG	N022525	001	Jun 21, 2010	Mar	CAHN
		14MG	N022525	002	Jun 21, 2010	Mar	CAHN
		21MG	N022525	003	Jun 21, 2010	Mar	CAHN
+		28MG	N022525	004	Jun 21, 2010	Mar	CAHN

SOLUTION; ORAL

MEMANTINE HYDROCHLORIDE

AA	MACLEODS PHARMS LTD	2MG/ML	A202790	001	Oct 13, 2015	Sep	NEWA	
AA	SILARX PHARMS INC	2MG/ML	A204033	001	Oct 13, 2015	Sep	NEWA	
	NAMENDA							
AA	+	FOREST LABS LLC	2MG/ML	N021627	001	Apr 18, 2005	Sep	CFTG
	+		2MG/ML	N021627	001	Apr 18, 2005	Mar	CAHN

TABLET;ORAL									
MEMANTINE									
>D>	AB	SUN PHARMA GLOBAL	5MG	A090058	001	May 05, 2010	Oct	CTNA	
	AB		5MG	A090058	001	May 05, 2010	Mar	CMFD	
>D>	AB		10MG	A090058	002	May 05, 2010	Oct	CTNA	
	AB		10MG	A090058	002	May 05, 2010	Mar	CMFD	
MEMANTINE HYDROCHLORIDE									
	AB	ALEMBIC PHARMS LTD	5MG	A200891	001	Oct 13, 2015	Sep	NEWA	
	AB		10MG	A200891	002	Oct 13, 2015	Sep	NEWA	
	AB	AMNEAL PHARMS	5MG	A090041	001	Apr 10, 2015	Mar	NEWA	
	AB		10MG	A090041	002	Apr 10, 2015	Mar	NEWA	
	AB	AUROBINDO PHARMA LTD	5MG	A203175	001	Oct 13, 2015	Sep	NEWA	
	AB		10MG	A203175	002	Oct 13, 2015	Sep	NEWA	
	AB	DR REDDYS LABS LTD	5MG	A090048	001	Apr 14, 2010	Jun	CMFD	
	AB		10MG	A090048	002	Apr 14, 2010	Jun	CMFD	
	AB	JUBILANT GENERICS	5MG	A091585	001	Oct 13, 2015	Sep	NEWA	
	AB		10MG	A091585	002	Oct 13, 2015	Sep	NEWA	
	AB	LUPIN LTD	5MG	A090051	001	Apr 10, 2015	Mar	NEWA	
	AB		10MG	A090051	002	Apr 10, 2015	Mar	NEWA	
	AB	MACLEODS PHARMS LTD	5MG	A202840	001	Oct 13, 2015	Sep	NEWA	
	AB		10MG	A202840	002	Oct 13, 2015	Sep	NEWA	
	AB	MYLAN PHARMS INC	5MG	A079225	001	Jan 30, 2015	Jun	CMFD	
	@		5MG	A079225	001	Jan 30, 2015	Mar	DISC	
	AB		5MG	A079225	001	Jan 30, 2015	Jan	NEWA	
	AB		10MG	A079225	002	Jan 30, 2015	Jun	CMFD	
	@		10MG	A079225	002	Jan 30, 2015	Mar	DISC	
	AB		10MG	A079225	002	Jan 30, 2015	Jan	NEWA	
>A>	AB	SUN PHARMA GLOBAL	5MG	A090058	001	May 05, 2010	Oct	CTNA	
>A>	AB		10MG	A090058	002	May 05, 2010	Oct	CTNA	
	AB	TEVA PHARMS	5MG	A090052	001	Oct 25, 2011	May	CMFD	
	AB		10MG	A090052	002	Oct 25, 2011	May	CMFD	
	AB	TORRENT PHARMS LTD	5MG	A200155	001	Oct 13, 2015	Sep	NEWA	
	AB		10MG	A200155	002	Oct 13, 2015	Sep	NEWA	
	AB	UNICHEM LABS LTD	5MG	A200022	001	Oct 13, 2015	Sep	NEWA	
	AB		10MG	A200022	002	Oct 13, 2015	Sep	NEWA	
	AB	UPSHER SMITH	5MG	A090043	001	Jul 31, 2015	Jul	NEWA	
	AB		10MG	A090043	002	Jul 31, 2015	Jul	NEWA	
	AB	WOCKHARDT LTD	5MG	A090073	001	Sep 04, 2015	Aug	NEWA	
	AB		10MG	A090073	002	Sep 04, 2015	Aug	NEWA	
NAMENDA									
	AB	FOREST LABS LLC	5MG	N021487	001	Oct 16, 2003	Mar	CAHN	
	AB	+	10MG	N021487	002	Oct 16, 2003	Mar	CAHN	

MENOTROPINS (FSH;LH)

INJECTABLE;INTRAMUSCULAR, SUBCUTANEOUS

REPRONEX

@ FERRING 75 IU/VIAL;75 IU/VIAL

N021047 001 Aug 27, 1999 May DISC

MEPERIDINE HYDROCHLORIDE

INJECTABLE;INJECTION

MEPERIDINE HYDROCHLORIDE

AP		EUROHLTH INTL SARL	25MG/ML	A080445	001		Feb	CAHN	
AP			50MG/ML	A080445	002		Feb	CAHN	
AP			75MG/ML	A080445	003		Feb	CAHN	
AP			100MG/ML	A080445	004		Feb	CAHN	
	@	IGI LABS INC	25MG/ML	A089781	001	Mar 31, 1989	May	CAHN	
	@		50MG/ML	A089782	001	Mar 31, 1989	Mar	CAHN	
	@		50MG/ML	A089783	001	Mar 31, 1989	Mar	CAHN	
	@		50MG/ML	A089784	001	Mar 31, 1989	Mar	CAHN	
	@		75MG/ML	A089785	001	Mar 31, 1989	Mar	CAHN	
	@		100MG/ML	A089786	001	Mar 31, 1989	Mar	CAHN	
	@		100MG/ML	A089787	001	Mar 31, 1989	Mar	CAHN	
	@		100MG/ML	A089788	001	Mar 31, 1989	Mar	CAHN	

MEPERIDINE HYDROCHLORIDE; PROMETHAZINE HYDROCHLORIDE

INJECTABLE;INJECTION

MEPERGAN

@ EUROHLTH INTL SARL 25MG/ML;25MG/ML

N011730 001 Jun CAHN

MEROPENEM

POWDER;IV (INFUSION)

MEROPENEM AND SODIUM CHLORIDE IN DUPLEX CONTAINER

B BRAUN MEDICAL INC 500MG/VIAL
1GM/VIALN202106 001 Apr 30, 2015 Apr NEWA
N202106 002 Apr 30, 2015 Apr NEWAMESALAMINE

CAPSULE, EXTENDED RELEASE;ORAL

APRISO

+ VALEANT PHARMS INTL 375MG
ENEMA;RECTAL
MESALAMINE

N022301 001 Oct 31, 2008 Jul CAHN

AB G AND W LABS INC 4GM/60ML
SUPPOSITORY;RECTAL
CANASA

A076841 001 Sep 30, 2004 Aug CAHN

@ FOREST LABS LLC 500MG
+ 1GMN021252 001 Jan 05, 2001 Aug CAHN
N021252 002 Nov 05, 2004 Aug CAHN

TABLET, DELAYED RELEASE;ORAL

>D> ASACOL

>D> + WARNER CHILCOTT LLC 400MG

N019651 001 Jan 31, 1992 Oct DISC

>A> @ 400MG

N019651 001 Jan 31, 1992 Oct DISC

MESTRANOL; NORETHINDRONE

TABLET;ORAL-20

NORINYL

@ ACTAVIS LABS UT INC 0.1MG;2MG

N013625 004 Mar CAHN

TABLET;ORAL-21

NORINYL 1+50 21-DAY

@ ACTAVIS LABS UT INC 0.05MG;1MG

N013625 002 Mar CAHN

TABLET;ORAL-28

NORINYL 1+50 28-DAY

+ ACTAVIS LABS UT INC 0.05MG;1MG

N016659 001 Mar CAHN

METAPROTERENOL SULFATE

SOLUTION;INHALATION

METAPROTERENOL SULFATE

@ MYLAN SPECLT 0.4%
@ 0.6%A071786 001 Aug 05, 1988 Apr DISC
A070804 001 Aug 17, 1987 Apr DISC@ WOCKHARDT 0.4%
@ 0.6%A075586 001 May 30, 2002 Apr DISC
A075586 002 May 30, 2002 Apr DISC

SYRUP;ORAL

METAPROTERENOL SULFATE

@ G AND W LABS INC 10MG/5ML
@ 10MG/5MLA072761 001 Feb 27, 1992 Apr CAHN
A073034 001 Aug 30, 1991 Apr CAHNMETAXALONE

TABLET;ORAL

METAXALONE

COREPHARMA 400MG
640MGA040486 001 Feb 27, 2015 Feb NEWA
N022503 001 Jun 01, 2015 Jun NEWAMETFORMIN HYDROCHLORIDE

SOLUTION;ORAL

RIOMET

+ SUN PHARM INDS LTD 500MG/5ML

N021591 001 Sep 11, 2003 Apr CAHN

METFORMIN HYDROCHLORIDE; PIOGLITAZONE HYDROCHLORIDE

TABLET;ORAL

PIOGLITAZONE HYDROCHLORIDE AND METFORMIN HYDROCHLORIDE

>A> AB MACLEODS PHARMS LTD 500MG;EQ 15MG BASE
>A> AB 850MG;EQ 15MG BASEA204802 001 Nov 05, 2015 Oct NEWA
A204802 002 Nov 05, 2015 Oct NEWAMETFORMIN HYDROCHLORIDE; REPAGLINIDE

TABLET;ORAL

PRANDIMET

AB NOVO NORDISK INC 500MG;1MG
AB + 500MG;2MGN022386 001 Jun 23, 2008 Jun CFTG
N022386 002 Jun 23, 2008 Jun CFTG

REPAGLINIDE AND METFORMIN HYDROCHLORIDE

AB LUPIN LTD 500MG;1MG
AB 500MG;2MGA200624 001 Jul 15, 2015 Jun NEWA
A200624 002 Jul 15, 2015 Jun NEWA

METFORMIN HYDROCHLORIDE; ROSIGLITAZONE MALEATE

TABLET; ORAL

AVANDAMET

@ SB PHARMCO	500MG;EQ 2MG BASE	N021410	002	Oct 10, 2002	May DISC
@	500MG;EQ 4MG BASE	N021410	003	Oct 10, 2002	May DISC
@	1GM;EQ 2MG BASE	N021410	004	Aug 25, 2003	May DISC
@	1GM;EQ 4MG BASE	N021410	005	Aug 25, 2003	May DISC

ROSIGLITAZONE MALEATE AND METFORMIN HYDROCHLORIDE

TEVA

	500MG;EQ 2MG BASE	A077337	001	May 07, 2014	May CTEC
	500MG;EQ 4MG BASE	A077337	002	May 07, 2014	May CTEC
+	1GM;EQ 4MG BASE	A077337	004	May 07, 2014	May CRLD
	1GM;EQ 2MG BASE	A077337	003	May 07, 2014	May CTEC

METHADONE HYDROCHLORIDE

TABLET; ORAL

METHADONE HYDROCHLORIDE

AA	AUROLIFE PHARMA LLC	5MG	A203502	001	Aug 31, 2015	Aug NEWA
AA		10MG	A203502	002	Aug 31, 2015	Aug NEWA
AA	COREPHARMA	5MG	A090065	001	Aug 18, 2015	Aug NEWA
AA		10MG	A090065	002	Aug 18, 2015	Aug NEWA

METHIMAZOLE

TABLET; ORAL

METHIMAZOLE

AB	HERITAGE PHARMA	5MG	A040734	001	Dec 14, 2007	Mar CAHN
AB		10MG	A040734	002	Dec 14, 2007	Mar CAHN

METHOCARBAMOL

SOLUTION; IM-IV

ROBAXIN

AP	+	EUROHLTH INTL SARL	1GM/10ML (100MG/ML)	N011790	001	Jun CAHN
----	---	--------------------	---------------------	---------	-----	----------

METHOTREXATE SODIUM

INJECTABLE; INJECTION

METHOTREXATE PRESERVATIVE FREE

AP		FRESENIUS KABI USA	EQ 25MG BASE/ML	A040265	001	Feb 26, 1999	May CMFD
----	--	--------------------	-----------------	---------	-----	--------------	----------

METHOXSALLEN

CAPSULE; ORAL

METHOXSALLEN

AB	ACTAVIS INC	10MG	A202603	001	Jun 09, 2015	May NEWA
----	-------------	------	---------	-----	--------------	----------

METHYLPHENIDATE HYDROCHLORIDE

CAPSULE, EXTENDED RELEASE; ORAL

APTENSIO XR

RHODES PHARMS

	10MG	N205831	001	Apr 17, 2015	Apr NEWA
	15MG	N205831	002	Apr 17, 2015	Apr NEWA
	20MG	N205831	003	Apr 17, 2015	Apr NEWA
	30MG	N205831	004	Apr 17, 2015	Apr NEWA
	40MG	N205831	005	Apr 17, 2015	Apr NEWA
	50MG	N205831	006	Apr 17, 2015	Apr NEWA
+	60MG	N205831	007	Apr 17, 2015	Apr NEWA

METHYLPHENIDATE HYDROCHLORIDE

AB2	MALLINCKRODT INC	10MG	A203583	001	Sep 29, 2015	Sep NEWA
AB2		20MG	A203583	002	Sep 29, 2015	Sep NEWA
AB2		30MG	A203583	003	Sep 29, 2015	Sep NEWA
AB2		40MG	A203583	004	Sep 29, 2015	Sep NEWA
AB2		50MG	A203583	005	Sep 29, 2015	Sep NEWA
AB2		60MG	A203583	006	Sep 29, 2015	Sep NEWA

RITALIN LA

AB1	NOVARTIS	40MG	N021284	003	Jun 05, 2002	Feb CRLD
+		60MG	N021284	005	Oct 27, 2014	Feb CRLD

SOLUTION; ORAL

METHYLPHENIDATE HYDROCHLORIDE

AA	NOVEL LABS INC	5MG/5ML	A204602	001	Aug 14, 2015	Aug NEWA
AA		10MG/5ML	A204602	002	Aug 14, 2015	Aug NEWA

TABLET; ORAL

METHYLPHENIDATE HYDROCHLORIDE

AB	ASCENT PHARMS INC	5MG	A207416	001	Sep 22, 2015	Sep NEWA
AB		10MG	A207416	002	Sep 22, 2015	Sep NEWA
AB		20MG	A207416	003	Sep 22, 2015	Sep NEWA

TABLET, CHEWABLE;ORAL
METHYLIN

AB	MALLINCKRODT	2.5MG	N021475	001	Apr 15, 2003	Feb CFTG
AB		5MG	N021475	002	Apr 15, 2003	Feb CFTG
AB	+	10MG	N021475	003	Apr 15, 2003	Feb CFTG
	METHYLPHENIDATE HYDROCHLORIDE					
AB	NOVEL LABS INC	2.5MG	A204115	001	Feb 25, 2015	Feb NEWA
AB		5MG	A204115	002	Feb 25, 2015	Feb NEWA
AB		10MG	A204115	003	Feb 25, 2015	Feb NEWA

TABLET, EXTENDED RELEASE;ORAL
METHYLIN ER

AB	MALLINCKRODT INC	10MG	A075629	001	May 09, 2000	May CTEC
	METHYLPHENIDATE HYDROCHLORIDE					
AB	ABHAI	10MG	A207488	001	Jun 09, 2015	May NEWA
AB		20MG	A207488	002	Jun 09, 2015	May NEWA

METHYLTESTOSTERONE

CAPSULE;ORAL

	METHYLTESTOSTERONE					
AB	IMPAX LABS INC	10MG	A204851	001	Sep 21, 2015	Sep NEWA
	TESTRED					
AB	+	VALEANT PHARM INTL	10MG	A083976	001	Sep CTEC

METOPROLOL TARTRATE

INJECTABLE;INJECTION
METOPROLOL TARTRATE

AP	CLARIS PHARMASERVICE	1MG/ML	A078950	001	Apr 29, 2013	Apr CAHN
	TABLET;ORAL					
	METOPROLOL TARTRATE					
	MYLAN	37.5MG	A076704	004	Mar 18, 2015	Mar NEWA
		75MG	A076704	005	Mar 18, 2015	Mar NEWA

METRONIDAZOLE

CREAM;TOPICAL

	NORITATE						
	+	VALEANT PHARMS NORTH	1%	N020743	001	Sep 26, 1997	Feb CAHN
	GEL;VAGINAL						
	METRONIDAZOLE						
	+	ACTAVIS LABS UT INC	1.3%	N205223	001	Mar 24, 2014	Feb CAHN
	NUVESSA						
	+	ACTAVIS LABS UT INC	1.3%	N205223	001	Mar 24, 2014	Feb CTNA
	INJECTABLE;INJECTION						
	METRONIDAZOLE						
	@	EUROHLTH INTL SARL	500MG/100ML	N018907	001	Mar 30, 1984	Aug CAHN
	METRONIDAZOLE IN PLASTIC CONTAINER						
AP		CLARIS PHARMASERVICE	500MG/100ML	A078084	001	Mar 31, 2008	Apr CAHN
	TABLET;ORAL						
	METRONIDAZOLE						
AB		APPCO PHARMA LLC	250MG	A205245	001	Sep 23, 2015	Sep NEWA
AB			500MG	A205245	002	Sep 23, 2015	Sep NEWA
AB		AUROBINDO PHARMA LTD	250MG	A203974	001	May 29, 2015	May NEWA
AB			500MG	A203974	002	May 29, 2015	May NEWA

MEXILETINE HYDROCHLORIDE

CAPSULE;ORAL

MEXILETINE HYDROCHLORIDE							
@	IDT AUSTRALIA LTD	150MG	A074450	001	May 16, 1996	Oct	CAHN
@		200MG	A074450	002	May 16, 1996	Oct	CAHN
@		250MG	A074450	003	May 16, 1996	Oct	CAHN
@	SANDOZ	150MG	A074450	001	May 16, 1996	Oct	CAHN
@		200MG	A074450	002	May 16, 1996	Oct	CAHN
@		250MG	A074450	003	May 16, 1996	Oct	CAHN

MICONAZOLE

TABLET;BUCCAL

ORAVIG							
+	DARA BIOSCIENCES	50MG	N022404	001	Apr 16, 2010	Apr	CAHN

MIDAZOLAM HYDROCHLORIDE

INJECTABLE;INJECTION

MIDAZOLAM HYDROCHLORIDE

	@ CLARIS PHARMASERVICE	EQ 1MG BASE/ML	A075637	001	Oct 31, 2000	Apr CAHN
	@	EQ 5MG BASE/ML	A075637	002	Oct 31, 2000	Apr CAHN
AP	EUROHLTH INTL SARL	EQ 1MG BASE/ML	A075243	001	Jun 20, 2000	Jun CAHN
AP		EQ 5MG BASE/ML	A075243	002	Jun 20, 2000	Jun CAHN
	@ IGI LABS INC	EQ 5MG BASE/ML	A075263	001	Jun 26, 2000	Apr CAHN
	@ WOCKHARDT	EQ 1MG BASE/ML	A078141	001	May 30, 2008	Mar DISC
	@	EQ 1MG BASE/ML	A078511	001	Nov 10, 2008	Mar DISC
	@	EQ 5MG BASE/ML	A078141	002	May 30, 2008	Mar DISC
	@	EQ 5MG BASE/ML	A078511	002	Nov 10, 2008	Mar DISC

SYRUP;ORAL

MIDAZOLAM HYDROCHLORIDE

AA	SUN PHARM INDS LTD	EQ 2MG BASE/ML	A076058	001	Mar 15, 2002	Apr CAHN
----	--------------------	----------------	---------	-----	--------------	----------

MIGLITOL

TABLET;ORAL

GLYSET

AB	PHARMACIA AND UPJOHN	25MG	N020682	001	Dec 18, 1996	Mar CTEC
AA		25MG	N020682	001	Dec 18, 1996	Feb CFTG
AB		50MG	N020682	002	Dec 18, 1996	Mar CTEC
AA		50MG	N020682	002	Dec 18, 1996	Feb CFTG
AB	+	100MG	N020682	003	Dec 18, 1996	Mar CTEC
AA	+	100MG	N020682	003	Dec 18, 1996	Feb CFTG

MIGLITOL

AB	ORIENT PHARMA CO LTD	25MG	A203965	001	Feb 24, 2015	Mar CTEC
AA		25MG	A203965	001	Feb 24, 2015	Feb NEWA
AB		50MG	A203965	002	Feb 24, 2015	Mar CTEC
AA		50MG	A203965	002	Feb 24, 2015	Feb NEWA
AB		100MG	A203965	003	Feb 24, 2015	Mar CTEC
AA		100MG	A203965	003	Feb 24, 2015	Feb NEWA

MILRINONE LACTATE

INJECTABLE;INJECTION

MILRINONE LACTATE

AP	BEDFORD	EQ 1MG BASE/ML	A075660	001	May 28, 2002	Jan CRLD
AP	EUROHLTH INTL SARL	EQ 1MG BASE/ML	A075530	001	May 28, 2002	Jun CAHN
	@	EQ 1MG BASE/ML	A075852	001	May 28, 2002	Sep CAHN
AP	+ HIKMA FARMACEUTICA	EQ 1MG BASE/ML	A077966	001	Dec 03, 2010	Jan CRLD

MINOCYCLINE HYDROCHLORIDE

CAPSULE;ORAL

MINOCYCLINE HYDROCHLORIDE

AB	SUN PHARM INDS LTD	EQ 50MG BASE	A065062	001	Nov 30, 2000	Apr CAHN
AB		EQ 75MG BASE	A065062	002	Nov 30, 2000	Apr CAHN
AB		EQ 100MG BASE	A065062	003	Nov 30, 2000	Apr CAHN
AB	TORRENT PHARMA INC	EQ 50MG BASE	A065062	001	Nov 30, 2000	Jun CAHN
AB		EQ 75MG BASE	A065062	002	Nov 30, 2000	Jun CAHN
AB		EQ 100MG BASE	A065062	003	Nov 30, 2000	Jun CAHN

CAPSULE, EXTENDED RELEASE;ORAL

XIMINO

@ SUN PHARM INDS LTD

	EQ 45MG BASE	N201922	001	Jul 11, 2012	Apr CAHN
	EQ 67.5MG BASE	N201922	002	Jul 11, 2012	Apr CAHN
	EQ 90MG BASE	N201922	003	Jul 11, 2012	Apr CAHN
	EQ 112.5MG BASE	N201922	004	Jul 11, 2012	Apr CAHN
	EQ 135MG BASE	N201922	005	Jul 11, 2012	Apr CAHN

TABLET;ORAL

MINOCYCLINE HYDROCHLORIDE

AB	SUN PHARM INDS LTD	EQ 50MG BASE	A065156	001	Jan 06, 2004	Apr CAHN
AB		EQ 75MG BASE	A065156	002	Jan 06, 2004	Apr CAHN
AB		EQ 100MG BASE	A065156	003	Jan 06, 2004	Apr CAHN
AB	TORRENT PHARMA INC	EQ 50MG BASE	A065156	001	Jan 06, 2004	Jun CAHN
AB		EQ 75MG BASE	A065156	002	Jan 06, 2004	Jun CAHN
AB		EQ 100MG BASE	A065156	003	Jan 06, 2004	Jun CAHN

TABLET, EXTENDED RELEASE;ORAL

MINOCYCLINE HYDROCHLORIDE

AB	+ SANDOZ	EQ 135MG BASE	A090422	003	Aug 13, 2009	Sep CRLD
AB	SUN PHARM INDS LTD	EQ 45MG BASE	A091118	001	Sep 25, 2014	Apr CAHN
AB		EQ 80MG BASE	A091118	004	Sep 25, 2014	Apr CAHN
AB		EQ 90MG BASE	A091118	005	Sep 25, 2014	Apr CAHN

TABLET, EXTENDED RELEASE;ORAL
MINOCYCLINE HYDROCHLORIDE

AB		EQ 105MG BASE	A091118	006	Sep 25, 2014	Apr CAHN
AB		EQ 135MG BASE	A091118	008	Sep 25, 2014	Apr CAHN
	SOLODYN					
	MEDICIS	EQ 55MG BASE	N050808	008	Aug 27, 2010	Sep CRLD
AB		EQ 80MG BASE	N050808	007	Aug 27, 2010	Sep CRLD
AB	+	EQ 115MG BASE	N050808	005	Jul 23, 2009	Sep CRLD

MIVACURIUM CHLORIDE

SOLUTION;INTRAVENOUS
MIVACRON

	ABBVIE	EQ 10MG BASE/5ML (EQ 2MG BASE/ML)	N020098	004	Jan 22, 1992	Jan NEWA
+		EQ 20MG BASE/10ML (EQ 2MG BASE/ML)	N020098	005	Jan 22, 1992	Jan NEWA

MOLINDONE HYDROCHLORIDE

TABLET;ORAL
MOLINDONE HYDROCHLORIDE

	COREPHARMA	5MG	A090453	001	Mar 20, 2015	Mar NEWA
		10MG	A090453	002	Mar 20, 2015	Mar NEWA
+		25MG	A090453	003	Mar 20, 2015	Mar NEWA

MONTELUKAST SODIUM

GRANULE;ORAL
MONTELUKAST SODIUM

AB	AJANTA PHARMA LTD	EQ 4MG BASE/PACKET	A203438	001	Jul 31, 2015	Jul NEWA
	TABLET;ORAL					
	MONTELUKAST SODIUM					
AB	AJANTA PHARMA LTD	EQ 10MG BASE	A203432	001	Jul 31, 2015	Jul NEWA
AB	AMNEAL PHARMS	EQ 10MG BASE	A204604	001	Sep 04, 2015	Aug NEWA
AB	KREMERS URBAN PHARMS	EQ 10MG BASE	A201522	001	Aug 03, 2012	Mar CAHN
AB	UNICHEM LABS LTD	EQ 10MG BASE	A204290	001	Oct 08, 2015	Sep NEWA

TABLET, CHEWABLE;ORAL
MONTELUKAST SODIUM

	AB	AJANTA PHARMA LTD	EQ 4MG BASE	A203328	001	Jul 31, 2015	Jul NEWA
	AB		EQ 5MG BASE	A203328	002	Jul 31, 2015	Jul NEWA
>A>	AB	ANBISON LAB CO LTD	EQ 4MG BASE	A205695	001	Nov 05, 2015	Oct NEWA
>A>	AB		EQ 5MG BASE	A205695	002	Nov 05, 2015	Oct NEWA
	AB	HETERO LABS LTD V	EQ 4MG BASE	A204093	001	May 22, 2015	May NEWA
	AB		EQ 5MG BASE	A204093	002	May 22, 2015	May NEWA
	AB	JUBILANT GENERICS	EQ 4MG BASE	A203795	001	Feb 27, 2015	Feb NEWA
	AB		EQ 5MG BASE	A203795	002	Feb 27, 2015	Feb NEWA
	AB	KREMERS URBAN PHARMS	EQ 4MG BASE	A200405	001	Aug 03, 2012	Mar CAHN
	AB		EQ 5MG BASE	A200405	002	Aug 03, 2012	Mar CAHN
	AB	MACLEODS PHARMS LTD	EQ 4MG BASE	A203582	001	Mar 12, 2015	Feb NEWA
	AB		EQ 5MG BASE	A203582	002	Mar 12, 2015	Feb NEWA

MORPHINE SULFATE

CAPSULE, EXTENDED RELEASE;ORAL
AVINZA

	@ KING PHARMS LLC	30MG	N021260	001	Mar 20, 2002	Sep DISC
	@	45MG	N021260	005	Dec 18, 2008	Sep DISC
	@	60MG	N021260	002	Mar 20, 2002	Sep DISC
	@	75MG	N021260	006	Dec 18, 2008	Sep DISC
	@	90MG	N021260	003	Mar 20, 2002	Sep DISC
	@	120MG	N021260	004	Mar 20, 2002	Sep DISC
	KADIAN					
AB1	+	ACTAVIS LABS UT INC	N020616	008	Apr 20, 2007	Mar CAHN
AB1		20MG	N020616	001	Jul 03, 1996	Mar CAHN
AB1		30MG	N020616	004	Mar 09, 2001	Mar CAHN
AB1		40MG	N020616	009	Jul 09, 2012	May CTEC
		40MG	N020616	009	Jul 09, 2012	Mar CAHN
AB1		50MG	N020616	002	Jul 03, 1996	Mar CAHN
AB1		60MG	N020616	005	Mar 09, 2001	Mar CAHN
AB1		70MG	N020616	010	Jul 09, 2012	May CTEC
		70MG	N020616	010	Jul 09, 2012	Mar CAHN
AB1		80MG	N020616	006	Oct 27, 2006	Mar CAHN
AB1	+	100MG	N020616	003	Jul 03, 1996	Mar CAHN
		130MG	N020616	011	Jul 09, 2012	Mar CAHN
		150MG	N020616	012	Jul 09, 2012	Mar CAHN
AB1	+	200MG	N020616	007	Feb 27, 2007	Mar CAHN

CAPSULE, EXTENDED RELEASE;ORAL									
MORPHINE SULFATE									
	ACTAVIS ELIZABETH	30MG	A079040	001	Jan 16, 2013	Sep	CTEC		
		45MG	A079040	002	Jan 16, 2013	Sep	CTEC		
		60MG	A079040	003	Jan 16, 2013	Sep	CTEC		
		75MG	A079040	004	Jan 16, 2013	Sep	CTEC		
		90MG	A079040	005	Jan 16, 2013	Sep	CTEC		
	+	120MG	A079040	006	Jan 16, 2013	Sep	CTEC		
AB1	TEVA PHARMS USA	40MG	A202718	007	Jun 03, 2015	May	NEWA		
AB1		70MG	A202718	008	Jun 03, 2015	May	NEWA		
INJECTABLE;INJECTION									
DURAMORPH PF									
AP	+	EUROHLTH INTL SARL	0.5MG/ML	N018565	001	Sep 18, 1984	Jun	CAHN	
AP	+		1MG/ML	N018565	002	Sep 18, 1984	Jun	CAHN	
INFUMORPH									
	+	EUROHLTH INTL SARL	10MG/ML	N018565	003	Jul 19, 1991	Jun	CAHN	
	+		25MG/ML	N018565	004	Jul 19, 1991	Jun	CAHN	
MORPHINE SULFATE									
AP		EUROHLTH INTL SARL	4MG/ML	A205758	001	May 21, 2015	May	NEWA	
AP			8MG/ML	A205758	002	May 21, 2015	May	NEWA	
AP			10MG/ML	A205758	003	May 21, 2015	May	NEWA	
AP	+	HOSPIRA INC	4MG/ML	N202515	002	Nov 14, 2011	May	CFTG	
AP	+		8MG/ML	N202515	003	Nov 14, 2011	May	CFTG	
AP	+		10MG/ML	N202515	004	Nov 14, 2011	May	CFTG	
SOLUTION;ORAL									
MORPHINE SULFATE									
AA		TRIS PHARMA INC	10MG/5ML	A203518	001	May 12, 2015	May	NEWA	
AA			100MG/5ML	A203518	002	May 12, 2015	May	NEWA	
>A>	AA	VINTAGE PHARMS LLC	20MG/5ML	A202310	001	Oct 30, 2015	Oct	NEWA	
TABLET, EXTENDED RELEASE;ORAL									
MORPHABOND									
>A>		IDT	15MG	N206544	001	Oct 02, 2015	Oct	NEWA	
>A>			30MG	N206544	002	Oct 02, 2015	Oct	NEWA	
>A>			60MG	N206544	003	Oct 02, 2015	Oct	NEWA	
>A>	+		100MG	N206544	004	Oct 02, 2015	Oct	NEWA	
MORPHINE SULFATE									
AB		ACTAVIS ELIZABETH	15MG	A203849	001	Apr 06, 2015	Mar	NEWA	
AB			30MG	A203849	002	Apr 06, 2015	Mar	NEWA	
AB			60MG	A203849	003	Apr 06, 2015	Mar	NEWA	
AB			100MG	A203849	004	Apr 06, 2015	Mar	NEWA	
AB			200MG	A203849	005	Apr 06, 2015	Mar	NEWA	
AB		SUN PHARM INDS LTD	15MG	A078761	001	May 11, 2012	Apr	CAHN	
AB			30MG	A078761	002	May 11, 2012	Apr	CAHN	
AB			60MG	A078761	003	May 11, 2012	Apr	CAHN	
AB			100MG	A078761	004	May 11, 2012	Apr	CAHN	
AB			200MG	A078761	005	May 11, 2012	Apr	CAHN	
<u>MOXIFLOXACIN HYDROCHLORIDE</u>									
SOLUTION;IV (INFUSION)									
MOXIFLOXACIN HYDROCHLORIDE									
	+	FRESENIUS KABI USA	EQ 400MG BASE/250ML (EQ 1.6MG BASE/ML)	N205572	001	Apr 03, 2015	Apr	NEWA	
SOLUTION/DROPS;OPHTHALMIC									
MOXEZA									
AT2	+	ALCON PHARMS LTD	EQ 0.5% BASE	N022428	001	Nov 19, 2010	May	CFTG	
MOXIFLOXACIN HYDROCHLORIDE									
AT1		LUPIN LTD	EQ 0.5% BASE	A202867	001	Sep 04, 2014	May	CTEC	
AT2			EQ 0.5% BASE	A204079	001	May 28, 2015	May	NEWA	
AT1		WATSON LABS INC	EQ 0.5% BASE	A202525	001	Mar 06, 2015	May	CTEC	
AT			EQ 0.5% BASE	A202525	001	Mar 06, 2015	Feb	NEWA	
VIGAMOX									
AT1	+	ALCON PHARMS LTD	EQ 0.5% BASE	N021598	001	Apr 15, 2003	May	CTEC	
TABLET;ORAL									
MOXIFLOXACIN HYDROCHLORIDE									
AB		MYLAN PHARMS INC	EQ 400MG BASE	A204635	001	Aug 31, 2015	Aug	NEWA	
<u>MYCOPHENOLATE MOFETIL</u>									
CAPSULE;ORAL									
MYCOPHENOLATE MOFETIL									
>D>	AB	DR REDDYS LABS LTD	250MG	A091315	001	Oct 27, 2011	Oct	DISC	
>A>	@		250MG	A091315	001	Oct 27, 2011	Oct	DISC	

NADOLOLTABLET; ORAL
CORCARD

>D>	AB	KING PHARMS	20MG	N018063	005	Oct 28, 1986	Oct	CAHN
>D>	AB		40MG	N018063	001		Oct	CAHN
>D>	AB	+	80MG	N018063	002		Oct	CAHN
>D>		@	120MG	N018063	003		Oct	CAHN
>D>		@	160MG	N018063	004		Oct	CAHN
>A>	AB	US WORLD MEDS LLC	20MG	N018063	005	Oct 28, 1986	Oct	CAHN
>A>	AB		40MG	N018063	001		Oct	CAHN
>A>	AB	+	80MG	N018063	002		Oct	CAHN
>A>		@	120MG	N018063	003		Oct	CAHN
>A>		@	160MG	N018063	004		Oct	CAHN
		NADOLOL						
	AB	ORION CORP ORION	40MG	A201893	001	Sep 16, 2015	Aug	NEWA
	AB		80MG	A201893	002	Sep 16, 2015	Aug	NEWA

NALBUPHINE HYDROCHLORIDEINJECTABLE; INJECTION
NALBUPHINE HYDROCHLORIDE

@	IGI LABS INC	10MG/ML	A072070	001	Apr 10, 1989	Mar	CAHN
@		10MG/ML	A072071	001	Apr 10, 1989	Mar	CAHN
@		10MG/ML	A072072	001	Apr 10, 1989	Mar	CAHN
@		20MG/ML	A072073	001	Apr 10, 1989	Mar	CAHN
@		20MG/ML	A072074	001	Apr 10, 1989	Mar	CAHN
@		20MG/ML	A072075	001	Apr 10, 1989	Mar	CAHN

NALMEFENE HYDROCHLORIDEINJECTABLE; INJECTION
REVEX

@	EUROHLTH INTL SARL	EQ 0.1MG BASE/ML	N020459	001	Apr 17, 1995	Jun	CAHN
@		EQ 1MG BASE/ML	N020459	002	Apr 17, 1995	Jun	CAHN

NALOXONE HYDROCHLORIDEINJECTABLE; INJECTION
NALOXONE

@	EUROHLTH INTL SARL	0.4MG/ML	A070299	001	Sep 24, 1986	Mar	CAHN
	NALOXONE HYDROCHLORIDE						
@	IGI LABS INC	0.02MG/ML	A072082	001	Apr 11, 1989	Mar	CAHN
@		0.02MG/ML	A072083	001	Apr 11, 1989	Mar	CAHN
@		0.02MG/ML	A072084	001	Apr 11, 1989	Mar	CAHN
@		0.02MG/ML	A072085	001	Apr 11, 1989	Mar	CAHN
@		0.4MG/ML	A072086	001	Apr 11, 1989	Mar	CAHN
@		0.4MG/ML	A072087	001	Apr 11, 1989	Mar	CAHN
@		0.4MG/ML	A072088	001	Apr 11, 1989	Mar	CAHN
@		0.4MG/ML	A072089	001	Apr 11, 1989	Mar	CAHN
@		0.4MG/ML	A072090	001	Apr 11, 1989	Mar	CAHN
@		1MG/ML	A072091	001	Apr 11, 1989	Mar	CAHN
@		1MG/ML	A072092	001	Apr 11, 1989	Mar	CAHN
@		1MG/ML	A072093	001	Apr 11, 1989	Mar	CAHN
	NARCAN						
@	ADAPT	0.02MG/ML	N016636	002		Aug	CAHN
@		0.4MG/ML	N016636	001		Aug	CAHN
@		1MG/ML	N016636	003	Jun 14, 1982	Aug	CAHN

NALOXONE HYDROCHLORIDE; PENTAZOCINE HYDROCHLORIDE

TABLET; ORAL

NALOXONE HYDROCHLORIDE AND PENTAZOCINE HYDROCHLORIDE

AB	SUN PHARM INDS LTD	EQ 0.5MG BASE; EQ 50MG BASE	A075523	001	Mar 17, 2000	Apr	CAHN
----	--------------------	-----------------------------	---------	-----	--------------	-----	------

NAPROXENSUSPENSION; ORAL
NAPROSYN

AB	+	PEDIAPHARM INC	25MG/ML	N018965	001	Mar 23, 1987	Apr	CAHN
----	---	----------------	---------	---------	-----	--------------	-----	------

NAPROXEN SODIUMTABLET, EXTENDED RELEASE; ORAL
NAPRELAN

>D>	AB	ALMATICA PHARMA INC	EQ 375MG BASE	N020353	001	Jan 05, 1996	Oct	CAHN
>D>	AB		EQ 500MG BASE	N020353	002	Jan 05, 1996	Oct	CAHN
>D>		+	EQ 750MG BASE	N020353	003	Jan 05, 1996	Oct	CAHN

TABLET, EXTENDED RELEASE;ORAL
NAPRELAN

>A> AB	ALVOGEN MALTA	EQ 375MG BASE	N020353	001	Jan 05, 1996	Oct CAHN
>A> AB		EQ 500MG BASE	N020353	002	Jan 05, 1996	Oct CAHN
>A>	+	EQ 750MG BASE	N020353	003	Jan 05, 1996	Oct CAHN

NAPROXEN SODIUM; SUMATRIPTAN SUCCINATE

TABLET;ORAL
TREXIMET

PERNIX IRELAND LTD	60MG;EQ 10MG BASE	N021926	002	May 14, 2015	Jun NEWA
--------------------	-------------------	---------	-----	--------------	----------

NEBIVOLOL HYDROCHLORIDE

TABLET;ORAL

NEBIVOLOL HYDROCHLORIDE

@	ALKEM LABS LTD	EQ 2.5MG BASE	A203741	001	Jun 24, 2015	Jun DISC
		EQ 2.5MG BASE	A203741	001	Jun 24, 2015	Jun NEWA
@		EQ 5MG BASE	A203741	002	Jun 24, 2015	Jun DISC
		EQ 5MG BASE	A203741	002	Jun 24, 2015	Jun NEWA
@		EQ 10MG BASE	A203741	003	Jun 24, 2015	Jun DISC
		EQ 10MG BASE	A203741	003	Jun 24, 2015	Jun NEWA
@		EQ 20MG BASE	A203741	004	Jun 24, 2015	Jun DISC
		EQ 20MG BASE	A203741	004	Jun 24, 2015	Jun NEWA
@	AMERIGEN PHARMS LTD	EQ 2.5MG BASE	A203659	001	Apr 16, 2015	Apr DISC
AB		EQ 2.5MG BASE	A203659	001	Apr 16, 2015	Mar NEWA
@		EQ 5MG BASE	A203659	002	Apr 16, 2015	Apr DISC
AB		EQ 5MG BASE	A203659	002	Apr 16, 2015	Mar NEWA
@		EQ 10MG BASE	A203659	003	Apr 16, 2015	Apr DISC
AB		EQ 10MG BASE	A203659	003	Apr 16, 2015	Mar NEWA
@		EQ 20MG BASE	A203659	004	Apr 16, 2015	Apr DISC
AB		EQ 20MG BASE	A203659	004	Apr 16, 2015	Mar NEWA
@	INDCHEMIE HEALTH	EQ 2.5MG BASE	A203828	001	Jul 29, 2015	Jul DISC
		EQ 2.5MG BASE	A203828	001	Jul 29, 2015	Jul NEWA
@		EQ 5MG BASE	A203828	002	Jul 29, 2015	Jul DISC
		EQ 5MG BASE	A203828	002	Jul 29, 2015	Jul NEWA
@		EQ 10MG BASE	A203828	003	Jul 29, 2015	Jul DISC
		EQ 10MG BASE	A203828	003	Jul 29, 2015	Jul NEWA
@		EQ 20MG BASE	A203828	004	Jul 29, 2015	Jul DISC
		EQ 20MG BASE	A203828	004	Jul 29, 2015	Jul NEWA

NEFAZODONE HYDROCHLORIDE

TABLET;ORAL

NEFAZODONE HYDROCHLORIDE

@	IDT AUSTRALIA LTD	50MG	A076072	001	Sep 16, 2003	Apr CAHN
@		100MG	A076072	002	Sep 16, 2003	Apr CAHN
@		150MG	A076072	003	Sep 16, 2003	Apr CAHN
@		200MG	A076072	004	Sep 16, 2003	Apr CAHN
@		250MG	A076072	005	Sep 16, 2003	Apr CAHN
AB	SUN PHARM INDS LTD	50MG	A076409	001	Sep 16, 2003	Apr CAHN
AB		100MG	A076409	002	Sep 16, 2003	Apr CAHN
AB		150MG	A076409	003	Sep 16, 2003	Apr CAHN
AB		200MG	A076409	004	Sep 16, 2003	Apr CAHN
AB		250MG	A076409	005	Sep 16, 2003	Apr CAHN

NELARABINE

INJECTABLE;IV (INFUSION)
ARRANON

+	NOVARTIS PHARMS CORP	250MG/50ML (5MG/ML)	N021877	001	Oct 28, 2005	Mar CAHN
---	----------------------	---------------------	---------	-----	--------------	----------

NEOSTIGMINE METHYLSULFATE

SOLUTION;INTRAVENOUS

NEOSTIGMINE METHYLSULFATE

FRESENIUS KABI USA	5MG/10ML (0.5MG/ML)	N203629	001	Jan 08, 2015	Jan NEWA
	10MG/10ML (1MG/ML)	N203629	002	Jan 08, 2015	Jan NEWA

NEVIRAPINE

TABLET, EXTENDED RELEASE;ORAL

NEVIRAPINE

>A> AB	ALVOGEN MALTA	100MG	A204621	002	Nov 09, 2015	Oct NEWA
>A> AB		100MG	A204621	002	Nov 09, 2015	Oct CAHN
>A> AB		400MG	A204621	001	Jul 10, 2015	Oct CAHN
>D> AB	ALVOGEN PINE BROOK	400MG	A204621	001	Jul 10, 2015	Oct CAHN
AB		400MG	A204621	001	Jul 10, 2015	Jun NEWA
>A> AB	CIPLA LTD	400MG	A206448	001	Oct 15, 2015	Oct NEWA

TABLET, EXTENDED RELEASE;ORAL									
NEVIRAPINE									
>A>	AB	MYLAN PHARMS INC	100MG	A206271	001	Nov 09, 2015	Oct	NEWA	
VIRAMUNE XR									
>D>		BOEHRINGER INGELHEIM	100MG	N201152	002	Nov 08, 2012	Oct	CFTG	
>A>	AB		100MG	N201152	002	Nov 08, 2012	Oct	CFTG	
<u>NIACIN</u>									
TABLET, EXTENDED RELEASE;ORAL									
NIACIN									
AB		AMNEAL PHARMS	500MG	A203578	001	Jul 24, 2015	Jul	NEWA	
AB			1GM	A203578	002	Jul 24, 2015	Jul	NEWA	
<u>NIFEDIPINE</u>									
CAPSULE;ORAL									
NIFEDIPINE									
AB		HERITAGE PHARMA	10MG	A202644	001	Apr 25, 2013	Mar	CAHN	
AB			20MG	A202644	002	Apr 25, 2013	Mar	CAHN	
TABLET, EXTENDED RELEASE;ORAL									
NIFEDIPINE									
AB2		VALEANT PHARMS NORTH	30MG	A075289	002	Feb 06, 2001	Aug	CAHN	
AB2			60MG	A075289	001	Sep 27, 2000	Aug	CAHN	
<u>NILUTAMIDE</u>									
TABLET;ORAL									
NILANDRON									
		@ CONCORDIA PHARMS INC	50MG	N020169	001	Sep 19, 1996	Apr	CAHN	
		+	150MG	N020169	002	Apr 30, 1999	Apr	CAHN	
<u>NIMODIPINE</u>									
CAPSULE;ORAL									
NIMODIPINE									
AB	+	BANNER LIFE SCIENCES	30MG	A076740	001	Jan 17, 2008	Jan	CAHN	
AB		SOFGEN PHARMS	30MG	A201832	001	Jul 24, 2015	Jul	NEWA	
<u>NINTEDANIB ESYLATE</u>									
CAPSULE;ORAL									
OFEV									
		BOEHRINGER INGELHEIM	EQ 100MG BASE	N205832	001	Oct 15, 2014	Mar	CAIN	
		+	EQ 150MG BASE	N205832	002	Oct 15, 2014	Mar	CAIN	
<u>NITRIC OXIDE</u>									
GAS;INHALATION									
INOMAX									
		@ INO	100PPM	N020845	002	Dec 23, 1999	Jun	DISC	
<u>NITROFURANTOIN, MACROCRYSTALLINE</u>									
CAPSULE;ORAL									
MACRODANTIN									
>D>	AB	ALVOGEN INC	25MG	N016620	003		Oct	CAHN	
	AB		25MG	N016620	003		Jun	CTEC	
>D>	AB		50MG	N016620	001		Oct	CAHN	
>D>	AB	+	100MG	N016620	002		Oct	CAHN	
>A>	AB	ALVOGEN MALTA	25MG	N016620	003		Oct	CAHN	
>A>	AB		50MG	N016620	001		Oct	CAHN	
>A>	AB	+	100MG	N016620	002		Oct	CAHN	
NITROFURANTOIN									
AB		ACTAVIS LABS FL INC	25MG	A091095	001	Jun 18, 2015	Jun	NEWA	
AB			50MG	A091095	002	Jun 18, 2015	Jun	NEWA	
AB			100MG	A091095	003	Jun 18, 2015	Jun	NEWA	
<u>NITROFURANTOIN; NITROFURANTOIN, MACROCRYSTALLINE</u>									
CAPSULE;ORAL									
NITROFURANTOIN (MONOHYDRATE/MACROCRYSTALS)									
AB		WATSON LABS INC	75MG;25MG	A202250	001	Jul 08, 2015	Jun	NEWA	

NORETHINDRONETABLET; ORAL-28
NOR-QD

AB1	+	ACTAVIS LABS UT INC	0.35MG	N017060	001		Mar	CAHN
-----	---	---------------------	--------	---------	-----	--	-----	------

NORGESTRELTABLET; ORAL
OVRETTE

	@	LABORATOIRE HRA	0.075MG	N017031	001		Jun	CAHN
--	---	-----------------	---------	---------	-----	--	-----	------

NYSTATINCREAM; TOPICAL
NYSTATIN

AT		G AND W LABS INC	100,000 UNITS/GM	A061966	001		Jun	CMFD
----	--	------------------	------------------	---------	-----	--	-----	------

SUSPENSION; ORAL
NYSTATIN

AA		G AND W LABS INC	100,000 UNITS/ML	A062349	001	Jul 14, 1982	Apr	CAHN
	@		100,000 UNITS/ML	A062776	001	Dec 17, 1987	Apr	CAHN

NYSTATIN; TRIAMCINOLONE ACETONIDE

CREAM; TOPICAL

MYKACET

AT		G AND W LABS INC	100,000 UNITS/GM; 0.1%	A062367	001	May 28, 1985	Mar	CMFD
----	--	------------------	------------------------	---------	-----	--------------	-----	------

OINTMENT; TOPICAL

MYKACET

AT		G AND W LABS INC	100,000 UNITS/GM; 0.1%	A062733	001	Mar 09, 1987	Mar	CMFD
----	--	------------------	------------------------	---------	-----	--------------	-----	------

OFLOXACIN

TABLET; ORAL

OFLOXACIN

AB		LARKEN LABS	400MG	A076093	003	Sep 02, 2003	Jul	CMFD
----	--	-------------	-------	---------	-----	--------------	-----	------

OLANZAPINE

TABLET; ORAL

OLANZAPINE

>A>	AB	ALKEM LABS LTD	2.5MG	A202295	001	Oct 20, 2015	Oct	NEWA
>A>	AB		5MG	A202295	002	Oct 20, 2015	Oct	NEWA
>A>	AB		7.5MG	A202295	003	Oct 20, 2015	Oct	NEWA
>A>	AB		10MG	A202295	004	Oct 20, 2015	Oct	NEWA
>A>	AB		15MG	A202295	005	Oct 20, 2015	Oct	NEWA
>A>	AB		20MG	A202295	006	Oct 20, 2015	Oct	NEWA
	AB	IVAX PHARMS INC	20MG	A077301	001	Apr 29, 2015	Apr	NEWA

TABLET, ORALLY DISINTEGRATING; ORAL

OLANZAPINE

AB		MACLEODS PHARMS LTD	5MG	A203044	001	Feb 20, 2015	Feb	NEWA
AB			10MG	A203044	002	Feb 20, 2015	Feb	NEWA
AB			15MG	A203044	003	Feb 20, 2015	Feb	NEWA
AB			20MG	A203044	004	Feb 20, 2015	Feb	NEWA
AB		ORCHID HLTHCARE	5MG	A202937	001	Mar 02, 2015	Feb	NEWA
AB			10MG	A202937	002	Mar 02, 2015	Feb	NEWA
AB			15MG	A202937	003	Mar 02, 2015	Feb	NEWA
AB			20MG	A202937	004	Mar 02, 2015	Feb	NEWA

OLAPARIB

CAPSULE; ORAL

LYNPARZA

		ASTRAZENECA PHARMS	50MG	N206162	001	Dec 19, 2014	Jan	CTNA
--	--	--------------------	------	---------	-----	--------------	-----	------

OLODATEROL HYDROCHLORIDE; TIOTROPIUM BROMIDE

SPRAY, METERED; INHALATION

STIOLTO RESPIMAT

+		BOEHRINGER INGELHEIM	EQ 0.0025MG BASE/INH; EQ 0.0025MG BASE/INH	N206756	001	May 21, 2015	May	NEWA
---	--	----------------------	--	---------	-----	--------------	-----	------

OLOPATADINE HYDROCHLORIDE

SOLUTION/DROPS; OPHTHALMIC

OLOPATADINE HYDROCHLORIDE

AT		BARR LABS INC	EQ 0.2% BASE	A090848	001	Jul 13, 2015	Jun	NEWA
----	--	---------------	--------------	---------	-----	--------------	-----	------

PATADAY

AT	+	ALCON PHARMS LTD	EQ 0.2% BASE	N021545	001	Dec 22, 2004	Jun	CFTG
----	---	------------------	--------------	---------	-----	--------------	-----	------

SOLUTION/DROPS;OPHTHALMIC								
PAZEO								
+	ALCON RES LTD	EQ 0.7% BASE	N206276	001	Jan 30, 2015	Jan	NEWA	
<u>OMBITASVIR; PARITAPREVIR; RITONAVIR</u>								
TABLET;ORAL								
TECHNIVIE								
+	ABBVIE INC	12.5MG;75MG;50MG	N207931	001	Jul 24, 2015	Aug	CMS1	
+		12.5MG;75MG;50MG	N207931	001	Jul 25, 2015	Jul	NEWA	
<u>OMEPRAZOLE</u>								
CAPSULE, DELAYED REL PELLETS;ORAL								
OMEPRAZOLE								
AB	AUROBINDO PHARMA USA	10MG	A203270	001	Aug 19, 2015	Aug	NEWA	
AB		20MG	A203270	002	Aug 19, 2015	Aug	NEWA	
AB		40MG	A203270	003	Aug 19, 2015	Aug	NEWA	
AB	LUPIN LTD	40MG	A202384	001	Aug 25, 2015	Aug	NEWA	
<u>ONDANSETRON</u>								
TABLET, ORALLY DISINTEGRATING;ORAL								
ONDANSETRON								
AB	SUN PHARM INDS LTD	4MG	A078602	001	Feb 24, 2011	Apr	CAHN	
AB		8MG	A078602	002	Feb 24, 2011	Apr	CAHN	
ZOFRAN ODT								
AB	NOVARTIS PHARMS CORP	4MG	N020781	001	Jan 27, 1999	Mar	CAHN	
AB	+	8MG	N020781	002	Jan 27, 1999	Mar	CAHN	
<u>ONDANSETRON HYDROCHLORIDE</u>								
INJECTABLE;INJECTION								
ONDANSETRON HYDROCHLORIDE								
AP	ACCORD HLTHCARE	EQ 2MG BASE/ML	A206846	001	Jul 13, 2015	Jun	NEWA	
AP	CLARIS PHARMASERVICE	EQ 2MG BASE/ML	A078288	001	Feb 22, 2013	Apr	CAHN	
AP	EUROHLTH INTL SARL	EQ 2MG BASE/ML	A077365	001	Dec 26, 2006	Jun	CAHN	
ONDANSETRON HYDROCHLORIDE PRESERVATIVE FREE								
AP	CLARIS PHARMASERVICE	EQ 2MG BASE/ML	A078287	001	Feb 22, 2013	Apr	CAHN	
AP	EUROHLTH INTL SARL	EQ 2MG BASE/ML	A077541	001	Dec 26, 2006	Jun	CAHN	
	@ TARO PHARMS IRELAND	EQ 2MG BASE/ML	A078014	001	Mar 21, 2008	Jan	DISC	
ZOFRAN								
AP	+	NOVARTIS PHARMS CORP	EQ 2MG BASE/ML	N020007	001	Jan 04, 1991	Mar	CAHN
ZOFRAN PRESERVATIVE FREE								
AP	+	NOVARTIS PHARMS CORP	EQ 2MG BASE/ML	N020007	003	Dec 10, 1993	Mar	CAHN
SOLUTION;ORAL								
ZOFRAN								
AA	+	NOVARTIS PHARMS CORP	EQ 4MG BASE/5ML	N020605	001	Jan 24, 1997	Mar	CAHN
TABLET;ORAL								
ZOFRAN								
AB	NOVARTIS PHARMS CORP	EQ 4MG BASE	N020103	001	Dec 31, 1992	Mar	CAHN	
AB		EQ 8MG BASE	N020103	002	Dec 31, 1992	Mar	CAHN	
AB	+	EQ 24MG BASE	N020103	003	Aug 27, 1999	Mar	CAHN	
<u>ORPHENADRINE CITRATE</u>								
INJECTABLE;INJECTION								
NORFLEX								
	@ IGI LABS INC	30MG/ML	N013055	001		Apr	CAHN	
	@ MEDICIS	30MG/ML	N013055	001		Mar	DISC	
ORPHENADRINE CITRATE								
AP	+	AKORN	30MG/ML	A040484	001	May 24, 2006	Mar	CRLD
<u>OXACILLIN SODIUM</u>								
CAPSULE;ORAL								
OXACILLIN SODIUM								
	@ ANI PHARMS INC	EQ 250MG BASE	A062222	001		Aug	CAHN	
	@	EQ 500MG BASE	A062222	002		Aug	CAHN	
<u>OXANDROLONE</u>								
TABLET;ORAL								
OXANDRIN								
AB	GEMINI LABS LLC	2.5MG	N013718	001		Aug	CAHN	
AB	+	10MG	N013718	002	Nov 05, 2001	Aug	CAHN	

OXCARBAZEPINESUSPENSION;ORAL
OXCARBAZEPINE

AB	SUN PHARM INDS LTD	300MG/5ML	A078734	001	Jun 26, 2009	Apr CAHN
----	--------------------	-----------	---------	-----	--------------	----------

OXYBUTYNINFILM, EXTENDED RELEASE;TRANSDERMAL
OXYTROL

AB	+ ACTAVIS LABS UT INC	3.9MG/24HR	N021351	002	Feb 26, 2003	Mar CAHN
----	-----------------------	------------	---------	-----	--------------	----------

GEL, METERED;TRANSDERMAL
GELNIQUE 3%

	+ ACTAVIS LABS UT INC	3%	N202513	001	Dec 07, 2011	Mar CAHN
--	-----------------------	----	---------	-----	--------------	----------

OXYBUTYNIN CHLORIDEGEL;TRANSDERMAL
GELNIQUE

	+ ACTAVIS LABS UT INC	10%(100MG/PACKET)	N022204	001	Jan 27, 2009	Mar CAHN
--	-----------------------	-------------------	---------	-----	--------------	----------

OXYCODONE HYDROCHLORIDE

CAPSULE;ORAL

OXYCODONE HYDROCHLORIDE

AB	AVANTHI INC	5MG	A202773	001	Aug 17, 2015	Aug NEWA
----	-------------	-----	---------	-----	--------------	----------

AB	NOVEL LABS INC	5MG	A204752	001	Aug 24, 2015	Aug NEWA
----	----------------	-----	---------	-----	--------------	----------

SOLUTION;ORAL

OXYCODONE HYDROCHLORIDE

AA	ANI PHARMS INC	5MG/5ML	A204979	001	Jun 01, 2015	May NEWA
----	----------------	---------	---------	-----	--------------	----------

AA	NOVEL LABS INC	100MG/5ML	A204603	001	Apr 29, 2015	Apr NEWA
----	----------------	-----------	---------	-----	--------------	----------

AA	WOCKHARDT BIO AG	5MG/5ML	A206456	001	Jun 16, 2015	Jun NEWA
----	------------------	---------	---------	-----	--------------	----------

TABLET;ORAL

OXAYDO

ACURA PHARMS INC

5MG	N202080	001	Jun 17, 2011	Mar CTNA
-----	---------	-----	--------------	----------

7.5MG

N202080	002	Jun 17, 2011	Mar CTNA
---------	-----	--------------	----------

EGALET LTD

5MG	N202080	001	Jun 17, 2011	May CAHN
-----	---------	-----	--------------	----------

7.5MG	N202080	002	Jun 17, 2011	May CAHN
-------	---------	-----	--------------	----------

EGALET US INC

5MG	N202080	001	Jun 17, 2011	Jul CAHN
-----	---------	-----	--------------	----------

7.5MG	N202080	002	Jun 17, 2011	Jul CAHN
-------	---------	-----	--------------	----------

OXYCODONE HYDROCHLORIDE

AB	ACTAVIS ELIZABETH	5MG	A076636	003	Apr 07, 2015	Mar NEWA
----	-------------------	-----	---------	-----	--------------	----------

AB	EPIC PHARMA LLC	5MG	A202662	001	Sep 22, 2015	Sep NEWA
----	-----------------	-----	---------	-----	--------------	----------

AB		10MG	A202662	002	Sep 22, 2015	Sep NEWA
----	--	------	---------	-----	--------------	----------

AB		15MG	A202662	003	Sep 22, 2015	Sep NEWA
----	--	------	---------	-----	--------------	----------

AB		30MG	A202662	004	Sep 22, 2015	Sep NEWA
----	--	------	---------	-----	--------------	----------

AB	VINTAGE PHARMS	10MG	A077712	004	Apr 13, 2015	Mar NEWA
----	----------------	------	---------	-----	--------------	----------

AB		20MG	A077712	005	Apr 13, 2015	Mar NEWA
----	--	------	---------	-----	--------------	----------

OXYMORPHONE HYDROCHLORIDE

TABLET, EXTENDED RELEASE;ORAL

OXYMORPHONE HYDROCHLORIDE

AB	SUN PHARM INDS LTD	5MG	A203506	001	Apr 24, 2015	Apr NEWA
----	--------------------	-----	---------	-----	--------------	----------

AB		7.5MG	A203506	002	Apr 24, 2015	Apr NEWA
----	--	-------	---------	-----	--------------	----------

AB		10MG	A203506	003	Apr 24, 2015	Apr NEWA
----	--	------	---------	-----	--------------	----------

AB		15MG	A203506	004	Apr 24, 2015	Apr NEWA
----	--	------	---------	-----	--------------	----------

AB		20MG	A203506	005	Apr 24, 2015	Apr NEWA
----	--	------	---------	-----	--------------	----------

AB		30MG	A203506	006	Apr 24, 2015	Apr NEWA
----	--	------	---------	-----	--------------	----------

AB		40MG	A203506	007	Apr 24, 2015	Apr NEWA
----	--	------	---------	-----	--------------	----------

OXYTOCIN

INJECTABLE;INJECTION

OXYTOCIN

AP	+ EUROHLTH INTL SARL	10USP UNITS/ML (10USP UNITS/ML)	N018243	001		Feb CAHN
----	----------------------	---------------------------------	---------	-----	--	----------

AP	+	100USP UNITS/10ML (10USP UNITS/ML)	N018243	002	Jan 10, 2007	Feb CAHN
----	---	------------------------------------	---------	-----	--------------	----------

PALBOCICLIB

CAPSULE;ORAL

IBRANCE

PFIZER INC

75MG	N207103	001	Feb 03, 2015	Feb NEWA
------	---------	-----	--------------	----------

100MG	N207103	002	Feb 03, 2015	Feb NEWA
-------	---------	-----	--------------	----------

+	N207103	003	Feb 03, 2015	Feb NEWA
---	---------	-----	--------------	----------

PALIPERIDONE

TABLET, EXTENDED RELEASE;ORAL
INVEGA

AB	JANSSEN PHARMS	1.5MG	N021999	006	Aug 26, 2008	Jul CFTG
AB		3MG	N021999	001	Dec 19, 2006	Jul CFTG
AB	+	6MG	N021999	002	Dec 19, 2006	Jul CFTG
AB		9MG	N021999	003	Dec 19, 2006	Jul CFTG
	PALIPERIDONE					
AB	ACTAVIS LABS FL INC	1.5MG	A202645	001	Aug 03, 2015	Jul NEWA
AB		3MG	A202645	002	Aug 03, 2015	Jul NEWA
AB		6MG	A202645	003	Aug 03, 2015	Jul NEWA
AB		9MG	A202645	004	Aug 03, 2015	Jul NEWA
AB	MYLAN PHARMS INC	1.5MG	A203802	001	Sep 24, 2015	Sep NEWA
AB		3MG	A203802	002	Sep 24, 2015	Sep NEWA
AB		6MG	A203802	003	Sep 24, 2015	Sep NEWA
AB		9MG	A203802	004	Sep 24, 2015	Sep NEWA

PALIPERIDONE PALMITATE

SUSPENSION, EXTENDED RELEASE;INTRAMUSCULAR
INVEGA TRINZA

	JANSSEN PHARMS	273MG/0.875ML (273MG/0.875ML)	N207946	001	May 18, 2015	May NEWA
		410MG/1.315ML (311.79MG/ML)	N207946	002	May 18, 2015	May NEWA
		546MG/1.75ML (312MG/ML)	N207946	003	May 18, 2015	May NEWA
	+	819MG/2.625ML (312MG/ML)	N207946	004	May 18, 2015	May NEWA

PALONOSETRON HYDROCHLORIDE

INJECTABLE;INTRAVENOUS
ALOXI

AP	+	HELSINN HLTHCARE	EQ 0.075MG BASE/1.5ML (EQ 0.05MG BASE/ML)	N021372	002	Feb 29, 2008	Sep CFTG
AP	+		EQ 0.25MG BASE/5ML (EQ 0.05MG BASE/ML)	N021372	001	Jul 25, 2003	Sep CFTG
		PALONOSETRON HYDROCHLORIDE					
AP		SANDOZ INC	EQ 0.25MG BASE/5ML (EQ 0.05MG BASE/ML)	A202521	001	Oct 13, 2015	Sep NEWA
AP		TEVA PHARMS USA	EQ 0.075MG BASE/1.5ML (EQ 0.05MG BASE/ML)	A090713	002	Oct 13, 2015	Sep NEWA
AP			EQ 0.25MG BASE/5ML (EQ 0.05MG BASE/ML)	A090713	001	Oct 13, 2015	Sep NEWA

PANCURONIUM BROMIDE

INJECTABLE;INJECTION
PANCURONIUM BROMIDE

@	IGI LABS INC	1MG/ML	A072210	001	Mar 31, 1988	Mar CAHN
@		2MG/ML	A072211	001	Mar 31, 1988	Mar CAHN
@		2MG/ML	A072212	001	Mar 31, 1988	Mar CAHN
@		2MG/ML	A072213	001	Mar 31, 1988	Mar CAHN

PANOBINOSTAT

CAPSULE;ORAL
FARYDAK

	NOVARTIS PHARMS CORP	10MG	N205353	001	Feb 23, 2015	Feb NEWA
		15MG	N205353	002	Feb 23, 2015	Feb NEWA
	+	20MG	N205353	003	Feb 23, 2015	Feb NEWA

PANOBINOSTAT LACTATE

CAPSULE;ORAL
FARYDAK

	NOVARTIS PHARMS CORP	EQ 10MG BASE	N205353	001	Feb 23, 2015	Mar CAIN
		EQ 10MG BASE	N205353	001	Feb 23, 2015	Mar CPOT
		EQ 15MG BASE	N205353	002	Feb 23, 2015	Mar CAIN
		EQ 15MG BASE	N205353	002	Feb 23, 2015	Mar CPOT
	+	EQ 20MG BASE	N205353	003	Feb 23, 2015	Mar CAIN
	+	EQ 20MG BASE	N205353	003	Feb 23, 2015	Mar CPOT

PANTOPRAZOLE SODIUM

INJECTABLE;IV (INFUSION)
PANTOPRAZOLE SODIUM

AP	SANDOZ INC	EQ 40MG BASE/VIAL	A090296	001	Jul 14, 2015	Jun NEWA
	TABLET, DELAYED RELEASE;ORAL PANTOPRAZOLE SODIUM					
AB	KREMERS URBAN PHARMS	EQ 20MG BASE	A078281	001	Jan 20, 2011	Mar CAHN

TABLET, DELAYED RELEASE;ORAL
PANTOPRAZOLE SODIUM

AB		EQ 40MG BASE	A078281	002	Jan 20, 2011	Mar CAHN
AB	SUN PHARM INDS LTD	EQ 20MG BASE	A200794	001	May 02, 2012	Apr CAHN
AB		EQ 40MG BASE	A200794	002	May 02, 2012	Apr CAHN

PARICALCITOL

CAPSULE;ORAL
PARICALCITOL

AB	BANNER LIFE SCIENCES	1MCG	A202539	001	Mar 27, 2014	Jan CAHN
AB		2MCG	A202539	002	Mar 27, 2014	Jan CAHN
AB		4MCG	A202539	003	Mar 27, 2014	Jan CAHN

>A> PATROMER SORBITEX CALCIUM

>A> POWDER;ORAL
>A> VELTASSA

>A>	RELYPSA INC	EQ 8.4GM BASE/PACKET	N205739	001	Oct 21, 2015	Oct NEWA
>A>		EQ 16.8GM BASE/PACKET	N205739	002	Oct 21, 2015	Oct NEWA
>A>	+	EQ 25.2GM BASE/PACKET	N205739	003	Oct 21, 2015	Oct NEWA

PAZOPANIB HYDROCHLORIDE

TABLET;ORAL
VOTRIENT

+	NOVARTIS PHARMS CORP	EQ 200MG BASE	N022465	001	Oct 19, 2009	Mar CAHN
@		EQ 400MG BASE	N022465	002	Oct 19, 2009	Aug DISC
		EQ 400MG BASE	N022465	002	Oct 19, 2009	Mar CAHN

PENTOXIFYLLINE

TABLET, EXTENDED RELEASE;ORAL
PENTOXIFYLLINE

AB	VALEANT PHARMS	400MG	A075028	001	Jul 20, 1998	Feb CAHN
----	----------------	-------	---------	-----	--------------	----------

PHENDIMETRAZINE TARTRATE

CAPSULE, EXTENDED RELEASE;ORAL
BONTRIL

@	VALEANT	105MG	A088021	001	Sep 21, 1982	Jan DISC
+	SANDOZ	105MG	N018074	001		Jan CTEC

PHENOXYBENZAMINE HYDROCHLORIDE

CAPSULE;ORAL
DIBENZYLINE

AB	+	CONCORDIA PHARMS INC	10MG	N008708	001	Jun CAHN
----	---	----------------------	------	---------	-----	----------

PHENTERMINE HYDROCHLORIDE

CAPSULE;ORAL
PHENTERMINE HYDROCHLORIDE

AA	MIKAH PHARMA LLC	37.5MG	A040228	001	Jun 19, 1997	Jun CMFD
----	------------------	--------	---------	-----	--------------	----------

PHENYLEPHRINE HYDROCHLORIDE

SOLUTION/DROPS;OPHTHALMIC
PHENYLEPHRINE HYDROCHLORIDE

+	AKORN INC	2.5%	N207926	001	Jan 15, 2015	Sep CRLD
		2.5%	N207926	001	Jan 15, 2015	Jan NEWA
+		10%	N207926	002	Jan 15, 2015	Sep CRLD
		10%	N207926	002	Jan 15, 2015	Jan NEWA
+	PARAGON BIOTECK	2.5%	N203510	001	Mar 21, 2013	Sep CRLD

PHENYLEPHRINE HYDROCHLORIDE; PROMETHAZINE HYDROCHLORIDE

SYRUP;ORAL
PROMETH VC PLAIN

AA	+	G AND W LABS INC	5MG/5ML;6.25MG/5ML	A088761	001	Nov 08, 1984	Jul CAHN
----	---	------------------	--------------------	---------	-----	--------------	----------

PHENYTOIN SODIUM

CAPSULE;ORAL
EXTENDED PHENYTOIN SODIUM

	@	WOCKHARDT	30MG EXTENDED	A040759	001	Dec 18, 2007	Jun DISC
	@	WOCKHARDT USA	100MG EXTENDED	A040732	001	Jan 30, 2008	Jun DISC
AB		AUROBINDO PHARMA LTD	100MG EXTENDED	A204309	001	Jun 10, 2015	May NEWA

INJECTABLE; INJECTION									
PHENYTOIN SODIUM									
AP	+	EUROHLTH INTL SARL	50MG/ML		A084307	001		Feb	CAHN
<u>PHYTONADIONE</u>									
INJECTABLE; INJECTION									
AQUAMEPHYTON									
	@	IGI LABS INC	1MG/0.5ML		N012223	002		Apr	CAHN
	@		10MG/ML		N012223	001		Apr	CAHN
<u>PILOCARPINE HYDROCHLORIDE</u>									
GEL; OPHTHALMIC									
PILOPINE HS									
	@	ALCON	4%		N018796	001	Oct 01, 1984	Aug	DISC
TABLET; ORAL									
PILOCARPINE HYDROCHLORIDE									
AB		ELAN PHARMA INTL LTD	5MG		A076746	001	Nov 16, 2004	Mar	CAHN
<u>PIMOZIDE</u>									
TABLET; ORAL									
ORAP									
AB		TEVA	1MG		N017473	003	Aug 27, 1997	Sep	CFTG
AB	+		2MG		N017473	001	Jul 31, 1984	Sep	CFTG
PIMOZIDE									
AB		PAR PHARM	1MG		A204521	001	Sep 28, 2015	Sep	NEWA
AB			2MG		A204521	002	Sep 28, 2015	Sep	NEWA
<u>PINDOLOL</u>									
TABLET; ORAL									
PINDOLOL									
	@	G AND W LABS INC	5MG		A073661	001	Oct 31, 1993	Apr	CAHN
	@		5MG		A073687	001	Feb 26, 1993	Apr	CAHN
	@		5MG		A074123	001	Apr 17, 1997	Apr	CAHN
	@		10MG		A073661	002	Oct 31, 1993	Apr	CAHN
	@		10MG		A073687	002	Feb 26, 1993	Apr	CAHN
	@		10MG		A074123	002	Apr 17, 1997	Apr	CAHN
<u>PIRBUTEROL ACETATE</u>									
AEROSOL, METERED; INHALATION									
MAXAIR									
	@	MEDICIS	EQ 0.2MG BASE/INH		N020014	001	Nov 30, 1992	Jan	DISC
<u>PIRFENIDONE</u>									
CAPSULE; ORAL									
ESBRIET									
	+	GENENTECH INC	267MG		N022535	001	Oct 15, 2014	Feb	CAHN
<u>PIROXICAM</u>									
CAPSULE; ORAL									
PIROXICAM									
AB		MYLAN PHARMS INC	10MG		A074116	001	Jun 15, 1993	May	CAHN
AB			20MG		A074118	001	Jun 15, 1993	May	CAHN
<u>PODOFILOX</u>									
GEL; TOPICAL									
CONDYLOX									
	+	ACTAVIS LABS UT INC	0.5%		N020529	001	Mar 13, 1997	Feb	CAHN
SOLUTION; TOPICAL									
CONDYLOX									
AT	+	ACTAVIS LABS UT INC	0.5%		N019795	001	Dec 13, 1990	Jan	CAHN
PODOFILOX									
AT		BAUSCH AND LOMB INC	0.5%		A090184	001	Jul 21, 2010	May	CAHN
<u>POLYMYXIN B SULFATE; TRIMETHOPRIM SULFATE</u>									
SOLUTION/DROPS; OPHTHALMIC									
TRIMETHOPRIM SULFATE AND POLYMYXIN B SULFATE									
AT		ALCON RES LTD	10,000 UNITS/ML; EQ 1MG BASE/ML		A064211	001	Apr 13, 1998	Jan	CAHN

PONATINIB HYDROCHLORIDE

TABLET; ORAL

ICLUSIG

ARIAD

EQ 30MG BASE

N203469 003 Apr 23, 2015 Apr NEWA

POTASSIUM CHLORIDE

CAPSULE, EXTENDED RELEASE; ORAL

KLOR-CON

AB UPSHER SMITH

8MEQ

A203106 001 Jul 10, 2015 Jun NEWA

AB 10MEQ

A203106 002 Jul 10, 2015 Jun NEWA

FOR SOLUTION; ORAL

POTASSIUM CHLORIDE

PHARMA RES SOFTWARE 20MEQ

N208019 001 Aug 19, 2015 Aug NEWA

TABLET, EXTENDED RELEASE; ORAL

POTASSIUM CHLORIDE

AB1 ADARE PHARMS INC 20MEQ

A076368 001 Aug 18, 2004 Jul CAHN

AB2 MYLAN PHARMS INC 8MEQ

A204662 001 Aug 21, 2014 Feb CPOT

AB2 10MEQ

A204662 002 Aug 21, 2014 Feb CPOT

>A> AB2 PADDOCK LLC 8MEQ

A205993 001 Nov 05, 2015 Oct NEWA

>A> AB2 10MEQ

A205993 002 Nov 05, 2015 Oct NEWA

PRAMIPEXOLE DIHYDROCHLORIDE

TABLET; ORAL

PRAMIPEXOLE DIHYDROCHLORIDE

AB GLENMARK GENERICS 0.75MG

A090781 006 Sep 11, 2015 Aug NEWA

TABLET, EXTENDED RELEASE; ORAL

PRAMIPEXOLE DIHYDROCHLORIDE

AB DR REDDYS LABS LTD 0.375MG

A203354 001 Aug 07, 2015 Jul NEWA

AB 0.75MG

A203354 002 Aug 07, 2015 Jul NEWA

AB 1.5MG

A203354 003 Aug 07, 2015 Jul NEWA

AB 3MG

A203354 004 Aug 07, 2015 Jul NEWA

AB 4.5MG

A203354 005 Aug 07, 2015 Jul NEWA

PREDNICARBATE

OINTMENT; TOPICAL

DERMATOP

AB + VALEANT PHARMS NORTH 0.1%

N019568 001 Sep 23, 1991 Apr CAHN

PREDNISONE

TABLET; ORAL

PREDNISONE

@ HIKMA PHARMS 1MG

A040890 001 Nov 01, 2010 Aug DISC

PREGABALIN

CAPSULE; ORAL

LYRICA

PF PRISM CV 25MG

N021446 001 Dec 30, 2004 Apr CTEC

50MG

N021446 002 Dec 30, 2004 Apr CTEC

75MG

N021446 003 Dec 30, 2004 Apr CTEC

100MG

N021446 004 Dec 30, 2004 Apr CTEC

150MG

N021446 005 Dec 30, 2004 Apr CTEC

200MG

N021446 006 Dec 30, 2004 Apr CTEC

225MG

N021446 007 Dec 30, 2004 Apr CTEC

+ 300MG

N021446 008 Dec 30, 2004 Apr CTEC

PROCAINAMIDE HYDROCHLORIDE

CAPSULE; ORAL

PROCAINAMIDE HYDROCHLORIDE

@ IDT AUSTRALIA LTD 250MG

A089219 001 Jul 01, 1986 Jun CAHN

@ 500MG

A089221 001 Jul 01, 1986 Jun CAHN

TABLET, EXTENDED RELEASE; ORAL

PROCAINAMIDE HYDROCHLORIDE

@ IDT AUSTRALIA LTD 250MG

A089369 001 Aug 14, 1987 Jun CAHN

@ 500MG

A089370 001 Jan 09, 1987 Jun CAHN

@ 750MG

A089371 001 Aug 14, 1987 Jun CAHN

PROCHLORPERAZINE EDISYLATE

INJECTABLE;INJECTION
PROCHLORPERAZINE EDISYLATE

AP	+	EUROHLTH INTL SARL	EQ 5MG BASE/ML	A089903	001	Aug 29, 1989	Feb CAHN
----	---	--------------------	----------------	---------	-----	--------------	----------

PROGESTERONE

CAPSULE;ORAL
PROGESTERONE

AB		BANNER LIFE SCIENCES	100MG	A200900	001	Aug 16, 2013	Jan CAHN
AB			200MG	A200900	002	Aug 16, 2013	Jan CAHN

GEL;VAGINAL
CRINONE

ACTAVIS LABS UT INC 4%
+ 8%

N020701	001	Jul 31, 1997	Feb CAHN
N020701	002	Jul 31, 1997	Feb CAHN

INJECTABLE;INJECTION
PROGESTERONE

AO	+	ACTAVIS LABS UT INC	50MG/ML	N017362	002		Mar CAHN
----	---	---------------------	---------	---------	-----	--	----------

PROMETHAZINE HYDROCHLORIDE

INJECTABLE;INJECTION
PROMETHAZINE HYDROCHLORIDE

AP	+	EUROHLTH INTL SARL	25MG/ML	A083312	001		Jun CAHN
AP	+		50MG/ML	A083312	002		Jun CAHN

SUPPOSITORY;RECTAL
PHENERGAN

@ DELCOR ASSET CORP 12.5MG
@ 25MG

N010926	002		Apr CAHN
N010926	001		Apr CAHN

TABLET;ORAL

PROMETHAZINE HYDROCHLORIDE

AB		HERITAGE PHARMA	12.5MG	A040673	001	Mar 05, 2008	Mar CAHN
AB			25MG	A040673	002	Mar 05, 2008	Mar CAHN
AB			50MG	A040673	003	Mar 05, 2008	Mar CAHN

PROPAFENONE HYDROCHLORIDE

CAPSULE, EXTENDED RELEASE;ORAL
PROPAFENONE HYDROCHLORIDE

AB		WATSON LABS INC	225MG	A202688	001	Aug 24, 2015	Aug NEWA
AB			325MG	A202688	002	Aug 24, 2015	Aug NEWA
AB			425MG	A202688	003	Aug 24, 2015	Aug NEWA

PYRIDOSTIGMINE BROMIDE

TABLET;ORAL

PYRIDOSTIGMINE BROMIDE

@ ANI PHARMS INC 30MG
@ 60MG

AB		ZYDUS PHARMS USA INC	60MG	A205650	001	Jun 22, 2015	Jun NEWA
----	--	----------------------	------	---------	-----	--------------	----------

TABLET, EXTENDED RELEASE;ORAL

MESTINON

AB	+	VALEANT PHARMS LLC	180MG	N011665	001		Jun CFTG
----	---	--------------------	-------	---------	-----	--	----------

PYRIDOSTIGMINE BROMIDE

AB		ALVOGEN INC	180MG	A204737	001	Jun 26, 2015	Jun NEWA
AB		IMPAX LABS INC	180MG	A203184	001	Sep 15, 2015	Aug NEWA

PYRIMETHAMINE

TABLET;ORAL
DARAPRIM

+ TURING PHARMS AG 25MG

N008578	001		Aug CAHN
---------	-----	--	----------

QUAZEPAM

TABLET;ORAL
DORAL

@ SCIECURE PHARMA INC 15MG

N018708	001	Dec 27, 1985	Jun DISC
---------	-----	--------------	----------

QUETIAPINE FUMARATE

TABLET;ORAL
SEROQUEL

AB	+	ASTRAZENECA PHARMS	EQ 25MG BASE	N020639	001	Sep 26, 1997	May CAHN
AB			EQ 50MG BASE	N020639	007	Oct 04, 2005	May CAHN
AB			EQ 100MG BASE	N020639	002	Sep 26, 1997	May CAHN
	@		EQ 150MG BASE	N020639	004	Dec 20, 1998	May CAHN

TABLET;ORAL							
SEROQUEL							
AB		EQ 200MG BASE	N020639	003	Sep 26, 1997	May	CAHN
AB	+	EQ 300MG BASE	N020639	005	Jul 26, 2000	May	CAHN
AB		EQ 400MG BASE	N020639	006	Oct 04, 2005	May	CAHN
<u>QUINAPRIL HYDROCHLORIDE</u>							
TABLET;ORAL							
QUINAPRIL HYDROCHLORIDE							
AB	SUN PHARM INDS LTD	EQ 5MG BASE	A076607	001	Dec 15, 2004	Apr	CAHN
AB		EQ 10MG BASE	A076607	002	Dec 15, 2004	Apr	CAHN
AB		EQ 20MG BASE	A076607	003	Dec 15, 2004	Apr	CAHN
AB		EQ 40MG BASE	A076607	004	Dec 15, 2004	Apr	CAHN
<u>QUINIDINE GLUCONATE</u>							
TABLET, EXTENDED RELEASE;ORAL							
QUINIDINE GLUCONATE							
	@ CYCLE PHARMS LTD	324MG	A088431	001	Jan 06, 1984	Jun	CAHN
<u>QUINIDINE SULFATE</u>							
TABLET;ORAL							
QUINIDINE SULFATE							
	@ CYCLE PHARMS LTD	200MG	A083640	001		Jun	CAHN
	@	300MG	A085632	001		Jun	CAHN
TABLET, EXTENDED RELEASE;ORAL							
QUINIDINE SULFATE							
+	G AND W LABS INC	300MG	A040045	001	Jun 30, 1994	Apr	CAHN
<u>QUININE SULFATE</u>							
CAPSULE;ORAL							
QUININE SULFATE							
AB	AMNEAL PHARMS	324MG	A203729	001	Jul 15, 2015	Jun	NEWA
AB	LUPIN LTD	324MG	A203112	001	Apr 24, 2015	Apr	NEWA
AB	RICONPHARMA LLC	324MG	A204372	001	Jul 22, 2015	Jul	NEWA
<u>RABEPRAZOLE SODIUM</u>							
TABLET, DELAYED RELEASE;ORAL							
RABEPRAZOLE SODIUM							
AB	AMNEAL PHARMS	20MG	A204179	001	Jul 31, 2015	Jul	NEWA
<u>RALOXIFENE HYDROCHLORIDE</u>							
TABLET;ORAL							
RALOXIFENE HYDROCHLORIDE							
AB	AUROBINDO PHARMA LTD	60MG	A204310	001	Aug 28, 2015	Aug	NEWA
AB	WATSON LABS INC	60MG	A200825	001	Jan 21, 2015	Jan	NEWA
<u>RAMELTEON</u>							
TABLET;ORAL							
RAMELTEON							
AB	ACTAVIS LABS FL INC	8MG	A091610	001	Aug 19, 2015	Aug	NEWA
<u>RANITIDINE HYDROCHLORIDE</u>							
INJECTABLE;INJECTION							
ZANTAC							
AP	+ CONCORDIA PHARMS INC	EQ 25MG BASE/ML	N019090	001	Oct 19, 1984	Jun	CAHN
TABLET;ORAL							
RANITIDINE HYDROCHLORIDE							
	@ SUN PHARM INDS LTD	EQ 150MG BASE	A075439	001	Apr 19, 2000	Apr	CAHN
	@	EQ 300MG BASE	A075439	002	Apr 19, 2000	Apr	CAHN
<u>REPAGLINIDE</u>							
TABLET;ORAL							
REPAGLINIDE							
AB	STANDARD CHEM PHARM	0.5MG	A091517	001	Apr 24, 2015	Apr	NEWA
AB		1MG	A091517	002	Apr 24, 2015	Apr	NEWA
AB		2MG	A091517	003	Apr 24, 2015	Apr	NEWA

RIBAVIRIN

CAPSULE;ORAL

REBETOL

@ MERCK SHARP DOHME

200MG

N020903 001 Jun 03, 1998 Jun DISC

RISEDRONATE SODIUM

TABLET, DELAYED RELEASE;ORAL

ATELVIA

AB + WARNER CHILCOTT LLC 35MG

N022560 001 Oct 08, 2010 May CFTG

RISEDRONATE SODIUM

AB TEVA PHARMS USA 35MG

A203217 001 May 18, 2015 May NEWA

RISPERIDONE

TABLET, ORALLY DISINTEGRATING;ORAL

RISPERIDONE

AB SUN PHARM INDS LTD 0.5MG

A077542 001 Aug 06, 2010 Apr CAHN

AB 1MG

A077542 002 Aug 06, 2010 Apr CAHN

AB 2MG

A077542 003 Aug 06, 2010 Apr CAHN

AB 3MG

A078474 001 Aug 06, 2010 Apr CAHN

AB 4MG

A078474 002 Aug 06, 2010 Apr CAHN

RIVAROXABAN

TABLET;ORAL

XARELTO

JANSSSEN PHARMS

10MG

N022406 001 Jul 01, 2011 Apr CRLD

RIVASTIGMINE

FILM, EXTENDED RELEASE;TRANSDERMAL

EXELON

AB NOVARTIS 4.6MG/24HR

N022083 001 Jul 06, 2007 Aug CFTG

AB + 9.5MG/24HR

N022083 002 Jul 06, 2007 Aug CFTG

AB 13.3MG/24HR

N022083 005 Aug 31, 2012 Aug CFTG

RIVASTIGMINE

AB ALVOGEN INC 4.6MG/24HR

A204403 001 Sep 03, 2015 Aug NEWA

AB 9.5MG/24HR

A204403 002 Sep 03, 2015 Aug NEWA

AB 13.3MG/24HR

A204403 003 Aug 31, 2015 Aug NEWA

AB ALVOGEN PINE BROOK 4.6MG/24HR

A204403 001 Sep 03, 2015 Aug CAHN

AB 9.5MG/24HR

A204403 002 Sep 03, 2015 Aug CAHN

AB 13.3MG/24HR

A204403 003 Aug 31, 2015 Aug CAHN

RIVASTIGMINE TARTRATE

CAPSULE;ORAL

RIVASTIGMINE TARTRATE

AB ORCHID HLTHCARE EQ 1.5MG BASE

A090879 001 Jun 10, 2015 May NEWA

AB EQ 3MG BASE

A090879 002 Jun 10, 2015 May NEWA

AB EQ 4.5MG BASE

A090879 003 Jun 10, 2015 May NEWA

AB EQ 6MG BASE

A090879 004 Jun 10, 2015 May NEWA

RIZATRIPTAN BENZOATE

TABLET, ORALLY DISINTEGRATING;ORAL

RIZATRIPTAN BENZOATE

>A> AB JUBILANT GENERICS EQ 5MG BASE

A203334 001 Oct 16, 2015 Oct NEWA

>A> AB EQ 10MG BASE

A203334 002 Oct 16, 2015 Oct NEWA

ROCURONIUM BROMIDE

INJECTABLE;INJECTION

ROCURONIUM BROMIDE

AP SAGENT PHARMS 50MG/5ML (10MG/ML)

A091458 001 Jul 28, 2010 Aug CAHN

AP 100MG/10ML (10MG/ML)

A091458 002 Jul 28, 2010 Aug CAHN

ROFLUMILAST

TABLET;ORAL

DALIRESP

+ ASTRAZENECA PHARMS 500MCG

N022522 001 Feb 28, 2011 Mar CAHN

ROLAPITANT HYDROCHLORIDE

TABLET;ORAL

VARUBI

+ TESARO INC EQ 90MG BASE

N206500 001 Sep 01, 2015 Sep NEWA

ROPINIROLE HYDROCHLORIDE

TABLET;ORAL

ROPINIROLE HYDROCHLORIDE

AB	G AND W LABS INC	EQ 0.25MG BASE	A077460	001	May 05, 2008	Apr CAHN
AB		EQ 0.5MG BASE	A077460	002	May 05, 2008	Apr CAHN
AB		EQ 1MG BASE	A077460	003	May 05, 2008	Apr CAHN
AB		EQ 2MG BASE	A077460	004	May 05, 2008	Apr CAHN
AB		EQ 3MG BASE	A077460	005	May 05, 2008	Apr CAHN
AB		EQ 4MG BASE	A077460	006	May 05, 2008	Apr CAHN
AB		EQ 5MG BASE	A077460	007	May 19, 2008	Apr CAHN

SACUBITRIL; VALSARTAN

TABLET;ORAL

ENTRESTO

	NOVARTIS PHARMS CORP	24MG;26MG	N207620	001	Jul 07, 2015	Jul NEWA
		49MG;51MG	N207620	002	Jul 07, 2015	Jul NEWA
+		97MG;103MG	N207620	003	Jul 07, 2015	Jul NEWA

SAPROPTERIN DIHYDROCHLORIDE

POWDER;ORAL

KUVAN

>A>	BIOMARIN PHARM	500MG/PACKET	N205065	002	Oct 27, 2015	Oct NEWA
-----	----------------	--------------	---------	-----	--------------	----------

SCOPOLAMINE

FILM, EXTENDED RELEASE;TRANSDERMAL

SCOPOLAMINE

AB	PERRIGO PHARMS CO	1MG/72HR	A078830	001	Jan 30, 2015	Mar CAHN
AB	PERRIGO R AND D	1MG/72HR	A078830	001	Jan 30, 2015	Jan NEWA
AB	+ NOVARTIS	1MG/72HR	N017874	001		Jan CFTG

SELEGILINE HYDROCHLORIDE

TABLET;ORAL

SELEGILINE HYDROCHLORIDE

@	G AND W LABS INC	5MG	A074537	001	Aug 02, 1996	Apr CAHN
@		5MG	A074744	001	Jan 27, 1997	Apr CAHN
@		5MG	A074756	001	Nov 25, 1998	Apr CAHN

SERTRALINE HYDROCHLORIDE

TABLET;ORAL

SERTRALINE HYDROCHLORIDE

@	HIKMA PHARMS	EQ 25MG BASE	A077864	001	Aug 10, 2009	May DISC
@		EQ 50MG BASE	A077864	002	Aug 10, 2009	May DISC
@		EQ 100MG BASE	A077864	003	Aug 10, 2009	May DISC
AB	SUN PHARM INDS LTD	EQ 25MG BASE	A077977	001	Feb 06, 2007	Apr CAHN
AB		EQ 50MG BASE	A077977	002	Feb 06, 2007	Apr CAHN
AB		EQ 100MG BASE	A077977	003	Feb 06, 2007	Apr CAHN
		EQ 150MG BASE	A077977	004	Feb 06, 2007	Apr CAHN
		EQ 200MG BASE	A077977	005	Feb 06, 2007	Apr CAHN

SEVOFLURANE

LIQUID;INHALATION

SEVOFLURANE

>A>	AN SHANGHAI HENGRUI	100%	A203793	001	Nov 03, 2015	Oct NEWA
-----	---------------------	------	---------	-----	--------------	----------

SILDENAFIL CITRATE

SOLUTION;INTRAVENOUS

REVATIO

AP	+ PFIZER	EQ 10MG BASE/12.5ML (EQ 0.8MG BASE/ML)	N022473	001	Nov 18, 2009	Mar CFTG
AP	AUROBINDO PHARMA LTD	EQ 10MG BASE/12.5ML (EQ 0.8MG BASE/ML)	A203988	001	Apr 01, 2015	Mar NEWA

SILODOSIN

CAPSULE;ORAL

RAPAFLO

+	ACTAVIS LABS UT INC	4MG	N022206	001	Oct 08, 2008	Mar CAHN
		8MG	N022206	002	Oct 08, 2008	Mar CAHN

SIMVASTATINTABLET; ORAL
SIMVASTATIN

>A>	AB	BIOCON LIMITED	5MG	A078034	001	Dec 20, 2006	Oct CAHN
>A>	AB		10MG	A078034	002	Dec 20, 2006	Oct CAHN
>A>	AB		20MG	A078034	003	Dec 20, 2006	Oct CAHN
>A>	AB		40MG	A078034	004	Dec 20, 2006	Oct CAHN
>A>	AB		80MG	A078034	005	Dec 20, 2006	Oct CAHN
>D>	AB	BLU CARIBE	5MG	A078034	001	Dec 20, 2006	Oct CAHN
>D>	AB		10MG	A078034	002	Dec 20, 2006	Oct CAHN
>D>	AB		20MG	A078034	003	Dec 20, 2006	Oct CAHN
>D>	AB		40MG	A078034	004	Dec 20, 2006	Oct CAHN
>D>	AB		80MG	A078034	005	Dec 20, 2006	Oct CAHN
	AB	SUN PHARM INDS LTD	5MG	A076285	001	Dec 20, 2006	Apr CAHN
	AB		10MG	A076285	002	Dec 20, 2006	Apr CAHN
	AB		20MG	A076285	003	Dec 20, 2006	Apr CAHN
	AB		40MG	A076285	004	Dec 20, 2006	Apr CAHN
	AB		80MG	A076285	005	Jun 23, 2006	Apr CAHN

SODIUM CHLORIDEINJECTABLE; INJECTION
SODIUM CHLORIDE 0.9%

AP		EUROHLTH INTL SARL	9MG/ML	A201850	001	Jan 20, 2012	Feb CAHN
		SODIUM CHLORIDE 0.9%					
		EUROHLTH INTL SARL	9MG/ML	A201833	001	Sep 24, 2013	Feb CAHN
		SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER					
+		LIEBEL-FLARSHEIM	45MG/50ML (9MG/ML)	N021569	001	Jul 27, 2006	Feb CAHN
			112.5MG/125ML (9MG/ML)	N021569	002	Jul 27, 2006	Feb CAHN
+			405MG/50ML (9MG/ML)	N021569	001	Jul 27, 2006	Feb CPOT
			1012.5MG/125ML (9MG/ML)	N021569	002	Jul 27, 2006	Feb CPOT

SODIUM FERRIC GLUCONATE COMPLEXINJECTABLE; INJECTION
SODIUM FERRIC GLUCONATE COMPLEX IN SUCROSE

AB		EUROHLTH INTL SARL	62.5MG/5ML	A078215	001	Mar 31, 2011	Jun CAHN
----	--	--------------------	------------	---------	-----	--------------	----------

SODIUM FLUORIDE F-18INJECTABLE; INTRAVENOUS
SODIUM FLUORIDE F-18

>A>	AP	3D IMAGING DRUG	10-200mCi/ML	A203777	001	Oct 19, 2015	Oct NEWA
	AP	CARDINAL HEALTH 414	10-200mCi/ML	A203780	001	Jul 30, 2015	Jul NEWA
	AP	HOT SHOTS NM LLC	10-200mCi/ML	A204530	001	Jul 29, 2015	Jul NEWA
	AP	IBA MOLECULAR N AM	10-200mCi/ML	A203592	001	Aug 18, 2015	Aug NEWA
	AP	MIPS CRF	10-200mCi/ML	A204517	001	Jul 21, 2015	Jul NEWA
	AP	PRECISION NUCLEAR	10-200mCi/ML	A204542	001	Feb 27, 2015	Feb NEWA
	AP	SPECTRON MRC LLC	10-200mCi/ML	A203912	001	Apr 22, 2015	Apr NEWA
>A>	AP	TRIAD ISOTOPES INC	10-200mCi/ML	A203968	001	Oct 23, 2015	Oct NEWA
	AP	UNIV UTAH CYCLOTRON	10-200mCi/ML	A204497	001	Apr 20, 2015	Apr NEWA

SODIUM IODIDE I-123CAPSULE; ORAL
SODIUM IODIDE I 123

AA	+	CARDINAL HEALTH 418	100uCi	N018671	001	May 27, 1982	Apr CAHN
AA	+		200uCi	N018671	002	May 27, 1982	Apr CAHN
	@		400uCi	N018671	003	May 27, 1982	Apr CAHN

SODIUM LACTATEINJECTABLE; INJECTION
SODIUM LACTATE 0.167 MOLAR IN PLASTIC CONTAINER
@ BAXTER HLTHCARE 1.87GM/100ML
SODIUM LACTATE 1/6 MOLAR IN PLASTIC CONTAINER
B BRAUN 1.87GM/100ML

N016692	001		Sep DISC
N020004	001	Apr 21, 1992	Sep CTEC

SODIUM POLYSTYRENE SULFONATEPOWDER; ORAL, RECTAL
KALEXATE

		KVK TECH	15GM/BOT	A040905	002	Apr 03, 2015	Mar NEWA
		KAYEXALATE					
AA	+	CONCORDIA PHARMS INC	453.6GM/BOT	N011287	001		Apr CAHN

<u>SODIUM TETRADECYL SULFATE</u>									
INJECTABLE; INJECTION									
SOTRADECOL									
	+	MYLAN INSTITUTIONAL	20MG/2ML (10MG/ML)		A040541	001	Nov 12, 2004	Jul	CRLD
<u>SOMATROPIN RECOMBINANT</u>									
INJECTABLE; INJECTION									
NORDITROPIN FLEXPRO									
		NOVO NORDISK INC	30MG/3ML		N021148	011	Jan 23, 2015	Jan	NEWA
NORDITROPIN NORDIFLEX									
	@	NOVO NORDISK INC	30MG/3ML		N021148	007	Mar 10, 2009	Jul	DISC
			30MG/3ML		N021148	007	Mar 10, 2009	Mar	CMFD
	@		30MG/3ML		N021148	007	Mar 10, 2009	Jan	DISC
NUTROPIN									
	@	GENENTECH	5MG/VIAL		N020168	001	Nov 17, 1993	Jun	DISC
	@		10MG/VIAL		N020168	002	Nov 17, 1993	Jun	DISC
BX	+		10MG/VIAL		N020168	002	Nov 17, 1993	Mar	CTEC
NUTROPIN AQ									
	@	GENENTECH	10MG/2ML (5MG/ML)		N020522	001	Dec 29, 1995	Jun	DISC
NUTROPIN AQ NUSPIN									
	+	GENENTECH	5MG/2ML (2.5MG/ML)		N020522	003	Jan 03, 2008	Jun	CTNA
	+		10MG/2ML (5MG/ML)		N020522	005	Jan 03, 2008	Jun	NEWA
	+		20MG/2ML (10MG/ML)		N020522	004	Jan 03, 2008	Jun	CTNA
NUTROPIN AQ PEN									
	+	GENENTECH	20MG/2ML (10MG/ML)		N020522	006	Jan 03, 2008	Jun	NEWA
ZOMACTON									
BX	+	FERRING	5MG/VIAL		N019774	002	Jan 04, 2002	Mar	CTNA
BX			10MG/VIAL		N019774	003	Mar 07, 2012	Apr	CRLD
BX	+		10MG/VIAL		N019774	003	Mar 07, 2012	Mar	NEWA
<u>SONIDEGIB PHOSPHATE</u>									
CAPSULE; ORAL									
ODOMZO									
	+	NOVARTIS PHARMS CORP	EQ 200MG BASE		N205266	001	Jul 24, 2015	Jul	NEWA
<u>SOTALOL HYDROCHLORIDE</u>									
SOLUTION; INTRAVENOUS									
SOTALOL HYDROCHLORIDE									
	+	ALTATHERA PHARMS LLC	150MG/10ML (15MG/ML)		N022306	001	Jul 02, 2009	Apr	CAHN
TABLET; ORAL									
BETAPACE									
AB1		COVIS PHARMA SARL	80MG		N019865	001	Oct 30, 1992	Mar	CAHN
AB1			120MG		N019865	005	Apr 20, 1994	Mar	CAHN
AB1	+		160MG		N019865	002	Oct 30, 1992	Mar	CAHN
AB1			240MG		N019865	003	Oct 30, 1992	Mar	CAHN
	@		320MG		N019865	004	Oct 30, 1992	Mar	CAHN
<u>STERILE WATER FOR INJECTION</u>									
LIQUID; N/A									
STERILE WATER FOR INJECTION									
AP		EUROHLTH INTL SARL	100%		A206369	001	Sep 02, 2015	Aug	NEWA
<u>SUCCINYLCHOLINE CHLORIDE</u>									
INJECTABLE; INJECTION									
QUELICIN PRESERVATIVE FREE									
	@	HOSPIRA	100MG/ML		N008845	004		Jun	DISC
<u>SUCRALFATE</u>									
TABLET; ORAL									
SUCRALFATE									
AB		MYLAN PHARMS INC	1GM		A074415	001	Jun 08, 1998	May	CAHN
<u>SUFENTANIL CITRATE</u>									
INJECTABLE; INJECTION									
SUFENTANIL CITRATE									
AP		EUROHLTH INTL SARL	EQ 0.05MG BASE/ML		A074413	001	Dec 15, 1995	Jun	CAHN

SULFACETAMIDE SODIUM

LOTION;TOPICAL
KLARON

AB + VALEANT PHARMS NORTH 10% N019931 001 Dec 23, 1996 Mar CAHN

OINTMENT;OPHTHALMIC

>D> CETAMIDE

>D> AT + ALCON 10% A080021 001 Oct DISC

>A> @ 10% A080021 001 Oct DISC

SULFACETAMIDE SODIUM

>D> AT PERRIGO CO TENNESSEE 10% A080029 001 Oct CRLD

>A> + 10% A080029 001 Oct CRLD

SOLUTION/DROPS;OPHTHALMIC

SULFACETAMIDE SODIUM

AT AKORN 10% A040215 001 May 25, 1999 Mar CMFD

SULFAMETHOXAZOLE; TRIMETHOPRIM

SUSPENSION;ORAL

SULFAMETHOXAZOLE AND TRIMETHOPRIM

@ ANI PHARMS INC 200MG/5ML;40MG/5ML A070028 001 Jun 02, 1987 Jul CAHN

SULFANILAMIDE

CREAM;VAGINAL

SULFANILAMIDE

@ G AND W LABS INC 15% A088718 001 Sep 19, 1985 Apr CAHN

SULFISOXAZOLE

TABLET;ORAL

SULFISOXAZOLE

>A> @ ANI PHARMS INC 500MG A080142 001 Oct CAHN

>D> @ IVAX SUB TEVA PHARMS 500MG A080142 001 Oct CAHN

SULINDAC

TABLET;ORAL

SULINDAC

@ ANI PHARMS INC 150MG A072972 001 Feb 28, 1992 Aug CAHN

@ 200MG A072973 001 Feb 28, 1992 Aug CAHN

SUMATRIPTAN SUCCINATE

TABLET;ORAL

SUMATRIPTAN SUCCINATE

@ SANDOZ EQ 25MG BASE A076976 001 Aug 10, 2009 Sep DISC

@ EQ 50MG BASE A076976 002 Aug 10, 2009 Sep DISC

@ EQ 100MG BASE A076976 003 Aug 10, 2009 Sep DISC

AB SUN PHARM INDS LTD EQ 25MG BASE A076554 001 Aug 10, 2009 Apr CAHN

AB EQ 50MG BASE A076554 002 Aug 10, 2009 Apr CAHN

AB EQ 100MG BASE A076572 001 Feb 09, 2009 Apr CAHN

TACROLIMUS

TABLET, EXTENDED RELEASE;ORAL

ENVARUS XR

VELOXIS PHARMS INC EQ 0.75MG BASE N206406 001 Jul 10, 2015 Jul NEWA

EQ 1MG BASE N206406 002 Jul 10, 2015 Jul NEWA

+ EQ 4MG BASE N206406 003 Jul 10, 2015 Jul NEWA

TAPENTADOL HYDROCHLORIDE

SOLUTION;ORAL

NUCYNTA

+ DEPOMED INC EQ 20MG BASE/ML N203794 001 Oct 15, 2012 May CAHN

TABLET;ORAL

NUCYNTA

DEPOMED INC EQ 50MG BASE N022304 001 Nov 20, 2008 May CAHN

EQ 75MG BASE N022304 002 Nov 20, 2008 May CAHN

+ EQ 100MG BASE N022304 003 Nov 20, 2008 May CAHN

TABLET, EXTENDED RELEASE;ORAL

NUCYNTA ER

DEPOMED INC EQ 50MG BASE N200533 001 Aug 25, 2011 May CAHN

EQ 100MG BASE N200533 002 Aug 25, 2011 May CAHN

EQ 150MG BASE N200533 003 Aug 25, 2011 May CAHN

EQ 200MG BASE N200533 004 Aug 25, 2011 May CAHN

+ EQ 250MG BASE N200533 005 Aug 25, 2011 May CAHN

TEDIZOLID PHOSPHATEPOWDER;IV (INFUSION)
SIVEXTRO

+ CUBIST PHARMS LLC 200MG/VIAL

N205436 001 Jun 20, 2014 Sep CAHN

TABLET;ORAL
SIVEXTRO

+ CUBIST PHARMS LLC 200MG

N205435 001 Jun 20, 2014 Sep CAHN

TELAPREVIRTABLET;ORAL
INCIVEK

@ VERTEX PHARMS 375MG

N201917 001 May 23, 2011 Jan DISC

TELMISARTANTABLET;ORAL
TELMISARTAN

AB AMNEAL PHARMS 20MG

A204415 001 Sep 08, 2015 Aug NEWA

AB 40MG

A204415 002 Sep 08, 2015 Aug NEWA

AB 80MG

A204415 003 Sep 08, 2015 Aug NEWA

AB AUROBINDO PHARMA LTD 20MG

A206511 001 Sep 03, 2015 Aug NEWA

AB 40MG

A206511 002 Sep 03, 2015 Aug NEWA

AB 80MG

A206511 003 Sep 03, 2015 Aug NEWA

>A> AB INVENTIA HLTHCARE 20MG

A205150 001 Oct 30, 2015 Oct NEWA

>A> AB 40MG

A205150 002 Oct 30, 2015 Oct NEWA

>A> AB 80MG

A205150 003 Oct 30, 2015 Oct NEWA

TEMAZEPAMCAPSULE;ORAL
TEMAZEPAM

AB VINTAGE PHARMS 7.5MG

A201781 001 Jun 04, 2015 May NEWA

AB 15MG

A201781 002 Jun 04, 2015 May NEWA

AB 22.5MG

A201781 003 Jun 04, 2015 May NEWA

AB 30MG

A201781 004 Jun 04, 2015 May NEWA

TEMOZOLOMIDECAPSULE;ORAL
TEMOZOLOMIDE

AB AMNEAL PHARMS 5MG

A203691 001 May 08, 2015 Apr NEWA

AB 20MG

A203691 002 May 08, 2015 Apr NEWA

AB 100MG

A203691 003 May 08, 2015 Apr NEWA

AB 140MG

A203691 004 May 08, 2015 Apr NEWA

AB 180MG

A203691 005 May 08, 2015 Apr NEWA

AB 250MG

A203691 006 May 08, 2015 Apr NEWA

TENOFOVIR DISOPROXIL FUMARATETABLET;ORAL
TENOFOVIR DISOPROXIL FUMARATE

AB TEVA PHARMS USA 300MG

A091612 001 Mar 18, 2015 Mar NEWA

VIREAD

AB + GILEAD SCIENCES INC 300MG

N021356 001 Oct 26, 2001 Mar CFTG

TERBINAFINEGEL;TOPICAL
LAMISIL

@ GLAXOSMITHKLINE CONS 1%

N020846 001 Apr 29, 1998 Aug CAHN

TERBINAFINE HYDROCHLORIDESOLUTION;TOPICAL
LAMISIL

@ GLAXOSMITHKLINE CONS 1%

N020749 001 Oct 17, 1997 Aug CAHN

TABLET;ORAL
TERBINAFINE HYDROCHLORIDE

@ WOCKHARDT EQ 250MG BASE

A078229 001 Jul 02, 2007 Feb DISC

TERCONAZOLESUPPOSITORY;VAGINAL
TERCONAZOLE

AB TARO 80MG

A077553 001 Mar 09, 2007 Sep CMFD

TESTOSTERONEGEL;TRANSDERMAL
ANDROGEL

AB1	ABBVIE	25MG/2.5GM PACKET	N021015	001	Feb 28, 2000	Jan CTEC	
AB1	+	50MG/5GM PACKET	N021015	002	Feb 28, 2000	Jan CTEC	
	TESTIM						
AB2	+	AUXILIUM PHARMS	50MG/5GM PACKET	N021454	001	Oct 31, 2002	Jan CTEC
	TESTOSTERONE						
	@ ACTAVIS LABS UT INC	1% (2.5GM/PACKET)	A076737	001	Jan 27, 2006	Mar CAHN	
	@	1% (5GM/PACKET)	A076737	002	Jan 27, 2006	Mar CAHN	
AB1		25MG/2.5GM PACKET	A076737	001	Jan 27, 2006	Jul CMFD	
AB1		50MG/5GM PACKET	A076737	002	Jan 27, 2006	Jul CMFD	
BX	ANI PHARMS INC	25MG/2.5GM PACKET	N202763	001	Feb 14, 2012	May CAHN	
BX		50MG/5GM PACKET	N202763	002	Feb 14, 2012	May CAHN	
AB1	PAR PHARM	25MG/2.5GM PACKET	A076744	001	May 23, 2007	Aug CMFD	
AB1		50MG/5GM PACKET	A076744	002	May 23, 2007	Aug CMFD	
AB1	PERRIGO ISRAEL	25MG/2.5GM PACKET	N203098	002	Jan 31, 2013	Jan CTEC	
AB1		50MG/5GM PACKET	N203098	003	Jan 31, 2013	Jan CTEC	
	VOGELXO						
AB2	UPSHER SMITH	50MG/5GM PACKET	N204399	002	Jun 04, 2014	Jan CTEC	
	GEL, METERED;TRANSDERMAL						
	ANDROGEL						
AB	+	ABBVIE	1.62% (20.25MG/1.25GM ACTUATION)	N022309	001	Apr 29, 2011	Jul CFTG
	FORTESTA						
AB	+	ENDO PHARMS	10MG/0.5GM ACTUATION	N021463	001	Dec 29, 2010	Jul CFTG
	TESTOSTERONE						
AB	ACTAVIS LABS UT INC	10MG/0.5GM ACTUATION	A204571	001	Aug 05, 2015	Jul NEWA	
AB		12.5MG/1.25GM ACTUATION	A076737	003	Mar 09, 2015	Aug NEWA	
AB	PERRIGO ISRAEL	1.62% (20.25MG/1.25GM ACTUATION)	A204268	001	Aug 04, 2015	Jul NEWA	

TETRABENAZINE

TABLET;ORAL

TETRABENAZINE

AB	SUN PHARMA GLOBAL	12.5MG	A206129	001	Aug 17, 2015	Aug NEWA
AB		25MG	A206129	002	Aug 17, 2015	Aug NEWA
	XENAZINE					
AB	VALEANT PHARMS NORTH	12.5MG	N021894	001	Aug 15, 2008	Aug CFTG
		12.5MG	N021894	001	Aug 15, 2008	Feb CAHN
AB	+	25MG	N021894	002	Aug 15, 2008	Aug CFTG
	+	25MG	N021894	002	Aug 15, 2008	Feb CAHN

TETRACYCLINE HYDROCHLORIDE

CAPSULE;ORAL

ACHROMYCIN V

AB	+	HERITAGE PHARMS INC	500MG	N050278	001		Apr	CRLD
		TETRACYCLINE HYDROCHLORIDE						
	@	CHARTWELL CIENCA	250MG	A062752	001	Aug 12, 1988	Sep	CAHN
	@		500MG	A062752	002	Aug 12, 1988	Sep	CAHN
	@	IVAX SUB TEVA PHARMS	250MG	A060704	001		Apr	DISC
	@		500MG	A060704	002		Apr	DISC

THEOPHYLLINE

TABLET;ORAL

THEOLAIR

@ MEDICIS

@

		125MG	A086399	001		Mar DISC
		250MG	A086399	002		Mar DISC
	TABLET, EXTENDED RELEASE;ORAL					
	THEOPHYLLINE					
AB	MYLAN PHARMS INC	400MG	A040595	001	Apr 21, 2006	May CAHN
AB	+	600MG	A040560	002	Apr 21, 2006	May CAHN

THIOTEPA

INJECTABLE;INJECTION

THIOTEPA

+	EUROHLTH INTL SARL	15MG/VIAL	A075547	001	Apr 02, 2001	May CRLD
---	--------------------	-----------	---------	-----	--------------	----------

TICAGRELORTABLET; ORAL
BRILINTA

ASTRAZENECA LP

60MG

N022433 002 Sep 03, 2015 Sep NEWA

TIGECYCLINE

INJECTABLE; IV (INFUSION)

TIGECYCLINE

AP SANDOZ INC

50MG/VIAL

A091620 001 May 27, 2015 May NEWA

TYGACIL

AP + PF PRISM CV

50MG/VIAL

N021821 001 Jun 15, 2005 May CFTG

TIMOLOL MALEATE

SOLUTION/DROPS; OPHTHALMIC

ISTALOL

AT2 + BAUSCH AND LOMB

EQ 0.5% BASE

N021516 001 Jun 04, 2004 Apr CFTG

TIMOLOL MALEATE

AT1 AKORN

EQ 0.5% BASE

A074466 001 Mar 25, 1997 Apr CTEC

AT1

EQ 0.5% BASE

A074516 001 Mar 25, 1997 Apr CTEC

AT1 ALCON RES LTD

EQ 0.5% BASE

A074262 001 Apr 28, 1995 Apr CTEC

AT2 APOTEX INC

EQ 0.5% BASE

A204936 001 Apr 17, 2015 Apr NEWA

AT1 BAUSCH AND LOMB

EQ 0.5% BASE

A074776 001 Mar 25, 1997 Apr CTEC

AT1 FDC LTD

EQ 0.5% BASE

A077259 002 Apr 30, 2008 Apr CTEC

AT1 HI TECH PHARMA

EQ 0.5% BASE

A075163 001 Sep 10, 2002 Apr CTEC

AT1 PACIFIC PHARMA

EQ 0.5% BASE

A074747 001 Mar 25, 1997 Apr CTEC

AT1 WOCKHARDT

EQ 0.5% BASE

A078771 002 Sep 28, 2009 Apr CTEC

TIMOPTIC

AT1 + ATON

EQ 0.5% BASE

N018086 002 Apr CTEC

TINIDAZOLE

TABLET; ORAL

TINIDAZOLE

AB EDENBRIDGE PHARMS

250MG

A203808 001 Aug 04, 2015 Jul NEWA

AB

500MG

A203808 002 Aug 04, 2015 Jul NEWA

TIOTROPIUM BROMIDE

SPRAY, METERED; INHALATION

SPIRIVA RESPIMAT

BOEHRINGER INGELHEIM

EQ 0.00125MG BASE/INH

N021936 002 Sep 15, 2015 Sep NEWA

TIPIRACIL HYDROCHLORIDE; TRIFLURIDINE

TABLET; ORAL

LONSURF

TAIHO ONCOLOGY

EQ 6.14MG BASE; 15MG

N207981 001 Sep 22, 2015 Sep NEWA

+

EQ 8.19MG BASE; 20MG

N207981 002 Sep 22, 2015 Sep NEWA

TOBRAMYCIN

SOLUTION; INHALATION

KITABIS PAK

AN PULMOFLOW INC

300MG/5ML

N205433 001 Dec 02, 2014 Feb CTEC

TOBRAMYCIN

AN AMNEAL PHARMS

300MG/5ML

A205501 001 Jul 13, 2015 Jun NEWA

SOLUTION/DROPS; OPHTHALMIC

TOBREX

AT + ALCON LABS INC

0.3%

N050541 001 Mar CAHN

TOBRAMYCIN SULFATE

INJECTABLE; INJECTION

TOBRAMYCIN SULFATE

@ IGI LABS INC

EQ 10MG BASE/ML

A063119 001 Oct 31, 1994 Mar CAHN

@

EQ 40MG BASE/ML

A063120 001 Oct 31, 1994 Mar CAHN

@

EQ 40MG BASE/ML

A063121 001 Oct 31, 1994 Mar CAHN

@

EQ 40MG BASE/ML

A063122 001 Oct 31, 1994 Mar CAHN

TOBRAMYCIN SULFATE (PHARMACY BULK)

+ FRESENIUS KABI USA

EQ 40MG BASE/ML

A065120 001 Nov 29, 2002 Jul CTEC

AP +

EQ 40MG BASE/ML

A065120 001 Nov 29, 2002 Jul CRLD

@ HOSPIRA

EQ 40MG BASE/ML

A063116 001 May 18, 1992 Jul DISC

AP

EQ 40MG BASE/ML

A063116 001 May 18, 1992 Jul CTNA

TOLAZAMIDETABLET; ORAL
TOLAZAMIDE

@ G AND W LABS INC	100MG	N018894	001	Nov 02, 1984	Apr CAHN
@	250MG	N018894	002	Nov 02, 1984	Apr CAHN
@	500MG	N018894	003	Nov 02, 1984	Apr CAHN

TOLCAPONETABLET; ORAL
TASMAR

AB	+ VALEANT PHARMS LLC	100MG	N020697	001	Jan 29, 1998	Mar CFTG
AB	PAR PHARM INC	100MG	A204584	001	Mar 26, 2015	Mar NEWA

TOLMETIN SODIUMTABLET; ORAL
TOLMETIN SODIUM

@ G AND W LABS INC	EQ 600MG BASE	A074399	001	Mar 28, 1996	May CAHN
@	EQ 600MG BASE	A074729	001	Feb 27, 1997	Apr CAHN

TOLTERODINE TARTRATECAPSULE, EXTENDED RELEASE; ORAL
TOLTERODINE TARTRATE

AB	TORRENT PHARMS LTD	2MG	A203016	001	Aug 11, 2015	Jul NEWA
AB		4MG	A203016	002	Aug 11, 2015	Jul NEWA

TABLET; ORAL

TOLTERODINE TARTRATE

AB	IVAX SUB TEVA PHARMS	1MG	A077006	001	Feb 23, 2015	Feb NEWA
AB		2MG	A077006	002	Feb 23, 2015	Feb NEWA
AB	MACLEODS PHARMS LTD	1MG	A203409	001	Aug 31, 2015	Aug NEWA
AB		2MG	A203409	002	Aug 31, 2015	Aug NEWA

TOPIRAMATETABLET; ORAL
TOPIRAMATE

AB	SUN PHARM INDS LTD	25MG	A076327	001	Mar 27, 2009	Apr CAHN
AB		100MG	A076327	002	Mar 27, 2009	Apr CAHN
AB		200MG	A076327	003	Mar 27, 2009	Apr CAHN
	@ WOCKHARDT USA	25MG	A090353	001	Sep 01, 2010	Apr DISC
	@	50MG	A090353	002	Sep 01, 2010	Apr DISC
	@	100MG	A090353	003	Sep 01, 2010	Apr DISC
	@	200MG	A090353	004	Sep 01, 2010	Apr DISC
	TOPIRAMATE					
	@ HIKMA PHARMS	25MG	A091185	001	Nov 25, 2013	May DISC
	@	50MG	A091185	002	Nov 25, 2013	May DISC
	@	100MG	A091185	003	Nov 25, 2013	May DISC
	@	200MG	A091185	004	Nov 25, 2013	May DISC

TOPOTECAN HYDROCHLORIDECAPSULE; ORAL
HYCANTIN

NOVARTIS PHARMS CORP	EQ 0.25MG BASE	N020981	001	Oct 11, 2007	Mar CAHN
+	EQ 1MG BASE	N020981	002	Oct 11, 2007	Mar CAHN

INJECTABLE; INJECTION
HYCANTIN

AP	+ NOVARTIS PHARMS CORP	EQ 4MG BASE/VIAL	N020671	001	May 28, 1996	Mar CAHN
AP	TOPOTECAN HYDROCHLORIDE					
	CHEM WERTH INC	EQ 4MG BASE/VIAL	A201166	001	Aug 08, 2012	May CAHN

TORSEMIDEINJECTABLE; INJECTION
TORSEMIDE

@ EUROHLTH INTL SARL	20MG/2ML (10MG/ML)	A078007	001	Jun 11, 2008	Jan DISC
@	50MG/5ML (10MG/ML)	A078007	002	Jun 11, 2008	Jan DISC
@ LUITPOLD	20MG/2ML (10MG/ML)	A090656	001	Apr 21, 2010	Jan DISC
@	50MG/5ML (10MG/ML)	A090656	002	Apr 21, 2010	Jan DISC

>A>	<u>TRABECTEDIN</u>							
>A>	POWDER; IV (INFUSION)							
>A>	YONDELIS							
>A>	+	JANSSEN PRODS	1MG/VIAL		N207953	001	Oct 23, 2015	Oct NEWA
	<u>TRAMADOL HYDROCHLORIDE</u>							
	TABLET; ORAL							
	TRAMADOL HYDROCHLORIDE							
AB		MACLEODS PHARMS LTD	50MG		A205702	001	Sep 25, 2015	Sep NEWA
	TABLET, EXTENDED RELEASE; ORAL							
	TRAMADOL HYDROCHLORIDE							
>A>	AB1	AUROBINDO PHARMA LTD	100MG		A204421	001	Oct 20, 2015	Oct NEWA
>A>	AB1		200MG		A204421	002	Oct 20, 2015	Oct NEWA
>A>	AB1		300MG		A204421	003	Oct 20, 2015	Oct NEWA
	<u>TRAMETINIB DIMETHYL SULFOXIDE</u>							
	TABLET; ORAL							
	MEKINIST							
		NOVARTIS PHARMS CORP	EQ 0.5MG NON-SOLVATED PARENT		N204114	001	May 29, 2013	Mar CAHN
			EQ 1MG NON-SOLVATED PARENT		N204114	002	May 29, 2013	Mar CAHN
	+		EQ 2MG NON-SOLVATED PARENT		N204114	003	May 29, 2013	Mar CAHN
	<u>TRANEXAMIC ACID</u>							
	INJECTABLE; INJECTION							
	TRANEXAMIC ACID							
AP		FRESENIUS KABI USA	100MG/ML		A091596	001	Mar 02, 2012	Apr CMFD
	TABLET; ORAL							
	TRANEXAMIC ACID							
AB		MYLAN	650MG		A205133	001	Sep 21, 2015	Sep NEWA
	<u>TRANLYCYPROMINE SULFATE</u>							
	TABLET; ORAL							
	PARNATE							
AB	+	CONCORDIA PHARMS INC	EQ 10MG BASE		N012342	003	Aug 16, 1985	Jun CAHN
	<u>TRAVOPROST</u>							
	SOLUTION/DROPS; OPHTHALMIC							
	IZBA							
		@ ALCON LABS INC	0.003%		N204822	001	May 15, 2014	Jul DISC
	TRAVATAN Z							
AT	+	ALCON PHARMS LTD	0.004%		N021994	001	Sep 21, 2006	Jun CTEC
	TRAVOPROST							
AT		APOTEX INC	0.004%		A203431	001	Jul 10, 2015	Jun NEWA
	<u>TRAZODONE HYDROCHLORIDE</u>							
	TABLET; ORAL							
	DESYREL							
		@ PRAGMA PHARMS LLC	50MG		N018207	001		May CAHN
		@	100MG		N018207	002		May CAHN
		@	150MG		N018207	003	Mar 25, 1985	May CAHN
		@	300MG		N018207	004	Nov 07, 1988	May CAHN
	<u>TRETINOIN</u>							
	CREAM; TOPICAL							
	RENOVA							
	+	VALEANT PHARMS NORTH	0.02%		N021108	001	Aug 31, 2000	Apr CAHN
AB2	+		0.05%		N019963	001	Dec 29, 1995	Apr CAHN
	RETIN-A							
AB	+	VALEANT PHARMS NORTH	0.1%		N017340	001		Apr CAHN
	GEL; TOPICAL							
	ATRALIN							
AB	+	DOW PHARM	0.05%		N022070	001	Jul 26, 2007	Jul CTEC
	TRETINOIN							
AB		SPEAR PHARMS INC	0.05%		A207955	001	Aug 13, 2015	Jul NEWA

TRIAMCINOLONE ACETONIDE

CREAM; TOPICAL

TRIAMCINOLONE ACETONIDE

AT	G AND W LABS	0.025%	A089797	001	May 31, 1991	Apr	CMFD
AT		0.1%	A089798	001	May 31, 1991	Apr	CMFD
	TRIDERM						
AT	CROWN LABS	0.025%	A088042	002	Mar 25, 2015	Mar	NEWA
AT		0.5%	A088042	003	Mar 25, 2015	Mar	NEWA
	LOTION; TOPICAL						
	TRIAMCINOLONE ACETONIDE						
AT	G AND W LABS INC	0.1%	A089129	001	Aug 14, 1986	Mar	CMFD
	OINTMENT; TOPICAL						
	KENALOG						
AT	DELCOR ASSET CORP	0.025%	N011600	003		Mar	CMFD
AT		0.1%	N011600	001		Mar	CMFD
	TRIAMCINOLONE ACETONIDE						
AT	G AND W LABS	0.025%	A089795	001	Dec 23, 1988	Aug	CMFD
AT		0.1%	A089796	001	Dec 23, 1988	Aug	CMFD
	SPRAY; TOPICAL						
	KENALOG						
AT	+ RANBAXY	0.147MG/GM	N012104	001		Mar	CFTG
AT	+ SUN PHARM INDS LTD	0.147MG/GM	N012104	001		Aug	CAHN
	TRIAMCINOLONE ACETONIDE						
AT	PERRIGO UK FINCO	0.147MG/GM	A205782	001	Apr 13, 2015	Mar	NEWA

TRIAMTERENE

CAPSULE; ORAL

DYRENIUM

	CONCORDIA PHARMS INC	50MG	N013174	001		Apr	CAHN
+		100MG	N013174	002		Apr	CAHN

TRIMIPRAMINE MALEATE

CAPSULE; ORAL

SURMONTIL

AB	+ ODYSSEY PHARMS	EQ 50MG BASE	N016792	002		Jun	CRLD
AB		EQ 100MG BASE	N016792	003	Sep 15, 1982	Jun	CRLD

TRIPLE SULFA (SULFABENZAMIDE; SULFACETAMIDE; SULFATHIAZOLE)

CREAM; VAGINAL

VAGILIA

@	G AND W LABS INC	3.7%; 2.86%; 3.42%	A088821	001	Nov 09, 1987	Jul	CAHN
---	------------------	--------------------	---------	-----	--------------	-----	------

TRIPTORELIN PAMOATE

INJECTABLE; INTRAMUSCULAR

TRELSTAR

+	ACTAVIS LABS UT INC	EQ 3.75MG BASE/VIAL	N020715	001	Jun 15, 2000	Jan	CAHN
+		EQ 11.25MG BASE/VIAL	N021288	001	Jun 29, 2001	Jan	CAHN
+		EQ 22.5MG BASE/VIAL	N022437	001	Mar 10, 2010	Jan	CAHN

TROSPIMUM CHLORIDE

CAPSULE, EXTENDED RELEASE; ORAL

SANCTURA XR

@	ALLERGAN	60MG	N022103	001	Aug 03, 2007	May	DISC
---	----------	------	---------	-----	--------------	-----	------

TROSPIMUM CHLORIDE

AB	ACTAVIS LABS FL INC	60MG	A091289	001	Oct 12, 2012	Jun	CRLD
AB	+	60MG	A091289	001	Oct 12, 2012	May	CRLD
AB	SANDOZ INC	60MG	A091635	001	Apr 29, 2015	Apr	NEWA

TABLET; ORAL

SANCTURA

@	ALLERGAN	20MG	N021595	001	May 28, 2004	May	DISC
---	----------	------	---------	-----	--------------	-----	------

TROSPIMUM CHLORIDE

AB	GLENMARK GENERICS	20MG	A091575	001	Aug 13, 2010	Jun	CRLD
AB	+	20MG	A091575	001	Aug 13, 2010	May	CRLD

UNOPROSTONE ISOPROPYL

SOLUTION/DROPS; OPHTHALMIC

RESCULA

+	R-TECH UENO LTD	0.15%	N021214	001	Aug 03, 2000	May	CAHN
+	SUCAMPO PHARMA LLC	0.15%	N021214	001	Aug 03, 2000	Jan	CAHN

URIDINE TRIACETATEGRANULE;ORAL
XURIDEN

+ WELLSTAT THERAP 2GM/PACKET N208169 001 Sep 04, 2015 Sep NEWA

URSODIOLCAPSULE;ORAL
ACTIGALLAB + @ ACTAVIS LABS UT INC 150MG N019594 001 Dec 31, 1987 Mar CAHN
300MG N019594 002 Dec 31, 1987 Mar CAHNVALACYCLOVIR HYDROCHLORIDE

TABLET;ORAL

VALACYCLOVIR HYDROCHLORIDE

AB HETERO LABS LTD V EQ 500MG BASE A203047 001 Apr 08, 2015 Mar NEWA
AB EQ 1GM BASE A203047 002 Apr 08, 2015 Mar NEWA
AB SUN PHARM INDS LTD EQ 500MG BASE A076588 001 Jan 31, 2007 Apr CAHN
AB EQ 1GM BASE A076588 002 Jan 31, 2007 Apr CAHNVALPROIC ACIDCAPSULE;ORAL
VALPROIC ACID

AB BANNER LIFE SCIENCES 250MG A073484 001 Jun 29, 1993 Jan CAHN

CAPSULE, DELAYED RELEASE;ORAL
STAVZOR@ BANNER LIFE SCIENCES 125MG N022152 001 Jul 29, 2008 Jan CAHN
@ 250MG N022152 002 Jul 29, 2008 Jan CAHN
@ 500MG N022152 003 Jul 29, 2008 Jan CAHNVALSARTAN

TABLET;ORAL

VALSARTAN

AB PRINSTON INC 40MG A204821 001 Jun 09, 2015 May NEWA
AB 80MG A204821 002 Jun 09, 2015 May NEWA
AB 160MG A204821 003 Jun 09, 2015 May NEWA
AB 320MG A204821 004 Jun 09, 2015 May NEWAVANCOMYCIN HYDROCHLORIDE

CAPSULE;ORAL

VANCOMYCIN HYDROCHLORIDE

AB LUPIN LTD EQ 125MG BASE A090439 001 Jan 28, 2015 Jan NEWA
AB EQ 250MG BASE A090439 002 Jan 28, 2015 Jan NEWA

INJECTABLE;INJECTION

VANCOLED

@ EUROHLTH INTL SARL EQ 500MG BASE/VIAL A062682 001 Jul 22, 1986 Jun CAHN
@ EQ 1GM BASE/VIAL A062682 002 Mar 30, 1988 Jun CAHN
@ EQ 2GM BASE/VIAL A062682 003 May 11, 1988 Jun CAHN
@ EQ 5GM BASE/VIAL A062682 004 May 11, 1988 Jun CAHN
@ EQ 10GM BASE/VIAL A062682 005 May 11, 1988 Jun CAHN

VANCOMYCIN HYDROCHLORIDE

AP XELLIA PHARMS APS EQ 500MG BASE/VIAL A091377 001 Sep 09, 2015 Aug NEWA
AP EQ 1GM BASE/VIAL A091377 002 Sep 09, 2015 Aug NEWAVARDENAFIL HYDROCHLORIDETABLET, ORALLY DISINTEGRATING;ORAL
STAXYN

AB + BAYER HLTHCARE 10MG N200179 001 Jun 17, 2010 Apr CFTG

VARDENAFIL HYDROCHLORIDE

AB WATSON LABS INC 10MG A203689 001 Apr 22, 2015 Apr NEWA

VENLAFAXINE HYDROCHLORIDECAPSULE, EXTENDED RELEASE;ORAL
VENLAFAXINE HYDROCHLORIDEAB VALEANT PHARMS NORTH EQ 37.5MG BASE A090071 001 Apr 15, 2011 Feb CAHN
AB EQ 75MG BASE A090071 002 Apr 15, 2011 Feb CAHN
AB EQ 150MG BASE A090071 003 Apr 15, 2011 Feb CAHN

TABLET;ORAL

VENLAFAXINE HYDROCHLORIDE

AB YAOPHARMA CO LTD EQ 25MG BASE A202036 001 May 28, 2015 May NEWA
AB EQ 37.5MG BASE A202036 002 May 28, 2015 May NEWA
AB EQ 50MG BASE A202036 003 May 28, 2015 May NEWA

TABLET;ORAL

VENLAFAXINE HYDROCHLORIDE

AB		EQ 75MG BASE	A202036	004	May 28, 2015	May	NEWA
AB		EQ 100MG BASE	A202036	005	May 28, 2015	May	NEWA

VERAPAMIL HYDROCHLORIDE

CAPSULE, EXTENDED RELEASE;ORAL

VERELAN

AB	RECRO GAINESVILLE	120MG	N019614	001	May 29, 1990	Apr	CAHN
AB		180MG	N019614	003	Jan 09, 1992	Apr	CAHN
AB		240MG	N019614	002	May 29, 1990	Apr	CAHN
	+	360MG	N019614	004	May 10, 1996	Apr	CAHN
	VERELAN PM						
AB	RECRO GAINESVILLE	100MG	N020943	001	Nov 25, 1998	Apr	CAHN
AB		200MG	N020943	002	Nov 25, 1998	Apr	CAHN
AB	+	300MG	N020943	003	Nov 25, 1998	Apr	CAHN

INJECTABLE;INJECTION

CALAN

@	EXELA PHARMA SCS LLC	2.5MG/ML	N018925	001	Mar 30, 1984	Aug	CAHN
---	----------------------	----------	---------	-----	--------------	-----	------

ISOPTIN

@	MT ADAMS	2.5MG/ML	N018485	001		Apr	CAHN
---	----------	----------	---------	-----	--	-----	------

TABLET;ORAL

ISOPTIN

@	MT ADAMS	40MG	N018593	003	Nov 23, 1987	Apr	CAHN
@		80MG	N018593	001	Mar 08, 1982	Apr	CAHN
@		120MG	N018593	002	Mar 08, 1982	Apr	CAHN

VERAPAMIL HYDROCHLORIDE

>A>	AB	HERITAGE PHARMS INC	40MG	A071881	002	Oct 14, 2015	Oct	NEWA
-----	----	---------------------	------	---------	-----	--------------	-----	------

VERTEPORFIN

INJECTABLE;INJECTION

VISUDYNE

+	VALEANT LUXEMBOURG	15MG/VIAL	N021119	001	Apr 12, 2000	Mar	CAHN
---	--------------------	-----------	---------	-----	--------------	-----	------

VILAZODONE HYDROCHLORIDE

TABLET;ORAL

VIIBRYD

+	FOREST LABS LLC	10MG	N022567	001	Jan 21, 2011	Mar	CAHN
		20MG	N022567	002	Jan 21, 2011	Mar	CAHN
		40MG	N022567	003	Jan 21, 2011	Mar	CAHN

VINORELBINE TARTRATE

INJECTABLE;INJECTION

VINORELBINE TARTRATE

AP	EUROHLTH INTL SARL	EQ 10MG BASE/ML	A075992	001	Jun 10, 2003	Sep	CAHN
----	--------------------	-----------------	---------	-----	--------------	-----	------

VORICONAZOLE

TABLET;ORAL

VORICONAZOLE

AB	GLENMARK PHARMS LTD	50MG	A203503	001	Sep 02, 2015	Aug	NEWA
AB		200MG	A203503	002	Sep 02, 2015	Aug	NEWA

ZAFIRLUKAST

TABLET;ORAL

ACCOLATE

AB	PAR PHARM INC	10MG	N020547	003	Sep 17, 1999	Feb	CAHN
AB	+	20MG	N020547	001	Sep 26, 1996	Feb	CAHN

ZOLEDRONIC ACID

INJECTABLE;IV (INFUSION)

ZOLEDRONIC ACID

AP	FRESENIUS KABI USA	EQ 4MG BASE/5ML	A091516	001	Apr 23, 2015	Apr	NEWA
AP	HOSPIRA INC	EQ 4MG BASE/5ML	A090621	001	Mar 19, 2015	Mar	NEWA
AP	MYLAN LABS LTD	EQ 4MG BASE/5ML	A202650	001	Mar 04, 2013	Jul	CAHN
AP	USV NORTH AMERICA	EQ 4MG BASE/5ML	A202923	001	Sep 04, 2014	Mar	CPOT

ZOLMITRIPTAN

TABLET;ORAL

ZOLMITRIPTAN

AB	ALEMBIC PHARMS LTD	2.5MG	A204232	001	Sep 30, 2015	Sep NEWA
AB		5MG	A204232	002	Sep 30, 2015	Sep NEWA
AB	MACLEODS PHARMS LTD	2.5MG	A203772	001	Sep 30, 2015	Sep NEWA
AB		5MG	A203772	002	Sep 30, 2015	Sep NEWA

TABLET, ORALLY DISINTEGRATING;ORAL

ZOLMITRIPTAN

AB	JUBILANT GENERICS	2.5MG	A202956	001	Sep 17, 2015	Sep NEWA
AB		5MG	A202956	002	Sep 17, 2015	Sep NEWA
>A> AB	MACLEODS PHARMS LTD	2.5MG	A204336	001	Oct 22, 2015	Oct NEWA
>A> AB		5MG	A204336	002	Oct 22, 2015	Oct NEWA

ZOLPIDEM TARTRATE

SPRAY, METERED;ORAL

ZOLPIMIST

+	AMHERST PHARMS LLC	5MG/SPRAY	N022196	001	Dec 19, 2008	Sep CAHN
---	--------------------	-----------	---------	-----	--------------	----------

TABLET;ORAL

ZOLPIDEM TARTRATE

@	HIKMA	5MG	A078129	001	Apr 30, 2008	Mar DISC
@		10MG	A078129	002	Apr 30, 2008	Mar DISC
AB	SUN PHARM INDS LTD	5MG	A078055	001	Apr 23, 2007	Apr CAHN
AB		10MG	A078055	002	Apr 23, 2007	Apr CAHN

TABLET;SUBLINGUAL

INTERMEZZO

AB	PURDUE PHARMA	1.75MG	N022328	001	Nov 23, 2011	May CFTG
AB	+	3.5MG	N022328	002	Nov 23, 2011	May CFTG

ZOLPIDEM TARTRATE

AB	NOVEL LABS INC	1.75MG	A204299	001	Jun 03, 2015	May NEWA
AB		3.5MG	A204299	002	Jun 03, 2015	May NEWA

ZONISAMIDE

CAPSULE;ORAL

ZONISAMIDE

AB	BANNER LIFE SCIENCES	25MG	A077813	001	Aug 16, 2006	Jan CAHN
AB		50MG	A077813	002	Aug 16, 2006	Jan CAHN
AB		100MG	A077813	003	Aug 16, 2006	Jan CAHN

ACETAMINOPHEN

SUPPOSITORY;RECTAL

TYLENOL

@ J AND J CONSUMER INC 120MG

N017756 002

Aug CAHN

@ 650MG

N017756 001

Aug CAHN

TABLET, EXTENDED RELEASE;ORAL

ACETAMINOPHEN

SUN PHARM INDS LTD 650MG

A078569 001

Dec 14, 2011

Apr CAHN

@ 650MG

A090205 001

Nov 18, 2009

Apr CAHN

TYLENOL

+ J AND J CONSUMER INC 650MG

N019872 001

Jun 08, 1994

Aug CAHN

+ 650MG

N019872 002

Jan 11, 2001

Aug CAHN

AVOBENZONE; OCTINOXATE; OXYBENZONE

LOTION;TOPICAL

SHADE UVAGUARD

+ BAYER HEALTHCARE LLC 3%;7.5%;3%

N020045 001

Dec 07, 1992

Mar CAHN

BUDESONIDE

SPRAY, METERED;NASAL

RHINOCORT ALLERGY

+ ASTRAZENECA PHARMS 0.032MG/SPRAY

N020746 003

Mar 23, 2015

Mar NEWA

BUTENAFINE HYDROCHLORIDE

CREAM;TOPICAL

LOTRIMIN ULTRA

+ BAYER HEALTHCARE LLC 1%

N021307 001

Dec 07, 2001

Mar CAHN

CALCIUM CARBONATE; FAMOTIDINE; MAGNESIUM HYDROXIDE

TABLET, CHEWABLE;ORAL

PEPCID COMPLETE

+ J AND J CONSUMER INC 800MG;10MG;165MG

N020958 001

Oct 16, 2000

Aug CAHN

CETIRIZINE HYDROCHLORIDE

CAPSULE;ORAL

CETIRIZINE HYDROCHLORIDE ALLERGY

BANNER LIFE SCIENCES 5MG

N022429 001

Jul 23, 2009

Jan CAHN

+ 10MG

N022429 004

Jul 23, 2009

Jan CAHN

CETIRIZINE HYDROCHLORIDE HIVES RELIEF

BANNER LIFE SCIENCES 5MG

N022429 003

Jul 23, 2009

Jan CAHN

+ 10MG

N022429 002

Jul 23, 2009

Jan CAHN

SYRUP;ORAL

CHILDREN'S ZYRTEC ALLERGY

+ J AND J CONSUMER INC 5MG/5ML

N022155 002

Nov 16, 2007

Aug CAHN

CHILDREN'S ZYRTEC HIVES RELIEF

+ J AND J CONSUMER INC 5MG/5ML

N022155 001

Nov 16, 2007

Aug CAHN

TABLET;ORAL

CETIRIZINE HYDROCHLORIDE ALLERGY

AUROBINDO PHARMA LTD 5MG

A090760 001

Aug 05, 2015

Jul NEWA

10MG

A090760 003

Aug 05, 2015

Jul NEWA

SUN PHARM INDS LTD 5MG

A077498 001

Dec 27, 2007

Apr CAHN

10MG

A077498 002

Dec 27, 2007

Apr CAHN

CETIRIZINE HYDROCHLORIDE HIVES

SUN PHARM INDS LTD 5MG

A077498 003

Dec 27, 2007

Apr CAHN

10MG

A077498 004

Dec 27, 2007

Apr CAHN

CETIRIZINE HYDROCHLORIDE HIVES RELIEF

AUROBINDO PHARMA LTD 5MG

A090760 002

Aug 05, 2015

Jul NEWA

10MG

A090760 004

Aug 05, 2015

Jul NEWA

ZYRTEC ALLERGY

J AND J CONSUMER INC 5MG

N019835 003

Nov 16, 2007

Aug CAHN

+ 10MG

N019835 004

Nov 16, 2007

Aug CAHN

ZYRTEC HIVES RELIEF

J AND J CONSUMER INC 5MG

N019835 005

Nov 16, 2007

Aug CAHN

+ 10MG

N019835 006

Nov 16, 2007

Aug CAHN

TABLET, CHEWABLE;ORAL

CHILDREN'S CETIRIZINE HYDROCHLORIDE ALLERGY

JUBILANT GENERICS 5MG

A091116 001

Feb 19, 2015

Feb NEWA

10MG

A091116 002

Feb 19, 2015

Feb NEWA

SANDOZ 5MG

A078692 001

Feb 14, 2008

Feb CTNA

TABLET, CHEWABLE;ORAL				
CHILDREN'S CETIRIZINE HYDROCHLORIDE ALLERGY				
+	10MG	A078692	002	Feb 14, 2008 Feb CTNA
CHILDREN'S CETIRIZINE HYDROCHLORIDE HIVES RELIEF				
	JUBILANT GENERICS 5MG	A091116	003	Feb 19, 2015 Feb NEWA
	10MG	A091116	004	Feb 19, 2015 Feb NEWA
CHILDREN'S ZYRTEC ALLERGY				
@	J AND J CONSUMER INC 5MG	N021621	003	Nov 16, 2007 Aug CAHN
@	10MG	N021621	004	Nov 16, 2007 Aug CAHN
CHILDREN'S ZYRTEC HIVES RELIEF				
@	J AND J CONSUMER INC 5MG	N021621	005	Nov 16, 2007 Aug CAHN
@	10MG	N021621	006	Nov 16, 2007 Aug CAHN
TABLET, ORALLY DISINTEGRATING;ORAL				
CETIRIZINE HYDROCHLORIDE ALLERGY				
	PAR PHARM INC 10MG	A205490	001	Sep 02, 2015 Aug NEWA
ZYRTEC ALLERGY				
+	J AND J CONSUMER INC 10MG	N022578	001	Sep 03, 2010 Aug CAHN
<u>CETIRIZINE HYDROCHLORIDE; PSEUDOEPHEDRINE HYDROCHLORIDE</u>				
TABLET, EXTENDED RELEASE;ORAL				
ZYRTEC-D 12 HOUR				
+	J AND J CONSUMER INC 5MG;120MG	N021150	002	Nov 09, 2007 Aug CAHN
<u>CHLORPHENIRAMINE MALEATE</u>				
TABLET, EXTENDED RELEASE;ORAL				
CHLOR-TRIMETON				
@	BAYER HEALTHCARE LLC 8MG	N007638	001	Mar CAHN
+	12MG	N007638	002	Mar CAHN
<u>CHLORPHENIRAMINE MALEATE; PSEUDOEPHEDRINE SULFATE</u>				
TABLET, EXTENDED RELEASE;ORAL				
CHLOR-TRIMETON				
+	BAYER HEALTHCARE LLC 8MG;120MG	N018397	001	Mar CAHN
<u>CLEMASTINE FUMARATE</u>				
TABLET;ORAL				
CLEMASTINE FUMARATE				
@	ANI PHARMS INC 1.34MG	A073282	002	Dec 03, 1992 Jul CAHN
<u>CLOTTRIMAZOLE</u>				
CREAM;VAGINAL				
GYNE-LOTRIMIN				
+	BAYER HEALTHCARE LLC 1%	N018052	002	Nov 30, 1990 Mar CAHN
GYNE-LOTRIMIN 3				
+	BAYER HEALTHCARE LLC 2%	N020574	001	Nov 24, 1998 Mar CAHN
CREAM, TABLET;TOPICAL, VAGINAL				
GYNE-LOTRIMIN COMBINATION PACK				
+	BAYER HEALTHCARE LLC 1%,100MG	N020289	002	Apr 26, 1993 Mar CAHN
TABLET;VAGINAL				
GYNE-LOTRIMIN				
+	BAYER HEALTHCARE LLC 100MG	N017717	002	Nov 30, 1990 Mar CAHN
<u>DEXTROMETHORPHAN HYDROBROMIDE; GUAIFENESIN</u>				
TABLET, EXTENDED RELEASE;ORAL				
GUAIFENESIN AND DEXTROMETHORPHAN HYDROBROMIDE				
	ACTAVIS LABS FL INC 30MG;600MG	A091070	001	Aug 31, 2015 Aug NEWA
	60MG;1.2GM	A091070	002	Aug 31, 2015 Aug NEWA
<u>DIPHENHYDRAMINE HYDROCHLORIDE; IBUPROFEN</u>				
CAPSULE;ORAL				
IBUPROFEN AND DIPHENHYDRAMINE HYDROCHLORIDE				
	BANNER LIFE SCIENCES 25MG;EQ 200MG FREE ACID AND POTASSIUM SALT	A090397	001	Nov 22, 2010 Jan CAHN
<u>FAMOTIDINE</u>				
TABLET;ORAL				
FAMOTIDINE				
	SUN PHARM INDS LTD 10MG	A090283	001	Nov 17, 2009 Apr CAHN
	20MG	A090283	002	Nov 17, 2009 Apr CAHN
PEPCID AC				
	J AND J CONSUMER INC 10MG	N020325	001	Apr 28, 1995 Jul CAHN

TABLET;ORAL
PEPCID AC

+	20MG	N020325	002	Sep 23, 2003	Jul CAHN
	PEPCID AC				
	J AND J CONSUMER INC 10MG	N020902	001	Aug 05, 1999	Aug CAHN
	TABLET, CHEWABLE;ORAL				
	PEPCID AC				
	@ J AND J CONSUMER INC 10MG	N020801	001	Sep 24, 1998	Aug CAHN
+	20MG	N020801	002	Dec 17, 2007	Aug CAHN

FEXOFENADINE HYDROCHLORIDE

TABLET;ORAL

FEXOFENADINE HYDROCHLORIDE ALLERGY

SCIEGEN PHARMS INC	60MG	A204507	002	Sep 16, 2015	Aug NEWA
	180MG	A204507	003	Sep 16, 2015	Aug NEWA

FEXOFENADINE HYDROCHLORIDE HIVES

SCIEGEN PHARMS INC	60MG	A204507	004	Sep 16, 2015	Aug NEWA
	180MG	A204507	005	Sep 16, 2015	Aug NEWA

FEXOFENADINE HYDROCHLORIDE; PSEUDOEPHEDRINE HYDROCHLORIDE

TABLET, EXTENDED RELEASE;ORAL

FEXOFENADINE HYDROCHLORIDE AND PSEUDOEPHEDRINE HYDROCHLORIDE

SUN PHARMA GLOBAL	60MG;120MG	A090818	001	Jan 29, 2015	Jan NEWA
-------------------	------------	---------	-----	--------------	----------

GUAIFENESIN

TABLET, EXTENDED RELEASE;ORAL

GUAIFENESIN

ACTAVIS LABS FL INC	1.2GM	A091009	002	Sep 03, 2015	Aug NEWA
---------------------	-------	---------	-----	--------------	----------

GUAIFENESIN; PSEUDOEPHEDRINE HYDROCHLORIDE

TABLET, EXTENDED RELEASE;ORAL

GUAIFENESIN AND PSEUDOEPHEDRINE HYDROCHLORIDE

ACTAVIS LABS FL INC	600MG;60MG	A091071	001	May 27, 2015	May NEWA
	1.2GM;120MG	A091071	002	May 27, 2015	May NEWA

IBUPROFEN

CAPSULE;ORAL

IBUPROFEN

BANNER LIFE SCIENCES	EQ 200MG FREE ACID AND POTASSIUM SALT	A078682	001	Mar 24, 2009	Jan CAHN
----------------------	---------------------------------------	---------	-----	--------------	----------

MIDOL LIQUID GELS

+	BANNER LIFE SCIENCES	200MG	N021472	001	Oct 18, 2002	Jan CAHN
---	----------------------	-------	---------	-----	--------------	----------

SUSPENSION;ORAL

CHILDREN'S MOTRIN

+	J AND J CONSUMER INC	100MG/5ML	N020516	001	Jun 16, 1995	Aug CAHN
---	----------------------	-----------	---------	-----	--------------	----------

SUSPENSION/DROPS;ORAL

CHILDREN'S MOTRIN

+	J AND J CONSUMER INC	40MG/ML	N020603	001	Jun 10, 1996	Aug CAHN
---	----------------------	---------	---------	-----	--------------	----------

TABLET;ORAL

IBUPROFEN

>A>	@ ANI PHARMS INC	200MG	A071144	001	Jan 20, 1987	Oct CAHN
	@	200MG	A072901	001	Dec 19, 1991	Aug CAHN
	@	200MG	A072903	001	Dec 19, 1991	Aug CAHN

>D>	@ IVAX SUB TEVA PHARMS	200MG	A071144	001	Jan 20, 1987	Oct CAHN
-----	------------------------	-------	---------	-----	--------------	----------

JUNIOR STRENGTH MOTRIN

J AND J CONSUMER INC	100MG	N020602	001	Jun 10, 1996	Aug CAHN
----------------------	-------	---------	-----	--------------	----------

MOTRIN IB

+	J AND J CONSUMER INC	200MG	N019012	003	Dec 17, 1990	Aug CAHN
---	----------------------	-------	---------	-----	--------------	----------

MOTRIN MIGRAINE PAIN

+	J AND J CONSUMER INC	200MG	N019012	004	Feb 25, 2000	Aug CAHN
---	----------------------	-------	---------	-----	--------------	----------

NUPRIN

@ J AND J CONSUMER INC	200MG	N019012	001	May 18, 1984	Aug CAHN
@	200MG	N019012	002	Jul 29, 1987	Aug CAHN

TABLET, CHEWABLE;ORAL

CHILDREN'S MOTRIN

J AND J CONSUMER INC	50MG	N020601	001	Nov 15, 1996	Aug CAHN
----------------------	------	---------	-----	--------------	----------

JUNIOR STRENGTH MOTRIN

+	J AND J CONSUMER INC	100MG	N020601	003	Nov 15, 1996	Aug CAHN
---	----------------------	-------	---------	-----	--------------	----------

IBUPROFEN SODIUM

TABLET; ORAL

IBUPROFEN SODIUM

PERRIGO R AND D

EQ 200MG BASE

A206581 001 Aug 03, 2015 Jul NEWA

IBUPROFEN; PSEUDOEPHEDRINE HYDROCHLORIDE

SUSPENSION; ORAL

CHILDREN'S MOTRIN COLD

+ J AND J CONSUMER INC 100MG/5ML; 15MG/5ML

N021128 001 Aug 01, 2000 Aug CAHN

TABLET; ORAL

SINE-AID IB

J AND J CONSUMER INC 200MG; 30MG

N019899 001 Dec 31, 1992 Aug CAHN

KETOTIFEN FUMARATE

SOLUTION/DROPS; OPHTHALMIC

ALAWAY

BAUSCH AND LOMB

EQ 0.035% BASE

N021996 002 Feb 11, 2015 Feb NEWA

LEVONORGESTREL

TABLET; ORAL

LEVONORGESTREL

LOTUS PHARM CO LTD

1.5MG

A202246 001 Jun 05, 2015 May NEWA

OC PHARMA

1.5MG

A202380 001 May 29, 2015 May NEWA

LOPERAMIDE HYDROCHLORIDE

CAPSULE; ORAL

LOPERAMIDE HYDROCHLORIDE

BANNER LIFE SCIENCES

1MG

N021855 001 Aug 04, 2005 Jan CAHN

+ 2MG

N021855 002 Aug 04, 2005 Jan CAHN

SOLUTION; ORAL

IMODIUM A-D

+ J AND J CONSUMER INC 1MG/5ML

N019487 001 Mar 01, 1988 Aug CAHN

SUSPENSION; ORAL

IMODIUM A-D

+ J AND J CONSUMER INC 1MG/7.5ML

N019487 002 Jul 08, 2004 Aug CAHN

TABLET; ORAL

IMODIUM A-D

+ J AND J CONSUMER INC 2MG

N019860 001 Nov 22, 1989 Aug CAHN

TABLET, CHEWABLE; ORAL

IMODIUM A-D EZ CHEWS

+ J AND J CONSUMER INC 2MG

N020448 001 Jul 24, 1997 Aug CAHN

LOPERAMIDE HYDROCHLORIDE; SIMETHICONE

TABLET; ORAL

IMODIUM MULTI-SYMPTOM RELIEF

+ J AND J CONSUMER INC 2MG; 125MG

N021140 001 Nov 30, 2000 Aug CAHN

LOPERAMIDE HYDROCHLORIDE AND SIMETHICONE

SUN PHARM INDS LTD 2MG; 125MG

A077500 001 Sep 06, 2006 Apr CAHN

TABLET, CHEWABLE; ORAL

IMODIUM MULTI-SYMPTOM RELIEF

+ J AND J CONSUMER INC 2MG; 125MG

N020606 001 Jun 26, 1996 Aug CAHN

LORATADINE

CAPSULE; ORAL

CLARITIN

+ BAYER HEALTHCARE LLC 10MG

N021952 001 Jun 16, 2008 Mar CAHN

SYRUP; ORAL

CLARITIN

+ BAYER HEALTHCARE LLC 1MG/ML

N020641 002 Nov 27, 2002 Mar CAHN

CLARITIN HIVES RELIEF

@ BAYER HEALTHCARE LLC 1MG/ML

N020641 003 Nov 19, 2003 Mar CAHN

LORATADINE

TARO

1MG/ML

A201865 001 Jul 31, 2015 Jul NEWA

TABLET; ORAL

LORATADINE

SUN PHARM INDS LTD

10MG

A076134 001 Aug 18, 2003 Apr CAHN

TABLET, CHEWABLE; ORAL

CHILDREN'S CLARITIN

+ BAYER HEALTHCARE LLC 5MG

N021891 001 Aug 23, 2006 Mar CAHN

TABLET, ORALLY DISINTEGRATING;ORAL CLARITIN REDITABS									
+	BAYER HEALTHCARE LLC	5MG			N021993	001	Dec 12, 2006	Mar	CAHN
LORATADINE REDIDOSE									
	SUN PHARM INDS LTD	10MG			A077153	001	Apr 11, 2007	Apr	CAHN
<u>LORATADINE; PSEUDOEPHEDRINE SULFATE</u>									
TABLET, EXTENDED RELEASE;ORAL CLARITIN-D									
+	BAYER HEALTHCARE LLC	5MG;120MG			N019670	002	Nov 27, 2002	Mar	CAHN
CLARITIN-D 24 HOUR									
+	BAYER HEALTHCARE LLC	10MG;240MG			N020470	002	Nov 27, 2002	Mar	CAHN
LORATADINE AND PSEUDOEPHEDRINE SULFATE									
	SUN PHARM INDS LTD	10MG;240MG			A076557	001	Sep 22, 2004	Apr	CAHN
<u>NAPROXEN SODIUM</u>									
CAPSULE;ORAL NAPROXEN SODIUM									
+	BANNER LIFE SCIENCES	EQ 200MG BASE			N021920	001	Feb 17, 2006	Jan	CAHN
TABLET;ORAL NAPROXEN SODIUM									
	SUN PHARM INDS LTD	EQ 200MG BASE			A091183	001	May 20, 2011	Apr	CAHN
<u>NICOTINE POLACRILEX</u>									
GUM, CHEWING;BUCCAL NICOTINE POLACRILEX									
@	IVAX SUB TEVA PHARMS	EQ 2MG BASE			A076880	001	Feb 18, 2009	Mar	DISC
@		EQ 4MG BASE			A077850	001	Feb 18, 2009	Mar	DISC
<u>OMEPRAZOLE MAGNESIUM</u>									
TABLET, DELAYED RELEASE;ORAL OMEPRAZOLE MAGNESIUM									
	PERRIGO R AND D	EQ 20MG BASE			A204152	001	Jul 30, 2015	Jul	NEWA
<u>OMEPRAZOLE; SODIUM BICARBONATE</u>									
CAPSULE;ORAL ZEGERID OTC									
+	BAYER HEALTHCARE LLC	20MG;1.1GM			N022281	001	Dec 01, 2009	Mar	CAHN
FOR SUSPENSION;ORAL ZEGERID OTC									
+	BAYER HEALTHCARE LLC	20MG/PACKET;1.68GM/PACKET			N022283	001	Jun 17, 2013	Mar	CAHN
<u>OXYMETAZOLINE HYDROCHLORIDE</u>									
SOLUTION/DROPS;OPHTHALMIC OCUCLEAR									
	BAYER HEALTHCARE LLC	0.025%			N018471	001	May 30, 1986	Mar	CAHN
<u>POLYETHYLENE GLYCOL 3350</u>									
FOR SOLUTION;ORAL MIRALAX									
+	BAYER HEALTHCARE LLC	17GM/SCOOPFUL			N022015	001	Oct 06, 2006	Mar	CAHN
POLYETHYLENE GLYCOL 3350									
	RARITAN PHARMS INC	17GM/SCOOPFUL			A202071	001	Dec 28, 2012	Jan	CAHN
<u>PSEUDOEPHEDRINE HYDROCHLORIDE</u>									
TABLET, EXTENDED RELEASE;ORAL PSEUDOEPHEDRINE HYDROCHLORIDE									
	SUN PHARM INDS LTD	120MG			A077442	001	Sep 28, 2005	Apr	CAHN
SUDAFED 24 HOUR									
+	J AND J CONSUMER INC	240MG			N020021	002	Dec 15, 1992	Aug	CAHN
<u>RANITIDINE HYDROCHLORIDE</u>									
TABLET;ORAL RANITIDINE HYDROCHLORIDE									
@	SUN PHARM INDS LTD	EQ 75MG BASE			A075132	001	Jan 14, 2000	Apr	CAHN
@	WOCKHARDT	EQ 75MG BASE			A078884	001	Jul 31, 2008	Jan	DISC

**DRUG PRODUCTS WITH APPROVAL UNDER SECTION 505 OF THE ACT
ADMINISTERED BY THE CENTER FOR BIOLOGICS EVALUATION AND RESEARCH LIST**

CUMULATIVE SUPPLEMENT NUMBER 10 OCTOBER 2015

NO OCTOBER 2015 APPROVALS

ORPHAN PRODUCT DESIGNATIONS AND APPROVALS LIST

The list of List of Orphan Designations and Approvals is available at:

<http://www.fda.gov/orphan/designat/list.htm>

**DRUG PRODUCTS WHICH MUST DEMONSTRATE *IN VIVO* BIOAVAILABILITY
ONLY IF PRODUCT FAILS TO ACHIEVE ADEQUATE DISSOLUTION**

NO OCTOBER 2015 ADDITIONS

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 10 - October 2015

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>ABACAVIR SULFATE - ZIAGEN</u>						
N 020977 001					D-147	Mar 23, 2018
<u>ABACAVIR SULFATE - ZIAGEN</u>						
N 020978 001					D-147	Mar 23, 2018
<u>ABACAVIR SULFATE; DOLUTEGRAVIR SODIUM; LAMIVUDINE - TRIUMEO</u>						
N 205551 001	6417191	Mar 28, 2016	DP U-1572			
	6417191*PED	Sep 28, 2016				
<u>ABACAVIR SULFATE; LAMIVUDINE - EPZICOM</u>						
N 021652 001	6417191	Mar 28, 2016	DP U-257			
	6417191*PED	Sep 28, 2016				
<u>ACETAMINOPHEN; OXYCODONE HYDROCHLORIDE - XARTEMIS XR</u>						
N 204031 001	8980319	Dec 21, 2030	DP			
	8992975	May 16, 2032	DP			
	9050335	May 16, 2032	DP			
<u>ACLIDINIUM BROMIDE - TUDORZA PRESSAIR</u>						
N 202450 001	9056100	Jul 07, 2020	DP U-1263			
<u>ACYCLOVIR; HYDROCORTISONE - XERESE</u>						
N 022436 001	7223387	Jul 24, 2021	DP U-1006			
	7223387	Jul 24, 2021	DP U-1484			
<u>ADAPALENE; BENZOYL PEROXIDE - EPIDUO</u>						
N 022320 001	8936800	Dec 23, 2022	DP U-1078			
<u>ADAPALENE; BENZOYL PEROXIDE - EPIDUO FORTE</u>						
N 207917 001	8445543	Jul 12, 2027	U-1078		NP	Jul 15, 2018
	8703820	Mar 12, 2023	U-1078			
	8729127	Mar 12, 2023	U-1078			
	8785420	Dec 23, 2022	U-1078			
	8909305	Dec 23, 2022	U-1078			
	8936800	Dec 23, 2022	DP U-1078			
<u>ALBUTEROL SULFATE - PROAIR RESPICLICK</u>						
N 205636 001	6446627	Dec 18, 2017	DP		NP	Mar 12, 2018
	6701917	Jun 23, 2021	DP			
	6718972	Jun 23, 2021	DP			
	6748947	Jun 23, 2021	DP			
	6871646	Jun 23, 2021	DP			
	7540282	May 06, 2023	DP			
	8006690	Jun 23, 2021	DP			
	8651103	Mar 26, 2028	DP			
<u>ALBUTEROL SULFATE; IPRATROPIUM BROMIDE - COMBIVENT RESPIMAT</u>						
N 021747 001	8733341	Dec 16, 2029	DP			
	9027967	Mar 31, 2027	DP			
<u>ALCAFTADINE - LASTACFT</u>						
N 022134 001	>A> 8664215	Dec 23, 2027	U-1493			
<u>ALOGLIPTIN BENZOATE; PIOGLITAZONE HYDROCHLORIDE - OSENI</u>						
N 022426 001	8637079	Jun 04, 2029	DP			
<u>ALOGLIPTIN BENZOATE; PIOGLITAZONE HYDROCHLORIDE - OSENI</u>						
N 022426 002	8637079	Jun 04, 2029	DP			

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 10 - October 2015

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>ALOGLIPTIN BENZOATE; PIOGLITAZONE HYDROCHLORIDE - OSENI</u>						
N 022426 003	8637079	Jun 04, 2029	DP			
<u>ALOGLIPTIN BENZOATE; PIOGLITAZONE HYDROCHLORIDE - OSENI</u>						
N 022426 004	8637079	Jun 04, 2029	DP			
<u>ALOGLIPTIN BENZOATE; PIOGLITAZONE HYDROCHLORIDE - OSENI</u>						
N 022426 005	8637079	Jun 04, 2029	DP			
<u>ALOGLIPTIN BENZOATE; PIOGLITAZONE HYDROCHLORIDE - OSENI</u>						
N 022426 006	8637079	Jun 04, 2029	DP			
<u>ALVIMOPAN - ENTEREG</u>						
N 021775 001	8946262	Feb 12, 2030	U-1655			
<u>AMBRISENTAN - LETAIRIS</u>						
N 022081 001	>A> 8377933	Dec 11, 2027	U-1754		>A> I-716	Oct 02, 2018
<u>AMBRISENTAN - LETAIRIS</u>						
N 022081 002	>A> 8377933	Dec 11, 2027	U-1754		>A> I-716	Oct 02, 2018
<u>AMOXICILLIN - MOXATAG</u>						
N 050813 001	8778924	Dec 08, 2026	DS DP U-897			
<u>AMPHETAMINE - DYANA VEL XR</u>						
N 208147 001	>A> 8062667	Mar 29, 2029	DP		>A> NP	Oct 19, 2018
	>A> 8597684	Mar 15, 2027	DP			
	>A> 8747902	Mar 15, 2027	DP			
	>A> 8883217	Mar 15, 2027	DP			
<u>APIXABAN - ELIQUIS</u>						
N 202155 001	6967208	Feb 03, 2023	DS DP U-1167			
	6967208	Feb 03, 2023	DS DP U-1200			
	6967208	Feb 03, 2023	DS DP U-1301			
	6967208	Feb 03, 2023	DS DP U-1302			
	6967208	Feb 03, 2023	DS DP U-1323			
	6967208	Feb 03, 2023	DS DP U-1501			
	6967208	Feb 03, 2023	DS DP U-1502			
	6967208	Feb 03, 2023	DS DP U-1729			
	6967208	Feb 03, 2023	DS DP U-1730			
<u>APIXABAN - ELIQUIS</u>						
N 202155 002	6413980	Dec 22, 2019	DS DP U-1200			
	6413980	Dec 22, 2019	DS DP U-1301			
	6413980	Dec 22, 2019	DS DP U-1302			
	6967208	Feb 03, 2023	DS DP U-1200			
	6967208	Feb 03, 2023	DS DP U-1301			
	6967208	Feb 03, 2023	DS DP U-1302			
	6967208	Feb 03, 2023	DS DP U-1323			
<u>APREMILAST - OTEZLA</u>						
N 205437 001	9018243	Mar 19, 2023	U-1505			
	9018243	Mar 19, 2023	U-1595			
<u>APREMILAST - OTEZLA</u>						
N 205437 002	9018243	Mar 19, 2023	U-1505			
	9018243	Mar 19, 2023	U-1595			
<u>APREMILAST - OTEZLA</u>						
N 205437 003	9018243	Mar 19, 2023	U-1505			
	9018243	Mar 19, 2023	U-1595			

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 10 - October 2015

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>APREPITANT - EMEND</u>						
N 021549 001	6096742	Jul 01, 2018	DS DP U-745		NPP	Aug 28, 2018
	6096742	Jul 01, 2018	DS DP U-1743			
	6096742	Jul 01, 2018	DS DP U-1744			
	8258132	Sep 26, 2027	DP U-901			
	8258132	Sep 26, 2027	DP U-1743			
<u>APREPITANT - EMEND</u>						
N 021549 002	6096742	Jul 01, 2018	DS DP U-745		NPP	Aug 28, 2018
	6096742	Jul 01, 2018	DS DP U-1743			
	6096742	Jul 01, 2018	DS DP U-1744			
	8258132	Sep 26, 2027	DP U-901			
	8258132	Sep 26, 2027	DP U-1743			
<u>APREPITANT - EMEND</u>						
N 021549 003	6096742	Jul 01, 2018	DS DP U-745		NPP	Aug 28, 2018
	6096742	Jul 01, 2018	DS DP U-1743			
	6096742	Jul 01, 2018	DS DP U-1744			
	8258132	Sep 26, 2027	DP U-901			
	8258132	Sep 26, 2027	DP U-1743			
<u>ARIPIPRAZOLE - ABILIFY</u>						
N 021436 001	9089567	Jan 28, 2022	U-543		ODE	Dec 12, 2021
	9125939	Jul 28, 2026	U-1749			
<u>ARIPIPRAZOLE - ABILIFY</u>						
N 021436 002	9089567	Jan 28, 2022	U-543		ODE	Dec 12, 2021
	9125939	Jul 28, 2026	U-1749			
<u>ARIPIPRAZOLE - ABILIFY</u>						
N 021436 003	9089567	Jan 28, 2022	U-543		ODE	Dec 12, 2021
	9125939	Jul 28, 2026	U-1749			
<u>ARIPIPRAZOLE - ABILIFY</u>						
N 021436 004	9089567	Jan 28, 2022	U-543		ODE	Dec 12, 2021
	9125939	Jul 28, 2026	U-1749			
<u>ARIPIPRAZOLE - ABILIFY</u>						
N 021436 005	9089567	Jan 28, 2022	U-543		ODE	Dec 12, 2021
	9125939	Jul 28, 2026	U-1749			
<u>ARIPIPRAZOLE - ABILIFY</u>						
N 021436 006	9089567	Jan 28, 2022	U-543		ODE	Dec 12, 2021
	9125939	Jul 28, 2026	U-1749			
<u>ARIPIPRAZOLE - ABILIFY</u>						
N 021713 001	5006528	Oct 20, 2014	DS DP U-543		ODE	Dec 12, 2021
	5006528	Oct 20, 2014	DS DP U-761			
	5006528*PED	Apr 20, 2015				
	6977257	Apr 24, 2022	DP			
	6977257*PED	Oct 24, 2022				
<u>ARIPIPRAZOLE - ABILIFY</u>						
N 021729 002	9089567	Jan 28, 2022	U-543		ODE	Dec 12, 2021
	9125939	Jul 28, 2026	U-1749			
<u>ARIPIPRAZOLE - ABILIFY</u>						
N 021729 003	9089567	Jan 28, 2022	U-543		ODE	Dec 12, 2021
	9125939	Jul 28, 2026	U-1749			

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 10 - October 2015

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>ARIPRAZOLE - ABILIFY</u>						
N 021729 004					ODE	Dec 12, 2021
<u>ARIPRAZOLE - ABILIFY</u>						
N 021729 005					ODE	Dec 12, 2021
<u>ARIPRAZOLE - ABILIFY</u>						
N 021866 001	5006528	Oct 20, 2014	DS DP U-543		ODE	Dec 12, 2021
	5006528	Oct 20, 2014	DS DP U-763			
	5006528*PED	Apr 20, 2015				
<u>ARIPRAZOLE - ABILIFY MAINTENA KIT</u>						
N 202971 001	5006528	Oct 20, 2014	DS DP U-543			
	5006528	Oct 20, 2014	DS DP U-1632			
	5006528*PED	Apr 20, 2015				
	8030313	Oct 19, 2024	U-543			
	8030313	Oct 19, 2024	U-1632			
	8338427	Mar 15, 2025	DP U-543			
	8338427	Mar 15, 2025	DP U-1633			
	8338428	Aug 06, 2023	DP U-543			
	8338428	Aug 06, 2023	DP U-1633			
	8399469	Jun 29, 2025	DS			
	8759351	Aug 06, 2023	DP U-1530			
	8759351	Aug 06, 2023	DP U-1633			
	8993761	Sep 25, 2022	DS			
	9089567	Jan 28, 2022	U-543			
<u>ARIPRAZOLE - ABILIFY MAINTENA KIT</u>						
N 202971 002	5006528	Oct 20, 2014	DS DP U-543			
	5006528	Oct 20, 2014	DS DP U-1632			
	5006528*PED	Apr 20, 2015				
	8030313	Oct 19, 2024	U-543			
	8030313	Oct 19, 2024	U-1632			
	8338427	Mar 15, 2025	DP U-543			
	8338427	Mar 15, 2025	DP U-1633			
	8338428	Aug 06, 2023	DP U-543			
	8338428	Aug 06, 2023	DP U-1633			
	8399469	Jun 29, 2025	DS			
	8759351	Aug 06, 2023	DP U-1530			
	8759351	Aug 06, 2023	DP U-1633			
	8993761	Sep 25, 2022	DS			
	9089567	Jan 28, 2022	U-543			
<u>ARIPRAZOLE - ABILIFY MAINTENA KIT</u>						
N 202971 003	5006528	Oct 20, 2014	DS DP U-543			
	5006528	Oct 20, 2014	DS DP U-1632			
	5006528*PED	Apr 20, 2015				
	8030313	Oct 19, 2024	U-543			
	8030313	Oct 19, 2024	U-1632			
	8338427	Mar 15, 2025	DP U-543			
	8338427	Mar 15, 2025	DP U-1633			
	8338428	Aug 06, 2023	DP U-543			
	8338428	Aug 06, 2023	DP U-1633			
	8399469	Jun 29, 2025	DS			
	8759351	Aug 06, 2023	DP U-1530			
	8759351	Aug 06, 2023	DP U-1633			
	8993761	Sep 25, 2022	DS			
	9089567	Jan 28, 2022	U-543			
<u>ARIPRAZOLE - ABILIFY MAINTENA KIT</u>						
N 202971 004	5006528	Oct 20, 2014	DS DP U-543			
	5006528	Oct 20, 2014	DS DP U-1632			
	5006528*PED	Apr 20, 2015				
	8030313	Oct 19, 2024	U-543			
	8030313	Oct 19, 2024	U-1632			

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 10 - October 2015

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>ARIPRAZOLE - ABILIFY MAINTENA KIT</u>						
N 202971 004	8338427	Mar 15, 2025	DP U-543			
	8338427	Mar 15, 2025	DP U-1633			
	8338428	Aug 06, 2023	DP U-543			
	8338428	Aug 06, 2023	DP U-1633			
	8399469	Jun 29, 2025	DS			
	8759351	Aug 06, 2023	DP U-1530			
	8759351	Aug 06, 2023	DP U-1633			
	8993761	Sep 25, 2022	DS			
	9089567	Jan 28, 2022	U-543			
<u>ARIPRAZOLE LAUROXIL - ARISTADA</u>						
N 207533 001	>A> 8431576	Oct 26, 2030	DS		>A> NCE	Oct 05, 2020
	>A> 8796276	Jun 24, 2030	U-543			
	>A> 9034867	Nov 07, 2032	DP U-543			
<u>ARIPRAZOLE LAUROXIL - ARISTADA</u>						
N 207533 002	>A> 8431576	Oct 26, 2030	DS		>A> NCE	Oct 05, 2020
	>A> 8796276	Jun 24, 2030	U-543			
	>A> 9034867	Nov 07, 2032	DP U-543			
<u>ARIPRAZOLE LAUROXIL - ARISTADA</u>						
N 207533 003	>A> 8431576	Oct 26, 2030	DS		>A> NCE	Oct 05, 2020
	>A> 8796276	Jun 24, 2030	U-543			
	>A> 9034867	Nov 07, 2032	DP U-543			
<u>ASENAPINE MALEATE - SAPHRIS</u>						
N 022117 001	5763476	Jun 09, 2020	DP U-326		M-158	Mar 17, 2018
	5763476*PED	Dec 09, 2020			NPP	Mar 17, 2018
	7741358	Apr 06, 2026	DS DP U-1064		PED	Sep 17, 2018
	7741358*PED	Oct 06, 2026			PED	Sep 17, 2018
	8022228	Apr 06, 2026	DS DP			
	8022228*PED	Oct 06, 2026				
<u>ASENAPINE MALEATE - SAPHRIS</u>						
N 022117 002	5763476	Jun 09, 2020	DP U-326		M-158	Mar 17, 2018
	5763476*PED	Dec 09, 2020			NPP	Mar 17, 2018
	7741358	Apr 06, 2026	DS DP U-1064		PED	Sep 17, 2018
	7741358*PED	Oct 06, 2026			PED	Sep 17, 2018
	8022228	Apr 06, 2026	DS DP			
	8022228*PED	Oct 06, 2026				
<u>ASPIRIN - ASPIRIN</u>						
N 203697 001	9101637	Mar 23, 2022	U-1731			
	9101637	Mar 23, 2022	U-1732			
	9101637	Mar 23, 2022	U-1733			
<u>ATAZANAVIR SULFATE - REYATAZ</u>						
N 021567 001	5849911	Jun 20, 2017	DS DP U-167			
	5849911*PED	Dec 20, 2017				
	6087383	Dec 21, 2018	DS DP			
	6087383*PED	Jun 21, 2019				
<u>ATAZANAVIR SULFATE - REYATAZ</u>						
N 021567 002	5849911	Jun 20, 2017	DS DP U-167			
	5849911*PED	Dec 20, 2017				
	6087383	Dec 21, 2018	DS DP			
	6087383*PED	Jun 21, 2019				
<u>ATAZANAVIR SULFATE - REYATAZ</u>						
N 021567 003	5849911	Jun 20, 2017	DS DP U-167			
	5849911*PED	Dec 20, 2017				
	6087383	Dec 21, 2018	DS DP			
	6087383*PED	Jun 21, 2019				

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 10 - October 2015

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>ATAZANAVIR SULFATE - REYATAZ</u>						
N 021567 003	5849911	Jun 20, 2017	DS DP U-167			
	5849911*PED	Dec 20, 2017				
	6087383	Dec 21, 2018	DS DP			
	6087383*PED	Jun 21, 2019				
<u>ATAZANAVIR SULFATE - REYATAZ</u>						
N 021567 004	5849911	Jun 20, 2017	DS DP U-167			
	5849911*PED	Dec 20, 2017				
	6087383	Dec 21, 2018	DS DP			
	6087383*PED	Jun 21, 2019				
<u>ATAZANAVIR SULFATE - REYATAZ</u>						
N 206352 001	5849911	Jun 20, 2017	DS DP U-167		NP	Jun 02, 2017
	5849911*PED	Dec 20, 2017			NPP	Sep 24, 2018
	6087383	Dec 21, 2018	DS DP		PED	Dec 02, 2017
	6087383*PED	Jun 21, 2019			PED	Mar 24, 2019
<u>ATAZANAVIR SULFATE; COBICISTAT - EVOTAZ</u>						
N 206353 001	5849911	Jun 20, 2017	DS DP U-167			
	5849911*PED	Dec 20, 2017				
	6087383	Dec 21, 2018	DS DP			
	6087383*PED	Jun 21, 2019				
	8148374	Sep 03, 2029	DS DP U-1279			
<u>AVIBACTAM SODIUM; CEFTAZIDIME - AVYCAZ</u>						
N 206494 001	7112592	Feb 24, 2022	DS DP U-282			
	7612087	Nov 12, 2026	DP			
	8178554	Jul 24, 2021	DS DP U-282			
	8471025	Aug 12, 2031	DS			
	8835455	Oct 08, 2030	DP			
	8969566	Jun 15, 2032	DS			
<u>AZELAIC ACID - FINACEA</u>						
N 207071 001	6730288	Sep 08, 2019	DP		NP	Jul 29, 2018
	7700076	Sep 18, 2027	DP			
	8435498	Mar 01, 2024	U-1727			
	8722021	Oct 24, 2023	DP			
	8900554	Oct 24, 2023	DP			
<u>AZELASTINE HYDROCHLORIDE - ASTEPRO</u>						
N 022203 001					NPP	Feb 20, 2018
					NPP	Feb 20, 2018
<u>AZELASTINE HYDROCHLORIDE; FLUTICASONE PROPIONATE - DYMISTA</u>						
N 202236 001	8163723	Aug 29, 2023	U-77		NPP	Feb 20, 2018
	8163723	Aug 29, 2023	U-81			
	8163723	Aug 29, 2023	U-644			
	8163723	Aug 29, 2023	U-707			
	8163723	Aug 29, 2023	U-1667			
<u>AZILSARTAN KAMEDOXOMIL - EDARBI</u>						
N 200796 001	9066936	Mar 26, 2028	DP			
<u>AZILSARTAN KAMEDOXOMIL - EDARBI</u>						
N 200796 002	9066936	Mar 26, 2028	DP			
<u>AZILSARTAN KAMEDOXOMIL; CHLORTHALIDONE - EDARBYCLOR</u>						
N 202331 001	9066936	Mar 26, 2028	DP			
<u>AZILSARTAN KAMEDOXOMIL; CHLORTHALIDONE - EDARBYCLOR</u>						
N 202331 002	9066936	Mar 26, 2028	DP			

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 10 - October 2015

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>BENZOYL PEROXIDE; CLINDAMYCIN PHOSPHATE - ACANYA</u>						
N 050819 001	8895070	Jun 03, 2029	U-124			
	9078870	Jun 03, 2029	DP			
<u>BESIFLOXACIN HYDROCHLORIDE - BESIVANCE</u>						
N 022308 001	8937062	Nov 13, 2029	U-80			
<u>BETAMETHASONE DIPROPIONATE; CALCIPOTRIENE - ENSTILAR</u>						
N 207589 001	>A> 6753013	Jun 10, 2031	DP U-1761		>A> NP	Oct 16, 2018
	>A> 9119781	Jun 10, 2031	DP U-1761			
<u>BEXAROTENE - TARGRETIN</u>						
N 021055 001					M-164	Jul 29, 2018
<u>BIMATOPROST - LUMIGAN</u>						
N 022184 001	8933120	Mar 16, 2025	DP			
	8933127	Mar 16, 2025	DP			
<u>BIMATOPROST - LATISSE</u>						
N 022369 001	7351404	May 25, 2024	U-939	Y		
	7388029	Jan 21, 2022	U-938	Y		
	8541466	Jan 31, 2021	U-1217			
	8986715	Jan 15, 2023	U-1217			
<u>BORTEZOMIB - VELCADE</u>						
N 021602 001	5780454	May 03, 2017	DS DP		D-141	Oct 08, 2017
	5780454*PED	Nov 03, 2017			D-142	Oct 08, 2017
	6713446	Jan 25, 2022	DS DP		I-695	Oct 08, 2017
	6713446*PED	Jul 25, 2022			M-139	Aug 08, 2017
	6958319	Jan 25, 2022	DS DP		M-165	Sep 14, 2018
	6958319*PED	Jul 25, 2022			ODE	Oct 08, 2021
					PED	Feb 08, 2018
					PED	Apr 08, 2018
					PED	Apr 08, 2018
					PED	Apr 08, 2018
					PED	Mar 14, 2019
					PED	Apr 08, 2022
<u>BREXPIRAZOLE - REXULTI</u>						
N 205422 001	7888362	Feb 23, 2027	DS		NCE	Jul 10, 2020
	8349840	Apr 12, 2026	DP U-1529			
	8618109	Apr 12, 2026	U-543			
<u>BREXPIRAZOLE - REXULTI</u>						
N 205422 002	7888362	Feb 23, 2027	DS		NCE	Jul 10, 2020
	8349840	Apr 12, 2026	DP U-1529			
	8618109	Apr 12, 2026	U-543			
<u>BREXPIRAZOLE - REXULTI</u>						
N 205422 003	7888362	Feb 23, 2027	DS		NCE	Jul 10, 2020
	8349840	Apr 12, 2026	DP U-1529			
	8618109	Apr 12, 2026	U-543			
<u>BREXPIRAZOLE - REXULTI</u>						
N 205422 004	7888362	Feb 23, 2027	DS		NCE	Jul 10, 2020
	8349840	Apr 12, 2026	DP U-1529			
	8618109	Apr 12, 2026	U-543			
<u>BREXPIRAZOLE - REXULTI</u>						
N 205422 005	7888362	Feb 23, 2027	DS		NCE	Jul 10, 2020
	8349840	Apr 12, 2026	DP U-1529			
	8618109	Apr 12, 2026	U-543			

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 10 - October 2015

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>BREXPIRAZOLE - REXULTI</u>						
N 205422 006	7888362	Feb 23, 2027	DS		NCE	Jul 10, 2020
	8349840	Apr 12, 2026	DP U-1529			
	8618109	Apr 12, 2026	U-543			
<u>BRIMONIDINE TARTRATE; BRINZOLAMIDE - SIMBRINZA</u>						
N 204251 001	9044484	Oct 30, 2030	DP			
<u>BROMFENAC SODIUM - PROLENSA</u>						
N 203168 001 >A>	9144609	Jan 16, 2024	DP			
<u>BROMOCRIPTINE MESYLATE - CYCLOSET</u>						
N 020866 001	8877708	Jun 07, 2030	DP U-1706			
<u>BUDESONIDE - UCERIS</u>						
N 203634 001	9132093	Sep 07, 2031	DP			
<u>BUDESONIDE - UCERIS</u>						
N 205613 001	5914122	Dec 19, 2015	DP			
<u>BUPRENORPHINE HYDROCHLORIDE - BELBUCA</u>						
N 207932 001					>A> NP	Oct 23, 2018
<u>BUPRENORPHINE HYDROCHLORIDE - BELBUCA</u>						
N 207932 002					>A> NP	Oct 23, 2018
<u>BUPRENORPHINE HYDROCHLORIDE - BELBUCA</u>						
N 207932 003					>A> NP	Oct 23, 2018
<u>BUPRENORPHINE HYDROCHLORIDE - BELBUCA</u>						
N 207932 004					>A> NP	Oct 23, 2018
<u>BUPRENORPHINE HYDROCHLORIDE - BELBUCA</u>						
N 207932 005					>A> NP	Oct 23, 2018
<u>BUPRENORPHINE HYDROCHLORIDE - BELBUCA</u>						
N 207932 006					>A> NP	Oct 23, 2018
<u>BUPRENORPHINE HYDROCHLORIDE - BELBUCA</u>						
N 207932 007					>A> NP	Oct 23, 2018
<u>BUPRENORPHINE HYDROCHLORIDE; NALOXONE HYDROCHLORIDE - ZUBSOLV</u>						
N 204242 001	8470361	May 22, 2030	DP U-1425		I-713	Aug 10, 2018
	8940330	Sep 18, 2032	DP			
<u>BUPRENORPHINE HYDROCHLORIDE; NALOXONE HYDROCHLORIDE - ZUBSOLV</u>						
N 204242 002	8470361	May 22, 2030	DP U-1425		I-713	Aug 10, 2018
	8940330	Sep 18, 2032	DP			
<u>BUPRENORPHINE HYDROCHLORIDE; NALOXONE HYDROCHLORIDE - ZUBSOLV</u>						
N 204242 003	8470361	May 22, 2030	DP U-1425		I-713	Aug 10, 2018
	8940330	Sep 18, 2032	DP			
<u>BUPRENORPHINE HYDROCHLORIDE; NALOXONE HYDROCHLORIDE - ZUBSOLV</u>						
N 204242 004	8470361	May 22, 2030	DP U-1425		I-713	Aug 10, 2018
	8940330	Sep 18, 2032	DP			
<u>BUPRENORPHINE HYDROCHLORIDE; NALOXONE HYDROCHLORIDE - ZUBSOLV</u>						
N 204242 005	8454996	Sep 24, 2019	U-1421		I-713	Aug 10, 2018
	8470361	May 22, 2030	DP U-1425			
	8658198	Dec 03, 2027	DP U-1494			

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 10 - October 2015

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>BUPRENORPHINE HYDROCHLORIDE; NALOXONE HYDROCHLORIDE - ZUBSOLV</u>						
N 204242 005	8940330	Sep 18, 2032	DP			
<u>BUPROPION HYDROCHLORIDE; NALTREXONE HYDROCHLORIDE - CONTRAVE</u>						
N 200063 001	8916195	Feb 02, 2030	U-1639			
	9107837	Jun 04, 2027	U-1639			
>A>	9125868	Nov 08, 2027	U-1585			
<u>CALCIUM ACETATE - PHOSLO GELCAPS</u>						
N 021160 003	6875445	Jul 30, 2021	DP			
<u>CALCIUM ACETATE - PHOSLYRA</u>						
N 022581 001	9089528	Jul 20, 2027	U-1469			
<u>CALCIUM CHLORIDE; MAGNESIUM CHLORIDE; POTASSIUM CHLORIDE; SODIUM BICARBONATE; SODIUM CHLORIDE; SODIUM PHOSPHATE - PHOXILLUM BK 4/2.5 IN PLASTIC CONTAINER</u>						
N 207026 001					ODE	Jan 13, 2022
<u>CALCIUM CHLORIDE; MAGNESIUM CHLORIDE; POTASSIUM CHLORIDE; SODIUM BICARBONATE; SODIUM CHLORIDE; SODIUM PHOSPHATE - PHOXILLUM B22K 4/0 IN PLASTIC CONTAINER</u>						
N 207026 002					ODE	Jan 13, 2022
<u>CANGRELOR - KENGREAL</u>						
N 204958 001	6114313	Dec 11, 2017	DP U-1715		NCE	Jun 22, 2020
	6130208	Jun 29, 2018	DP U-1715			
	8680052	Mar 09, 2033	U-1715			
	8759316	May 13, 2029	U-1715			
<u>CARBIDOPA; LEVODOPA - RYTARY</u>						
N 203312 001	7094427	May 29, 2022	DP U-1645		NDF	Jan 07, 2018
	8377474	Dec 26, 2028	DP U-219			
	8377474	Dec 26, 2028	DP U-1645			
	8454998	Dec 26, 2028	DP U-219			
	8454998	Dec 26, 2028	DP U-1645			
	8454998	Dec 26, 2028	DP U-1646			
	8454998	Dec 26, 2028	DP U-1647			
	8454998	Dec 26, 2028	DP U-1649			
	8557283	Dec 26, 2028	DP U-219			
	8557283	Dec 26, 2028	DP U-1645			
	9089607	Dec 26, 2028	DP U-1645			
	9089607	Dec 26, 2028	DP U-1720			
	9089608	Dec 26, 2028	DP			
<u>CARBIDOPA; LEVODOPA - RYTARY</u>						
N 203312 002	7094427	May 29, 2022	DP U-1645		NDF	Jan 07, 2018
	8377474	Dec 26, 2028	DP U-219			
	8377474	Dec 26, 2028	DP U-1645			
	8454998	Dec 26, 2028	DP U-219			
	8454998	Dec 26, 2028	DP U-1645			
	8454998	Dec 26, 2028	DP U-1646			
	8454998	Dec 26, 2028	DP U-1647			
	8454998	Dec 26, 2028	DP U-1649			
	8557283	Dec 26, 2028	DP U-219			
	8557283	Dec 26, 2028	DP U-1645			
	9089607	Dec 26, 2028	DP U-1645			
	9089607	Dec 26, 2028	DP U-1720			
	9089608	Dec 26, 2028	DP			
<u>CARBIDOPA; LEVODOPA - RYTARY</u>						
N 203312 003	7094427	May 29, 2022	DP U-1645		NDF	Jan 07, 2018
	8377474	Dec 26, 2028	DP U-219			
	8377474	Dec 26, 2028	DP U-1645			
	8454998	Dec 26, 2028	DP U-219			
	8454998	Dec 26, 2028	DP U-1645			

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 10 - October 2015

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>CARBIDOPA; LEVODOPA - RYTARY</u>						
N 203312 003	8454998	Dec 26, 2028	DP U-1646			
	8454998	Dec 26, 2028	DP U-1647			
	8454998	Dec 26, 2028	DP U-1649			
	8557283	Dec 26, 2028	DP U-219			
	8557283	Dec 26, 2028	DP U-1645			
	9089607	Dec 26, 2028	DP U-1645			
	9089607	Dec 26, 2028	DP U-1720			
	9089608	Dec 26, 2028	DP			
<u>CARBIDOPA; LEVODOPA - RYTARY</u>						
N 203312 004	7094427	May 29, 2022	DP U-1645		NDF	Jan 07, 2018
	8377474	Dec 26, 2028	DP U-219			
	8377474	Dec 26, 2028	DP U-1645			
	8454998	Dec 26, 2028	DP U-219			
	8454998	Dec 26, 2028	DP U-1645			
	8454998	Dec 26, 2028	DP U-1646			
	8454998	Dec 26, 2028	DP U-1647			
	8454998	Dec 26, 2028	DP U-1649			
	8557283	Dec 26, 2028	DP U-219			
	8557283	Dec 26, 2028	DP U-1645			
	9089607	Dec 26, 2028	DP U-1645			
	9089607	Dec 26, 2028	DP U-1720			
	9089608	Dec 26, 2028	DP			
<u>CARBIDOPA; LEVODOPA - DUOPA</u>						
N 203952 001					NP ODE	Jan 09, 2018 Jan 09, 2022
<u>CARFILZOMIB - KYPROLIS</u>						
N 202714 001					I-712	Jul 24, 2018
<u>CARIPRAZINE HYDROCHLORIDE - VRAYLAR</u>						
N 204370 001	>A> 7737142	Mar 27, 2027	DS DP U-1750		NCE	Sep 17, 2020
	>A> 7943621	Dec 16, 2028	DS DP			
<u>CARIPRAZINE HYDROCHLORIDE - VRAYLAR</u>						
N 204370 002	>A> 7737142	Mar 27, 2027	DS DP U-1750		NCE	Sep 17, 2020
	>A> 7943621	Dec 16, 2028	DS DP			
<u>CARIPRAZINE HYDROCHLORIDE - VRAYLAR</u>						
N 204370 003	>A> 7737142	Mar 27, 2027	DS DP U-1750		NCE	Sep 17, 2020
	>A> 7943621	Dec 16, 2028	DS DP			
<u>CARIPRAZINE HYDROCHLORIDE - VRAYLAR</u>						
N 204370 004	>A> 7737142	Mar 27, 2027	DS DP U-1750		NCE	Sep 17, 2020
	>A> 7943621	Dec 16, 2028	DS DP			
<u>CEFTAROLINE FOSAMIL - TEFLARO</u>						
N 200327 001	6417175	Apr 11, 2022	DS DP U-1676			
<u>CEFTAROLINE FOSAMIL - TEFLARO</u>						
N 200327 002	6417175	Apr 11, 2022	DS DP U-1676			
<u>CEFTOLOZANE SULFATE; TAZOBACTAM SODIUM - ZERBAXA</u>						
N 206829 001	8968753	Mar 14, 2034	U-1672			
	8968753	Mar 14, 2034	U-1673			
<u>CELECOXIB - CELECOXIB</u>						
A 076898 002					PC	Jun 02, 2015

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 10 - October 2015

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>CELECOXIB - CELECOXIB</u>						
A 076898 003					PC	Jun 02, 2015
<u>CELECOXIB - CELECOXIB</u>						
A 076898 004					PC	Jun 02, 2015
<u>CELECOXIB - CELECOXIB</u>						
A 078857 002					PC	Jun 02, 2015
<u>CELECOXIB - CELECOXIB</u>						
A 078857 003					PC	Jun 02, 2015
<u>CELECOXIB - CELECOXIB</u>						
A 078857 004					PC	Jun 02, 2015
<u>CELECOXIB - CELECOXIB</u>						
A 200562 002					PC	Jun 02, 2015
<u>CELECOXIB - CELECOXIB</u>						
A 200562 003					PC	Jun 02, 2015
<u>CELECOXIB - CELECOXIB</u>						
A 200562 004					PC	Jun 02, 2015
<u>CHLORPHENIRAMINE MALEATE; CODEINE PHOSPHATE - CODEINE PHOSPHATE AND CHLORPHENIRAMINE MALEATE</u>						
N 206323 001	6248363	Nov 23, 2019	DP U-1716			
	6383471	Apr 06, 2019	DP U-1716			
	9066942	Jan 03, 2032	U-1716			
>A>	9107921	Jan 03, 2032	DP			
<u>CHLORPHENIRAMINE POLISTIREX; CODEINE POLISTIREX - TUZISTRA XR</u>						
N 207768 001	8062667	Mar 29, 2029	DP			
	8790700	Mar 15, 2027	DP			
<u>CHOLIC ACID - CHOLBAM</u>						
N 205750 001					ODE	Mar 17, 2022
<u>CHOLIC ACID - CHOLBAM</u>						
N 205750 002					ODE	Mar 17, 2022
<u>CICLESONIDE - ALVESCO</u>						
N 021658 002	8371292	Feb 01, 2028	U-1355			
<u>CICLESONIDE - ALVESCO</u>						
N 021658 003	8371292	Feb 01, 2028	U-1355			
<u>CICLESONIDE - OMNARIS</u>						
N 022004 001	8371292	Feb 01, 2028	U-1356			
<u>CICLESONIDE - ZETONNA</u>						
N 202129 001	8371292	Feb 01, 2028	U-1357			
<u>CIPROFLOXACIN; DEXAMETHASONE - CIPRODEX</u>						
N 021537 001	>A> 9149486	Sep 13, 2022	DP U-1578			
<u>CLOBETASOL PROPIONATE - CLOBETASOL PROPIONATE</u>						
A 090898 001					PC	Jul 01, 2015

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 10 - October 2015

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>CLOBETASOL PROPIONATE - OLUX E</u>						
N 022013 001	8962000	Aug 31, 2025	DP U-1410			
<u>COBICISTAT; DARUNAVIR ETHANOLATE - PREZCOBIX</u>						
N 205395 001	5843946	Dec 01, 2015	DP U-1660			
	5843946*PED	Jun 01, 2016				
	7470506	Jun 23, 2019	U-1660			
	7470506*PED	Dec 23, 2019				
	7700645	Dec 26, 2026	DS DP			
	7700645*PED	Jun 26, 2027				
	8148374	Sep 03, 2029	DS DP U-1660			
	8518987	Feb 16, 2024	DS DP			
	8518987*PED	Aug 16, 2024				
	8597876	Jun 23, 2019	U-1660			
	8597876*PED	Dec 23, 2019				
	RE42889	Oct 19, 2016	DP			
	RE42889*PED	Apr 19, 2017				
	RE43596	May 09, 2017	DS DP			
	RE43596*PED	Nov 09, 2017				
	RE43802	Oct 19, 2016	U-1660			
	RE43802*PED	Apr 19, 2017				
<u>COBICISTAT; ELVITEGRAVIR; EMTRICITABINE; TENOFOVIR DISOPROXIL FUMARATE - STRIBILD</u>						
N 203100 001	8981103	Oct 26, 2026	DS DP		I-704	Dec 17, 2017
<u>COLCHICINE - MITIGARE</u>						
N 204820 001	8927607	Aug 22, 2033	U-1020			
<u>CRIZOTINIB - XALKORI</u>						
N 202570 001	7230098	Aug 26, 2025	DS		M-163	Sep 14, 2018
<u>CRIZOTINIB - XALKORI</u>						
N 202570 002	7230098	Aug 26, 2025	DS		M-163	Sep 14, 2018
<u>CROFELEMER - FULYZAO</u>						
N 202292 001	8962680	Oct 31, 2031	U-1319			
<u>CYANOCOBALAMIN - NASCOBAL</u>						
N 021642 001	7229636	Aug 01, 2024	DP U-817			
	7879349	Aug 01, 2024	DP U-1152			
	8003353	Aug 01, 2024	U-817			
	8940714	Feb 26, 2024	U-1152			
<u>CYSTEAMINE BITARTRATE - PROCYSBI</u>						
N 203389 001	>A> 9173851	Jun 17, 2034	DP		NPP	Aug 14, 2018
<u>CYSTEAMINE BITARTRATE - PROCYSBI</u>						
N 203389 002	>A> 9173851	Jun 17, 2034	DP		NPP	Aug 14, 2018
<u>DABIGATRAN ETEXILATE MESYLATE - PRADAXA</u>						
N 022512 001	>A> 9034822	Jan 20, 2031	U-1759			
<u>DABIGATRAN ETEXILATE MESYLATE - PRADAXA</u>						
N 022512 002	>A> 9034822	Jan 20, 2031	U-1759			
<u>DABRAFENIB MESYLATE - TAFINLAR</u>						
N 202806 001	8703781	Oct 15, 2030	DS DP U-1713			
<u>DABRAFENIB MESYLATE - TAFINLAR</u>						
N 202806 002	8703781	Oct 15, 2030	DS DP U-1713			

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 10 - October 2015

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>DACLATASVIR DIHYDROCHLORIDE - DAKLINZA</u>						
N 206843 001	8329159	Apr 13, 2028	DS		NCE	Jul 24, 2020
	8629171	Jun 13, 2031	DS DP U-1724			
	8642025	Aug 11, 2027	DS DP U-1724			
	8642025	Aug 11, 2027	DS DP U-1725			
	8900566	Aug 08, 2027	U-1724			
	8900566	Aug 08, 2027	U-1725			
<u>DACLATASVIR DIHYDROCHLORIDE - DAKLINZA</u>						
N 206843 002	8329159	Apr 13, 2028	DS		NCE	Jul 24, 2020
	8629171	Jun 13, 2031	DS DP U-1724			
	8642025	Aug 11, 2027	DS DP U-1724			
	8642025	Aug 11, 2027	DS DP U-1725			
	8900566	Aug 08, 2027	U-1724			
	8900566	Aug 08, 2027	U-1725			
<u>DANTROLENE SODIUM - RYANODEX</u>						
N 205579 001					ODE	Jul 22, 2021
<u>DAPAGLIFLOZIN PROPANEDIOL - FARXIGA</u>						
N 202293 001					M-157	Mar 11, 2018
<u>DAPAGLIFLOZIN PROPANEDIOL - FARXIGA</u>						
N 202293 002					M-157	Mar 11, 2018
<u>DASABUVIR SODIUM ; OMBITASVIR; PARITAPREVIR; RITONAVIR - VIEKIRA PAK (COPACKAGED)</u>						
N 206619 001	6037157	Jun 26, 2016	U-1635			
	6703403	Jun 26, 2016	U-1635			
	7148359	Jul 19, 2019	DP			
	7364752	Nov 10, 2020	DP			
	8188104	May 17, 2029	DS DP U-1636			
	8268349	Aug 25, 2024	DP			
	8399015	Aug 25, 2024	DP			
	8420596	Apr 10, 2031	DS DP			
	8466159	Sep 04, 2032	U-1637			
	8492386	Sep 04, 2032	U-1637			
	8501238	Sep 17, 2028	DS DP U-1636			
	8642538	Sep 10, 2029	DS DP U-1638			
	8680106	Sep 04, 2032	U-1637			
	8685984	Sep 04, 2032	U-1637			
	8686026	Jun 09, 2031	DP			
	8691938	Apr 13, 2032	DS DP			
	9006387	Jun 10, 2030	U-1687			
	9044480	Apr 10, 2031	U-1638			
>A>	9139536	Nov 09, 2028	U-1753			
<u>DEFERASIROX - EXJADE</u>						
N 021882 001					ODE	Jan 23, 2020
<u>DEFERASIROX - EXJADE</u>						
N 021882 002					ODE	Jan 23, 2020
<u>DEFERASIROX - EXJADE</u>						
N 021882 003					ODE	Jan 23, 2020
<u>DEFERASIROX - JADENU</u>						
N 206910 001	6465504	Apr 05, 2019	DS DP			
	6596750	Jun 24, 2017	DS U-735			
<u>DEFERASIROX - JADENU</u>						
N 206910 002	6465504	Apr 05, 2019	DS DP			
	6596750	Jun 24, 2017	DS U-735			

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 10 - October 2015

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>DEFERASIROX - JADENU</u>						
N 206910 003	6465504	Apr 05, 2019	DS DP			
	6596750	Jun 24, 2017	DS U-735			
<u>DEFERIPRONE - FERRIPROX</u>						
N 021825 001	7049328	Jun 28, 2021	U-735			
<u>DEFERIPRONE - FERRIPROX</u>						
N 208030 001	7049328	Jun 28, 2021	U-735		NCE	Oct 14, 2016
	8703156	Oct 29, 2029	DP U-735		ODE	Oct 14, 2016
<u>DEOXYCHOLIC ACID - KYBELLA</u>						
N 206333 001	7622130	Dec 10, 2027	U-1690			
	7754230	Dec 10, 2027	U-1690			
	8101593	Mar 02, 2030	DP			
	8242294	May 16, 2028	DS			
	8298556	Aug 03, 2025	U-1690			
	8367649	Mar 02, 2030	DP			
	8461140	Feb 21, 2028	DP			
	8546367	Feb 21, 2028	DP U-1690			
	8653058	Mar 02, 2030	DP			
	8846066	Feb 08, 2025	U-1690			
	8883770	Feb 21, 2028	DP			
<u>DESMOPRESSIN ACETATE - DESMOPRESSIN ACETATE</u>						
A 200653 001					PC	May 16, 2015
<u>DESMOPRESSIN ACETATE - DESMOPRESSIN ACETATE</u>						
A 200653 002					PC	May 16, 2015
<u>DESONIDE - VERDESO</u>						
N 021978 001	8962000	Aug 31, 2025	DP U-1412			
<u>DESVENLAFAXINE SUCCINATE - PRISTIQ</u>						
N 021992 003	6673838	Mar 01, 2022	DS U-860			
	6673838	Mar 01, 2022	DS U-1364			
	8269040	Jul 05, 2027	DS			
<u>DEXAMETHASONE - OZURDEX</u>						
N 022315 001	8043628	Oct 20, 2020	U-1205			
	8088407	Oct 20, 2020	U-1205			
	9012437	Oct 20, 2020	U-1205			
<u>DEXLANSOPRAZOLE - DEXILANT</u>						
N 022287 001	9011926	Feb 24, 2026	DP			
>A>	9145389	Jun 15, 2020	DS DP			
<u>DEXLANSOPRAZOLE - DEXILANT</u>						
N 022287 002	8784885	Oct 15, 2023	DP U-1552			
	8784885	Oct 15, 2023	DP U-1553			
	8784885	Oct 15, 2023	DP U-1554			
	8784885*PED	Apr 15, 2024				
	9011926	Feb 24, 2026	DP			
>A>	9145389	Jun 15, 2020	DS DP			
<u>DEXMEDETOMIDINE HYDROCHLORIDE - PRECEDEX</u>						
N 021038 004	6716867	Mar 31, 2019	U-1472			
	6716867*PED	Oct 01, 2019				
	8242158	Jan 04, 2032	DP			
	8242158*PED	Jul 04, 2032				
	8338470	Jan 04, 2032	DP			
	8338470*PED	Jul 04, 2032				
	8455527	Jan 04, 2032	U-421			

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 10 - October 2015

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>DEXMEDETOMIDINE HYDROCHLORIDE - PRECEDEX</u>						
N 021038 004	8455527*PED	Jul 04, 2032				
	8648106	Jan 04, 2032	DP			
	8648106*PED	Jul 04, 2032				
<u>DEXMETHYLPHENIDATE HYDROCHLORIDE - DEXMETHYLPHENIDATE HYDROCHLORIDE</u>						
A 078908 002					PC	Aug 01, 2015
<u>DEXMETHYLPHENIDATE HYDROCHLORIDE - DEXMETHYLPHENIDATE HYDROCHLORIDE</u>						
A 078908 003					PC	Dec 19, 2015
<u>DICHLORPHENAMIDE - KEVEYIS</u>						
N 011366 002					ODE	Aug 07, 2022
<u>DICLOFENAC - ZORVOLEX</u>						
N 204592 001	8999387	Apr 23, 2030	U-55			
	9017721	Apr 23, 2030	DP			
	>A> 9173854	Apr 23, 2030	DP			
	>A> 9180096	Apr 23, 2030	DP			
<u>DICLOFENAC - ZORVOLEX</u>						
N 204592 002	8999387	Apr 23, 2030	U-55			
	9017721	Apr 23, 2030	DP			
	>A> 9173854	Apr 23, 2030	DP			
	>A> 9180096	Apr 23, 2030	DP			
<u>DICLOFENAC POTASSIUM - CAMBIA</u>						
N 022165 001	8927604	Jun 16, 2026	U-436			
<u>DICLOFENAC SODIUM - DYLOJECT</u>						
N 022396 001	6407079	Jun 18, 2019	DP			
	8946292	Mar 22, 2027	U-1659			
<u>DICLOFENAC SODIUM - PENNSAID</u>						
N 204623 001	9066913	Oct 17, 2027	DP U-1488			
	9101591	Oct 17, 2027	DP U-1488			
	9132110	Oct 17, 2027	U-1488			
	>A> 9168304	Oct 16, 2027	DP			
	>A> 9168305	Oct 17, 2027	U-1488			
<u>DIPHENHYDRAMINE HYDROCHLORIDE; IBUPROFEN - ADVIL PM</u>						
N 021393 001	>A> 9155718	Jan 17, 2022	DP			
<u>DOLUTEGRAVIR SODIUM - TIVICAY</u>						
N 204790 001					M-166	Jul 30, 2018
<u>DONEPEZIL HYDROCHLORIDE; MEMANTINE HYDROCHLORIDE - NAMZARIC</u>						
N 206439 001	5061703	Apr 11, 2015	U-1641			
	5061703*PED	Oct 11, 2015				
	8058291	Dec 05, 2029	U-1641			
	8168209	Nov 22, 2025	DP			
	8168209*PED	May 22, 2026				
	8173708	Nov 22, 2025	U-1641			
	8173708*PED	May 22, 2026				
	8283379	Nov 22, 2025	U-1641			
	8283379*PED	May 22, 2026				
	8293794	Nov 22, 2025	DP			
<u>DONEPEZIL HYDROCHLORIDE; MEMANTINE HYDROCHLORIDE - NAMZARIC</u>						
N 206439 002	5061703	Apr 11, 2015	U-1641			
	5061703*PED	Oct 11, 2015				
	8039009	Mar 24, 2029	U-1641			
	8039009*PED	Sep 24, 2029				

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 10 - October 2015

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>DONEPEZIL HYDROCHLORIDE; MEMANTINE HYDROCHLORIDE - NAMZARIC</u>						
N 206439 002	8058291	Dec 05, 2029	U-1641			
	8168209	Nov 22, 2025	DP			
	8168209*PED	May 22, 2026				
	8173708	Nov 22, 2025	U-1641			
	8173708*PED	May 22, 2026				
	8283379	Nov 22, 2025	U-1641			
	8283379*PED	May 22, 2026				
	8293794	Nov 22, 2025	DP			
	8329752	Nov 22, 2025	DP			
	8329752*PED	May 22, 2026				
	8338485	Nov 22, 2025	DP			
	8338486	Nov 22, 2025	U-1641			
	8362085	Nov 22, 2025	U-1641			
	8362085*PED	May 22, 2026				
	8580858	Nov 22, 2025	U-1641			
	8598233	Nov 22, 2025	DP			
	8598233*PED	May 22, 2026				
<u>DOXEPIH HYDROCHLORIDE - SILENOR</u>						
N 022036 001	9107898	May 01, 2028	DP U-620			
<u>DOXEPIH HYDROCHLORIDE - SILENOR</u>						
N 022036 002	9107898	May 01, 2028	DP U-620			
<u>DOXYCYCLINE HYCLATE - DOXTERIC</u>						
N 050795 006	6958161	Dec 15, 2022	DP U-918			
	8715724	Feb 03, 2028	DP			
<u>DRONEDARONE HYDROCHLORIDE - MULTAQ</u>						
N 022425 001	9107900	Apr 16, 2029	U-1726			
	9107900	Apr 16, 2029	U-1728			
<u>DULOXETINE HYDROCHLORIDE - DULOXETINE HYDROCHLORIDE</u>						
A 090694 003					PC	Jan 11, 2016
<u>EDOXABAN TOSYLATE - SAVAYSA</u>						
N 206316 001	7365205	Jun 12, 2023	DS		NCE	Jan 08, 2020
<u>EDOXABAN TOSYLATE - SAVAYSA</u>						
N 206316 002	7365205	Jun 12, 2023	DS		NCE	Jan 08, 2020
<u>EDOXABAN TOSYLATE - SAVAYSA</u>						
N 206316 003	7365205	Jun 12, 2023	DS		NCE	Jan 08, 2020
<u>EFAVIRENZ; EMTRICITABINE; TENOFOVIR DISOPROXIL FUMARATE - ATRIPLA</u>						
N 021937 001	9018192	Jun 13, 2026	U-750			
	9018192	Jun 13, 2026	U-1170			
<u>ELTROMBOPAG OLAMINE - PROMACTA</u>						
N 022291 001	6280959	Oct 30, 2018	DS DP U-930		D-149	Jun 11, 2018
	6280959	Oct 30, 2018	DS DP U-1306		I-711	Jun 11, 2018
	6280959	Oct 30, 2018	DS DP U-1575		ODE	Aug 26, 2021
	6280959	Oct 30, 2018	DS DP U-1714		PED	Dec 11, 2018
	6280959*PED	Apr 30, 2019			PED	Dec 11, 2018
	7160870	Nov 20, 2022	DS DP U-930		PED	Feb 26, 2022
	7160870	Nov 20, 2022	DS DP U-1306			
	7160870	Nov 20, 2022	DS DP U-1575			
	7160870	Nov 20, 2022	DS DP U-1714			
	7160870*PED	May 20, 2023				
	7332481	May 24, 2021	U-930			
	7332481	May 24, 2021	U-1306			
	7332481	May 24, 2021	U-1575			
	7332481	May 24, 2021	U-1714			

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 10 - October 2015

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>ELTROMBOPAG OLAMINE - PROMACTA</u>						
N 022291 001	7332481*PED	Nov 24, 2021				
	7452874	May 24, 2021	DS DP U-1714			
	7452874*PED	Nov 24, 2021				
	7473686	May 24, 2021	DS DP U-930			
	7473686	May 24, 2021	DS DP U-1306			
	7473686	May 24, 2021	DS DP U-1575			
	7473686	May 24, 2021	DS DP U-1714			
	7473686*PED	Nov 24, 2021				
	7547719	Jul 13, 2025	DS DP U-930			
	7547719	Jul 13, 2025	DS DP U-1306			
	7547719	Jul 13, 2025	DS DP U-1575			
	7547719	Jul 13, 2025	DS DP U-1714			
	7547719*PED	Jan 13, 2026				
	7790704	May 24, 2021	U-930			
	7790704	May 24, 2021	U-1306			
	7790704	May 24, 2021	U-1575			
	7790704	May 24, 2021	U-1714			
	7790704*PED	Nov 24, 2021				
	7795293	May 21, 2023	U-930			
	7795293	May 21, 2023	U-1306			
	7795293	May 21, 2023	U-1575			
	7795293	May 21, 2023	U-1714			
	7795293*PED	Nov 21, 2023				
	8052993	Aug 01, 2027	DP U-930			
	8052993	Aug 01, 2027	DP U-1306			
	8052993	Aug 01, 2027	DP U-1575			
	8052993	Aug 01, 2027	DP U-1714			
	8052993*PED	Feb 01, 2028				
	8052994	Aug 01, 2027	DP U-1714			
	8052994*PED	Feb 01, 2028				
	8062665	Aug 01, 2027	DP U-1714			
	8062665*PED	Feb 01, 2028				
	8071129	Aug 01, 2027	DP U-1714			
	8071129*PED	Feb 01, 2028				
	8828430	Aug 01, 2027	DP U-1306			
	8828430	Aug 01, 2027	DP U-1619			
	8828430	Aug 01, 2027	DP U-1714			
	8828430*PED	Feb 01, 2028				
<u>ELTROMBOPAG OLAMINE - PROMACTA</u>						
N 022291 002	6280959	Oct 30, 2018	DS DP U-930		D-149	Jun 11, 2018
	6280959	Oct 30, 2018	DS DP U-1306		I-711	Jun 11, 2018
	6280959	Oct 30, 2018	DS DP U-1575		ODE	Aug 26, 2021
	6280959	Oct 30, 2018	DS DP U-1714		PED	Dec 11, 2018
	6280959*PED	Apr 30, 2019			PED	Dec 11, 2018
	7160870	Nov 20, 2022	DS DP U-930		PED	Feb 26, 2022
	7160870	Nov 20, 2022	DS DP U-1306			
	7160870	Nov 20, 2022	DS DP U-1575			
	7160870	Nov 20, 2022	DS DP U-1714			
	7160870*PED	May 20, 2023				
	7332481	May 24, 2021	U-930			
	7332481	May 24, 2021	U-1306			
	7332481	May 24, 2021	U-1575			
	7332481	May 24, 2021	U-1714			
	7332481*PED	Nov 24, 2021				
	7452874	May 24, 2021	DS DP U-1714			
	7452874*PED	Nov 24, 2021				
	7473686	May 24, 2021	DS DP U-930			
	7473686	May 24, 2021	DS DP U-1306			
	7473686	May 24, 2021	DS DP U-1575			
	7473686	May 24, 2021	DS DP U-1714			
	7473686*PED	Nov 24, 2021				
	7547719	Jul 13, 2025	DS DP U-930			
	7547719	Jul 13, 2025	DS DP U-1306			
	7547719	Jul 13, 2025	DS DP U-1575			
	7547719	Jul 13, 2025	DS DP U-1714			

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 10 - October 2015

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>ELTROMBOPAG OLAMINE - PROMACTA</u>						
N 022291 002	7547719*PED	Jan 13, 2026				
	7790704	May 24, 2021	U-930			
	7790704	May 24, 2021	U-1306			
	7790704	May 24, 2021	U-1575			
	7790704	May 24, 2021	U-1714			
	7790704*PED	Nov 24, 2021				
	7795293	May 21, 2023	U-930			
	7795293	May 21, 2023	U-1306			
	7795293	May 21, 2023	U-1575			
	7795293	May 21, 2023	U-1714			
	7795293*PED	Nov 21, 2023				
	8052993	Aug 01, 2027	DP U-1714			
	8052993*PED	Feb 01, 2028				
	8052994	Aug 01, 2027	DP U-930			
	8052994	Aug 01, 2027	DP U-1306			
	8052994	Aug 01, 2027	DP U-1575			
	8052994	Aug 01, 2027	DP U-1714			
	8052994*PED	Feb 01, 2028				
	8062665	Aug 01, 2027	DP U-1714			
	8062665*PED	Feb 01, 2028				
	8071129	Aug 01, 2027	DP U-1714			
	8071129*PED	Feb 01, 2028				
	8828430	Aug 01, 2027	DP U-1306			
	8828430	Aug 01, 2027	DP U-1619			
	8828430	Aug 01, 2027	DP U-1714			
	8828430*PED	Feb 01, 2028				
<u>ELTROMBOPAG OLAMINE - PROMACTA</u>						
N 022291 003	6280959	Oct 30, 2018	DS DP U-930		D-149	Jun 11, 2018
	6280959	Oct 30, 2018	DS DP U-1306		I-711	Jun 11, 2018
	6280959	Oct 30, 2018	DS DP U-1575		ODE	Aug 26, 2021
	6280959	Oct 30, 2018	DS DP U-1714		PED	Dec 11, 2018
	6280959*PED	Apr 30, 2019			PED	Dec 11, 2018
	7160870	Nov 20, 2022	DS DP U-930		PED	Feb 26, 2022
	7160870	Nov 20, 2022	DS DP U-1306			
	7160870	Nov 20, 2022	DS DP U-1575			
	7160870	Nov 20, 2022	DS DP U-1714			
	7160870*PED	May 20, 2023				
	7332481	May 24, 2021	U-930			
	7332481	May 24, 2021	U-1306			
	7332481	May 24, 2021	U-1575			
	7332481	May 24, 2021	U-1714			
	7332481*PED	Nov 24, 2021				
	7452874	May 24, 2021	DS DP U-1714			
	7452874*PED	Nov 24, 2021				
	7473686	May 24, 2021	DS DP U-930			
	7473686	May 24, 2021	DS DP U-1306			
	7473686	May 24, 2021	DS DP U-1575			
	7473686	May 24, 2021	DS DP U-1714			
	7473686*PED	Nov 24, 2021				
	7547719	Jul 13, 2025	DS DP U-930			
	7547719	Jul 13, 2025	DS DP U-1306			
	7547719	Jul 13, 2025	DS DP U-1575			
	7547719	Jul 13, 2025	DS DP U-1714			
	7547719*PED	Jan 13, 2026				
	7790704	May 24, 2021	U-930			
	7790704	May 24, 2021	U-1306			
	7790704	May 24, 2021	U-1575			
	7790704	May 24, 2021	U-1714			
	7790704*PED	Nov 24, 2021				
	7795293	May 21, 2023	U-930			
	7795293	May 21, 2023	U-1306			
	7795293	May 21, 2023	U-1575			
	7795293	May 21, 2023	U-1714			
	7795293*PED	Nov 21, 2023				
	8052993	Aug 01, 2027	DP U-1714			

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 10 - October 2015

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>ELTROMBOPAG OLAMINE - PROMACTA</u>						
N 022291 003	8052993*PED	Feb 01, 2028				
	8052994	Aug 01, 2027	DP U-1714			
	8052994*PED	Feb 01, 2028				
	8062665	Aug 01, 2027	DP U-714			
	8062665	Aug 01, 2027	DP U-930			
	8062665	Aug 01, 2027	DP U-1306			
	8062665	Aug 01, 2027	DP U-1575			
	8062665*PED	Feb 01, 2028				
	8071129	Aug 01, 2027	DP U-1714			
	8071129*PED	Feb 01, 2028				
	8828430	Aug 01, 2027	DP U-1306			
	8828430	Aug 01, 2027	DP U-1619			
	8828430	Aug 01, 2027	DP U-1714			
	8828430*PED	Feb 01, 2028				
<u>ELTROMBOPAG OLAMINE - PROMACTA</u>						
N 022291 004	6280959	Oct 30, 2018	DS DP U-930		D-149	Jun 11, 2018
	6280959	Oct 30, 2018	DS DP U-1306		I-711	Jun 11, 2018
	6280959	Oct 30, 2018	DS DP U-1575		ODE	Aug 26, 2021
	6280959	Oct 30, 2018	DS DP U-1714		PED	Dec 11, 2018
	6280959*PED	Apr 30, 2019			PED	Dec 11, 2018
	7160870	Nov 20, 2022	DS DP U-930		PED	Feb 26, 2022
	7160870	Nov 20, 2022	DS DP U-1306			
	7160870	Nov 20, 2022	DS DP U-1575			
	7160870	Nov 20, 2022	DS DP U-1714			
	7160870*PED	May 20, 2023				
	7332481	May 24, 2021	U-930			
	7332481	May 24, 2021	U-1306			
	7332481	May 24, 2021	U-1575			
	7332481	May 24, 2021	U-1714			
	7332481*PED	Nov 24, 2021				
	7452874	May 24, 2021	DS DP U-1714			
	7452874*PED	Nov 24, 2021				
	7473686	May 24, 2021	DS DP U-930			
	7473686	May 24, 2021	DS DP U-1306			
	7473686	May 24, 2021	DS DP U-1575			
	7473686	May 24, 2021	DS DP U-1714			
	7473686*PED	Nov 24, 2021				
	7547719	Jul 13, 2025	DS DP U-930			
	7547719	Jul 13, 2025	DS DP U-1306			
	7547719	Jul 13, 2025	DS DP U-1575			
	7547719	Jul 13, 2025	DS DP U-1714			
	7547719*PED	Jan 13, 2026				
	7790704	May 24, 2021	U-930			
	7790704	May 24, 2021	U-1306			
	7790704	May 24, 2021	U-1575			
	7790704	May 24, 2021	U-1714			
	7790704*PED	Nov 24, 2021				
	7795293	May 21, 2023	U-930			
	7795293	May 21, 2023	U-1306			
	7795293	May 21, 2023	U-1575			
	7795293	May 21, 2023	U-1714			
	7795293*PED	Nov 21, 2023				
	8052993	Aug 01, 2027	DP U-1714			
	8052993*PED	Feb 01, 2028				
	8052994	Aug 01, 2027	DP U-1714			
	8052994*PED	Feb 01, 2028				
	8062665	Aug 01, 2027	DP U-1714			
	8062665*PED	Feb 01, 2028				
	8071129	Aug 01, 2027	DP U-930			
	8071129	Aug 01, 2027	DP U-1306			
	8071129	Aug 01, 2027	DP U-1575			
	8071129	Aug 01, 2027	DP U-1714			
	8071129*PED	Feb 01, 2028				
	8828430	Aug 01, 2027	DP U-1306			
	8828430	Aug 01, 2027	DP U-1619			

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 10 - October 2015

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE	
<u>ELTROMBOPAG OLAMINE - PROMACTA</u>							
N 022291 004	8828430	Aug 01, 2027	DP U-1714				
	8828430*PED	Feb 01, 2028					
<u>ELTROMBOPAG OLAMINE - PROMACTA</u>							
N 022291 005	6280959	Oct 30, 2018	DS DP U-930		D-149	Jun 11, 2018	
	6280959	Oct 30, 2018	DS DP U-1306		I-711	Jun 11, 2018	
	6280959	Oct 30, 2018	DS DP U-1575		ODE	Aug 26, 2021	
	6280959	Oct 30, 2018	DS DP U-1714		PED	Dec 11, 2018	
	6280959*PED	Apr 30, 2019			PED	Dec 11, 2018	
	7160870	Nov 20, 2022	DS DP U-930		PED	Feb 26, 2022	
	7160870	Nov 20, 2022	DS DP U-1306				
	7160870	Nov 20, 2022	DS DP U-1575				
	7160870	Nov 20, 2022	DS DP U-1714				
	7160870*PED	May 20, 2023					
	7332481	May 24, 2021	U-930				
	7332481	May 24, 2021	U-1306				
	7332481	May 24, 2021	U-1575				
	7332481	May 24, 2021	U-1714				
	7332481*PED	Nov 24, 2021					
	7452874	May 24, 2021	DS DP U-1714				
	7452874*PED	Nov 24, 2021					
	7473686	May 24, 2021	DS DP U-930				
	7473686	May 24, 2021	DS DP U-1306				
	7473686	May 24, 2021	DS DP U-1575				
	7473686	May 24, 2021	DS DP U-1714				
	7473686*PED	Nov 24, 2021					
	7547719	Jul 13, 2025	DS DP U-930				
	7547719	Jul 13, 2025	DS DP U-1306				
	7547719	Jul 13, 2025	DS DP U-1575				
	7547719*PED	Jan 13, 2026					
	7790704	May 24, 2021	U-930				
	7790704	May 24, 2021	U-1306				
	7790704	May 24, 2021	U-1575				
	7790704*PED	Nov 24, 2021					
	7795293	May 21, 2023	U-930				
	7795293	May 21, 2023	U-1306				
	7795293	May 21, 2023	U-1575				
	7795293*PED	Nov 21, 2023					
	8052995	Aug 01, 2027	DP U-1306				
	8052995	Aug 01, 2027	DP U-1575				
	8052995*PED	Feb 01, 2028					
	<u>ELTROMBOPAG OLAMINE - PROMACTA</u>						
	N 207027 001	6280959	Oct 30, 2018	DS DP U-1736		D-149	Jun 11, 2018
		7160870	Nov 20, 2022	DS DP U-1736		I-711	Jun 11, 2018
7332481		May 24, 2021	U-1736		ODE	Nov 20, 2015	
7452874		May 24, 2021	DS DP		PED	Dec 11, 2018	
7473686		May 24, 2021	DS DP U-1736		PED	Dec 11, 2018	
7547719		Jul 13, 2025	DS DP U-1736				
7790704		May 24, 2021	U-1736				
7795293		May 24, 2023	U-1736				
<u>ELUXADOLINE - VIBERZI</u>							
N 206940 001	7741356	Mar 25, 2028	DS DP		NCE	May 27, 2020	
	7786158	Mar 14, 2025	DS				
	8344011	Mar 14, 2025	U-1709				
	8609709	Mar 14, 2025	DS				
	8691860	Jul 07, 2028	DS U-1709				
	9115091	Jul 07, 2028	DS DP U-1738				
<u>ELUXADOLINE - VIBERZI</u>							
N 206940 002	7741356	Mar 25, 2028	DS DP		NCE	May 27, 2020	
	7786158	Mar 14, 2025	DS				
	8344011	Mar 14, 2025	U-1709				
	8609709	Mar 14, 2025	DS				

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 10 - October 2015

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>ELUXADOLINE - VIBERZI</u>						
N 206940 002	8691860	Jul 07, 2028	DS U-1709			
	9115091	Jul 07, 2028	DS DP U-1738			
<u>ELVITEGRAVIR - VITEKTA</u>						
N 203093 001	8981103	Oct 26, 2026	DS DP			
<u>ELVITEGRAVIR - VITEKTA</u>						
N 203093 002	8981103	Oct 26, 2026	DS DP			
<u>EMPAGLIFLOZIN - JARDIANCE</u>						
N 204629 001					M-160 M-161	Jun 26, 2018 Jun 26, 2018
<u>EMPAGLIFLOZIN - JARDIANCE</u>						
N 204629 002					M-160 M-161	Jun 26, 2018 Jun 26, 2018
<u>EMPAGLIFLOZIN; LINAGLIPTIN - GLYXAMBI</u>						
N 206073 001	6303661	Apr 24, 2017	U-1651		NC	Jan 30, 2018
	6890898	Feb 02, 2019	U-1652		NCE	May 02, 2016
	7078381	Feb 02, 2019	U-1651		NCE	Aug 01, 2019
	7407955	Aug 12, 2023	DS DP			
	7459428	Feb 02, 2019	U-1651			
	7579449	Nov 05, 2025	DS			
	7713938	Apr 15, 2027	DS DP			
	8119648	Aug 12, 2023	U-1651			
	8178541	Aug 12, 2023	DP U-1653			
	8178541	Aug 12, 2023	DP U-1654			
	8551957	Oct 19, 2029	DP U-1651			
	8673927	May 04, 2027	DP U-1652			
	8846695	Jun 04, 2030	U-1652			
	8883805	Nov 26, 2025	DP			
<u>EMPAGLIFLOZIN; LINAGLIPTIN - GLYXAMBI</u>						
N 206073 002	6303661	Apr 24, 2017	U-1651		NC	Jan 30, 2018
	6890898	Feb 02, 2019	U-1652		NCE	May 02, 2016
	7078381	Feb 02, 2019	U-1651		NCE	Aug 01, 2019
	7407955	Aug 12, 2023	DS DP			
	7459428	Feb 02, 2019	U-1651			
	7579449	Nov 05, 2025	DS			
	7713938	Apr 15, 2027	DS DP			
	8119648	Aug 12, 2023	U-1651			
	8178541	Aug 12, 2023	DP U-1653			
	8178541	Aug 12, 2023	DP U-1654			
	8551957	Oct 19, 2029	DP U-1651			
	8673927	May 04, 2024	DP U-1652			
	8846695	Jun 04, 2030	U-1652			
	8883805	Nov 26, 2025	DP			
<u>EMPAGLIFLOZIN; METFORMIN HYDROCHLORIDE - SYNJARDY</u>						
N 206111 001	7579449	Nov 05, 2025	DS		NCE	Aug 01, 2019
	7713938	Apr 15, 2027	DS DP		NP	Aug 26, 2018
<u>EMPAGLIFLOZIN; METFORMIN HYDROCHLORIDE - SYNJARDY</u>						
N 206111 002	7579449	Nov 05, 2025	DS		NCE	Aug 01, 2019
	7713938	Apr 15, 2027	DS DP		NP	Aug 26, 2018
<u>EMPAGLIFLOZIN; METFORMIN HYDROCHLORIDE - SYNJARDY</u>						
N 206111 003	7579449	Nov 05, 2025	DS		NCE	Aug 01, 2019
	7713938	Apr 15, 2027	DS DP		NP	Aug 26, 2018

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 10 - October 2015

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>EMPAGLIFLOZIN; METFORMIN HYDROCHLORIDE - SYNJARDY</u>						
N 206111 004	7579449	Nov 05, 2025	DS		NCE	Aug 01, 2019
	7713938	Apr 15, 2027	DS DP		NP	Aug 26, 2018
<u>EMTRICITABINE; RILPIVIRINE HYDROCHLORIDE; TENOFOVIR DISOPROXIL FUMARATE - COMPLERA</u>						
N 202123 001 >A>	7125879	Aug 09, 2022	DS DP U-257			
<u>ENZALUTAMIDE - XTANDI</u>						
N 203415 001	9126941	May 15, 2026	U-1588			
<u>EPINEPHRINE - AUVI-Q</u>						
N 201739 001	8920377	Nov 23, 2024	DP			
	8926594	Mar 31, 2026	DP			
	9056170	Nov 23, 2024	DP			
>A>	9149579	Jul 19, 2025	U-1758			
<u>EPINEPHRINE - AUVI-Q</u>						
N 201739 002	8920377	Nov 23, 2024	DP			
	8926594	Mar 31, 2026	DP			
	9056170	Nov 23, 2024	DP			
>A>	9149579	Jul 19, 2025	U-1758			
<u>EPINEPHRINE - ADRENALIN</u>						
N 204640 001	9119876	Mar 13, 2035	DP			
<u>ERIBULIN MESYLATE - HALAVEN</u>						
N 201532 001	6214865	Jul 20, 2023	DS			
<u>ERLOTINIB HYDROCHLORIDE - TARCEVA</u>						
N 021743 001	5747498	Nov 08, 2018	DS DP U-659		I-671	May 14, 2016
	5747498*PED	May 08, 2019			PED	Nov 14, 2016
	6900221	Nov 09, 2020	DS DP U-659			
	6900221	Nov 09, 2020	DS DP U-875			
	6900221	Nov 09, 2020	DS DP U-1046			
	6900221	Nov 09, 2020	DS DP U-1403			
	6900221*PED	May 09, 2021				
	7087613	Nov 09, 2020	U-659			
	7087613	Nov 09, 2020	U-1045			
	7087613	Nov 09, 2020	U-1403			
	7087613*PED	May 09, 2021				
	RE41065	Nov 08, 2018	DS DP			
	RE41065*PED	May 08, 2019				
<u>ERLOTINIB HYDROCHLORIDE - TARCEVA</u>						
N 021743 002	5747498	Nov 08, 2018	DS DP U-659		I-671	May 14, 2016
	5747498*PED	May 08, 2019			PED	Nov 14, 2016
	6900221	Nov 09, 2020	DS DP U-659			
	6900221	Nov 09, 2020	DS DP U-875			
	6900221	Nov 09, 2020	DS DP U-1046			
	6900221	Nov 09, 2020	DS DP U-1403			
	6900221*PED	May 09, 2021				
	7087613	Nov 09, 2020	U-659			
	7087613	Nov 09, 2020	U-1045			
	7087613	Nov 09, 2020	U-1403			
	7087613*PED	May 09, 2021				
	RE41065	Nov 08, 2018	DS DP			
	RE41065*PED	May 08, 2019				
<u>ERLOTINIB HYDROCHLORIDE - TARCEVA</u>						
N 021743 003	5747498	Nov 08, 2018	DS DP U-659		I-671	May 14, 2016
	5747498*PED	May 08, 2019			PED	Nov 14, 2016
	6900221	Nov 09, 2020	DS DP U-659			
	6900221	Nov 09, 2020	DS DP U-875			
	6900221	Nov 09, 2020	DS DP U-1046			

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 10 - October 2015

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>ERLOTINIB HYDROCHLORIDE - TARCEVA</u>						
N 021743 003	6900221	Nov 09, 2020	DS DP U-1403			
	6900221*PED	May 09, 2021				
	7087613	Nov 09, 2020	U-659			
	7087613	Nov 09, 2020	U-1045			
	7087613	Nov 09, 2020	U-1403			
	7087613*PED	May 09, 2021				
	RE41065	Nov 08, 2018	DS DP			
	RE41065*PED	May 08, 2019				
<u>ESLICARBAZEPINE ACETATE - APTIOM</u>						
N 022416 001	5753646	Jun 27, 2016	DS DP U-1451		D-150	Aug 27, 2018
	5753646	Jun 27, 2016	DS DP U-1746		I-715	Aug 27, 2018
<u>ESLICARBAZEPINE ACETATE - APTIOM</u>						
N 022416 002	5753646	Jun 27, 2016	DS DP U-1451		D-150	Aug 27, 2018
	5753646	Jun 27, 2016	DS DP U-1746		I-715	Aug 27, 2018
<u>ESLICARBAZEPINE ACETATE - APTIOM</u>						
N 022416 003	5753646	Jun 27, 2016	DS DP U-1451		D-150	Aug 27, 2018
	5753646	Jun 27, 2016	DS DP U-1746		I-715	Aug 27, 2018
<u>ESLICARBAZEPINE ACETATE - APTIOM</u>						
N 022416 004	5753646	Jun 27, 2016	DS DP U-1451		D-150	Aug 27, 2018
	5753646	Jun 27, 2016	DS DP U-1746		I-715	Aug 27, 2018
<u>ESOMEPRAZOLE MAGNESIUM - NEXIUM 24HR</u>						
N 204655 001	5690960	Nov 25, 2014	DP U-1509			
	5690960*PED	May 25, 2015				
	5714504	Feb 03, 2015	DP U-1509			
	5714504*PED	Aug 03, 2015				
	5877192*PED	Nov 27, 2014				
	5900424	May 04, 2016	DS U-1509			
	5900424*PED	Nov 04, 2016				
	6369085	May 25, 2018	DS DP U-1509			
	6369085*PED	Nov 25, 2018				
	6428810	Nov 03, 2019	DP U-1509			
	6428810*PED	May 03, 2020				
	6875872*PED	Nov 27, 2014				
	7411070	May 25, 2018	DS			
	7411070*PED	Nov 25, 2018				
<u>ESOMEPRAZOLE MAGNESIUM; NAPROXEN - VIMOVO</u>						
N 022511 001	8945621	Oct 17, 2031	U-1661			
>A>	9161920	May 31, 2022	U-1760			
<u>ESOMEPRAZOLE MAGNESIUM; NAPROXEN - VIMOVO</u>						
N 022511 002	8945621	Oct 17, 2031	U-1661			
>A>	9161920	May 31, 2022	U-1760			
<u>ESTRADIOL - MINIVELLE</u>						
N 203752 005	6841716	Apr 27, 2020	DP			
	8231906	Jul 04, 2030	DS DP			
<u>EVEROLIMUS - AFINITOR</u>						
N 022334 001	8410131	Nov 01, 2025	DS DP U-1368			
	8410131*PED	May 01, 2026				
	9006224	Jul 01, 2028	U-1681			
<u>EVEROLIMUS - AFINITOR</u>						
N 022334 002	8410131	Nov 01, 2025	DS DP U-1368			
	8410131*PED	May 01, 2026				
	9006224	Jul 01, 2028	U-1681			

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 10 - October 2015

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>EVEROLIMUS - AFINITOR</u>						
N 022334 002	8410131	Nov 01, 2025	DS DP U-1368			
	8410131*PED	May 01, 2026				
	9006224	Jul 01, 2028	U-1681			
<u>EVEROLIMUS - AFINITOR</u>						
N 022334 003	8410131	Nov 01, 2025	DS DP U-1368			
	8410131*PED	May 01, 2026				
	9006224	Jul 01, 2028	U-1681			
<u>EVEROLIMUS - AFINITOR</u>						
N 022334 004	8410131	Nov 01, 2025	DS DP U-1368			
	8410131*PED	May 01, 2026				
	9006224	Jul 01, 2028	U-1681			
<u>EXENATIDE SYNTHETIC - BYDUREON</u>						
N 022200 001					M-162	Sep 24, 2018
<u>FEBUXOSTAT - ULORIC</u>						
N 021856 001	9107912	Sep 08, 2031	U-1346			
<u>FEBUXOSTAT - ULORIC</u>						
N 021856 002	9107912	Sep 08, 2031	U-1346			
<u>FENTANYL CITRATE - LAZANDA</u>						
N 022569 001	9078814	Jan 08, 2024	DP			
<u>FENTANYL CITRATE - LAZANDA</u>						
N 022569 002	9078814	Jan 08, 2024	DP			
<u>FENTANYL HYDROCHLORIDE - IONSYS</u>						
N 021338 001	6169920	Jan 02, 2018	DP U-736			
	6181963	Nov 02, 2019	DP			
	8301238	Sep 30, 2031	DP			
	8428708	May 21, 2032	U-736			
	8428709	Jun 11, 2032	DP U-736			
	8781571	Mar 31, 2032	DP U-736			
	9095706	Jan 17, 2033	DP			
<u>FERRIC CITRATE - AURYXIA</u>						
N 205874 001	8901349	Feb 18, 2024	U-1577			
	9050316	Feb 18, 2024	U-1577			
<u>FERRIC PYROPHOSPHATE CITRATE - TRIFERIC</u>						
N 206317 001	6689275	Dec 31, 2016	U-1656			
	6779468	Dec 31, 2016	U-1656			
	7816404	Apr 17, 2029	DP U-1656			
<u>FEXOFENADINE HYDROCHLORIDE - CHILDREN'S ALLEGRA ALLERGY</u>						
N 201373 001	8933097	Aug 16, 2032	DP			
<u>FEXOFENADINE HYDROCHLORIDE - CHILDREN'S ALLEGRA HIVES</u>						
N 201373 002	8933097	Aug 16, 2032	DP			
<u>FINAFLOXACIN - XTORO</u>						
N 206307 001	6133260	Apr 12, 2017	DS DP			
	6432948	Apr 12, 2017	DS DP			
	8536167	Aug 08, 2031	U-1679			
	9119859	Jul 02, 2030	U-1679			

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 10 - October 2015

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>FLIBANSERIN - ADDYI</u>						
N 022526 001	7151103	May 09, 2023	U-1734		NCE	Aug 18, 2020
	7420057	Aug 01, 2022	DS DP			
	8227471	May 09, 2023	U-1734			
<u>FLUOROURACIL - TOLAK</u>						
N 022259 001 >A>	7169401	Jul 18, 2023	DP		NP	Sep 18, 2018
<u>FLUTEMETAMOL F-18 - VIZAMYL</u>						
N 203137 001	8916131	Sep 16, 2028	DP			
<u>FLUTEMETAMOL F-18 - VIZAMYL</u>						
N 203137 002	8916131	Sep 16, 2028	DP			
<u>FLUTICASONE FUROATE; VILANTEROL TRIFENATATE - BREO ELLIPTA</u>						
N 204275 001	6537983	Aug 03, 2021	DP U-1401		I-708	Apr 30, 2018
	6537983	Aug 03, 2021	DP U-1691			
	6759398	Aug 03, 2021	DP U-1401			
	6759398	Aug 03, 2021	DP U-1691			
	7101866	Aug 03, 2021	DS DP U-1401			
	7101866	Aug 03, 2021	DS DP U-1691			
	7439393	Sep 11, 2022	DS DP U-1401			
	7439393	Sep 11, 2022	DS DP U-1691			
	8511304	Jun 14, 2027	DP U-1424			
	8511304	Jun 14, 2027	DP U-1691			
	RE44874	Mar 23, 2023	DS DP U-1548			
	RE44874	Mar 23, 2023	DS DP U-1691			
<u>FLUTICASONE FUROATE; VILANTEROL TRIFENATATE - BREO ELLIPTA</u>						
N 204275 002	5873360	Feb 23, 2016	DP		NP	Apr 30, 2018
	6537983	Aug 03, 2021	DP U-1691			
	6759398	Aug 03, 2021	DP U-1691			
	7101866	Aug 03, 2021	DS DP U-1691			
	7439393	Sep 11, 2022	DS DP U-1691			
	7629335	Aug 03, 2021	DP			
	7776895	Sep 11, 2022	DP			
	8113199	Oct 23, 2027	DP			
	8161968	Feb 05, 2028	DP			
	8511304	Jun 14, 2027	DP U-1691			
	8534281	Aug 10, 2029	DP			
	8746242	Oct 11, 2030	DP			
	RE44874	Mar 23, 2023	DS DP U-1691			
<u>FLUTICASONE PROPIONATE - CUTIVATE</u>						
N 021152 001					NPP	Jan 16, 2018
<u>GADOXETATE DISODIUM - EQVIST</u>						
N 022090 001					M-155	Mar 27, 2018
<u>GADOXETATE DISODIUM - EQVIST</u>						
N 022090 002					M-155	Mar 27, 2018
<u>GEFITINIB - IRESSA</u>						
N 206995 001 >A>	5770599	May 05, 2017	DS DP U-1755		NP ODE	Jul 13, 2018 Jul 13, 2022
<u>GLATIRAMER ACETATE - COPAXONE</u>						
N 020622 003	8969302	Aug 19, 2030	U-441			
	9155776	Aug 19, 2030	U-441			
<u>GLYCEROL PHENYLBUTYRATE - RAVICTI</u>						
N 203284 001	9095559	Mar 09, 2032	U-1383			

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 10 - October 2015

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>GUANFACINE HYDROCHLORIDE - GUANFACINE HYDROCHLORIDE</u>						
A 200881 001					PC	May 30, 2015
<u>GUANFACINE HYDROCHLORIDE - GUANFACINE HYDROCHLORIDE</u>						
A 200881 002					PC	May 30, 2015
<u>GUANFACINE HYDROCHLORIDE - GUANFACINE HYDROCHLORIDE</u>						
A 200881 003					PC	May 30, 2015
<u>GUANFACINE HYDROCHLORIDE - GUANFACINE HYDROCHLORIDE</u>						
A 200881 004					PC	May 30, 2015
<u>GUANFACINE HYDROCHLORIDE - INTUNIV</u>						
N 022037 001					M-154	Mar 18, 2018
<u>GUANFACINE HYDROCHLORIDE - INTUNIV</u>						
N 022037 002					M-154	Mar 18, 2018
<u>GUANFACINE HYDROCHLORIDE - INTUNIV</u>						
N 022037 003					M-154	Mar 18, 2018
<u>GUANFACINE HYDROCHLORIDE - INTUNIV</u>						
N 022037 004					M-154	Mar 18, 2018
<u>HYDROCODONE BITARTRATE - ZOHYDRO ER</u>						
N 202880 001	9132096	Sep 12, 2034	DP			
<u>HYDROCODONE BITARTRATE - ZOHYDRO ER</u>						
N 202880 002	9132096	Sep 12, 2034	DP			
<u>HYDROCODONE BITARTRATE - ZOHYDRO ER</u>						
N 202880 003	9132096	Sep 12, 2034	DP			
<u>HYDROCODONE BITARTRATE - ZOHYDRO ER</u>						
N 202880 004	9132096	Sep 12, 2034	DP			
<u>HYDROCODONE BITARTRATE - ZOHYDRO ER</u>						
N 202880 005	9132096	Sep 12, 2034	DP			
<u>HYDROCODONE BITARTRATE - ZOHYDRO ER</u>						
N 202880 006	9132096	Sep 12, 2034	DP			
<u>HYDROCODONE BITARTRATE - HYSINGLA</u>						
N 206627 001	9023401	Oct 30, 2021	DP			
	9056052	Oct 30, 2021	DP			
	9060940	Oct 30, 2021	U-1556			
	9084816	Aug 24, 2027	DP			
	9095614	Aug 24, 2027	U-1556			
	9095615	Aug 24, 2027	DP			
<u>HYDROCODONE BITARTRATE - HYSINGLA</u>						
N 206627 002	9023401	Oct 30, 2021	DP			
	9056052	Oct 30, 2021	DP			
	9060940	Oct 30, 2021	U-1556			
	9084816	Aug 24, 2027	DP			
	9095614	Aug 24, 2027	U-1556			
	9095615	Aug 24, 2027	DP			
<u>HYDROCODONE BITARTRATE - HYSINGLA</u>						
N 206627 003	9023401	Oct 30, 2021	DP			
	9056052	Oct 30, 2021	DP			

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 10 - October 2015

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>HYDROCODONE BITARTRATE - HYSINGLA</u>						
N 206627 003	9060940	Oct 30, 2021	U-1556			
	9084816	Aug 24, 2027	DP			
	9095614	Aug 24, 2027	U-1556			
	9095615	Aug 24, 2027	DP			
<u>HYDROCODONE BITARTRATE - HYSINGLA</u>						
N 206627 004	9023401	Oct 30, 2021	DP			
	9056052	Oct 30, 2021	DP			
	9060940	Oct 30, 2021	U-1556			
	9084816	Aug 24, 2027	DP			
	9095614	Aug 24, 2027	U-1556			
	9095615	Aug 24, 2027	DP			
<u>HYDROCODONE BITARTRATE - HYSINGLA</u>						
N 206627 005	9056052	Oct 30, 2021	DP			
	9060940	Oct 30, 2021	U-1556			
	9084816	Aug 24, 2027	DP			
	9095614	Aug 24, 2027	U-1556			
	9095615	Aug 24, 2027	DP			
<u>HYDROCODONE BITARTRATE - HYSINGLA</u>						
N 206627 006	9056052	Oct 30, 2021	DP			
	9060940	Oct 30, 2021	U-1556			
	9084816	Aug 24, 2027	DP			
	9095614	Aug 24, 2027	U-1556			
	9095615	Aug 24, 2027	DP			
<u>HYDROCODONE BITARTRATE - HYSINGLA</u>						
N 206627 007	9056052	Oct 30, 2021	DP			
	9060940	Oct 30, 2021	U-1556			
	9084816	Aug 24, 2027	DP			
	9095614	Aug 24, 2027	U-1556			
	9095615	Aug 24, 2027	DP			
<u>IBRUTINIB - IMBRUVICA</u>						
N 205552 001	8497277	Dec 28, 2026	U-1456		I-702	Jan 29, 2018
	8497277	Dec 28, 2026	U-1491		ODE	Jan 29, 2022
	8497277	Dec 28, 2026	U-1650			
	8957079	Dec 28, 2026	DS DP			
	8999999	Jun 03, 2031	U-1683			
	8999999	Jun 03, 2031	U-1684			
	9125889	Jun 03, 2031	U-1745			
<u>IBUPROFEN - CALDOLOR</u>						
N 022348 002	8871810	Sep 30, 2029	U-1599			
	9012508	Sep 14, 2030	U-981			
	9114068	Sep 30, 2029	U-1735			
>A>	9138404	Sep 30, 2029	U-1756			
<u>ICATIBANT ACETATE - FIRAZYR</u>						
N 022150 001	5648333	Jul 15, 2019	DS DP	U-1187		
<u>IDELALISIB - ZYDELIG</u>						
N 205858 001	8138195	Apr 24, 2021	DS DP	U-1549		
	8865730	Mar 05, 2033	DS DP	U-1615		
	8980901	May 12, 2025		U-1678		
>A>	9149477	May 12, 2025		U-1757		
	RE44599	Jul 21, 2025		U-1558		
	RE44599	Jul 21, 2025		U-1615		
<u>IDELALISIB - ZYDELIG</u>						
N 205858 002	8138195	Apr 24, 2021	DS DP	U-1549		
	8865730	Mar 05, 2033	DS DP	U-1615		

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 10 - October 2015

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>IDELALISIB - ZYDELIG</u>						
N 205858 002	8980901	May 12, 2025	U-1678			
	>A> 9149477	May 12, 2025	U-1757			
	RE44599	Jul 21, 2025	U-1558			
	RE44599	Jul 21, 2025	U-1615			
<u>ILOPERIDONE - FANAPT</u>						
N 022192 001	8652776	Aug 31, 2030	U-1685			
	8999638	Oct 28, 2030	U-1674			
	9072742	Jan 16, 2031	U-1674			
	9074254	Dec 28, 2031	U-1674			
	9074255	Dec 17, 2030	U-1674			
	9074256	Feb 10, 2031	U-1674			
	9138432	Sep 30, 2025	U-1737			
	9157121	Apr 05, 2030	U-1674			
<u>ILOPERIDONE - FANAPT</u>						
N 022192 002	8652776	Aug 31, 2030	U-1685			
	8999638	Oct 28, 2030	U-1674			
	9072742	Jan 16, 2031	U-1674			
	9074254	Dec 28, 2031	U-1674			
	9074255	Dec 17, 2030	U-1674			
	9074256	Feb 10, 2031	U-1674			
	9138432	Sep 30, 2025	U-1737			
	9157121	Apr 05, 2030	U-1674			
<u>ILOPERIDONE - FANAPT</u>						
N 022192 003	8652776	Aug 31, 2030	U-1685			
	8999638	Oct 28, 2030	U-1674			
	9072742	Jan 16, 2031	U-1674			
	9074254	Dec 28, 2031	U-1674			
	9074255	Dec 17, 2030	U-1674			
	9074256	Feb 10, 2031	U-1674			
	9138432	Sep 30, 2025	U-1737			
	9157121	Apr 05, 2030	U-1674			
<u>ILOPERIDONE - FANAPT</u>						
N 022192 004	8652776	Aug 31, 2030	U-1685			
	8999638	Oct 28, 2030	U-1674			
	9072742	Jan 16, 2031	U-1674			
	9074254	Dec 28, 2031	U-1674			
	9074255	Dec 17, 2030	U-1674			
	9074256	Feb 10, 2031	U-1674			
	9138432	Sep 30, 2025	U-1737			
	9157121	Apr 05, 2030	U-1674			
<u>ILOPERIDONE - FANAPT</u>						
N 022192 005	8652776	Aug 31, 2030	U-1685			
	8999638	Oct 28, 2030	U-1674			
	9072742	Jan 16, 2031	U-1674			
	9074254	Dec 28, 2031	U-1674			
	9074255	Dec 17, 2030	U-1674			
	9074256	Feb 10, 2031	U-1674			
	9138432	Sep 30, 2025	U-1737			
	9157121	Apr 05, 2030	U-1674			
<u>ILOPERIDONE - FANAPT</u>						
N 022192 006	8652776	Aug 31, 2030	U-1685			
	8999638	Oct 28, 2030	U-1674			
	9072742	Jan 16, 2031	U-1674			
	9074254	Dec 28, 2031	U-1674			
	9074255	Dec 17, 2030	U-1674			
	9074256	Feb 10, 2031	U-1674			
	9138432	Sep 30, 2025	U-1737			
	9157121	Apr 05, 2030	U-1674			

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 10 - October 2015

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>ILOPERIDONE - FANAPT</u>						
N 022192 006	8652776	Aug 31, 2030	U-1685			
	8999638	Oct 28, 2030	U-1674			
	9072742	Jan 16, 2031	U-1674			
	9074254	Dec 28, 2031	U-1674			
	9074255	Dec 17, 2030	U-1674			
	9074256	Feb 10, 2031	U-1674			
	9138432	Sep 30, 2025	U-1737			
	9157121	Apr 05, 2030	U-1674			
<u>ILOPERIDONE - FANAPT</u>						
N 022192 007	8652776	Aug 31, 2030	U-1685			
	8999638	Oct 28, 2030	U-1674			
	9072742	Jan 16, 2031	U-1674			
	9074254	Dec 28, 2031	U-1674			
	9074255	Dec 17, 2030	U-1674			
	9074256	Feb 10, 2031	U-1674			
	9138432	Sep 30, 2025	U-1737			
	9157121	Apr 05, 2030	U-1674			
<u>INDACATEROL MALEATE - ARCAPTA NEOHALER</u>						
N 022383 001	8658673	Jun 02, 2020	DS DP U-1168			
<u>INDOMETHACIN - TIVORBEX</u>						
N 204768 001	8992982	Apr 23, 2030	DP			
	9089471	Apr 23, 2030	U-55			
<u>INDOMETHACIN - TIVORBEX</u>						
N 204768 002	8992982	Apr 23, 2030	DP			
	9089471	Apr 23, 2030	U-55			
<u>INSULIN ASPART RECOMBINANT - NOVOLOG FLEXTOUCH</u>						
N 020986 005	8920383	Jul 17, 2026	DP			
	9108002	Jan 20, 2026	DP			
	9132239	Feb 01, 2032	DP			
<u>INSULIN ASPART; INSULIN DEGLUDEC - RYZODEG 70/30</u>						
N 203313 001	5866538	Jun 20, 2017	DP		NCE	Sep 25, 2020
	6899699	Jan 02, 2022	DP			
	7615532	May 25, 2025	DS DP			
	7686786	Aug 03, 2026	DP			
	8672898	Jan 02, 2022	DP			
	8684969	Oct 20, 2025	DP			
	8920383	Jul 17, 2026	DP			
	9108002	Jan 20, 2026	DP			
	9132239	Feb 01, 2032	DP			
<u>INSULIN DEGLUDEC - TRESIBA</u>						
N 203314 001	6899699	Jan 02, 2022	DP		NCE	Sep 25, 2020
	7615532	May 25, 2025	DS DP			
	7686786	Aug 03, 2026	DP			
	8672898	Jan 02, 2022	DP			
	8684969	Oct 20, 2025	DP			
	8920383	Jul 17, 2026	DP			
	9108002	Jan 20, 2026	DP			
	9132239	Feb 01, 2032	DP			
<u>INSULIN DEGLUDEC - TRESIBA</u>						
N 203314 002	6899699	Jan 02, 2022	DP		NCE	Sep 25, 2020
	7615532	May 25, 2025	DS DP			
	7686786	Aug 03, 2026	DP			
	8672898	Jan 02, 2022	DP			
	8684969	Oct 20, 2025	DP			
	8920383	Jul 17, 2026	DP			

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 10 - October 2015

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>INSULIN DEGLUDEC - TRESIBA</u>						
N 203314 002	9108002	Jan 20, 2026	DP			
	9132239	Feb 01, 2032	DP			
<u>INSULIN DETEMIR RECOMBINANT - LEVEMIR FLEXTOUCH</u>						
N 021536 005	8920383	Jul 17, 2026	DP			
	9108002	Jan 20, 2026	DP			
	9132239	Feb 01, 2032	DP			
<u>INSULIN GLARGINE RECOMBINANT - LANTUS SOLOSTAR</u>						
N 021081 002	8992486	Jun 05, 2024	DP			
	9011391	Mar 26, 2024	DP			
<u>INSULIN GLARGINE RECOMBINANT - TOUJEO SOLOSTAR</u>						
N 206538 001	7918833	Sep 23, 2027	DP		NP	Feb 25, 2018
	7918833*PED	Mar 23, 2028				
	8512297	Sep 15, 2024	DP			
	8556864	Mar 03, 2024	DP			
	8603044	Mar 02, 2024	DP			
	8679069	Apr 12, 2025	DP			
	8992486	Jun 05, 2024	DP			
	9011391	Mar 26, 2024	DP			
<u>INSULIN GLULISINE RECOMBINANT - APIDRA SOLOSTAR</u>						
N 021629 003	8992486	Jun 05, 2024	DP			
	9011391	Mar 26, 2024	DP			
<u>INSULIN LISPRO RECOMBINANT - HUMALOG KWIKPEN</u>						
N 205747 001	6034054	Jun 11, 2018	DP U-1707			
	6034054	Jun 11, 2018	DP U-1708			
	6551992	Jun 11, 2018	DP U-1707			
	6551992	Jun 11, 2018	DP U-1708			
	7291132	Aug 09, 2024	DP			
<u>INSULIN RECOMBINANT HUMAN - AFREZZA</u>						
N 022472 001 >A>	8729019	Dec 26, 2028	DP			
	8912193	Jun 12, 2029	DP U-1538			
<u>INSULIN RECOMBINANT HUMAN - AFREZZA</u>						
N 022472 002	7943572	Aug 10, 2026	U-1539			
	8424518	Oct 17, 2031	DP			
	8623817	Sep 18, 2029	U-1537			
>A>	8729019	Dec 26, 2028	DP			
	8912193	Jun 12, 2029	DP U-1538			
<u>INSULIN RECOMBINANT HUMAN - AFREZZA</u>						
N 022472 003	6444226	Jun 29, 2020	DP U-1534		NP	Jun 27, 2017
	6652885	Jun 29, 2020	U-1535			
	7305986	Jan 16, 2023	DP			
	7464706	Mar 02, 2023	DP			
	7648960	Jun 29, 2020	U-1535			
	7943178	Jun 29, 2020	DP U-1535			
	7943572	Aug 10, 2026	U-1539			
	8119593	Aug 11, 2029	U-1537			
	8146588	Apr 24, 2023	DP			
	8156936	Jan 16, 2023	DP			
	8215300	Nov 24, 2022	DP			
	8258095	Aug 11, 2029	U-1537			
	8389470	Jun 29, 2020	DP U-1697			
	8394414	May 15, 2015	DP U-1533			
	8424518	Oct 17, 2031	DP			
	8485180	Mar 25, 2030	DP			
	8499757	Feb 19, 2032	DP			
	8551528	Jun 11, 2030	DP			

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 10 - October 2015

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>INSULIN RECOMBINANT HUMAN - AFREZZA</u>						
N 022472 003	8623817	Sep 18, 2029	U-1537			
	8636001	Jul 12, 2032	DP			
>A>	8729019	Dec 26, 2028	DP			
	8734845	Jun 11, 2030	DP			
	8778403	Jun 11, 2030	DP U-1538			
	8889099	Jun 29, 2020	DP U-1621			
	8912193	Jun 12, 2029	DP U-1538			
<u>IPRATROPIUM BROMIDE - ATROVENT HFA</u>						
N 021527 001	8474447	Jan 17, 2030	DP			
<u>IRINOTECAN HYDROCHLORIDE - ONIVYDE</u>						
N 207793 001					>A> NP	Oct 22, 2018
<u>ISAVUCONAZONIUM SULFATE - CRESEMBA</u>						
N 207500 001	6812238	Oct 31, 2020	DS		NCE	Mar 06, 2020
	7459561	Oct 31, 2020	DS		ODE	Mar 06, 2022
					GAIN	Mar 06, 2025
					GAIN	Mar 06, 2027
<u>ISAVUCONAZONIUM SULFATE - CRESEMBA</u>						
N 207501 001	6812238	Oct 31, 2020	DS		NCE	Mar 06, 2020
	7459561	Oct 31, 2020	DS		ODE	Mar 06, 2022
					GAIN	Mar 06, 2025
					GAIN	Mar 06, 2027
<u>ISOTRETINOIN - ABSORICA</u>						
N 021951 001	8952064	Sep 21, 2021	DP			
	9078925	Sep 21, 2021	DP			
	9089534	Sep 21, 2021	DP			
<u>ISOTRETINOIN - ABSORICA</u>						
N 021951 002	8952064	Sep 21, 2021	DP			
	9078925	Sep 21, 2021	DP			
	9089534	Sep 21, 2021	DP			
<u>ISOTRETINOIN - ABSORICA</u>						
N 021951 003	8952064	Sep 21, 2021	DP			
	9078925	Sep 21, 2021	DP			
	9089534	Sep 21, 2021	DP			
<u>ISOTRETINOIN - ABSORICA</u>						
N 021951 004	8952064	Sep 21, 2021	DP			
	9078925	Sep 21, 2021	DP			
	9089534	Sep 21, 2021	DP			
<u>ISOTRETINOIN - ABSORICA</u>						
N 021951 005	7435427	Sep 21, 2021	DP			
	8367102	Sep 21, 2021	U-1347			
	8952064	Sep 21, 2021	DP			
	9078925	Sep 21, 2021	DP			
	9089534	Sep 21, 2021	DP			
<u>ISOTRETINOIN - ABSORICA</u>						
N 021951 006	7435427	Sep 21, 2021	DP			
	8367102	Sep 21, 2021	U-1347			
	8952064	Sep 21, 2021	DP			
	9078925	Sep 21, 2021	DP			
	9089534	Sep 21, 2021	DP			

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 10 - October 2015

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>IVABRADINE HYDROCHLORIDE - CORLANOR</u>						
N 206143 001	7361649	Apr 17, 2026	DS DP U-1694		NCE	Apr 15, 2020
	7361650	Apr 14, 2026	DS DP U-1694			
	7867996	Feb 22, 2026	DS DP U-1694			
	7879842	Feb 22, 2026	DS DP U-1694			
<u>IVABRADINE HYDROCHLORIDE - CORLANOR</u>						
N 206143 002	7361649	Apr 17, 2026	DS DP U-1694		NCE	Apr 15, 2020
	7361650	Apr 14, 2026	DS DP U-1694			
	7867996	Feb 22, 2026	DS DP U-1694			
	7879842	Feb 22, 2026	DS DP U-1694			
<u>IVACAFTOR - KALYDECO</u>						
N 203188 001	8354427	Jul 06, 2026	U-1311		I-705	Dec 30, 2017
<u>IVACAFTOR - KALYDECO</u>						
N 207925 001	7495103	May 20, 2027	DS DP			
	8324242	Apr 18, 2027	U-1311			
	8354427	Jul 06, 2026	U-1311			
	8410274	Dec 28, 2026	DP			
	8754224	Dec 28, 2026	DS DP			
	8883206	Feb 27, 2033	DP			
<u>IVACAFTOR - KALYDECO</u>						
N 207925 002	7495103	May 20, 2027	DS DP			
	8324242	Apr 18, 2027	U-1311			
	8354427	Jul 06, 2026	U-1311			
	8410274	Dec 28, 2026	DP			
	8754224	Dec 28, 2026	DS DP			
	8883206	Feb 27, 2033	DP			
<u>IVACAFTOR; LUMACAFTOR - ORKAMBI</u>						
N 206038 001	7495103	May 20, 2027	DS DP		NCE	Jul 02, 2020
	8324242	Apr 18, 2027	U-1311		ODE	Jul 02, 2022
	8410274	Dec 28, 2026	DP			
	8507534	Sep 20, 2030	DS DP			
	8653103	Dec 04, 2028	DP			
	8716338	Nov 08, 2026	DP U-1718			
	8741933	Nov 08, 2026	U-1717			
	8754224	Dec 28, 2026	DS DP			
	8846718	Dec 04, 2028	U-1717			
	8993600	Dec 11, 2030	DP			
<u>IVERMECTIN - SOOLANTRA</u>						
N 206255 001	5952372	Sep 18, 2018	U-1631			
	6133310	Apr 26, 2019	U-1631			
	7550440	Apr 22, 2024	DP U-1631			
	8080530	Apr 22, 2024	DP U-1631			
	8093219	Apr 22, 2024	DP U-1631			
	8415311	Apr 22, 2024	DP U-1631			
	8470788	Apr 22, 2024	DP U-1631			
	8815816	Apr 22, 2024	DP U-1631			
	9089587	Mar 13, 2034	U-1631			
<u>KETOROLAC TROMETHAMINE - ACULAR LS</u>						
N 021528 001	8946281	May 28, 2024	U-1662			
<u>KETOROLAC TROMETHAMINE - ACUVAIL</u>						
N 022427 001	8992952	Aug 05, 2024	DP			
<u>KETOROLAC TROMETHAMINE; PHENYLEPHRINE HYDROCHLORIDE - OMIIDRIA</u>						
N 205388 001	9066856	Oct 23, 2033	DP			

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 10 - October 2015

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>LAMIVUDINE - LAMIVUDINE</u>						
A 203564 001					PC	Sep 01, 2015
<u>LAMIVUDINE - EPIVIR</u>						
N 020564 001	5905082	May 18, 2016	DS DP		D-147	Mar 23, 2018
	5905082*PED	Nov 18, 2016				
<u>LAMIVUDINE - EPIVIR</u>						
N 020564 003	5905082	May 18, 2016	DS DP		D-147	Mar 23, 2018
	5905082*PED	Nov 18, 2016				
<u>LAMIVUDINE - EPIVIR</u>						
N 020596 001	5905082	May 18, 2016	DS DP		D-147	Mar 23, 2018
	6004968	Mar 20, 2018	DP U-248			
	6004968*PED	Sep 20, 2018				
<u>LAMIVUDINE; RALTEGRAVIR POTASSIUM - DUTREBIS</u>						
N 206510 001	7169780	Oct 03, 2023	DS DP			
	7217713	Oct 21, 2022		U-1663		
	7435734	Oct 21, 2022		U-1663		
	7754731	Mar 11, 2029	DS DP	U-1663		
	7820660	Apr 25, 2023	DS			
<u>LAMOTRIGINE - LAMOTRIGINE</u>						
A 200828 001					PC	Sep 28, 2015
<u>LAMOTRIGINE - LAMOTRIGINE</u>						
A 200828 002					PC	Sep 28, 2015
<u>LAMOTRIGINE - LAMOTRIGINE</u>						
A 200828 003					PC	Sep 28, 2015
<u>LAMOTRIGINE - LAMOTRIGINE</u>						
A 200828 004					PC	Sep 28, 2015
<u>LAMOTRIGINE - LAMICTAL</u>						
N 020241 001					M-159	May 18, 2018
<u>LAMOTRIGINE - LAMICTAL</u>						
N 020241 002					M-159	May 18, 2018
<u>LAMOTRIGINE - LAMICTAL</u>						
N 020241 003					M-159	May 18, 2018
<u>LAMOTRIGINE - LAMICTAL</u>						
N 020241 004					M-159	May 18, 2018
<u>LAMOTRIGINE - LAMICTAL</u>						
N 020241 005					M-159	May 18, 2018
<u>LAMOTRIGINE - LAMICTAL</u>						
N 020241 006					M-159	May 18, 2018
<u>LAMOTRIGINE - LAMICTAL CD</u>						
N 020764 001					M-159	May 18, 2018
<u>LAMOTRIGINE - LAMICTAL CD</u>						
N 020764 002					M-159	May 18, 2018

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 10 - October 2015

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>LAMOTRIGINE - LAMICTAL CD</u>						
N 020764 003					M-159	May 18, 2018
<u>LAMOTRIGINE - LAMICTAL CD</u>						
N 020764 004					M-159	May 18, 2018
<u>LAMOTRIGINE - LAMICTAL XR</u>						
N 022115 001 >A> 9144547		Sep 22, 2023	DP			
<u>LAMOTRIGINE - LAMICTAL XR</u>						
N 022115 002 >A> 9144547		Sep 22, 2023	DP			
<u>LAMOTRIGINE - LAMICTAL XR</u>						
N 022115 003 >A> 9144547		Sep 22, 2023	DP			
<u>LAMOTRIGINE - LAMICTAL XR</u>						
N 022115 004 >A> 9144547		Sep 22, 2023	DP			
<u>LAMOTRIGINE - LAMICTAL XR</u>						
N 022115 005 >A> 9144547		Sep 22, 2023	DP			
<u>LAMOTRIGINE - LAMICTAL XR</u>						
N 022115 006 >A> 9144547		Sep 22, 2023	DP			
<u>LAMOTRIGINE - LAMICTAL ODT</u>						
N 022251 001					M-159	May 18, 2018
<u>LAMOTRIGINE - LAMICTAL ODT</u>						
N 022251 002					M-159	May 18, 2018
<u>LAMOTRIGINE - LAMICTAL ODT</u>						
N 022251 003					M-159	May 18, 2018
<u>LAMOTRIGINE - LAMICTAL ODT</u>						
N 022251 004					M-159	May 18, 2018
<u>LANTHANUM CARBONATE - FOSRENOL</u>						
N 204734 001 8980327		Dec 01, 2030	DP			
<u>LANTHANUM CARBONATE - FOSRENOL</u>						
N 204734 002 8980327		Dec 01, 2030	DP			
<u>LAPATINIB DITOSYLATE - TYKERB</u>						
N 022059 001 8821927		Sep 18, 2029	DS DP			
<u>LEDIPASVIR; SOFOSBUVIR - HARVONI</u>						
N 205834 001 9085573		Mar 21, 2028	DS DP U-1470			
<u>LENALIDOMIDE - REVLIMID</u>						
N 021880 001 9056120		Apr 11, 2023	U-1215		I-706	Feb 17, 2018
9101621		May 15, 2023	U-1216		ODE	Feb 17, 2022
9101622		May 15, 2023	U-1216			
<u>LENALIDOMIDE - REVLIMID</u>						
N 021880 002 9056120		Apr 11, 2023	U-1215		I-706	Feb 17, 2018
9101621		May 15, 2023	U-1216		ODE	Feb 17, 2022
9101622		May 15, 2023	U-1216			

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 10 - October 2015

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>LENALIDOMIDE - REVLIMID</u>						
N 021880 003	9056120	Apr 11, 2023	U-1215		I-706	Feb 17, 2018
	9101621	May 15, 2023	U-1216		ODE	Feb 17, 2022
	9101622	May 15, 2023	U-1216			
<u>LENALIDOMIDE - REVLIMID</u>						
N 021880 004	9056120	Apr 11, 2023	U-1215		I-706	Feb 17, 2018
	9101621	May 15, 2023	U-1216		ODE	Feb 17, 2022
	9101622	May 15, 2023	U-1216			
<u>LENALIDOMIDE - REVLIMID</u>						
N 021880 005	9056120	Apr 11, 2023	U-1215		I-706	Feb 17, 2018
	9101621	May 15, 2023	U-1216		ODE	Feb 17, 2022
	9101622	May 15, 2023	U-1216			
<u>LENALIDOMIDE - REVLIMID</u>						
N 021880 006	5635517	Oct 04, 2019	DS	U-1211	I-706	Feb 17, 2018
	9056120	Apr 11, 2023		U-1215	ODE	Feb 17, 2022
	9101621	May 15, 2023		U-1216		
	9101622	May 15, 2023		U-1216		
<u>LENAVATINIB MESYLATE - LENVIMA</u>						
N 206947 001	7253286	Oct 19, 2021	DS DP		NCE	Feb 13, 2020
	7612208	Sep 19, 2026	DS DP		ODE	Feb 13, 2022
	9006256	Jul 27, 2027		U-1695		
<u>LENAVATINIB MESYLATE - LENVIMA</u>						
N 206947 002	7253286	Oct 19, 2021	DS DP		NCE	Feb 13, 2020
	7612208	Sep 19, 2026	DS DP		ODE	Feb 13, 2022
	9006256	Jul 27, 2027		U-1695		
<u>LEUPROLIDE ACETATE - LUPRON DEPOT</u>						
N 020517 003	7429559	Jan 13, 2019	DP			
	8815801	Jun 28, 2022	DP			
	8921326	Feb 05, 2031	DP	U-1666		
<u>LEVALBUTEROL HYDROCHLORIDE - XOPENEX</u>						
N 020837 001					M-151	Jan 22, 2018
<u>LEVALBUTEROL HYDROCHLORIDE - XOPENEX</u>						
N 020837 002					M-151	Jan 22, 2018
<u>LEVALBUTEROL HYDROCHLORIDE - XOPENEX</u>						
N 020837 003					M-151	Jan 22, 2018
<u>LEVALBUTEROL HYDROCHLORIDE - XOPENEX</u>						
N 020837 004					M-151	Jan 22, 2018
<u>LEVALBUTEROL TARTRATE - XOPENEX HFA</u>						
N 021730 001					M-156	Mar 12, 2018
<u>LEVETIRACETAM - SPRITAM</u>						
N 207958 001	6471992	Feb 20, 2018	DP			
<u>LEVETIRACETAM - SPRITAM</u>						
N 207958 002	6471992	Feb 20, 2018	DP			
<u>LEVETIRACETAM - SPRITAM</u>						
N 207958 003	6471992	Feb 20, 2018	DP			

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 10 - October 2015

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>LEVETIRACETAM - SPRITAM</u>						
N 207958 004	6471992	Feb 20, 2018	DP			
<u>LEVOLEUCOVORIN CALCIUM - LEVOLEUCOVORIN CALCIUM</u>						
A 203563 001					PC	Oct 20, 2015
<u>LEVOLEUCOVORIN CALCIUM - LEVOLEUCOVORIN CALCIUM</u>						
A 203563 002					PC	Oct 20, 2015
<u>LEVONORGESTREL - LILETTA</u>						
N 206229 001					NP	Feb 26, 2018
<u>LEVOTHYROXINE SODIUM - LEVOTHYROXINE SODIUM</u>						
N 202231 001	9006289	Oct 03, 2032	DP			
	>A> 9168238	Aug 29, 2032	DP			
	>A> 9168239	Aug 29, 2032	DP			
<u>LEVOTHYROXINE SODIUM - LEVOTHYROXINE SODIUM</u>						
N 202231 002	9006289	Oct 03, 2032	DP			
	>A> 9168238	Aug 29, 2032	DP			
	>A> 9168239	Aug 29, 2032	DP			
<u>LEVOTHYROXINE SODIUM - LEVOTHYROXINE SODIUM</u>						
N 202231 003	9006289	Oct 03, 2032	DP			
	>A> 9168238	Aug 29, 2032	DP			
	>A> 9168239	Aug 29, 2032	DP			
<u>LINACLOTIDE - LINZESS</u>						
N 202811 001	8933030	Feb 17, 2031	DP			
<u>LINACLOTIDE - LINZESS</u>						
N 202811 002	8933030	Feb 17, 2031	DP			
<u>LINAGLIPTIN - TRADJENTA</u>						
N 201280 001	8673927	May 04, 2027	U-1503			
	8853156	Mar 05, 2031	U-1642			
<u>LINAGLIPTIN; METFORMIN HYDROCHLORIDE - JENTADUETO</u>						
N 201281 001	8673927	May 04, 2027	U-1503			
	>A> 9155705	May 21, 2030	DP			
<u>LINAGLIPTIN; METFORMIN HYDROCHLORIDE - JENTADUETO</u>						
N 201281 002	8673927	May 04, 2027	U-1503			
	>A> 9155705	May 21, 2030	DP			
<u>LINAGLIPTIN; METFORMIN HYDROCHLORIDE - JENTADUETO</u>						
N 201281 003	8673927	May 04, 2027	U-1503			
	>A> 9155705	May 21, 2030	DP			
<u>LINEZOLID - LINEZOLID</u>						
A 078061 001					PC	Dec 19, 2015
<u>LINEZOLID - LINEZOLID</u>						
A 200222 001					PC	Jul 04, 2015
<u>LINEZOLID - ZYVOX</u>						
N 021131 002	6559305	Jan 29, 2021	DS			
	6559305*PED	Jul 29, 2021				

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 10 - October 2015

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>LINEZOLID - ZYVOX</u>						
N 021131 003	6559305	Jan 29, 2021	DS			
	6559305*PED	Jul 29, 2021				
<u>LIRAGLUTIDE RECOMBINANT - VICTOZA</u>						
N 022341 001	8846618	Jun 27, 2022	DP			
<u>LIRAGLUTIDE RECOMBINANT - SAXENDA</u>						
N 206321 001	6268343	Aug 22, 2022	DS DP U-1255			
	6458924	Aug 22, 2017	DS DP U-1255			
	6899699	Jan 01, 2022	DP			
	7235627	Aug 22, 2017	DS DP			
	7686786	Aug 03, 2026	DP			
	8114833	Aug 13, 2025	DP			
	8672898	Jan 02, 2022	DP			
	8684969	Oct 20, 2025	DP			
	8846618	Jun 27, 2022	DP			
	8920383	Jul 17, 2026	DP			
	9108002	Jan 26, 2026	DP			
	9132239	Feb 01, 2032	DP			
<u>LISDEXAMFETAMINE DIMESYLATE - VYVANSE</u>						
N 021977 001	7105486	Feb 24, 2023	U-727		I-703	Jan 30, 2018
	7223735	Feb 24, 2023	DP			
	7671031	Feb 24, 2023	U-727			
	7674774	Feb 24, 2023	DP U-842			
	7678770	Feb 24, 2023	U-842			
	7678771	Feb 24, 2023	DP U-842			
	7687467	Feb 24, 2023	DP U-842			
	7700561	Feb 24, 2023	DP			
<u>LISDEXAMFETAMINE DIMESYLATE - VYVANSE</u>						
N 021977 002	7105486	Feb 24, 2023	U-727		I-703	Jan 30, 2018
	7223735	Feb 24, 2023	DP			
	7671031	Feb 24, 2023	U-727			
	7674774	Feb 24, 2023	DP U-842			
	7678770	Feb 24, 2023	U-842			
	7678771	Feb 24, 2023	DP U-842			
	7687467	Feb 24, 2023	DP U-842			
	7700561	Feb 24, 2023	DP			
<u>LISDEXAMFETAMINE DIMESYLATE - VYVANSE</u>						
N 021977 003	7105486	Feb 24, 2023	U-727		I-703	Jan 30, 2018
	7223735	Feb 24, 2023	DP			
	7671031	Feb 24, 2023	U-727			
	7674774	Feb 24, 2023	DP U-842			
	7678770	Feb 24, 2023	U-842			
	7678771	Feb 24, 2023	DP U-842			
	7687467	Feb 24, 2023	DP U-842			
	7700561	Feb 24, 2023	DP			
<u>LISDEXAMFETAMINE DIMESYLATE - VYVANSE</u>						
N 021977 004	7105486	Feb 24, 2023	U-727		I-703	Jan 30, 2018
	7105486	Feb 24, 2023	U-842			
	7223735	Feb 24, 2023	DP			
	7671031	Feb 24, 2023	U-727			
	7674774	Feb 24, 2023	DP U-842			
	7678770	Feb 24, 2023	U-842			
	7678771	Feb 24, 2023	DP U-842			
	7687467	Feb 24, 2023	DP U-842			
	7700561	Feb 24, 2023	DP			

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 10 - October 2015

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>LISDEXAMFETAMINE DIMESYLATE - VYVANSE</u>						
N 021977 005	7105486	Feb 24, 2023	U-842		I-703	Jan 30, 2018
	7671031	Feb 24, 2023	U-727			
	7674774	Feb 24, 2023	DP U-842			
	7678770	Feb 24, 2023	U-842			
	7678771	Feb 24, 2023	DP U-842			
	7687467	Feb 24, 2023	DP U-842			
	7700561	Feb 24, 2023	DP			
<u>LISDEXAMFETAMINE DIMESYLATE - VYVANSE</u>						
N 021977 006	7105486	Feb 24, 2023	U-727		I-703	Jan 30, 2018
	7105486	Feb 24, 2023	U-842			
	7223735	Feb 24, 2023	DP			
	7671031	Feb 24, 2023	U-727			
	7674774	Feb 24, 2023	DP U-842			
	7678770	Feb 24, 2023	U-842			
	7678771	Feb 24, 2023	DP U-842			
	7687467	Feb 24, 2023	DP U-842			
	7700561	Feb 24, 2023	DP			
<u>LISDEXAMFETAMINE DIMESYLATE - VYVANSE</u>						
N 021977 007	7223735	Feb 24, 2023	DP		I-703	Jan 30, 2018
	7655630	Feb 24, 2023	DS			
	7659253	Feb 24, 2023	DS DP U-727			
	7659254	Feb 24, 2023	U-1034			
	7662787	Feb 24, 2023	DS			
	7662788	Feb 24, 2023	U-727			
	7671030	Feb 24, 2023	DP U-727			
	7671031	Feb 24, 2023	U-727			
	7674774	Feb 24, 2023	DP U-842			
	7678770	Feb 24, 2023	U-842			
	7678771	Feb 24, 2023	DP			
	7687466	Feb 24, 2023	DP			
	7687467	Feb 24, 2023	DP U-842			
	7700561	Feb 24, 2023	DP			
	7713936	Feb 24, 2023	U-727			
	7718619	Feb 24, 2023	DP U-842			
<u>LOMITAPIDE MESYLATE - JUXTAPID</u>						
N 203858 001	5712279	Feb 21, 2016	DS U-1317			
<u>LOMITAPIDE MESYLATE - JUXTAPID</u>						
N 203858 002	5712279	Feb 21, 2016	DS U-1317			
<u>LOMITAPIDE MESYLATE - JUXTAPID</u>						
N 203858 003	5712279	Feb 21, 2016	DS U-1317			
<u>LOMITAPIDE MESYLATE - JUXTAPID</u>						
N 203858 004	5712279	Feb 21, 2016	DS U-1317		NCE	Dec 21, 2017
	6492365	Dec 10, 2019	U-1318		ODE	Dec 21, 2019
	7932268	Aug 19, 2027	U-1316			
	8618135	Mar 07, 2025	U-1316			
<u>LOMITAPIDE MESYLATE - JUXTAPID</u>						
N 203858 005	5712279	Feb 21, 2016	DS U-1317		NCE	Dec 21, 2017
	6492365	Dec 10, 2019	U-1318		ODE	Dec 21, 2019
	7932268	Aug 19, 2027	U-1316			
	8618135	Mar 07, 2025	U-1316			
<u>LOMITAPIDE MESYLATE - JUXTAPID</u>						
N 203858 006	5712279	Feb 21, 2016	DS U-1317		NCE	Dec 21, 2017
	6492365	Dec 10, 2019	U-1318		ODE	Dec 21, 2019
	7932268	Aug 19, 2027	U-1316			
	8618135	Mar 07, 2025	U-1316			

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 10 - October 2015

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>LOMITAPIDE MESYLATE - JUXTAPID</u>						
N 203858 006	5712279	Feb 21, 2016	DS	U-1317	NCE	Dec 21, 2017
	6492365	Dec 10, 2019		U-1318	ODE	Dec 21, 2019
	7932268	Aug 19, 2027		U-1316		
	8618135	Mar 07, 2025		U-1316		
<u>LORATADINE - CLARITIN</u>						
N 020641 002	6132758	Jun 01, 2018	DP			
<u>LORCASERIN HYDROCHLORIDE - BELVIO</u>						
N 022529 001	8946207	Jun 16, 2024	DP			
	8980881	Dec 20, 2025		U-1252		
	8980881	Dec 20, 2025		U-1253		
	8980881	Dec 20, 2025		U-1254		
	8980881	Dec 20, 2025		U-1255		
	8999970	Feb 07, 2033		U-1688		
	8999970	Feb 07, 2033		U-1689		
	8999970	Feb 07, 2033		U-1692		
<u>LOXAPINE - ADASUVE</u>						
N 022549 001	8955512	Oct 26, 2021	DP			
	8991387	May 21, 2024	DP			
<u>LULICONAZOLE - LUZU</u>						
N 204153 001	8980931	Apr 28, 2034	DP			
	9012484	Sep 06, 2033	DS DP	U-540		
<u>LURASIDONE HYDROCHLORIDE - LATUDA</u>						
N 200603 001	RE45573	Jun 23, 2025	DS			
<u>LURASIDONE HYDROCHLORIDE - LATUDA</u>						
N 200603 002	RE45573	Jun 23, 2025	DS			
<u>LURASIDONE HYDROCHLORIDE - LATUDA</u>						
N 200603 003	RE45573	Jun 23, 2025	DS			
<u>LURASIDONE HYDROCHLORIDE - LATUDA</u>						
N 200603 004	RE45573	Jun 23, 2025	DS			
<u>LURASIDONE HYDROCHLORIDE - LATUDA</u>						
N 200603 005	RE45573	Jun 23, 2025	DS			
<u>MEGESTROL ACETATE - MEGACE ES</u>						
N 021778 001	9040088	Apr 22, 2024		U-755		
	9101540	Apr 22, 2024	DP	U-755		
	9101549	Apr 22, 2024		U-755		
	9107827	Apr 22, 2024		U-755		
<u>MELOXICAM - VIVLODEX</u>						
N 207233 001					>A> NP	Oct 22, 2018
<u>MELOXICAM - VIVLODEX</u>						
N 207233 002					>A> NP	Oct 22, 2018
<u>MESALAMINE - ASACOL HD</u>						
N 021830 001	9089492	Nov 15, 2021	DP			
<u>MESALAMINE - APRISO</u>						
N 022301 001	8940328	Apr 20, 2018	DP			
	8956647	Apr 20, 2018	DP			

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 10 - October 2015

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>METFORMIN HYDROCHLORIDE; PIOGLITAZONE HYDROCHLORIDE - ACTOPLUS MET</u>						
N 021842 001	9101660	Jan 22, 2027	DP			
<u>METFORMIN HYDROCHLORIDE; PIOGLITAZONE HYDROCHLORIDE - ACTOPLUS MET</u>						
N 021842 002	9101660	Jan 22, 2027	DP			
<u>METFORMIN HYDROCHLORIDE; PIOGLITAZONE HYDROCHLORIDE - ACTOPLUS MET XR</u>						
N 022024 001	9060941	Sep 19, 2023	DP			
<u>METFORMIN HYDROCHLORIDE; PIOGLITAZONE HYDROCHLORIDE - ACTOPLUS MET XR</u>						
N 022024 002	9060941	Sep 19, 2023	DP			
<u>METHOTREXATE - OTREXUP</u>						
N 204824 001	8945063	Mar 19, 2030	DP U-1442			
<u>METHOTREXATE - OTREXUP</u>						
N 204824 002	8945063	Mar 19, 2030	DP U-1442			
<u>METHOTREXATE - OTREXUP</u>						
N 204824 003	8945063	Mar 19, 2030	DP U-1442			
<u>METHOTREXATE - OTREXUP</u>						
N 204824 004	8945063	Mar 19, 2030	DP U-1442			
<u>METHOTREXATE - OTREXUP</u>						
N 204824 005	8945063	Mar 19, 2030	DP U-1442			
<u>METHYLPHENIDATE - DAYTRANA</u>						
N 021514 001	9034370	Oct 07, 2025	DP			
<u>METHYLPHENIDATE - DAYTRANA</u>						
N 021514 002	9034370	Oct 07, 2025	DP			
<u>METHYLPHENIDATE - DAYTRANA</u>						
N 021514 003	9034370	Oct 07, 2025	DP			
<u>METHYLPHENIDATE - DAYTRANA</u>						
N 021514 004	9034370	Oct 07, 2025	DP			
<u>METHYLPHENIDATE HYDROCHLORIDE - CONCERTA</u>						
N 021121 001	9000038	Jul 31, 2017	U-666			
	9000038	Jul 31, 2017	U-1693			
	9000038*PED	Jan 31, 2018				
	9029416	Jul 31, 2017	DP U-666			
	9144549	Jul 31, 2017	U-1747			
	9144549	Jul 31, 2017	U-1748			
<u>METHYLPHENIDATE HYDROCHLORIDE - CONCERTA</u>						
N 021121 002	9000038	Jul 31, 2017	U-666			
	9000038	Jul 31, 2017	U-1693			
	9000038*PED	Jan 31, 2018				
	9029416	Jul 31, 2017	DP U-666			
	9144549	Jul 31, 2017	U-1747			
	9144549	Jul 31, 2017	U-1748			
<u>METHYLPHENIDATE HYDROCHLORIDE - CONCERTA</u>						
N 021121 003	9000038	Jul 31, 2017	U-666			
	9000038	Jul 31, 2017	U-1693			
	9000038*PED	Jan 31, 2018				
	9029416	Jul 31, 2017	DP U-666			
	9144549	Jul 31, 2017	U-1747			
	9144549	Jul 31, 2017	U-1748			

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 10 - October 2015

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>METHYLPHENIDATE HYDROCHLORIDE - CONCERTA</u>						
N 021121 003	9000038	Jul 31, 2017	U-666			
	9000038	Jul 31, 2017	U-1693			
	9000038*PED	Jan 31, 2018				
	9029416	Jul 31, 2017	DP U-666			
	9144549	Jul 31, 2017	U-1747			
	9144549	Jul 31, 2017	U-1748			
<u>METHYLPHENIDATE HYDROCHLORIDE - CONCERTA</u>						
N 021121 004	9000038	Jul 31, 2017	U-666			
	9000038	Jul 31, 2017	U-1693			
	9000038*PED	Jan 31, 2018				
	9029416	Jul 31, 2017	DP U-666			
	9144549	Jul 31, 2017	U-1747			
	9144549	Jul 31, 2017	U-1748			
<u>METHYLPHENIDATE HYDROCHLORIDE - QUILLIVANT XR</u>						
N 202100 001	8956649	Feb 15, 2031	DP U-1665			
	9040083	Feb 15, 2031	DP			
<u>METHYLPHENIDATE HYDROCHLORIDE - APTENSIO XR</u>						
N 205831 001	6419960	Dec 16, 2019	DP		NP	Apr 17, 2018
	7083808	Dec 16, 2019	DP			
	7247318	Dec 16, 2019	DP			
	7438930	Dec 16, 2019	DP			
	8580310	Dec 16, 2019	DP			
	9066869	Dec 16, 2019	DP			
<u>METHYLPHENIDATE HYDROCHLORIDE - APTENSIO XR</u>						
N 205831 002	6419960	Dec 16, 2019	DP		NP	Apr 17, 2018
	7083808	Dec 16, 2019	DP			
	7247318	Dec 16, 2019	DP			
	7438930	Dec 16, 2019	DP			
	8580310	Dec 16, 2019	DP			
	9066869	Dec 16, 2019	DP			
<u>METHYLPHENIDATE HYDROCHLORIDE - APTENSIO XR</u>						
N 205831 003	6419960	Dec 16, 2019	DP		NP	Apr 17, 2018
	7083808	Dec 16, 2019	DP			
	7247318	Dec 16, 2019	DP			
	7438930	Dec 16, 2019	DP			
	8580310	Dec 16, 2019	DP			
	9066869	Dec 16, 2019	DP			
<u>METHYLPHENIDATE HYDROCHLORIDE - APTENSIO XR</u>						
N 205831 004	6419960	Dec 16, 2019	DP		NP	Apr 17, 2018
	7083808	Dec 16, 2019	DP			
	7247318	Dec 16, 2019	DP			
	7438930	Dec 16, 2019	DP			
	8580310	Dec 16, 2019	DP			
	9066869	Dec 16, 2019	DP			
<u>METHYLPHENIDATE HYDROCHLORIDE - APTENSIO XR</u>						
N 205831 005	6419960	Dec 16, 2019	DP		NP	Apr 17, 2018
	7083808	Dec 16, 2019	DP			
	7247318	Dec 16, 2019	DP			
	7438930	Dec 16, 2019	DP			
	8580310	Dec 16, 2019	DP			
	9066869	Dec 16, 2019	DP			
<u>METHYLPHENIDATE HYDROCHLORIDE - APTENSIO XR</u>						
N 205831 006	6419960	Dec 16, 2019	DP		NP	Apr 17, 2018
	7083808	Dec 16, 2019	DP			
	7247318	Dec 16, 2019	DP			

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 10 - October 2015

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>METHYLPHENIDATE HYDROCHLORIDE - APTENSIO XR</u>						
N 205831 006	7438930	Dec 16, 2019	DP			
	8580310	Dec 16, 2019	DP			
	9066869	Dec 16, 2019	DP			
<u>METHYLPHENIDATE HYDROCHLORIDE - APTENSIO XR</u>						
N 205831 007	6419960	Dec 16, 2019	DP		NP	Apr 17, 2018
	7083808	Dec 16, 2019	DP			
	7247318	Dec 16, 2019	DP			
	7438930	Dec 16, 2019	DP			
	8580310	Dec 16, 2019	DP			
	9066869	Dec 16, 2019	DP			
<u>METRONIDAZOLE - NUVESSA</u>						
N 205223 001	7893097	Feb 19, 2028	DP			
	8658678	Jun 27, 2028	U-1682			
	8877792	Feb 02, 2028	DP			
	8946276	Jun 28, 2032	U-1664			
<u>MIFEPRISTONE - KORLYM</u>						
N 202107 001	8921348	Aug 27, 2028	U-1643			
<u>MINOCYCLINE HYDROCHLORIDE - MINOCIN</u>						
N 050444 001	9084802	May 12, 2031	U-282			
<u>MINOCYCLINE HYDROCHLORIDE - ARESTIN</u>						
N 050781 001	7699609	Mar 29, 2022	DP			
<u>MINOXIDIL - WOMEN'S ROGAINE</u>						
N 021812 002	6946120	Apr 20, 2019	DP U-702			
<u>MORPHINE SULFATE - MORPHINE SULFATE</u>						
N 204223 001	9072781	Mar 12, 2034	DP			
<u>MORPHINE SULFATE - MORPHINE SULFATE</u>						
N 204223 002	9072781	Mar 12, 2034	DP			
<u>MORPHINE SULFATE - MORPHINE SULFATE</u>						
N 204223 003	9072781	Mar 12, 2034	DP			
<u>MORPHINE SULFATE - MORPHINE SULFATE</u>						
N 204223 004	9072781	Mar 12, 2034	DP			
<u>MORPHINE SULFATE - MORPHINE SULFATE</u>						
N 204223 005	9072781	Mar 12, 2034	DP			
<u>MORPHINE SULFATE; NALTREXONE HYDROCHLORIDE - EMBEDA</u>						
N 022321 001	8623418	Nov 07, 2029	U-1640			
<u>MORPHINE SULFATE; NALTREXONE HYDROCHLORIDE - EMBEDA</u>						
N 022321 002	8623418	Nov 07, 2029	U-1640			
<u>MORPHINE SULFATE; NALTREXONE HYDROCHLORIDE - EMBEDA</u>						
N 022321 003	8623418	Nov 07, 2029	U-1640			
<u>MORPHINE SULFATE; NALTREXONE HYDROCHLORIDE - EMBEDA</u>						
N 022321 004	8623418	Nov 07, 2029	U-1640			
<u>MORPHINE SULFATE; NALTREXONE HYDROCHLORIDE - EMBEDA</u>						
N 022321 005	8623418	Nov 07, 2029	U-1640			

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 10 - October 2015

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>MORPHINE SULFATE; NALTREXONE HYDROCHLORIDE - EMBEDA</u>						
N 022321 006	8623418	Nov 07, 2029	U-1640			
<u>MOXIFLOXACIN HYDROCHLORIDE - MOXEZA</u>						
N 022428 001	9114168	May 29, 2029	DP			
<u>NAFTIFINE HYDROCHLORIDE - NAFTIN</u>						
N 204286 001 >A>	9161914	Jan 31, 2033	U-540			
<u>NALOXEGOL OXALATE - MOVANTIK</u>						
N 204760 001	7056500	Jun 29, 2024	DP U-1185			
	9012469	Apr 02, 2032	DS DP			
<u>NALOXEGOL OXALATE - MOVANTIK</u>						
N 204760 002	7056500	Jun 29, 2024	DP U-1185			
	9012469	Apr 02, 2032	DS DP			
<u>NALOXONE HYDROCHLORIDE - EVZIO</u>						
N 205787 001	8926594	Mar 31, 2026	DP			
	8939943	Feb 28, 2031	DP			
	9022022	Feb 28, 2031	DP			
	9056170	Nov 23, 2024	DP			
<u>NALOXONE HYDROCHLORIDE; OXYCODONE HYDROCHLORIDE - TARGINIO</u>						
N 205777 001	8969369	May 10, 2022	DP U-1556			
	9056051	May 10, 2022	DP U-1556			
	9073933	Mar 30, 2025	DS			
	9084729	May 10, 2022	DP U-1556			
>A>	9161937	May 10, 2022	DP U-1556			
>A>	9168252	May 10, 2022	DP U-1556			
<u>NALOXONE HYDROCHLORIDE; OXYCODONE HYDROCHLORIDE - TARGINIO</u>						
N 205777 002	8969369	May 10, 2022	DP U-1556			
	9056051	May 10, 2022	DP U-1556			
	9073933	Mar 30, 2025	DS			
	9084729	May 10, 2022	DP U-1556			
>A>	9161937	May 10, 2022	DP U-1556			
>A>	9168252	May 10, 2022	DP U-1556			
<u>NALOXONE HYDROCHLORIDE; OXYCODONE HYDROCHLORIDE - TARGINIO</u>						
N 205777 003	8969369	May 10, 2022	DP U-1556			
	9056051	May 10, 2022	DP U-1556			
	9073933	Mar 30, 2025	DS			
	9084729	May 10, 2022	DP U-1556			
>A>	9161937	May 10, 2022	DP U-1556			
>A>	9168252	May 10, 2022	DP U-1556			
<u>NAPROXEN SODIUM; SUMATRIPTAN SUCCINATE - TREXIMET</u>						
N 021926 001	6060499	Aug 14, 2017	DP U-867			
	6060499*PED	Feb 14, 2018				
	6586458	Aug 14, 2017	DP U-867			
	6586458*PED	Feb 14, 2018				
	7332183	Oct 02, 2025	DP U-867			
	7332183*PED	Apr 02, 2026				
	8022095	Aug 14, 2017	DP U-867			
	8022095*PED	Feb 14, 2018				
<u>NAPROXEN SODIUM; SUMATRIPTAN SUCCINATE - TREXIMET</u>						
N 021926 002	5872145	Aug 14, 2017	DP U-1719		NP	May 14, 2018
	5872145*PED	Feb 14, 2018			PED	Nov 14, 2018
	6060499	Aug 14, 2017	DP U-1719			
	6060499*PED	Feb 14, 2018				
	6586458	Aug 14, 2017	DP U-1719			
	6586458*PED	Feb 14, 2018				

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 10 - October 2015

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>NAPROXEN SODIUM; SUMATRIPTAN SUCCINATE - TREXIMET</u>						
N 021926 002	7332183	Oct 02, 2025	DP U-1719			
	7332183*PED	Apr 02, 2026				
<u>NEPAFENAC - ILEVRO</u>						
N 203491 001	8921337	Mar 31, 2032	DP			
<u>NETUPITANT; PALONOSETRON HYDROCHLORIDE - AKYNZEO</u>						
N 205718 001	8951969	Nov 18, 2030	DP			
<u>NICOTINE - NICODERM CO</u>						
N 020165 004	8999379	Feb 13, 2020	U-1686			
<u>NICOTINE - NICODERM CO</u>						
N 020165 005	8999379	Feb 13, 2020	U-1686			
<u>NICOTINE - NICODERM CO</u>						
N 020165 006	8999379	Feb 13, 2020	U-1686			
<u>NICOTINE POLACRILEX - NICORETTE</u>						
N 022360 001	8940772	Apr 30, 2029	DP			
<u>NICOTINE POLACRILEX - NICORETTE</u>						
N 022360 002	8940772	Apr 30, 2029	DP			
<u>NINTEDANIB ESYLATE - OFEV</u>						
N 205832 001	7989474	Apr 06, 2024	U-1677			
<u>NINTEDANIB ESYLATE - OFEV</u>						
N 205832 002	7989474	Apr 06, 2024	U-1677			
<u>NITRIC OXIDE - INOMAX</u>						
N 020845 003					>A> M-167	Oct 09, 2018
<u>OLAPARIB - LYNPARZA</u>						
N 206162 001	7151102	Apr 29, 2022	DS DP		ODE	Dec 19, 2021
	7449464	Oct 11, 2024	DS DP			
	7981889	Oct 11, 2024	DS DP			
	8143241	Aug 12, 2027			U-1634	
	8247416	Sep 24, 2028	DS			
	8859562	Aug 04, 2031			U-1634	
	8912187	Mar 12, 2024			U-1634	
<u>OLODATEROL HYDROCHLORIDE - STRIVERDI RESPIMAT</u>						
N 203108 001	8733341	Dec 16, 2029	DP			
	9027967	Mar 31, 2027	DP			
<u>OLODATEROL HYDROCHLORIDE; TIOTROPIUM BROMIDE - STIOLTO RESPIMAT</u>						
N 206756 001	5964416	Oct 04, 2016	DP		NC	May 21, 2018
	6149054	Dec 19, 2016	DP		NCE	Jul 31, 2019
	6176442	Oct 04, 2016	DP			
	6453795	Dec 05, 2016	DP			
	6726124	Oct 04, 2016	DP			
	6846413	Aug 28, 2018	DP			
	6977042	Aug 28, 2018	DP			
	6988496	Feb 23, 2020	DP			
	7056916	Dec 07, 2023	DS DP			
	7104470	Oct 04, 2016	DP			
	7220742	May 12, 2025	DS DP	U-1703		
	7246615	May 31, 2016	DP			
	7284474	Aug 26, 2024	DP			
	7396341	Oct 10, 2026	DP			

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 10 - October 2015

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>OLODATEROL HYDROCHLORIDE; TIOTROPIUM BROMIDE - STIOLTO RESPIMAT</u>						
N 206756 001	7491719	Nov 10, 2023	DS DP			
	7727984	Nov 10, 2023	DS			
	7786111	Nov 10, 2023	DP			
	7802568	Feb 26, 2019	DP			
	7837235	Mar 13, 2028	DP			
	7896264	May 26, 2025	DP			
	7988001	Aug 04, 2021	DP			
	8034809	May 12, 2025	U-1702			
	8044046	Nov 10, 2023	U-1702			
	8733341	Dec 16, 2029	DP			
	9027967	Mar 31, 2027	DP			
	RE39820	Jan 30, 2018	DS DP U-1702			
<u>OLOPATADINE HYDROCHLORIDE - PAZEO</u>						
N 206276 001	8791154	May 19, 2032	DP U-1680		NP PED	Jan 30, 2018 Jul 30, 2018
<u>OMBITASVIR; PARITAPREXVIR; RITONAVIR - TECHNIVIE</u>						
N 207931 001	6037157	Jun 26, 2016	U-1635		NCE	Dec 19, 2019
	6037157*PED	Dec 26, 2016			NP	Jul 24, 2018
	6703403	Jun 26, 2016	U-1635			
	6703403*PED	Dec 26, 2016				
	7148359	Jul 19, 2019	DP			
	7148359*PED	Jan 19, 2020				
	7364752	Nov 10, 2020	DP			
	7364752*PED	May 10, 2021				
	8268349	Aug 25, 2024	DP			
	8268349*PED	Feb 25, 2025				
	8399015	Aug 25, 2024	DP			
	8399015*PED	Feb 25, 2025				
	8420596	Apr 10, 2031	DS DP			
	8420596*PED	Oct 10, 2031				
	8642538	Sep 10, 2029	DS DP U-1638			
	8686026	Jun 09, 2031	DP			
	8691938	Apr 13, 2032	DS DP			
	9006387	Jun 10, 2030	U-1687			
	9044480	Apr 10, 2031	U-1638			
<u>OMEGA-3-CARBOXYLIC ACIDS - EPANOVA</u>						
N 205060 001	9012501	Feb 07, 2025	DP U-1511			
	9050308	Jan 04, 2033	U-1511			
	9050309	Jan 04, 2033	DS			
	9132112	Feb 07, 2025	DP U-1511			
<u>OMEPRazole - OMEPRazole</u>						
N 022032 001	9023391	Aug 16, 2025	DP			
<u>ONDANSETRON - ZUPLENZ</u>						
N 022524 001	9095577	Jul 13, 2030	DP			
<u>ONDANSETRON - ZUPLENZ</u>						
N 022524 002	9095577	Jul 13, 2030	DP			
<u>OSELTAMIVIR PHOSPHATE - TAMIFLU</u>						
N 021246 002	>A> 5763483	Aug 23, 2016	DS DP U-1113			
	>A> 5763483*PED	Feb 23, 2017				
<u>OSPemifene - OSPHENA</u>						
N 203505 001	8642079	Jul 09, 2028	DP			
<u>OXCARBAZEPINE - OXTELLAR XR</u>						
N 202810 001	9119791	Apr 13, 2027	U-1298			

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 10 - October 2015

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>OXCARBAZEPINE - OXTELLAR XR</u>						
N 202810 002	9119791	Apr 13, 2027	U-1298			
<u>OXCARBAZEPINE - OXTELLAR XR</u>						
N 202810 003	9119791	Apr 13, 2027	U-1298			
<u>OXYBUTYNIN CHLORIDE - GELNIQUE</u>						
N 022204 001	8920392	Mar 26, 2031	U-1644			
<u>OXYCODONE HYDROCHLORIDE - OXYCONTIN</u>						
N 022272 001	9060976	Aug 06, 2022	DP		M-153	Apr 16, 2016
	9073933	Mar 30, 2025	DS		NPP	Aug 13, 2018
<u>OXYCODONE HYDROCHLORIDE - OXYCONTIN</u>						
N 022272 002	9060976	Aug 06, 2022	DP		M-153	Apr 16, 2016
	9073933	Mar 30, 2025	DS		NPP	Aug 13, 2018
<u>OXYCODONE HYDROCHLORIDE - OXYCONTIN</u>						
N 022272 003	9060976	Aug 06, 2022	DP		M-153	Apr 16, 2016
	9073933	Mar 30, 2025	DS		NPP	Aug 13, 2018
<u>OXYCODONE HYDROCHLORIDE - OXYCONTIN</u>						
N 022272 004	9060976	Aug 06, 2022	DP		M-153	Apr 16, 2016
	9073933	Mar 30, 2025	DS		NPP	Aug 13, 2018
<u>OXYCODONE HYDROCHLORIDE - OXYCONTIN</u>						
N 022272 005	9060976	Aug 06, 2022	DP		M-153	Apr 16, 2016
	9073933	Mar 30, 2025	DS		NPP	Aug 13, 2018
<u>OXYCODONE HYDROCHLORIDE - OXYCONTIN</u>						
N 022272 006	9060976	Aug 06, 2022	DP		M-153	Apr 16, 2016
	9073933	Mar 30, 2025	DS		NPP	Aug 13, 2018
<u>OXYCODONE HYDROCHLORIDE - OXYCONTIN</u>						
N 022272 007	9060976	Aug 06, 2022	DP		M-153	Apr 16, 2016
	9073933	Mar 30, 2025	DS		NPP	Aug 13, 2018
<u>PACLITAXEL - ABRAXANE</u>						
N 021660 001	9101543	Feb 21, 2026	U-1434			
<u>PALBOCICLIB - IBRANCE</u>						
N 207103 001	6936612	Jan 22, 2023	DS DP		NCE	Feb 03, 2020
	7208489	Jan 16, 2023	DS DP			
	7456168	Jan 16, 2023	U-1658			
<u>PALBOCICLIB - IBRANCE</u>						
N 207103 002	6936612	Jan 22, 2023	DS DP		NCE	Feb 03, 2020
	7208489	Jan 16, 2023	DS DP			
	7456168	Jan 16, 2023	U-1658			
<u>PALBOCICLIB - IBRANCE</u>						
N 207103 003	6936612	Jan 22, 2023	DS DP		NCE	Feb 03, 2020
	7208489	Jan 16, 2023	DS DP			
	7456168	Jan 16, 2023	U-1658			
<u>PALIPERIDONE PALMITATE - INVEGA TRINZA</u>						
N 207946 001	6077843	May 12, 2017	DP U-543		NP	May 18, 2018
	6077843*PED	Nov 12, 2017				

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 10 - October 2015

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>PALIPERIDONE PALMITATE - INVEGA TRINZA</u>						
N 207946 002	6077843	May 12, 2017	DP U-543		NP	May 18, 2018
	6077843*PED	Nov 12, 2017				
<u>PALIPERIDONE PALMITATE - INVEGA TRINZA</u>						
N 207946 003	6077843	May 12, 2017	DP U-543		NP	May 18, 2018
	6077843*PED	Nov 12, 2017				
<u>PALIPERIDONE PALMITATE - INVEGA TRINZA</u>						
N 207946 004	6077843	May 12, 2017	DP U-543		NP	May 18, 2018
	6077843*PED	Nov 12, 2017				
<u>PALONOSETRON HYDROCHLORIDE - ALOXI</u>						
N 021372 001	9066980	Jan 30, 2024	DP U-528			
	9125905	Jan 30, 2024	DP			
	>A> 9173942	Jan 30, 2024	DP			
<u>PALONOSETRON HYDROCHLORIDE - ALOXI</u>						
N 021372 002	9125905	Jan 30, 2024	DP			
	>A> 9173942	Jan 30, 2024	DP			
<u>PANOBINOSTAT LACTATE - FARYDAK</u>						
N 205353 001	6552065	Aug 31, 2021	DS DP		NCE	Feb 23, 2020
	6833384	Sep 30, 2021	DS DP U-1669		ODE	Feb 23, 2022
	7067551	Aug 31, 2021	U-1669			
	7989494	Jan 17, 2028	DS DP			
	8883842	Jun 13, 2028	U-1669			
<u>PANOBINOSTAT LACTATE - FARYDAK</u>						
N 205353 002	6552065	Aug 31, 2021	DS DP		NCE	Feb 23, 2020
	6833384	Sep 30, 2021	DS DP U-1669		ODE	Feb 23, 2022
	7067551	Aug 31, 2021	U-1669			
	7989494	Jan 17, 2028	DS DP			
	8883842	Jun 13, 2028	U-1669			
<u>PANOBINOSTAT LACTATE - FARYDAK</u>						
N 205353 003	6552065	Aug 31, 2021	DS DP		NCE	Feb 23, 2020
	6833384	Sep 30, 2021	DS DP U-1669		ODE	Feb 23, 2022
	7067551	Aug 31, 2021	U-1669			
	7989494	Jan 17, 2028	DS DP			
	8883842	Jun 13, 2028	U-1669			
<u>PAROXETINE MESYLATE - BRISDELLE</u>						
N 204516 001	8946251	Aug 04, 2026	DS DP U-904			
<u>PATIRROMER SORBITEX CALCIUM - VELTASSA</u>						
N 205739 001					>A> NCE	Oct 21, 2020
<u>PATIRROMER SORBITEX CALCIUM - VELTASSA</u>						
N 205739 002					>A> NCE	Oct 21, 2020
<u>PATIRROMER SORBITEX CALCIUM - VELTASSA</u>						
N 205739 003					>A> NCE	Oct 21, 2020
<u>PERAMPANEL - FYCOMPA</u>						
N 202834 001					I-710	Jun 19, 2018
<u>PERAMPANEL - FYCOMPA</u>						
N 202834 002					I-710	Jun 19, 2018

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 10 - October 2015

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>PERAMPANEL - FYCOMPA</u>						
N 202834 003					I-710	Jun 19, 2018
<u>PERAMPANEL - FYCOMPA</u>						
N 202834 004					I-710	Jun 19, 2018
<u>PERAMPANEL - FYCOMPA</u>						
N 202834 005					I-710	Jun 19, 2018
<u>PERAMPANEL - FYCOMPA</u>						
N 202834 006					I-710	Jun 19, 2018
<u>PHENTERMINE HYDROCHLORIDE; TOPIRAMATE - QSYMIA</u>						
N 022580 001	9011905	Jun 09, 2028	DP			
	9011906	Jun 09, 2028	U-1262			
<u>PHENTERMINE HYDROCHLORIDE; TOPIRAMATE - QSYMIA</u>						
N 022580 002	9011905	Jun 09, 2028	DP			
	9011906	Jun 09, 2028	U-1262			
<u>PHENTERMINE HYDROCHLORIDE; TOPIRAMATE - QSYMIA</u>						
N 022580 003	9011905	Jun 09, 2028	DP			
	9011906	Jun 09, 2028	U-1262			
<u>PHENTERMINE HYDROCHLORIDE; TOPIRAMATE - QSYMIA</u>						
N 022580 004	9011905	Jun 09, 2028	DP			
	9011906	Jun 09, 2028	U-1262			
<u>PIRFENIDONE - ESBRIET</u>						
N 022535 001	7696236	Dec 18, 2027	U-1601			
<u>POLIDOCANOL - VARITHENA</u>						
N 205098 001	RE40640	Oct 14, 2016	DS DP U-1462			
<u>POMALIDOMIDE - POMALYST</u>						
N 204026 001					I-707	Apr 23, 2018
<u>POMALIDOMIDE - POMALYST</u>						
N 204026 002					I-707	Apr 23, 2018
<u>POMALIDOMIDE - POMALYST</u>						
N 204026 003					I-707	Apr 23, 2018
<u>POMALIDOMIDE - POMALYST</u>						
N 204026 004					I-707	Apr 23, 2018
<u>PONATINIB HYDROCHLORIDE - ICLUSIG</u>						
N 203469 001	9029533	Dec 22, 2026	U-836			
	9029533	Dec 22, 2026	U-1283			
	9029533	Dec 22, 2026	U-1699			
	9029533	Dec 22, 2026	U-1700			
	9029533	Dec 22, 2026	U-1701			
<u>PONATINIB HYDROCHLORIDE - ICLUSIG</u>						
N 203469 002	9029533	Dec 22, 2026	U-836			
	9029533	Dec 22, 2026	U-1283			
	9029533	Dec 22, 2026	U-1699			
	9029533	Dec 22, 2026	U-1700			
	9029533	Dec 22, 2026	U-1701			

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 10 - October 2015

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>PONATINIB HYDROCHLORIDE - ICLUSIG</u>						
N 203469 003	9029533	Dec 22, 2026	U-836			
	9029533	Dec 22, 2026	U-1283			
	9029533	Dec 22, 2026	U-1699			
	9029533	Dec 22, 2026	U-1700			
	9029533	Dec 22, 2026	U-1701			
<u>POSACONAZOLE - NOXAFIL</u>						
N 205596 001	9023790	Jul 04, 2031	DP U-1698			
<u>PREDNISONE - RAYOS</u>						
N 202020 001	9040085	Apr 23, 2024	U-1362			
<u>PREDNISONE - RAYOS</u>						
N 202020 002	9040085	Apr 23, 2024	U-1362			
<u>PREDNISONE - RAYOS</u>						
N 202020 003	9040085	Apr 23, 2024	U-1362			
<u>REGADENOSON - LEXISCAN</u>						
N 022161 001	9045519	Jun 22, 2019	DP			
	9085601	Feb 02, 2027	DP			
<u>REGORAFENIB - STIVARGA</u>						
N 203085 001	8637553	Feb 16, 2031	DS DP			
	8680124	Jun 02, 2030	U-1506			
<u>RIFAXIMIN - XIFAXAN</u>						
N 022554 001	6861053	Aug 11, 2019	U-1707		I-709	May 27, 2018
	6861053	Aug 11, 2019	U-1708			
	7452857	Aug 11, 2019	U-1707			
	7452857	Aug 11, 2019	U-1708			
	7605240	Aug 11, 2019	U-1707			
	7605240	Aug 11, 2019	U-1708			
	7718608	Aug 11, 2019	U-1707			
	7718608	Aug 11, 2019	U-1708			
	7915275	Feb 23, 2025	U-1707			
	7915275	Feb 23, 2025	U-1708			
	7935799	Aug 11, 2019	U-1707			
	7935799	Aug 11, 2019	U-1708			
	8193196	Sep 02, 2027	DS DP U-1707			
	8193196	Sep 02, 2027	DS DP U-1708			
	8309569	Jul 18, 2029	U-1707			
	8309569	Jul 18, 2029	U-1708			
	8741904	Feb 27, 2026	DS U-1526			
	8741904	Feb 27, 2026	DS U-1707			
	8741904	Feb 27, 2026	DS U-1708			
	8946252	Jul 24, 2029	U-1481			
	8969398	Oct 02, 2029	U-1481			
<u>RILPIVIRINE HYDROCHLORIDE - EDURANT</u>						
N 202022 001	>A> 7125879	Aug 09, 2022	DS DP U-1153		NPP	Aug 26, 2018
	>A> 7125879	Aug 09, 2022	DS DP U-1307			
	>A> 7125879	Aug 09, 2022	DS DP U-1740			
<u>RISEDRONATE SODIUM - RISEDRONATE SODIUM</u>						
A 077132 001					PC	Nov 28, 2015
<u>RISEDRONATE SODIUM - RISEDRONATE SODIUM</u>						
A 077132 002					PC	Nov 28, 2015

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 10 - October 2015

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>RISEDRONATE SODIUM - RISEDRONATE SODIUM</u>						
A 077132 003					PC	Nov 28, 2015
<u>RIVASTIGMINE - RIVASTIGMINE</u>						
A 204403 003					PC	Feb 29, 2016
<u>ROFLUMILAST - DALIRESP</u>						
N 022522 001	5712298	Jan 27, 2020	DS DP U-1115			
<u>ROLAPITANT HYDROCHLORIDE - VARUBI</u>						
N 206500 001	7049230	Dec 08, 2023	DS DP U-1741		NCE	Sep 01, 2020
	7563801	Apr 04, 2027	DP			
	7981905	Apr 04, 2027	U-1741			
	7981905	Apr 04, 2027	U-1742			
	8178550	Apr 04, 2027	DS DP			
	8361500	Oct 09, 2029	DP			
	8404702	Oct 09, 2029	U-1741			
	8470842	Jan 18, 2029	U-1741			
	8796299	Dec 17, 2022	U-1741			
<u>RUXOLITINIB PHOSPHATE - JAKAFI</u>						
N 202192 001	9079912	Dec 12, 2026	U-1573			
	9079912	Dec 12, 2026	U-1721			
<u>RUXOLITINIB PHOSPHATE - JAKAFI</u>						
N 202192 002	9079912	Dec 12, 2026	U-1573			
	9079912	Dec 12, 2026	U-1721			
<u>RUXOLITINIB PHOSPHATE - JAKAFI</u>						
N 202192 003	9079912	Dec 12, 2026	U-1573			
	9079912	Dec 12, 2026	U-1721			
<u>RUXOLITINIB PHOSPHATE - JAKAFI</u>						
N 202192 004	9079912	Dec 12, 2026	U-1573			
	9079912	Dec 12, 2026	U-1721			
<u>RUXOLITINIB PHOSPHATE - JAKAFI</u>						
N 202192 005	9079912	Dec 12, 2026	U-1573			
	9079912	Dec 12, 2026	U-1721			
<u>SACUBITRIL; VALSARTAN - ENTRESTO</u>						
N 207620 001	7468390	Nov 27, 2023	DP		NCE	Jul 07, 2020
	8101659	Jan 14, 2023	DP			
	8404744	Jan 14, 2023	DP			
	8796331	Jan 14, 2023	U-1723			
	8877938	May 27, 2027	DS DP			
<u>SACUBITRIL; VALSARTAN - ENTRESTO</u>						
N 207620 002	7468390	Nov 27, 2023	DP		NCE	Jul 07, 2020
	8101659	Jan 14, 2023	DP			
	8404744	Jan 14, 2023	DP			
	8796331	Jan 14, 2023	U-1723			
	8877938	May 27, 2027	DS DP			
<u>SACUBITRIL; VALSARTAN - ENTRESTO</u>						
N 207620 003	7468390	Nov 27, 2023	DP		NCE	Jul 07, 2020
	8101659	Jan 14, 2023	DP			
	8404744	Jan 14, 2023	DP			
	8796331	Jan 14, 2023	U-1723			
	8877938	May 27, 2027	DS DP			

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 10 - October 2015

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>SIMEPREVIR SODIUM - OLYSIO</u>						
N 205123 001	9040562	Jul 28, 2026	DS DP U-1467		>A> D-151 >A> I-717	Oct 05, 2018 Oct 05, 2018
<u>SIROLIMUS - RAPAMUNE</u>						
N 021083 001					ODE	May 28, 2022
<u>SIROLIMUS - RAPAMUNE</u>						
N 021110 001					ODE	May 28, 2022
<u>SIROLIMUS - RAPAMUNE</u>						
N 021110 002					ODE	May 28, 2022
<u>SIROLIMUS - RAPAMUNE</u>						
N 021110 003					ODE	May 28, 2022
<u>SIROLIMUS - RAPAMUNE</u>						
N 021110 004					ODE	May 28, 2022
<u>SODIUM OXYBATE - XYREM</u>						
N 021196 001	8952062	Dec 22, 2019	U-1101			
	8952062	Dec 22, 2019	U-1102			
	9050302	Mar 15, 2033	U-1532			
<u>SOFOSBUVIR - SOVALDI</u>						
N 204671 001	9085573	Mar 21, 2028	DS DP U-1470			
<u>SOMATROPIN RECOMBINANT - NORDITROPIN FLEXPRO</u>						
N 021148 008	8920383	Jul 17, 2026	DP			
	9108002	Jan 20, 2026	DP			
	9132239	Feb 01, 2032	DP			
<u>SOMATROPIN RECOMBINANT - NORDITROPIN FLEXPRO</u>						
N 021148 009	8920383	Jul 17, 2026	DP			
	9108002	Jan 20, 2026	DP			
	9132239	Feb 01, 2032	DP			
<u>SOMATROPIN RECOMBINANT - NORDITROPIN FLEXPRO</u>						
N 021148 010	8920383	Jul 17, 2026	DP			
	9108002	Jan 20, 2026	DP			
	9132239	Feb 01, 2032	DP			
<u>SOMATROPIN RECOMBINANT - NORDITROPIN FLEXPRO</u>						
N 021148 011	5849700	Dec 15, 2015	U-1041			
	5849704	Dec 15, 2015	DS DP U-1041			
	6899699	Jan 02, 2022	DP			
	7686786	Aug 03, 2026	DP			
	8672898	Jan 02, 2022	DP			
	8684969	Oct 20, 2025	DP			
	8841252	Dec 26, 2017	DP			
	8920383	Jul 17, 2026	DP			
	9108002	Jan 20, 2026	DP			
	9132239	Feb 01, 2032	DP			
<u>SONIDEGIB PHOSPHATE - ODOMZO</u>						
N 205266 001	8063043	Sep 15, 2029	DS DP		NCE	Jul 24, 2020
	8178563	Feb 06, 2029	DS U-1722			
<u>SORAFENIB TOSYLATE - NEXAVAR</u>						
N 021923 001	8124630	Jan 12, 2020	U-1459			
	8841330	Jan 12, 2020	U-1696			

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 10 - October 2015

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>SPINOSAD - NATROBA</u>						
N 022408 001	6063771	Jul 25, 2023	DP U-1670		M-152	Nov 30, 2017
<u>SUMATRIPTAN SUCCINATE - ZECUITY</u>						
N 202278 001	8983594	Nov 19, 2030	DP U-1328			
<u>TACROLIMUS - ENVARUSUS XR</u>						
N 206406 001	7994214	Aug 30, 2024	DP		ODE	Jul 10, 2022
	>A> 8486993	Aug 30, 2024	DP U-1752			
	>A> 8586084	Aug 30, 2024	U-1752			
	>A> 8591946	Aug 30, 2024	DP			
	>A> 8617599	Aug 30, 2024	DP			
	>A> 8623410	Aug 30, 2024	DP			
	>A> 8623411	Aug 30, 2024	U-1752			
	>A> 8664239	May 30, 2028	U-1752			
	>A> 8685998	May 30, 2028	DP U-1752			
	>A> 8889185	Aug 30, 2024	U-1752			
	>A> 8889186	Aug 30, 2024	U-1752			
<u>TACROLIMUS - ENVARUSUS XR</u>						
N 206406 002	7994214	Aug 30, 2024	DP		ODE	Jul 10, 2022
	>A> 8486993	Aug 30, 2024	DP U-1752			
	>A> 8586084	Aug 30, 2024	U-1752			
	>A> 8591946	Aug 30, 2024	DP			
	>A> 8617599	Aug 30, 2024	DP			
	>A> 8623410	Aug 30, 2024	DP			
	>A> 8623411	Aug 30, 2024	U-1752			
	>A> 8664239	May 30, 2028	U-1752			
	>A> 8685998	May 30, 2028	DP U-1752			
	>A> 8889185	Aug 30, 2024	U-1752			
	>A> 8889186	Aug 30, 2024	U-1752			
<u>TACROLIMUS - ENVARUSUS XR</u>						
N 206406 003	7994214	Aug 30, 2024	DP		ODE	Jul 10, 2022
	>A> 8486993	Aug 30, 2024	DP U-1752			
	>A> 8586084	Aug 30, 2024	U-1752			
	>A> 8591946	Aug 30, 2024	DP			
	>A> 8617599	Aug 30, 2024	DP			
	>A> 8623410	Aug 30, 2024	DP			
	>A> 8623411	Aug 30, 2024	U-1752			
	>A> 8664239	May 30, 2028	U-1752			
	>A> 8685998	May 30, 2028	DP U-1752			
	>A> 8889185	Aug 30, 2024	U-1752			
	>A> 8889186	Aug 30, 2024	U-1752			
<u>TAPENTADOL HYDROCHLORIDE - NUCYNТА ER</u>						
N 200533 001	8536130	Sep 22, 2028	U-1739			
<u>TAPENTADOL HYDROCHLORIDE - NUCYNТА ER</u>						
N 200533 002	8536130	Sep 22, 2028	U-1739			
<u>TAPENTADOL HYDROCHLORIDE - NUCYNТА ER</u>						
N 200533 003	8536130	Sep 22, 2028	U-1739			
<u>TAPENTADOL HYDROCHLORIDE - NUCYNТА ER</u>						
N 200533 004	8536130	Sep 22, 2028	U-1739			
<u>TAPENTADOL HYDROCHLORIDE - NUCYNТА ER</u>						
N 200533 005	8536130	Sep 22, 2028	U-1739			
<u>TASIMELTEON - HETLIOZ</u>						
N 205677 001	9060995	Jan 25, 2033	U-1710			

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 10 - October 2015

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>TEDUGLUTIDE RECOMBINANT - GATTEX KIT</u>						
N 203441 001	5789379	Apr 14, 2016	DS DP U-1320			
	9060992	Nov 01, 2025	U-1320			
<u>TESTOSTERONE - ANDROGEL</u>						
N 021015 001	9125816	Aug 30, 2020	U-490			
	9132089	Aug 30, 2020	U-490			
<u>TESTOSTERONE - ANDROGEL</u>						
N 021015 002	9125816	Aug 30, 2020	U-490			
	9132089	Aug 30, 2020	U-490			
<u>TESTOSTERONE - ANDROGEL</u>						
N 021015 003	9125816	Aug 30, 2020	U-490			
	9132089	Aug 30, 2020	U-490			
<u>TESTOSTERONE - ANDROGEL</u>						
N 022309 001	9125816	Aug 30, 2020	U-1103			
	9132089	Aug 30, 2020	U-1103			
<u>TESTOSTERONE - ANDROGEL</u>						
N 022309 002	9125816	Aug 30, 2020	U-1103			
	9132089	Aug 30, 2020	U-1103			
<u>TESTOSTERONE - ANDROGEL</u>						
N 022309 003	9125816	Aug 30, 2020	U-1103			
	9132089	Aug 30, 2020	U-1103			
<u>TESTOSTERONE - AXIRON</u>						
N 022504 001	8435944	Sep 27, 2027	U-1390			
	8993520	Jun 02, 2026	U-1390			
<u>TICAGRELOR - BRILINTA</u>						
N 022433 001					I-714	Sep 03, 2018
<u>TICAGRELOR - BRILINTA</u>						
N 022433 002	6251910	Jul 15, 2018	DS		>A> NCE	Jul 20, 2016
	6525060	Dec 02, 2019	DS DP U-1171		NS	Sep 03, 2018
	7250419	Dec 02, 2019	DS DP U-1171			
	7265124	Jul 09, 2021	DS DP U-1171			
>A>	8425934	Apr 17, 2030	DP			
<u>TIGECYCLINE - TYGACIL</u>						
N 021821 001	8975242	Oct 24, 2028	DP			
<u>TIOTROPIUM BROMIDE - SPIRIVA RESPIMAT</u>						
N 021936 001	8733341	Dec 16, 2029	DP			
	9027967	Mar 31, 2027	DP			
<u>TIOTROPIUM BROMIDE - SPIRIVA RESPIMAT</u>						
N 021936 002	5964416	Oct 04, 2016	DP		NP	Sep 15, 2018
	6149054	Dec 16, 2016	DP			
	6176442	May 31, 2016	DP			
	6453795	Dec 05, 2016	DP			
	6726124	Oct 04, 2016	DP			
	6846413	Aug 28, 2018	DP			
	6977042	Aug 28, 2018	DP			
	6988496	Feb 23, 2020	DP			
	7104470	Oct 04, 2016	DP			
	7246615	May 31, 2016	DP			
	7284474	Aug 26, 2024	DP			
	7396341	Oct 10, 2026	DP			
	7802568	Feb 26, 2019	DP			

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 10 - October 2015

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>TIOTROPIUM BROMIDE - SPIRIVA RESPIMAT</u>						
N 021936 002	7837235	Mar 13, 2028	DP			
	7896264	May 26, 2025	DP			
	7988001	Aug 04, 2021	DP			
	8733341	Dec 16, 2029	DP			
	9027967	Mar 31, 2027	DP			
	RE39820	Jan 30, 2018	DS DP			
<u>TIPIRACIL HYDROCHLORIDE; TRIFLURIDINE - LONSURF</u>						
N 207981 001	>A> 5744475	Mar 28, 2016	DS DP U-1751		NCE	Sep 22, 2020
	>A> 6479500	Mar 16, 2020	U-1751			
	>A> 7799783	Dec 16, 2026	U-1751			
<u>TIPIRACIL HYDROCHLORIDE; TRIFLURIDINE - LONSURF</u>						
N 207981 002	>A> 5744475	Mar 28, 2016	DS DP U-1751		NCE	Sep 22, 2020
	>A> 6479500	Mar 16, 2020	U-1751			
	>A> 7799783	Dec 16, 2026	U-1751			
<u>TOPIRAMATE - TROKENDI XR</u>						
N 201635 001	8298576	Apr 04, 2028	DP U-106			
	8992989	Nov 16, 2027	DP U-1675			
<u>TOPIRAMATE - TROKENDI XR</u>						
N 201635 002	8298576	Apr 04, 2028	DP U-106			
	8992989	Nov 16, 2027	DP U-1675			
<u>TOPIRAMATE - TROKENDI XR</u>						
N 201635 003	8298576	Apr 04, 2028	DP U-106			
	8992989	Nov 16, 2027	DP U-1675			
<u>TOPIRAMATE - TROKENDI XR</u>						
N 201635 004	8298576	Apr 04, 2028	DP U-106			
	8992989	Nov 16, 2027	DP U-1675			
<u>TOPIRAMATE - OUDEXY XR</u>						
N 205122 001	9101545	Mar 19, 2033	DP			
<u>TOPIRAMATE - OUDEXY XR</u>						
N 205122 002	9101545	Mar 19, 2033	DP			
<u>TOPIRAMATE - OUDEXY XR</u>						
N 205122 003	9101545	Mar 19, 2033	DP			
<u>TOPIRAMATE - OUDEXY XR</u>						
N 205122 004	9101545	Mar 19, 2033	DP			
<u>TOPIRAMATE - OUDEXY XR</u>						
N 205122 005	9101545	Mar 19, 2033	DP			
<u>TRABECTEDIN - YONDELIS</u>						
N 207953 001					>A> NCE	Oct 23, 2020
<u>TRAMETINIB DIMETHYL SULFOXIDE - MEKINIST</u>						
N 204114 001	8703781	Oct 15, 2030	DS DP U-1712			
<u>TRAMETINIB DIMETHYL SULFOXIDE - MEKINIST</u>						
N 204114 002	8703781	Oct 15, 2030	DS DP U-1712			
<u>TRAMETINIB DIMETHYL SULFOXIDE - MEKINIST</u>						
N 204114 003	8703781	Oct 15, 2030	DS DP U-1712			

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 10 - October 2015

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>TRANEXAMIC ACID - LYSTEDA</u>						
N 022430 001	8957113	Mar 04, 2025	DP U-1182			
	9060939	Mar 04, 2025	DP			
<u>TRAVOPROST - IZBA</u>						
N 204822 001	8178582	Oct 10, 2029	DP			
	9144561	Mar 13, 2029	DP			
<u>TRAZODONE HYDROCHLORIDE - DESYREL</u>						
N 018207 001	8133893	Mar 13, 2029	DS DP			
<u>TRAZODONE HYDROCHLORIDE - DESYREL</u>						
N 018207 002	8133893	Mar 13, 2029	DS DP			
<u>TRAZODONE HYDROCHLORIDE - DESYREL</u>						
N 018207 003	8133893	Mar 13, 2029	DS DP			
<u>TRAZODONE HYDROCHLORIDE - DESYREL</u>						
N 018207 004	8133893	Mar 13, 2029	DS DP			
<u>TREPROSTINIL DIOLAMINE - ORENITRAM</u>						
N 203496 001	7417070	Jul 30, 2026	DS			
	9050311	May 24, 2024	DS DP			
<u>TREPROSTINIL DIOLAMINE - ORENITRAM</u>						
N 203496 002	7417070	Jul 30, 2026	DS			
	9050311	May 24, 2024	DS DP			
<u>TREPROSTINIL DIOLAMINE - ORENITRAM</u>						
N 203496 003	7417070	Jul 30, 2026	DS			
	9050311	May 24, 2024	DS DP			
<u>TREPROSTINIL DIOLAMINE - ORENITRAM</u>						
N 203496 004	7417070	Jul 30, 2026	DS			
	9050311	May 24, 2024	DS DP			
<u>TRETINOIN - RETIN-A-MICRO</u>						
N 020475 003	5955109	Sep 21, 2016	DP U-134			
<u>ULIPRISTAL ACETATE - ELLA</u>						
N 022474 001	>A> 8512745	Jun 02, 2030	DP			
	8962603	Jun 12, 2030	U-1657			
<u>UMECLIDINIUM BROMIDE; VILANTEROL TRIFENATATE - ANORO ELLIPTA</u>						
N 203975 001	8511304	Jun 14, 2027	DP U-1476			
<u>URIDINE TRIACETATE - XURIDEN</u>						
N 208169 001	>A> 6258795	Jul 10, 2018	DP		NCE ODE	Sep 04, 2020 Sep 04, 2022
<u>VALGANCICLOVIR HYDROCHLORIDE - VALCYTE</u>						
N 021304 001					D-148 NPP	Apr 23, 2018 Apr 23, 2018
<u>VALGANCICLOVIR HYDROCHLORIDE - VALCYTE</u>						
N 022257 001					D-148 NPP	Apr 23, 2018 Apr 23, 2018
<u>VILAZODONE HYDROCHLORIDE - VIIBRYD</u>						
N 022567 001					D-146	Mar 16, 2018

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 10 - October 2015

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>VILAZODONE HYDROCHLORIDE - VIIBRYD</u>						
N 022567 002					D-146	Mar 16, 2018
<u>VILAZODONE HYDROCHLORIDE - VIIBRYD</u>						
N 022567 003					D-146	Mar 16, 2018
<u>VORTIOXETINE HYDROBROMIDE - BRINTELLIX</u>						
N 204447 001	8722684	Jun 30, 2031	DS DP			
	8969355	Jun 15, 2027	U-1668			
<u>VORTIOXETINE HYDROBROMIDE - BRINTELLIX</u>						
N 204447 002	8722684	Jun 30, 2031	DS DP			
	8969355	Jun 15, 2027	U-1668			
<u>VORTIOXETINE HYDROBROMIDE - BRINTELLIX</u>						
N 204447 003	8722684	Jun 30, 2031	DS DP			
	8969355	Jun 15, 2027	U-1668			
<u>VORTIOXETINE HYDROBROMIDE - BRINTELLIX</u>						
N 204447 004	8722684	Jun 30, 2031	DS DP			
	8969355	Jun 15, 2027	U-1668			
<u>ZOLMITRIPTAN - ZOMIG</u>						
N 021450 003					NPP	Jun 12, 2018
<u>ZOLMITRIPTAN - ZOMIG</u>						
N 021450 004					NPP	Jun 12, 2018

Footnote:

1. Patents are published upon receipt by the Orange book Staff and may not reflect the official receipt date as described in 21 CFR 314.53(d)(5).

2. Patents listed prior to August 18, 2003 are flagged with method of use claims only as applicable and submitted by the sponsor. They may not be flagged with respect to other claims which may apply.

PATENT AND EXCLUSIVITY TERMS

Due to space limitations in the patent and exclusivity columns, abbreviations and references have been developed. Refer to the APPROVED DRUG PRODUCTS WITH THERAPEUTIC EQUIVALENCE EVALUATIONS, 35th Edition for a full listing of patent and exclusivity terms (Abbreviations, Dosing Schedule, Indications, and Patent Use Codes).

The current complete list of patent terms is available at
<http://www.accessdata.fda.gov/scripts/cder/ob/docs/pattermsall.cfm>

The current complete list of exclusivity terms is available at
<http://www.accessdata.fda.gov/scripts/cder/ob/docs/excltermsall.cfm>